
<html lang="en"     class="pb-page"  data-request-id="c0ed418b-242a-42f6-ab02-166f4aae1a20"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c01385;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and Structure–Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody–Drug Conjugates" /></meta><meta name="dc.Creator" content="Naidu S.  Chowdari" /></meta><meta name="dc.Creator" content="Yong  Zhang" /></meta><meta name="dc.Creator" content="Ivar  McDonald" /></meta><meta name="dc.Creator" content="Walter  Johnson" /></meta><meta name="dc.Creator" content="David R.  Langley" /></meta><meta name="dc.Creator" content="Prasanna  Sivaprakasam" /></meta><meta name="dc.Creator" content="Robert  Mate" /></meta><meta name="dc.Creator" content="Tram  Huynh" /></meta><meta name="dc.Creator" content="Srikanth  Kotapati" /></meta><meta name="dc.Creator" content="Madhura  Deshpande" /></meta><meta name="dc.Creator" content="Chin  Pan" /></meta><meta name="dc.Creator" content="Daniel  Menezes" /></meta><meta name="dc.Creator" content="Yichong  Wang" /></meta><meta name="dc.Creator" content="Chetana  Rao" /></meta><meta name="dc.Creator" content="Ganapathy  Sarma" /></meta><meta name="dc.Creator" content="Bethanne M.  Warrack" /></meta><meta name="dc.Creator" content="Vangipuram S.  Rangan" /></meta><meta name="dc.Creator" content="Sung  Mei-Chen" /></meta><meta name="dc.Creator" content="Pina  Cardarelli" /></meta><meta name="dc.Creator" content="Shrikant  Deshpande" /></meta><meta name="dc.Creator" content="David  Passmore" /></meta><meta name="dc.Creator" content="Richard  Rampulla" /></meta><meta name="dc.Creator" content="Arvind  Mathur" /></meta><meta name="dc.Creator" content="Robert  Borzilleri" /></meta><meta name="dc.Creator" content="Arvind  Rajpal" /></meta><meta name="dc.Creator" content="Gregory  Vite" /></meta><meta name="dc.Creator" content="Sanjeev  Gangwar" /></meta><meta name="dc.Description" content="A series of tetrahydroisoquinoline-based benzodiazepine dimers were synthesized and tested for in vitro cytotoxicity against a panel of cancer cell lines. Structure–activity relationship investigat..." /></meta><meta name="Description" content="A series of tetrahydroisoquinoline-based benzodiazepine dimers were synthesized and tested for in vitro cytotoxicity against a panel of cancer cell lines. Structure–activity relationship investigat..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 6, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01385" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01385" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01385" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01385" /></link>
        
    
    

<title>Design, Synthesis, and Structure–Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody–Drug Conjugates | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01385" /></meta><meta property="og:title" content="Design, Synthesis, and Structure–Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody–Drug Conjugates" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0041.jpeg" /></meta><meta property="og:description" content="A series of tetrahydroisoquinoline-based benzodiazepine dimers were synthesized and tested for in vitro cytotoxicity against a panel of cancer cell lines. Structure–activity relationship investigation of various spacers guided by molecular modeling studies helped to identify compounds with picomolar activity. Payload 17 was conjugated to anti-mesothelin and anti-fucosylated monosialotetrahexosylganglioside (FucGM1) antibodies using lysosome-cleavable valine–citrulline dipeptide linkers via heterogeneous lysine conjugation and bacterial transglutaminase-mediated site-specific conjugation. In vitro, these antibody drug conjugates (ADCs) exhibited significant cytotoxic and target-mediated selectivity on human cancer cell lines. The pharmacokinetics and efficacy of these ADCs were further evaluated in gastric and lung cancer xenograft models in mice. Consistent pharmacokinetic profiles, high target specificity, and robust antitumor activity were observed in these models after a single dose of the ADC-46 (0.02 μmol/kg)." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01385"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01385">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01385&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01385&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01385&amp;href=/doi/10.1021/acs.jmedchem.0c01385" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 13913-13950</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01435" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01498" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Structure–Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody–Drug Conjugates</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Naidu S. Chowdari</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Naidu S. Chowdari</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#046a77676c6b736065766d446369656d682a676b69"><span class="__cf_email__" data-cfemail="ddb3aebeb5b2aab9bcafb49dbab0bcb4b1f3beb2b0">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Naidu+S.++Chowdari">Naidu S. Chowdari</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8795-2570" title="Orcid link">http://orcid.org/0000-0001-8795-2570</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yong Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yong Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Zhang">Yong Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1857-1883" title="Orcid link">http://orcid.org/0000-0003-1857-1883</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ivar McDonald</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ivar McDonald</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ivar++McDonald">Ivar McDonald</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Walter Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Walter Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Walter++Johnson">Walter Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David R. Langley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David R. Langley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+R.++Langley">David R. Langley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Prasanna Sivaprakasam</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Prasanna Sivaprakasam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Prasanna++Sivaprakasam">Prasanna Sivaprakasam</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert Mate</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert Mate</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Mate">Robert Mate</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tram Huynh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tram Huynh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tram++Huynh">Tram Huynh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Srikanth Kotapati</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Srikanth Kotapati</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Srikanth++Kotapati">Srikanth Kotapati</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2302-5350" title="Orcid link">http://orcid.org/0000-0003-2302-5350</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Madhura Deshpande</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Madhura Deshpande</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Madhura++Deshpande">Madhura Deshpande</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chin Pan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chin Pan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chin++Pan">Chin Pan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel Menezes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel Menezes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Menezes">Daniel Menezes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yichong Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yichong Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yichong++Wang">Yichong Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chetana Rao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chetana Rao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chetana++Rao">Chetana Rao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ganapathy Sarma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ganapathy Sarma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ganapathy++Sarma">Ganapathy Sarma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bethanne M. Warrack</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bethanne M. Warrack</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bethanne+M.++Warrack">Bethanne M. Warrack</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vangipuram S. Rangan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vangipuram S. Rangan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vangipuram+S.++Rangan">Vangipuram S. Rangan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sung Mei-Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sung Mei-Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sung++Mei-Chen">Sung Mei-Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pina Cardarelli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pina Cardarelli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pina++Cardarelli">Pina Cardarelli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shrikant Deshpande</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shrikant Deshpande</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shrikant++Deshpande">Shrikant Deshpande</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Passmore</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Passmore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Passmore">David Passmore</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard Rampulla</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Rampulla</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Rampulla">Richard Rampulla</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Arvind Mathur</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Arvind Mathur</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Arvind++Mathur">Arvind Mathur</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert Borzilleri</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert Borzilleri</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Borzilleri">Robert Borzilleri</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Arvind Rajpal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Arvind Rajpal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Arvind++Rajpal">Arvind Rajpal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gregory Vite</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gregory Vite</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gregory++Vite">Gregory Vite</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Sanjeev Gangwar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sanjeev Gangwar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sanjeev++Gangwar">Sanjeev Gangwar</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01385&amp;href=/doi/10.1021%2Facs.jmedchem.0c01385" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 13913–13950</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 6, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 August 2020</li><li><span class="item_label"><b>Published</b> online</span>6 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01385" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01385</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D13913%26pageCount%3D38%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DNaidu%2BS.%2BChowdari%252C%2BYong%2BZhang%252C%2BIvar%2BMcDonald%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D22%26contentID%3Dacs.jmedchem.0c01385%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BStructure%25E2%2580%2593Activity%2BRelationships%2Bof%2BNovel%2BTetrahydroisoquinolino%2BBenzodiazepine%2BDimer%2BAntitumor%2BAgents%2Band%2BTheir%2BApplication%2Bin%2BAntibody%25E2%2580%2593Drug%2BConjugates%26numPages%3D38%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D13950%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01385"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1642</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01385" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Structure–Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody–Drug Conjugates&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Naidu&quot;,&quot;last_name&quot;:&quot;S. Chowdari&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Ivar&quot;,&quot;last_name&quot;:&quot;McDonald&quot;},{&quot;first_name&quot;:&quot;Walter&quot;,&quot;last_name&quot;:&quot;Johnson&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;R. Langley&quot;},{&quot;first_name&quot;:&quot;Prasanna&quot;,&quot;last_name&quot;:&quot;Sivaprakasam&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Mate&quot;},{&quot;first_name&quot;:&quot;Tram&quot;,&quot;last_name&quot;:&quot;Huynh&quot;},{&quot;first_name&quot;:&quot;Srikanth&quot;,&quot;last_name&quot;:&quot;Kotapati&quot;},{&quot;first_name&quot;:&quot;Madhura&quot;,&quot;last_name&quot;:&quot;Deshpande&quot;},{&quot;first_name&quot;:&quot;Chin&quot;,&quot;last_name&quot;:&quot;Pan&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Menezes&quot;},{&quot;first_name&quot;:&quot;Yichong&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Chetana&quot;,&quot;last_name&quot;:&quot;Rao&quot;},{&quot;first_name&quot;:&quot;Ganapathy&quot;,&quot;last_name&quot;:&quot;Sarma&quot;},{&quot;first_name&quot;:&quot;Bethanne&quot;,&quot;last_name&quot;:&quot;M. Warrack&quot;},{&quot;first_name&quot;:&quot;Vangipuram&quot;,&quot;last_name&quot;:&quot;S. Rangan&quot;},{&quot;first_name&quot;:&quot;Sung&quot;,&quot;last_name&quot;:&quot;Mei-Chen&quot;},{&quot;first_name&quot;:&quot;Pina&quot;,&quot;last_name&quot;:&quot;Cardarelli&quot;},{&quot;first_name&quot;:&quot;Shrikant&quot;,&quot;last_name&quot;:&quot;Deshpande&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Passmore&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Rampulla&quot;},{&quot;first_name&quot;:&quot;Arvind&quot;,&quot;last_name&quot;:&quot;Mathur&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Borzilleri&quot;},{&quot;first_name&quot;:&quot;Arvind&quot;,&quot;last_name&quot;:&quot;Rajpal&quot;},{&quot;first_name&quot;:&quot;Gregory&quot;,&quot;last_name&quot;:&quot;Vite&quot;},{&quot;first_name&quot;:&quot;Sanjeev&quot;,&quot;last_name&quot;:&quot;Gangwar&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;13913-13950&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01385&quot;},&quot;abstract&quot;:&quot;A series of tetrahydroisoquinoline-based benzodiazepine dimers were synthesized and tested for in vitro cytotoxicity against a panel of cancer cell lines. Structure–activity relationship investigation of various spacers guided by molecular modeling studies helped to identify compounds with picomolar activity. Payload 17 was conjugated to anti-mesothelin and anti-fucosylated monosialotetrahexosylganglioside (FucGM1) antibodies using lysosome-cleavable valine–citrulline dipeptide linkers via heterogeneous lysine conjugation and bacterial transglutaminase-mediated site-specific conjugation. In vitro, these antibody drug conjugates (ADCs) exhibited significant cytotoxic and target-mediated selectivity on human cancer cell lines. The pharmacokinetics and efficacy of these ADCs were further evaluated in gastric and lung cancer xenograft models in mice. Consistent pharmacokinetic profiles, high target specificity, and robust antitumor activity were observed in these models after a single dose of the ADC-46 (0.02 μmo&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01385&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01385" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01385&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01385" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01385&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01385" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01385&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01385&amp;href=/doi/10.1021/acs.jmedchem.0c01385" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01385" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01385" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01385%26sid%3Dliteratum%253Aachs%26pmid%3D33155811%26genre%3Darticle%26aulast%3DChowdari%26date%3D2020%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BStructure%25E2%2580%2593Activity%2BRelationships%2Bof%2BNovel%2BTetrahydroisoquinolino%2BBenzodiazepine%2BDimer%2BAntitumor%2BAgents%2Band%2BTheir%2BApplication%2Bin%2BAntibody%25E2%2580%2593Drug%2BConjugates%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D22%26spage%3D13913%26epage%3D13950%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292425" title="Oligomers">Oligomers</a>,</li><li><a href="/action/doSearch?ConceptID=290975" title="Biopolymers">Biopolymers</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/jmcmar.2020.63.issue-22/20201125/jmcmar.2020.63.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0041.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of tetrahydroisoquinoline-based benzodiazepine dimers were synthesized and tested for in vitro cytotoxicity against a panel of cancer cell lines. Structure–activity relationship investigation of various spacers guided by molecular modeling studies helped to identify compounds with picomolar activity. Payload <b>17</b> was conjugated to anti-mesothelin and anti-fucosylated monosialotetrahexosylganglioside (FucGM1) antibodies using lysosome-cleavable valine–citrulline dipeptide linkers via heterogeneous lysine conjugation and bacterial transglutaminase-mediated site-specific conjugation. In vitro, these antibody drug conjugates (ADCs) exhibited significant cytotoxic and target-mediated selectivity on human cancer cell lines. The pharmacokinetics and efficacy of these ADCs were further evaluated in gastric and lung cancer xenograft models in mice. Consistent pharmacokinetic profiles, high target specificity, and robust antitumor activity were observed in these models after a single dose of the ADC-<b>46</b> (0.02 μmol/kg).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72672" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72672" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Antibody drug conjugates (ADCs) are gaining momentum in drug discovery for cancer therapy.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> FDA approval of brentuximab vedotin,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> trastuzumab emtansine,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and gemtuzumab ozogamicin<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> for various cancers largely fueled research in this area in both academic laboratories and the pharmaceutical industry. The first two drugs contain tubulin inhibitor payloads auristatin and maytansinoid, while gemtuzumab ozogamicin contains a DNA cleaving payload, calicheamicin. Subsequently, four more ADCs were approved based on these payloads for other cancer indications.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5−7)</a> Most recently, camptothecin-based ADCs, sacituzumab govitecan,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and trastuzumab deruxtecan<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> were approved for the treatment of metastatic breast cancer.</div><div class="NLM_p">Identification of novel and potent payloads with different mechanisms of action is becoming increasingly important with the increasing prevalence of drug-resistant cancers.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Pyrrolo[2,1-<i>c</i>][1,4]benzodiazepines (PBDs) are naturally occurring compounds isolated from <i>Streptomyces</i> species and are known for their antitumor activity.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> PBDs have been shown to bind in the minor groove of DNA, where they covalently cross-link exocyclic amino groups of guanine. PBD dimers with increased potency and selective DNA interstrand cross-linking have subsequently been reported.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Recently, PBDs <b>1</b> and <b>2</b> were employed as potent payloads in several ADCs currently being evaluated in clinical trials.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> An indolinobenzodiazepinene dimer-based ADC is also in development.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">Based on molecular modeling studies, we envisioned that replacement of the pyrrolidine ring in PBD, <b>DC</b>-<b>81</b>, with tetrahydroisoquinoline (THIQ) would result in compound <b>3</b> with additional DNA binding to provide improved activity (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19">(16−19)</a> We report here our structure–activity relationship (SAR) findings for various THIQ-based dimers with different spacer lengths and functional groups. Finally, compound <b>17</b> was conjugated to anti-mesothelin and anti-FucGM1 antibodies using a lysosome-cleavable valine–citrulline dipeptide linker, and the ADCs were evaluated for antitumor activity in mouse xenograft models.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of benzodiazepine-based dimers and monomers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06464" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06464" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To understand the SAR of THIQ-based benzodiazepine dimers, we prepared a series of compounds with pyrrolidine and THIQ rings with different spacer lengths. These dimers were evaluated in human cellular proliferation assays using lung (H226), gastric (N87), ovarian (OVCAR3), and colon (HCT116) carcinoma cell lines. By coupling <b>DC</b>-<b>81</b> with monomer <b>3</b> using a five-carbon spacer, we obtained compound <b>4</b>, which exhibited subnanomolar potency across different cell lines (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). We maintained the <i>S</i> stereochemistry on the new monomer, which should facilitate tight binding in the minor groove, consistent with reported data for PBDs.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Addition of a dimethyl amino group resulted in compound <b>5</b> with reduced potency. Introduction of a double bond into a five-membered ring provided compound <b>6</b> with improved potency. Replacement of the methyl group on an endocyclic double bond with aryl groups followed by decreasing the spacer length to three-carbon provided compounds <b>7–9</b> that gave a three- to sixfold reduction in potency. Addition of a methoxy group resulted in compounds <b>8</b> and <b>9</b> with twofold improvement in potency. Swapping an NH<sub>2</sub> group from the pyrrolidine monomer to the THIQ monomer did not alter the activity (<b>8</b> vs <b>9</b>). In general, THIQ-based compounds had IC<sub>50</sub> values comparable to traditional PBD dimers.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Cytotoxicity Data for Representative Benzodiazepine Dimers (IC<sub>50</sub> in nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0034.gif" alt="" id="gr33" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Cancer cell lines were incubated with compounds for 72 h. IC<sub>50</sub> values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay. NA = not available.</p></div></div><div></div></div><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> summarizes our efforts on different aliphatic spacers. We prepared payloads with spacer lengths of three and five carbons. Compound <b>10</b>, with a three-carbon spacer showed subnanomolar potency. Introduction of an NH<sub>2</sub> group provided compounds <b>11</b> and <b>12</b> with twofold loss in potency. Compound <b>13</b> is a THIQ-benzodiazepine version of compound <b>2</b>. As originally hypothesized, the THIQ-benzodiazepine monomeric units in compound <b>13</b> showed some additional van der Waals contacts and CH−π interactions with the sugar-phosphate backbone in our DNA binding models compared to compound <b>2</b>, which has the classical PBD units. Compound <b>13</b> with a five-carbon spacer was found to be twofold more potent compared to compound <b>10</b> with the three-carbon spacer. The higher potency of compound <b>13</b> was attributed to better binding with the DNA (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Unlike the three-carbon spacer analogue <b>10</b>, the five-carbon spacer analogue <b>13</b> exhibited a fully extended conformation of the alkyl spacer and presented the THIQ-benzodiazepine monomeric units slightly differently in the minor groove. This may have impacted favorably the covalent linking with the guanine base and/or maximized the van der Waals contacts with the sugar-phosphate backbone in compound <b>13</b> relative to compound <b>10</b>. This phenomenon of higher potency for five-carbon spacers versus three-carbon spacers is in agreement with reported data for PBDs.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Unlike compound <b>11</b>, introduction of NH<sub>2</sub> groups for compounds with five-carbon spacers increased potency sixfold as shown in the case of <b>14</b> and <b>15</b>. Spacers with ether (<b>16</b>), amino (<b>17</b>), and amide (<b>18</b>) groups showed reduced activity. Hydroxy and methoxy substituents on pendent phenyl ring were well tolerated with retention of high potency. Ethylene glycol monomer (<b>21</b>) and dimer (<b>22</b>) substitution on the aryl moiety were also well tolerated. Glycine amide <b>23</b> exhibited 18-fold reduction in potency compared to <b>14</b>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Putative binding model of compound <b>13</b> illustrating the formation of interstrand covalent cross-linking in an 8-mer duplex DNA and ligand overlay of compounds <b>24</b>, <b>25</b>, and <b>26</b>. (A) Surface representation of compound <b>13</b> (green carbon) bound to DNA. Compound <b>13</b> fits snugly in the DNA minor groove because of its high shape complementarity. (B) Specific interactions exhibited by compound <b>13</b> are highlighted. Compound <b>13</b> is hypothesized to make covalent bonds with the exocyclic N2 amino groups of guanines on both strands through its C11/C11′ reactive centers. The hydrogen bonds between the N10/N10′ of compound <b>13</b> and carbonyl oxygens on C2 of cytosines (adjacent to the covalently modified guanines) are denoted as yellow dotted lines. The inset in B shows the nucleotide sequence of the 8-mer duplex DNA and the putative cross-linking and hydrogen bonding sites of compound <b>13</b> (magenta guanines and cyan cytosines, respectively). (C) Ligand overlay of optimized structures of compounds <b>24</b> (green), <b>25</b> (magenta), and <b>26</b> (blue). The green arc shows the angle of curvature provided by the central phenyl spacer to the two monomeric payload units in compound <b>24</b>. The magenta curve shows the slightly flattened corresponding angle of curvature in compound <b>25</b>. The blue curve shows the highly contracted angle of curvature in compound <b>26</b>. The 1,3-, 1,4-, and 1,2-attachment points in the central phenyl spacer for the two monomeric payload units create moderate to significant differences in the overall angle of curvatures in compounds <b>24</b>, <b>25</b>, and <b>26</b> to complement the curvature of the DNA minor groove. The figure was prepared using Pymol (The PyMOL Molecular Graphics System, Versions 1.6.1.0 and 2.0 Schrödinger, LLC).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Cytotoxicity Data for the Dimers with Aliphatic Spacers (IC<sub>50</sub> in nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0035.gif" alt="" id="GRAPHIC-d7e727-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0036.gif" alt="" id="gr34" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Cancer cell lines were incubated with compounds for 72 h. IC<sub>50</sub> values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.</p></div></div><div></div></div><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> summarizes dimers with aryl spacers. Introduction of a benzene ring into the spacer with metasubstitution provided compound <b>24</b> with more than threefold improvement in potency compared to its aliphatic sibling <b>13</b> with a pentyl spacer. This improvement in activity is likely attributed to the CH−π interactions exhibited by the phenyl spacer acceptor of <b>24</b> with the aliphatic CH donors from the sugar moieties in the DNA. <i>para</i> and <i>ortho</i> substitution resulted in compounds <b>25</b> and <b>26</b> with substantially reduced activity. Molecular modeling studies highlighted the high complementarity of the angle of curvature in the <i>meta</i>-phenyl spacer compound <b>24</b> with the DNA minor groove curvature (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). The <i>para</i>-phenyl spacer compound <b>25</b> loses its ideal geometry for the minor groove binding, and this may in part explain the reduced potency. The <i>ortho</i>-phenyl spacer compound <b>26</b> deviates the most from its ideal geometry to complement the minor groove resulted in significant loss of potency. One of the two payload units is precluded from binding in the minor groove because of the least optimal geometrical separation of the monomeric payload units in compound <b>26</b> relative to compounds <b>24</b> and <b>25</b>. Amino (<b>27</b>), azido (<b>28</b>), and azido methyl (<b>29</b>) groups are well tolerated on the benzene ring. These groups can provide another viable option for appending linkers through amide bond and click chemistry. We incubated compound <b>27</b> with a double-stranded DNA at 37 °C for 4 h and identified DNA a cross-linking adduct as confirmed by liquid chromatography–mass spectrometry (LCMS) (see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01385/suppl_file/jm0c01385_si_001.pdf" class="ext-link">Supporting Information</a>). This is similar to the findings reported by others for PBDs.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Cytotoxicity Data for the Dimers with Aromatic Spacers (IC<sub>50</sub> in nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0037.gif" alt="" id="GRAPHIC-d7e824-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0038.gif" alt="" id="gr35" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Cancer cell lines were incubated with compounds for 72 h. IC<sub>50</sub> values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.</p></div></div><div></div></div><div class="NLM_p">We then moved to introducing heterocyclic spacers (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), which could potentially help to improve aqueous solubility. Compound <b>30</b>, with pyridine in the spacer, exhibited activity similar to phenyl-containing compound <b>24</b>. Walking the nitrogen to other carbons on the ring did not impact the activity (<b>31</b> and <b>32</b>). Introduction of an amino group on one monomer (<b>33</b>) also did not alter the activity. Introduction of CO<sub>2</sub>Me (<b>34</b>), Cl (<b>35</b>), and OMe (<b>36</b>) groups at the para-position on the pyridine spacer was also well tolerated. Hydroxy (<b>37</b>) and hydroxymethyl (<b>38</b>) substituents reduced activity more than 100-fold. Methoxy substitution at the meta-position (<b>39</b>) also lost 40-fold activity compared to the para-position (<b>36</b>). Compound <b>40</b> with a pyrazine spacer showed excellent activity similar to pyridine analogues <b>30–32</b>. Pyrazine <b>41</b> with a para-linkage showed reduced activity compared to the meta-linkage, a trend similar to the aryl spacers observed for compounds <b>24–26</b> in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Furan (<b>42</b>) and thiophene (<b>43</b>) containing spacers resulted in significant loss in activity.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Cytotoxicity Data for the Dimers with Heterocyclic Spacers (IC<sub>50</sub> in nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0039.gif" alt="" id="GRAPHIC-d7e915-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0040.gif" alt="" id="gr36" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Cancer cell lines were incubated with compounds for 72 h. IC<sub>50</sub> values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.</p></div></div><div></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Antibody Drug Conjugates</h3><div class="NLM_p">In the literature, PBD payloads <b>1</b> and <b>2</b> were conjugated to antibodies using maleimide chemistry through reduced interchain disulfide bonds and engineered cysteines. Payload <b>1</b> was coupled with a protease cleavable valine–alanine dipeptide linker using C-2 aniline,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> whereas <b>2</b> was linked through the N10 position.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> We preferred valine–citrulline over valine–alanine because of more efficient enzymatic cleavage of the former dipeptide linker. From our SAR studies, we have chosen highly potent payload <b>14</b> and moderately potent payload <b>17</b> to append linkers for making conjugates. To evaluate these two payloads, we prepared lysosome cleavable valine–citrulline dipeptide linker-payload compounds <b>44</b> and <b>45</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) and conjugated to an antibody which targets the mesothelin antigen<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> using heterogeneous thiolated lysine conjugation. Mesothelin is a 40 kDa protein present on normal mesothelial cells and overexpressed in several human cancer types, including mesothelioma, ovarian, nonsmall cell lung, gastric, and pancreatic adenocarcinoma. Some of the lysines present on the antibody were modified with 2-iminothiolane (2-IT) to introduce thiol groups,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> which were then used to conjugate linker-payloads using a Michael reaction through the maleimide group. These mesothelin-targeted ADCs <b>44</b> and <b>45</b> were tested for in vitro cytotoxic activity on N87 cell lines and found to exhibit IC<sub>50</sub> of 0.01 and 0.04 nM, respectively. We have also prepared ADC-<b>45</b> with PEG 8, and in vitro cytotoxicity was found to be similar to ADC-<b>45</b> without PEG. The IC<sub>50</sub> value of ADC-<b>45</b> was 32-fold lower than the corresponding payload alone (1.28 nM), while ADC-<b>44</b> and its payload <b>14</b> (0.03 nM) did not show much difference between their in vitro activity profiles. To understand the discrepancy of ADC-<b>45</b> and its payload activity, we measured the permeability of payloads <b>14</b> and <b>17</b> using a parallel artificial membrane permeability assay and found them to be 335 and 0 nM/s, respectively. The moderate activity of payload <b>17</b> alone in cell lines is attributed to the poor permeability, whereas ADC-<b>45</b> exhibited higher potency by overcoming the permeability issue. We envisioned that ADCs derived from poorly permeable payloads might be beneficial in preventing the leakage of the payloads from the cancer cells to the neighboring healthy tissue, thereby avoiding bystander killing. In addition, any premature release of payload in the systemic circulation might cause less harm to healthy tissue. This prompted us to choose ADC-<b>45</b> for further evaluation in tumor xenograft models.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures of ADCs <b>44–48</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We were interested in site-specific conjugation to take advantage of any benefits that this might offer. In this regard, linker-payloads <b>46–48</b> with an amino handle were prepared for bacterial transglutaminase (BTGase)-mediated site-specific conjugation<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> with glutamine at the Q295 position on mesothelin antibody. Antibodies with a glutamine handle were generated by insertion of an EEQYASTY tag at the Q295 position through N297A mutation.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Site-specific conjugation was then achieved using a BTGase enzyme-mediated transamidation with amine containing linker-payloads, producing ammonia as a byproduct. Linker-payloads <b>45–48</b> were conjugated to anti-mesothelin, anti-CD70,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and anti-FucGM1 antibodies,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> which specifically bind to target antigens expressed on N87 gastric cancer (mesothelin+), 786-O renal cell carcinoma (CD70+), and H187 (FucGM1+) lung carcinoma cell lines, respectively. Having the payload conjugated to three different antibodies, tools have been used to evaluate cytotoxicity in multiple tumor models and to examine the specificity and selectivity of this targeting approach (i.e., ADC with targeted antibody vs nontargeting antibody and assessments in cell lines with and without the respective target antigens). Lysine conjugation provided heterogeneous ADCs with an average drug to antibody ratio (DAR) of 1 for ADC-<b>44</b> and 3 for ADC-<b>45</b>, whereas site-specific conjugation provided homogeneous ADCs with a DAR of 2. First, we tested the mesothelin-targeted ADCs <b>45–48</b> for cytotoxic activity on N87 cell lines with IC<sub>50</sub> in the range of 0.02–0.08 nM (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). We did not observe significant differences in in vitro potencies between the heterogeneous conjugate <b>45</b> and homogeneous site-specific conjugates <b>46–48</b>. Nontargeting anti-CD70-<b>45</b> and anti-FucGM1-<b>45</b> showed significantly lower activity on the N87 cell line with IC<sub>50</sub> of 9.9 and 9.2 nM, respectively, confirming more than 200-fold specificity of the anti-mesothelin ADCs. Next, to confirm if these ADCs could be cleaved enzymatically using a lysosomal protease cathepsin B, ADC incubations were performed with cathepsin B in the 2-morpholinoethanesulfonic acid (MES) buffer (pH 5.5) at 37 °C for 4 h. These data revealed that >70% of payload was cleaved within 4 h, indicating that they are good substrates for enzyme binding at the cleavage site. To determine stability in vitro, ADCs were incubated in mouse serum at 37 °C for 24 h and found to be generally stable with minimal loss of payload (<3%). Site-specific conjugates with deeply embedded payloads are relatively more stable in serum compared to the heterogeneous conjugates, with their greater surface exposure of payloads.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro Stability and Cytotoxicity Data for the Anti-mesothelin ADCs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">% payload released</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ADC</th><th class="colsep0 rowsep0" align="center">PEG</th><th class="colsep0 rowsep0" align="center" char=".">DAR<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">cathepsin B digestion<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">mouse serum<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> for N87 cells (nM)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>meso</i>-<b>45</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">83</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>meso</i>-<b>46</b></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">73</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>meso</i>-<b>47</b></td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">85</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>meso</i>-<b>48</b></td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">DAR = drug–antibody ratio was measured by UV spectroscopy and LC–MS methods.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">ADCs were incubated with cathepsin B enzyme in MES buffer (pH 5.5) at 37 °C for 4 h and the cleaved payload was quantified by the LC–MS/MS MRM method.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">ADCs incubated in mouse serum at 37 °C for 24 h and the released payload was quantified using the LC–MS/MS MRM method.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Cancer cell lines were incubated with compounds for 72 h. IC<sub>50</sub> values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.</p></div></div></div><div class="NLM_p">We then evaluated these ADCs in preclinical studies to characterize their pharmacokinetics (PKs), tolerability, and efficacy profiles. Unconjugated anti-mesothelin antibody (1 mg/kg) and its conjugates ADC-<b>45</b> and ADC-<b>46</b> (0.02 μmol/kg) were administered to mice intraperitoneally (IP). Plasma samples were collected at various time points post single-dose administration and subject to quantitative ELISA and mass spectrophotometry analyses. Unconjugated antibody in circulation was assessed using an antihuman IgG reagent. ADC-conjugated payload was measured using 19H9 and 20F7 antibodies that recognized the drug-linker component of ADC. ADC-<b>45</b> prepared through heterogeneous lysine conjugation has a plasma half-life of 6 days compared to its unconjugated antibody counterpart, which has a half-life of 10 days (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Site-specific ADCs have shown a longer half-life of 16 days. We did not observe a difference between the half-life of ADC-<b>46</b> and its corresponding unconjugated antibody. In general, heterogeneous conjugates were cleared almost threefold faster than the corresponding site-specific conjugates.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plasma PK disposition of heterogeneous ADC-<b>45</b> (A) and site-specific ADC-<b>46</b> (B). Concentration of total ADC and unconjugated antibodies in plasma was determined with an ELISA-based quantitative assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next focused on evaluating these ADCs for toxicity and efficacy in preclinical models in vivo (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). A single IP dose of ADC-<b>45</b> to wild-type BALB/c mice demonstrated that ADCs were well tolerated up to the maximal dose tested of 0.05 μmol/kg corresponding to 2.5 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). No significant body weight loss was observed relative to vehicle-treated mice. In addition, no clinical symptoms of adverse tolerability were reported in mice. In vivo efficacy studies were conducted in a mesothelin-expressing N87 human gastric tumor xenograft model in SCID mice. Targeted anti-mesothelin ADC-<b>45</b> was administered at doses of 0.005, 0.02, and 0.05 μmol/kg. Anti-FucGM1 ADC-<b>45</b> was administered with 0.02 μmol/kg dose and served as a nontargeted, isotype-ADC control. Treatment with anti-mesothelin ADC-<b>45</b> resulted in a dose-dependent antitumor activity against N87 tumors (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). The mice that received an ADC dose of 0.005 μmol/kg elicited a partial tumor response, whereas doses of 0.05 μmol/kg resulted in complete tumor regression. While the anti-mesothelin ADC-<b>45</b> significantly inhibited tumor growth, the nontargeted anti-FucGM1 ADC-<b>45</b> demonstrated partial tumor growth inhibition at a dose of 0.02 μmol/kg, thus confirming immunological specificity. In the case of site-specific ADCs, we prepared ADCs with PEG lengths of 2 (ADC-<b>46</b>), 4 (ADC-<b>47</b>), and 8 (ADC-<b>48</b>). To examine the impact of varying ADC PEG length on tolerability, mice were then administered a single IP dose of 0.05 μmol/kg. Mice treated with PEG 2 and 4 ADCs showed <10% body weight loss, while those treated with the PEG 8 ADC exhibited >10% body weight loss (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Although we did not see the effect of PEG length on mouse serum stability in vitro over 24 h (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), PEG 8 ADC lost its payload overtime in circulation, causing associated toxicity. Thus, we selected PEG 2-incorporated anti-mesothelin ADC-<b>46</b> for further efficacy evaluation. In the N87 gastric tumor xenograft model, mice were administered a single IP dose of either 0.005, 0.02, or 0.05 μmol/kg of meso-<b>46</b> ADC, and tumor volume measurements were performed over the 60 day study duration (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Dose-responsive antitumor activity in vivo was observed with meso-<b>46</b> ADC against N87 tumors. Mice that received doses of 0.02 and 0.05 μmol/kg showed complete tumor regression, whereas those that had received the 0.005 μmol/kg dose showed a partial response. From a comparison across studies, the site-specific ADCs appeared twofold more potent when compared with their heterogeneous ADC counterparts at similar doses. The higher efficacy observed with site-specific conjugates may be attributed to the higher stability and drug exposure because of lack of competitive inhibition of antigen resulting from DAR 1 and unconjugated antibody species, which are known to negatively impact heterogeneous conjugates.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Percent body weight change from randomization of wild-type BALB/c mice treated with 0.005, 0.02, and 0.05 μmol/kg single dose of anti-Meso-<b>45</b>. (B) In vivo antitumor activity of the anti-Meso-<b>45</b> in N87 gastric xenograft cancer model in SCID mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Percent body weight change from randomization after a single administration of 0.05 μmol/kg of site-specific anti-mesothelin ADCs with varying PEG lengths in the N87 gastric tumor xenograft model in SCID mice. (B) In vivo antitumor activity of site-specific anti-mesothelin ADC-<b>46</b> in the N87 xenograft model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To demonstrate the broader scope of the ADC activity across tumor models, efficacy was explored in a SCLC tumor model. FucGM1 is highly expressed in a large subset of SCLC cancers,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> wherein therapeutic antibodies were previously developed against this target. To further improve the therapeutic benefit of these anti-FucGM1 antibodies, linker-payloads <b>45–48</b> were conjugated to generate anti-FucGM1-ADCs. FucGM1 ADCs were tested for cellular activity on the FucGM1-expressing H187 SCLC cell line in vitro. H187 cells do not express mesothelin and CD70, and hence, anti-mesothelin and anti-CD70 ADCs were used as nonbinding, isotype specific controls. FucGM1 ADCs <b>45–48</b> showed good in vitro potency (IC<sub>50</sub> = 1–3.5 nM) compared to isotype control ADCs (IC<sub>50</sub> = 10–100 nM) (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). The potency of FucGM1 ADCs against H187 SCLC cells was more than 10-fold lower compared to anti-mesothelin ADCs against N87 gastric cells (the IC<sub>50</sub> value ranged from 0.02 to 0.08 nM, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). This may be attributed to the lower expression density and kinetics of receptor internalization of FucGM1 on H187 SCLC cells.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vitro Antitumor Activity of ADCs on H187 Cells</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ADC</th><th class="colsep0 rowsep0" align="center">PEG</th><th class="colsep0 rowsep0" align="center" char=".">DAR<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>FucGM1</i>-45</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>CD70</i>-45</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="left">10.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>FucGM1</i>-46</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="left">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>meso</i>-46</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>FucGM1</i>-47</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="left">3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>meso</i>-47</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="left">37.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>FucGM1</i>-48</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="left">1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>meso</i>-48</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="left">26</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">DAR = drug–antibody ratio was measured by UV spectroscopy and LC–MS methods.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Cancer cell lines were incubated with compounds for 72 h. IC<sub>50</sub> values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.</p></div></div></div><div class="NLM_p">To examine the efficacy of anti-FucGM1 ADC-<b>45</b>, mice were dosed with a single IP administration of 0.01, 0.03, or 0.06 μmol/kg, and tumor growth was monitored for 55 days (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). While ADC-<b>45</b> dosed at 0.01 μmol/kg elicited significant tumor growth inhibition, the higher doses of 0.03 and 0.06 μmol/kg demonstrated strong and durable antitumor activity (seen as complete tumor regressions). Nontargeting anti-CD70-<b>45</b> ADC administered at 0.01 μmol/kg, although exhibiting some partial inhibition of tumor growth, induced less activity than an equivalent dose of FucGM1ADC-<b>45</b>. To compare the efficacy of heterogeneous lysine conjugates of FucGM1 ADC-<b>45</b> to the site-specific FucGM1 ADC-<b>46</b>, H187 tumor-bearing mice were treated with 0.02 and 0.005 μmol/kg of each ADC (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). At each of the dose levels tested, the site-specific ADCs were more efficacious compared to the heterogeneous lysine conjugates.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) In vivo antitumor activity of anti-FucGM1-<b>45</b> ADC in the H187 SCLC xenograft model. (B) In vivo antitumor activity of anti-FucGM1-<b>45</b> ADC vs site-specific anti-FucGM1-<b>46</b> ADC in the H187 SCLC xenograft model in SCID mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51626" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51626" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Synthesis of Payloads</h3><div class="NLM_p">Payloads <b>4–43</b> were prepared as depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> using three common intermediates <b>49–51</b> and various alkyl, aryl, and heteroaromatic spacers (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). SEM and Alloc protecting groups were chosen because of their robustness in later stage transformations for the synthesis of payloads and linker-payloads. Payloads were assembled from monomers through alkylation or a Mitsunobu reaction using various spacers. Dimers with SEM-protecting groups were reduced with LiBH<sub>4</sub> or LiEt<sub>3</sub>BH (superhydride), followed by mild acid treatment (silica gel or formic acid) to obtain bis-imine compounds. In the case of Alloc-protected compounds, Pd(PPh<sub>3</sub>)<sub>4</sub> in the presence of pyrrolidine or morpholine was used for deprotection to prepare bis-imine compounds.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Monomers and spacers employed in this work.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Retrosynthetic Analysis of Benzodiazepine Dimers</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Monomer <b>49</b> was prepared in five steps from nitro ester derivative <b>52</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Compound <b>52</b> was treated with aqueous NaOH at 50 °C for 5 h to provide acid <b>53</b>, which was reacted with oxalyl chloride, followed by quinoline derivative <b>54</b> to obtain amide <b>55</b> in 98% yield. The latter was treated with Zn/NH<sub>4</sub>Cl to provide reductive cyclization product <b>56</b> in 96% yield. The SEM-protecting group was installed using NaH as the base to provide <b>58</b>, which was subjected to debenzylation under palladium-catalyzed hydrogenation to obtain monomer <b>49</b> in 83% yield.</div><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of SEM Monomer <b>49</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaOH, THF–water, 50 °C, 5 h, 100%; (b) (1) (COCl)<sub>2</sub>, THF, DMF, rt, 2 h; (2) <b>54</b>, Et<sub>3</sub>N, THF, 4 h, 98%; (c) Zn, NH<sub>4</sub>Cl, MeOH, 50 °C, 16 h, 96%; (d) <b>57</b>, NaH, DMF, rt, 1 h, 78%; (d) 10% Pd/C, H<sub>2</sub>, EtOH, rt, 3 h, 83%.</p></p></figure><div class="NLM_p">Monomer <b>50</b> was prepared as shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Quinoline derivative <b>59</b> was protected with TBS to furnish <b>60</b>, which was reacted with benzoic acid derivative <b>61</b> using HATU coupling to give amide <b>62</b> in 66% yield. The nitro group was reduced with Zn/NH<sub>4</sub>Cl and protected with Alloc to provide compound <b>64</b>. The TBS-protecting group was removed by treatment with methanolic HCl to obtain <b>65</b>, which was subjected to Swern oxidation to obtain compound <b>66</b> in 92% yield. The hydroxyl group was protected with TBS using the TBS-OTf reagent in the presence of 2,6-lutidine to give fully protected compound <b>67</b> in 97% yield. Selective TIPS deprotection in the presence of TBS was accomplished with lithium acetate in DMF–water to provide Alloc monomer <b>50</b> in 71% yield.</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Alloc Monomer <b>50</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TBSCl, imidazole, CH<sub>3</sub>CN, rt, 1.5 h, 68%; (b) <b>61</b>, HATU, DCM, <i>i</i>-Pr<sub>2</sub>NEt, rt, 24 h, 66%; (c) Zn, NH<sub>4</sub>Cl, MeOH, rt, 24 h, 83%; (d) allyl chloroformate, pyridine, DCM, −78 °C to rt, 1 h, 88%; (e) HCl, MeOH, 20 min, rt, 84%; (f) (COCl)<sub>2</sub>, DMSO, DCM, −78 °C to rt, 30 min, 92%; (g) TBS-OTf, 2,6-lutidine, 0 °C, 30 min, 97%; (h) LiOAc, DMF–water, rt, 16 h, 71%.</p></p></figure><div class="NLM_p">Monomer <b>51</b> was prepared as shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Commercially available amino acid <b>68</b> was esterified with ethanol in the presence of sulfuric acid to provide <b>69</b>, which was subjected to nitration to furnish <b>70</b> in 91% yield. Compound <b>53</b> was converted to acid chloride and coupled with <b>70</b> to provide amide <b>71</b>, which was subjected to Zn-promoted reduction of both nitro groups to give cyclization product <b>72</b> in 82% yield. Trityl protection provided <b>73</b>, which was subsequently protected with SEM to obtain <b>74</b> in 80% yield. Trityl and benzyl protecting groups were removed using palladium-catalyzed hydrogenation to obtain <b>75</b>. Bis Alloc protection followed by selective hydrolysis of phenolic carbonate with LiOH provided monomer <b>51</b> with 75% yield.</div><figure id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Monomer <b>51</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) H<sub>2</sub>SO<sub>4</sub>, EtOH, 80 °C, 20 h, 83%; (b) H<sub>2</sub>SO<sub>4</sub>, HNO<sub>3</sub>, −5 °C, 30 min, 91%; (c) (1) <b>53</b>, (COCl)<sub>2</sub>, THF, DMF, rt, 2 h; (2) <b>70</b>, Et<sub>3</sub>N, THF, rt, 30 min, 78%; (d) Zn, NH<sub>4</sub>Cl, MeOH, 50 °C, 16 h, 82%; (e) Trityl-Cl, Et<sub>3</sub>N, DCM, rt, 3 h, 88%; (f) SEM-Cl, NaH, DMF, 0 °C to rt, 2 h, 80%; (g) 10% Pd/C, H<sub>2</sub>, EtOAc, rt, 2 days, 90%; (h) (1) allyl chloroformate, Et<sub>3</sub>N, 0 °C, 2 h; (2) LiOH, MeOH–water, rt, 16 h, 75%.</p></p></figure><div class="NLM_p">Payload <b>4</b> was synthesized as shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Monomer <b>49</b> was treated with 1,5-diiodopentane <b>4a</b> (5 equiv) in the presence of K<sub>2</sub>CO<sub>3</sub> at room temperature for 2 h to obtain monoalkylated compound <b>4b</b> in 77% yield. Compound <b>4b</b> was coupled with a known lactam <b>4c</b><a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> in the presence of K<sub>2</sub>CO<sub>3</sub> and treated with SEM-Cl to obtain compound <b>4e</b> in 20% yield over two steps. Dimer <b>4e</b> was subjected to LiBH<sub>4</sub> reduction, followed by silica gel treatment to obtain payload <b>4</b>.</div><figure id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Payload <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 2 h, 77%; (b) <b>4c</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C, 2 h; (c) SEM-Cl, NaH, DMF, 0 °C to rt, 2 h, 20%; (d) (1) LiBH<sub>4</sub>, THF, −78 °C, 1 h; (2) Silica gel, CHCl<sub>3</sub>–EtOH–water, 24 h, 9%.</p></p></figure><div class="NLM_p">Payload <b>5</b> was prepared as described in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. Compound <b>72</b> was subjected to reductive amination with formaldehyde in the presence of sodium cyanoborohydride to obtain dimethylamino compound <b>5a</b> in 98% yield. This was treated with SEM-Cl in the presence of NaH followed by debenzylation using Pd/C to provide compound <b>5c</b> in 76% yield. This was reacted with <b>5d</b> in the presence of K<sub>2</sub>CO<sub>3</sub> to obtain SEM-dimer <b>5e</b> in 82% yield. LiBH<sub>4</sub> reduction followed by silica gel treatment provided payload <b>5</b> in 44% yield.</div><figure id="sch6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Payload <b>5</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>72</b>, NaBH<sub>3</sub>CN, formaldehyde, AcOH, THF, rt, 2 h, 98%; (b) SEM-Cl, NaH, DMF, rt, 16 h; (c) 10% Pd/C, H<sub>2</sub>, EtOH/EtOAc, rt, 4 h, 76%; (d) <b>5d</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 14 h, 82%; (e) (1) LiBH<sub>4</sub>, THF, −78 °C, 2 h; (2) Silica gel, CHCl<sub>3</sub>–EtOH–water, 24 h, 44%.</p></p></figure><div class="NLM_p">Payload <b>6</b> was synthesized as shown in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. Monomer <b>50</b> was reacted with 1,5-diiodopentane in the presence of K<sub>2</sub>CO<sub>3</sub> to provide <b>6a</b> in 88% yield. This was coupled with PBD monomer <b>6b</b><a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> in the presence of K<sub>2</sub>CO<sub>3</sub> in DMF at 60 °C for 3 h to obtain dimer <b>6c</b> in 66% yield which was treated with Pd(PPh<sub>3</sub>)<sub>4</sub> and pyrrolidine to give payload <b>6</b> in 41% yield.</div><figure id="sch7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Payload <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1,5-diiodopentane, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 40 min, 88%; (b) <b>6b</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C, 3 h, 66%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, rt, 12 h, 41%.</p></p></figure><div class="NLM_p">Payload <b>7</b> was prepared as depicted in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>. Monomer <b>7b</b> was reacted with 1,3-dibromopropane <b>7a</b> in the presence of K<sub>2</sub>CO<sub>3</sub> to provide <b>7c</b> in 83% yield. The latter was reacted with monomer <b>49</b> in the presence of K<sub>2</sub>CO<sub>3</sub> to obtain alcohol <b>7d</b> in 80% yield. Swern oxidation provided ketone <b>7e</b> in 88% yield which was treated with trifluoromethanesulfonic anhydride in the presence of 2,6-lutidine to give triflate <b>7f</b> in 45% yield. This was subjected to Suzuki coupling with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline in the presence of the PdCl<sub>2</sub>(dppf) catalyst to provide <b>7g</b> in 69% yield. Superhydride reduction followed by formic acid treatment provided payload <b>7</b> in 37% yield.</div><figure id="sch8" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Payload <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>7a</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 3 h, 83%; (b) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 4 h, 80%; (c) (COCl)<sub>2</sub>, DMSO, Et<sub>3</sub>N, DCM, −78 to 0 °C, 15 min, 88%; (d) Tf<sub>2</sub>O, 2,6-lutidine, DCM, −78 to −30 °C, 3 h, 45%; (e) 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, PdCl<sub>2</sub>(dppf), 35 °C, 1 h, 69%; (f) (1) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h; (2) HCO<sub>2</sub>H, THF–EtOH–water, rt, 6 h, 37%.</p></p></figure><div class="NLM_p">Payload <b>8</b> was synthesized as shown in <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>. Acid <b>53</b> was treated with oxalyl chloride and coupled with amine <b>8a</b> to obtain amide <b>8b</b> in 68% yield, which was subjected to Zn/NH<sub>4</sub>Cl reduction to provide lactam <b>8c</b> in 82% yield. Protection of the phenolic group with tetrahydropyran in the presence of pyridinium <i>p</i>-toluenesulfonate (PPTS) in DCM provided <b>8d</b> in 77% yield. The latter was reacted with SEM-Cl in the presence of NaH to provide <b>8e</b> in 58% yield, which was subjected to debenzylation with Pd/C in the presence of hydrogen to give <b>8f</b> in 64% yield. This was treated with <b>7c</b> in the presence of K<sub>2</sub>CO<sub>3</sub> followed by THP deprotection with PPTS in methanol that provided <b>8g</b> in 91% yield. Thus, reaction of <b>8g</b> with iodomethane in the presence of K<sub>2</sub>CO<sub>3</sub> followed by oxidation with sulfur trioxide–pyridine provided <b>8i</b> in 52% yield. This was treated with trifluoromethanesulfonic anhydride in the presence of 2,6-lutidine to provide triflate <b>8j</b> in 63% yield, which was subjected to Suzuki coupling with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline in the presence of the PdCl<sub>2</sub>(dppf) catalyst to give <b>8k</b> in 63% yield. Superhydride reduction followed by formic acid treatment afforded payload <b>8</b> in 38% yield.</div><figure id="sch9" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Payload <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) <b>53</b>, (COCl)<sub>2</sub>, THF, rt, 2 h; (2) <b>8a</b>, Et<sub>3</sub>N, 0 °C, 2 h, 68%; (b) Zn, NH<sub>4</sub>Cl, MeOH, 50 °C, 16 h, 82%; (c) THP, PPTS, THF, rt, 16 h, 77%; (d) SEM-Cl, NaH, DMF, rt, 1 h, 58%; (e) 10% Pd/C, H<sub>2</sub>, EtOAc, rt, 2 h, 64%; (f) <b>7c</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 16 h, 91%; (g) MeI, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 16 h; (h) Pyr-SO<sub>3</sub>, DCM, rt, 16 h, 52%; (i) Tf<sub>2</sub>O, 2,6-lutidine, DCM, −78 to 0 °C, 2 h, 63%; (j) 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, PdCl<sub>2</sub>(dppf), K<sub>3</sub>PO<sub>4</sub>, THF, 45 °C, 2 h, 63%; (f) (1) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h; (2) HCO<sub>2</sub>H, THF–EtOH–water, rt, 2 h, 38%.</p></p></figure><div class="NLM_p">Payload <b>9</b> was prepared as described in <a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>. Monomer <b>51</b> was treated with <b>7c</b> in the presence of K<sub>2</sub>CO<sub>3</sub> in DMSO to provide alcohol <b>9a</b> in 91% yield, which was subjected to Swern oxidation to give ketone <b>9b</b> in 79% yield. The latter was treated with trifluoromethanesulfonic anhydride in the presence of 2,6-lutidine to provide triflate <b>9c</b> in 60% yield. Suzuki coupling of <b>9c</b> with (4-methoxyphenyl)boronic acid in the presence of PdCl<sub>2</sub>(dppf) catalyst provided <b>9d</b> in 93% yield. Superhydride reduction followed by silica gel treatment gave payload <b>9</b> in 39% yield.</div><figure id="sch10" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0019.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Payload <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>7c</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 5 h, 91%; (b) (COCl)<sub>2</sub>, DMSO, Et<sub>3</sub>N, DCM, −78 to 0 °C, 15 min, 79%; (c) Tf<sub>2</sub>O, 2,6-lutidine, DCM, −78 to −10 °C, 20 min, 60%; (d) (4-methoxyphenyl)boronic acid, PdCl<sub>2</sub>(dppf), K<sub>3</sub>PO<sub>4</sub>, THF, 35 °C, 2 h, 93%; (e) (1) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h; (2) Silica gel, CHCl<sub>3</sub>–EtOH–water, 3 days, 39%.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a> shows a general synthesis of symmetric dimer payloads from aliphatic spacers and monomer <b>49</b>. Thus, spacer <b>7a</b> was treated with monomer <b>49</b> in the presence of K<sub>2</sub>CO<sub>3</sub> at room temperature to obtain SEM-protected dimer <b>10b</b>. Reduction with LiBH<sub>4</sub> and subsequent treatment with silica gel provided payload <b>10</b> in 50% yield. In a similar fashion, payloads <b>13</b>, <b>16</b>, and <b>17</b> were prepared from the corresponding spacers <b>4a</b>, <b>16a</b>, and <b>17a</b>.</div><figure id="sch11" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0020.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Payloads <b>10</b>, <b>13</b>, <b>16</b>, and <b>17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>; (b) Pd(PPh<sub>3</sub>)<sub>4</sub>, morpholine, THF, rt, 2 h, 70%; (c) (1) LiBH<sub>4</sub> or LiEt<sub>3</sub>BH; (2) Silica gel, CHCl<sub>3</sub>–EtOH–water.</p></p></figure><div class="NLM_p">A typical synthesis of nonsymmetric dimer payloads was described in <a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>. Monomer <b>49</b> was reacted with 1,3-dibromopropane in the presence of K<sub>2</sub>CO<sub>3</sub> to obtain monoalkylated compound <b>11a</b>, which was further reacted with monomer <b>51</b> to obtain fully protected dimer <b>11b</b> in 92% yield. The Alloc group was removed using Pd(PPh<sub>3</sub>)<sub>4</sub> and morpholine to provide <b>11c</b>. The latter was reduced with superhydride, and subsequent treatment with silica gel provided payload <b>11</b> in 27% yield. Payloads <b>14</b> and <b>19</b> were prepared in a similar fashion. Phenol containing dimer <b>19a</b> was prepared from <b>4b</b> by reaction with monomer <b>8f</b> and subsequent deprotection of the THP group with PPTS in MeOH. Alkylation of <b>19a</b> with MeI, 2-bromoethanol, and 1-bromo-2-(2-methoxyethoxy)ethane followed by reduction provided payloads <b>20–22</b>, respectively. Payload <b>14</b> was coupled with Fmoc-glycine in the presence of HATU and deprotected with piperidine to give payload <b>23</b>.</div><figure id="sch12" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0021.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of Payloads <b>11</b>, <b>14</b>, and <b>19–23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 1–2 h; (b) <b>51</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 1–5 h; <b>19a</b>: (1) <b>8f</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 5 h (2) PPTS, MeOH, 40 °C, 1 h, 72%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, morpholine, DCM, 2 h; (d) MeI, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 3 h; (e) 2-bromoethanol, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 4 h; (f) 1-bromo-2-(2-methoxyethoxy)ethane, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 3 h; (g) (1) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h; (2) silica gel, CHCl<sub>3</sub>–EtOH–water, 24 h. (h) (1) Fmoc-Gly-OH, HATU, <i>i</i>-Pr<sub>2</sub>NEt, DMF, rt, 4 h; (2) piperidine, DMF, rt, 1 h.</p></p></figure><div class="NLM_p">Payloads <b>12</b>, <b>15</b>, and <b>18</b> were prepared as shown in <a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>. Dimerization of monomer <b>51</b> using spacers <b>4a</b> and <b>7a</b> in the presence of K<sub>2</sub>CO<sub>3</sub> followed by Alloc deprotection provided <b>12a</b> and <b>15a</b>. Thus, <b>15a</b> was converted to dimethylamino intermediate <b>15b</b> through mono Alloc protection/reductive amination/Alloc deprotection sequence. The dimer <b>18e</b> with the amide spacer was assembled from <b>18c</b> by chloroacetylation, followed by alkylation of monomer <b>51</b>. The monomer <b>18c</b> was constructed from tosylate <b>18a</b> through alkylation of <b>49</b>, followed by Cbz-protecting group removal with Pd/C.</div><figure id="sch13" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0022.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of Payloads <b>12</b>, <b>15</b>, and <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 2 h; (b) 10% Pd/C, H<sub>2</sub>, MeOH, rt, 5 h, 86%; (c) ClCH<sub>2</sub>COCl, Et<sub>3</sub>N, DCM, rt, 1 h; (d) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, 50 °C, 4 h, 73%; (e) (1) <b>51</b>, K<sub>2</sub>CO<sub>3</sub>, rt, 1–6 h; (2) Pd(PPh<sub>3</sub>)<sub>4</sub>, morpholine, DCM; (f) (1) Alloc-Cl, Et<sub>3</sub>N, THF, rt, 3 h, 85%; (2) NaBH<sub>3</sub>CN, formaldehyde, AcOH, MeOH/THF, rt, 15 h, 85%; (3) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, 15 h, 86%; (g) (1) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h; (2) silica gel, CHCl<sub>3</sub>–EtOH–water, rt, 24 h.</p></p></figure><div class="NLM_p">Payloads with aryl spacers were assembled, as described in <a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>. Monomer <b>29b</b> was prepared from <b>66</b> by TIPS deprotection with LiOAc in DMF/water. The reaction of <b>29b</b> with spacer <b>29a</b> in the presence of Cs<sub>2</sub>CO<sub>3</sub> gave dimer <b>29c</b>, whereas dimers <b>24b</b> and <b>28b</b> were prepared from the corresponding spacers <b>24a</b> and <b>28a</b> by reaction with monomer <b>50</b>. Bromide <b>29c</b> was converted to azide <b>29d</b>, followed by treatment of these dimers with Pd(PPh<sub>3</sub>)<sub>4</sub>/pyrrolidine, which provided payloads <b>24</b>, <b>28</b>, and <b>29</b>.</div><figure id="sch14" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0023.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Synthesis of Payloads <b>24</b>, <b>28</b>, and <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LiOAc, DMF/water, rt, 15 h, 94%; (b) <b>29a</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 2 h; (c) <b>50</b>, Cs<sub>2</sub>CO<sub>3</sub>, acetone, 40 °C, 1 h; (d) NaN<sub>3</sub>, DMF, rt, 15 h; (e) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, rt, 30–90 min.</p></p></figure><div class="NLM_p">Payloads with para-substituted aryl spacers were synthesized as shown in <a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>. Spacers <b>25a</b> and <b>41a</b> were treated with monomer <b>50</b> in the presence of K<sub>2</sub>CO<sub>3</sub> to provide protected dimers <b>25b</b> and <b>41b</b>, respectively. Alloc and TBS groups were removed using Pd(PPh<sub>3</sub>)<sub>4</sub> in the presence of pyrrolidine to give payloads <b>25</b> and <b>41</b>.</div><figure id="sch15" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0024.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Synthesis of Payloads <b>25</b> and <b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>50</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (b) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, rt, 1.5 h.</p></p></figure><div class="NLM_p">Payload <b>26</b> with an ortho-substituted aryl spacer was prepared as described in <a class="ref internalNav" href="#sch16" aria-label="Scheme 16">Scheme 16</a>. Spacer <b>26a</b> was treated with monomer <b>50</b> in the presence of Cs<sub>2</sub>CO<sub>3</sub> to provide protected dimer <b>26b</b>, which was subjected to deprotection with Pd(PPh<sub>3</sub>)<sub>4</sub> and pyrrolidine to give payload <b>26</b>.</div><figure id="sch16" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0025.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of Payload <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>50</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 1 h; 88% (b) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, rt, 1.5 h, 39%.</p></p></figure><div class="NLM_p">Payload <b>27</b> with an aniline spacer was synthesized as shown in <a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>. Nitro compound <b>27a</b> was reduced with 10% Pd/C and protected with Alloc–Cl to provide compound <b>27b</b>. This was reacted with mesyl chloride to obtain bis-mesylate <b>27c</b>, which was subjected to alkylation with monomer <b>49</b> in the presence of K<sub>2</sub>CO<sub>3</sub> at room temperature for 2 h to give SEM-protected dimer <b>27d</b>. The Alloc group was removed with Pd(PPh<sub>3</sub>)<sub>4</sub> in the presence of morpholine to provide <b>27e</b> in 87% yield. Reduction with LiBH<sub>4</sub> and subsequent treatment with silica gel provided payload <b>27</b> in 46% yield.</div><figure id="sch17" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0026.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of Payloads <b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) 10% Pd/C, H<sub>2</sub>, MeOH, rt, 5 h; (2) Alloc-Cl, K<sub>2</sub>CO<sub>3</sub>, THF, rt, 3 h, 22%; (b) mesyl chloride, Et<sub>3</sub>N, −10 °C, 1 h, 95%; (c) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 2 h; 66% (d) Pd(PPh<sub>3</sub>)<sub>4</sub>, morpholine, DCM, 0 °C, 2 h, 87%; (e) (1) LiBH<sub>4</sub>, THF/EtOH, rt, 2 h; (2) silica gel, CHCl<sub>3</sub>–EtOH–water, rt, 3 days, 46%.</p></p></figure><div class="NLM_p">Payloads with pyridyl spacers were assembled as described in <a class="ref internalNav" href="#sch18" aria-label="Scheme 18">Scheme 18</a>. Spacers <b>30a</b> and <b>38a</b> were treated with monomer <b>50</b> in the presence of Cs<sub>2</sub>CO<sub>3</sub> to provide TBS-protected dimers <b>30b</b> and <b>38b</b>. Whereas dimers <b>34b–37b</b> were synthesized from corresponding spacers <b>34a–37a</b> and monomer <b>29b</b>. The phenolic TBS group in <b>38b</b> was removed by treatment with TBAF to give <b>38c</b>. Imine groups were unmasked by treatment with Pd(PPh<sub>3</sub>)<sub>4</sub>/pyrrolidine to provide payloads <b>30</b> and <b>34–38</b>.</div><figure id="sch18" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0027.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Synthesis of Payloads <b>30</b> and <b>34–38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>50</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 1 h (b) <b>29b</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 1–2.5 h (c) TBAF, THF, rt, 30 min; (d) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, rt, 30 min.</p></p></figure><div class="NLM_p">Spacers with pyridyl isomers were fused as shown in <a class="ref internalNav" href="#sch19" aria-label="Scheme 19">Scheme 19</a>. The reaction of spacer <b>31a</b> with monomer <b>50</b> under Mitsunobu conditions (DIAD/PPh<sub>3</sub>) provided dimer <b>31b</b>. Dimer <b>32b</b> was prepared from spacer <b>32a</b> and monomer <b>29b</b> under Cs<sub>2</sub>CO<sub>3</sub>/DMF conditions, while <b>39b</b> and <b>40b</b> were prepared by reaction of the corresponding spacers <b>39a</b> and <b>40a</b> with monomer <b>50</b>. These dimers were treated with Pd(PPh<sub>3</sub>)<sub>4</sub> in the presence of pyrrolidine to provide payloads <b>31</b>, <b>32</b>, <b>39</b>, and <b>40</b>.</div><figure id="sch19" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0028.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Synthesis of Payloads <b>31</b>, <b>32</b>, <b>39</b>, and <b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>50</b>, DIAD, PPh<sub>3</sub>, THF, rt, 1.5 h, 15%; (b) <b>29b</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 1 h, 73%; (c) <b>50</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt; (d) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, rt, 30 min.</p></p></figure><div class="NLM_p">Payload <b>33</b> with the pendant aniline moiety was prepared as described in <a class="ref internalNav" href="#sch20" aria-label="Scheme 20">Scheme 20</a>. Spacer <b>30a</b> was treated with monomer <b>49</b> in the presence of K<sub>2</sub>CO<sub>3</sub> to provide compound <b>33a</b>, which was further reacted with monomer <b>51</b> in the presence of K<sub>2</sub>CO<sub>3</sub> to obtain compound <b>33b</b>. The Alloc group was removed with Pd(PPh<sub>3</sub>)<sub>4</sub> and morpholine to provide <b>33c</b>. Reduction with superhydride and subsequent treatment with silica gel gave payload <b>33</b> in 50% yield over three steps.</div><figure id="sch20" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0029.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Synthesis of Payload <b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 16 h, 89%; (b) <b>50</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 16 h, 79%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, rt, 1 h, 64%; (2) silica gel, CHCl<sub>3</sub>–EtOH–water, rt, 3 days, 82%.</p></p></figure><div class="NLM_p">Payloads with furan and thiophene spacers were synthesized as shown in <a class="ref internalNav" href="#sch21" aria-label="Scheme 21">Scheme 21</a>. Spacer <b>42a</b> was subjected to Mitsunobu reaction with <b>50</b> to provide protected dimer <b>42b</b>, whereas thiophene spacer <b>43a</b> was treated with monomer <b>50</b> in the presence of K<sub>2</sub>CO<sub>3</sub> to provide dimer <b>43b</b> in 42% yield. Alloc and TBS groups in dimers <b>42b</b> and <b>43b</b> were removed using Pd(PPh<sub>3</sub>)<sub>4</sub> in the presence of pyrrolidine to provide payloads <b>42</b> and <b>43</b>.</div><figure id="sch21" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0030.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Synthesis of Payloads <b>42</b> and <b>43</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>50</b>, DIAD, PPh<sub>3</sub>, THF, rt, 1.5 h, 8%; (b) <b>50</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, 40 °C, 3 h, 42%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, rt, 1 h.</p></p></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Synthesis of Linker-Payloads</h3><div class="NLM_p">We prepared linker-payloads with a maleimide handle for heterogeneous lysine 2-IT conjugations and amino handles for BTGase-mediated site-specific conjugations. Intermediate <b>14b</b> was reacted with Fmoc-protected valine–citrulline<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> dipeptide <b>76</b> using HATU coupling to provide <b>77</b> in 71% yield (<a class="ref internalNav" href="#sch22" aria-label="Scheme 22">Scheme 22</a>). Fmoc deprotection was achieved with piperidine in THF, followed by superhydride reduction and treatment with silica gel in CHCl<sub>3</sub>–EtOH–water giving <b>79</b> in 36% yield over three steps. Mal-dPEG8-NHS ester was reacted with <b>79</b> in the presence of 2,6-lutidine to provide linker payload <b>44</b> in 55% yield. Payload <b>17</b> was treated with maleimide-containing linker carbonate <b>80</b> in the presence of Hunig’s base to provide linker-payload <b>45</b> in 32% yield (<a class="ref internalNav" href="#sch23" aria-label="Scheme 23">Scheme 23</a>). Linker payloads for site-specific conjugations were synthesized as shown in <a class="ref internalNav" href="#sch24" aria-label="Scheme 24">Scheme 24</a>. Fmoc-Val-Cit-PABC derivative <b>81</b> was reacted with <b>17c</b> in the presence of Hunig’s base to provide <b>82</b> in 57% yield. The Fmoc-protecting group was removed using piperidine in DMF to provide <b>83</b> in 79% yield. Reduction of SEM amide <b>83</b> with superhydride and subsequent treatment with silica gel provided bis-imine <b>84</b> in 55% yield. This was treated with the activated ester of Fmoc-protected PEG2 acid and subsequently the Fmoc group was removed using piperidine to provide linker-payload <b>46</b> with an amino handle suitable for BTGase-mediated site-specific conjugations. Linker-payloads with PEG4 (<b>47</b>) and PEG8 (<b>48</b>) were prepared using similar methods. We also explored an alternative route for making <b>47</b> through intermediate <b>85</b>, where PEG was introduced prior to superhydride reduction.</div><figure id="sch22" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0031.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Synthesis of Linker-Payload <b>44</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>14b</b>, HATU, DMF, 2,6-lutidine, rt, 1 h, 71%; (b) piperidine, THF, rt, 2 h, 65%; (c) (1) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h; (2) silica gel, CHCl<sub>3</sub>–EtOH–water, rt, 36 h, 55%; (d) MAL-dPEG8-NHS ester, 2,6-lutidine, DMSO, rt, 1 h, 55%.</p></p></figure><figure id="sch23" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0032.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Synthesis of Linker-Payload <b>45</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>17</b>, <i>i</i>-Pr<sub>2</sub>NEt, DMSO, rt, 16 h, 32%.</p></p></figure><figure id="sch24" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0033.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Synthesis of Linker-Payload <b>46</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>17c</b>, <i>i</i>-Pr<sub>2</sub>NEt, NMP, rt, 16 h, 57%; (b) piperidine, THF, rt, 30 min, 79%; (c) (1) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h; (2) silica gel, DCM–EtOH–water, rt, 3 days, 55%; (d) (1) Fmoc-PEG<sub><i>n</i></sub>-acid, HATU, 2,6-lutidine, DMF, rt, 2 h; (2) Et<sub>2</sub>NH, DMF, rt, 1 h, 22%. (e) Fmoc-PEG4-OSu, THF, rt, 1 h, 48%; (f) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h, 30%.</p></p></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76544" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76544" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Novel benzodiazepine dimers with aliphatic, aromatic, and heteroaromatic spacers were prepared. Molecular models of select novel benzodiazepine dimers in an 8-mer GC-rich sequence-based-duplex DNA helped explain some of the observed SAR. Bis alkylation and Mitsunobu reactions were utilized to prepare dimers in a convergent fashion. Various substitutions on the spacer as well as the pendant aryl moiety in benzodiazepine dimers were well tolerated. Spacers with different lengths were explored and five-carbon spacers were found to be optimal for high cellular potency. Aryl spacers provided payloads with further improvement in potency, likely because of the additional interactions exhibited in the DNA minor groove as discerned by the molecular modeling studies. Payload <b>17</b> was conjugated to anti-mesothelin and anti-FucGM1 antibodies using a valine–citrulline dipeptide linker. A maleimide handle was used for heterogeneous conjugation with thiol-modified lysines present on the antibody. An amino handle was used for site-specific conjugation with glutamine at the Q295 position using the BTGase enzyme. The resulting ADCs showed picomolar activity in cytotoxic experiments using multiple cancer cell lines. Site-specific ADCs had better PK profiles and twofold greater efficacy compared to heterogeneous ADCs at similar doses. Mesothelin-positive N87 mouse xenograft models exhibited robust antitumor activity after a single dose of anti-mesothelin ADC-<b>46</b> (0.02 μmol/kg). Anti-FucGM1 ADC-<b>46</b> induced complete tumor growth inhibition at a 0.03 μmol/kg dose in an H187 mouse xenograft model.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34616" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34616" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All reagents and solvents were purchased from commercial sources and used without further purification. All anhydrous reactions were performed under a N<sub>2</sub> atmosphere. Analytical thin-layer chromatography was performed on silica gel 60 F254 aluminum sheets (EMD Chemicals, Gibbstown, NJ). <sup>1</sup>H NMR spectra were recorded on a Bruker 400 MHz spectrometer. All spectra were determined in the solvents indicated. Multiplicity patterns are designated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad; dd, doublet of doublets; dt, doublet of triplets. Preparative HPLC was performed on the Waters instrument using the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile: water with 0.05% formic acid; mobile phase B: 95:5 acetonitrile: water with 0.05% formic acid; gradient: a 0 min hold at 5% B, 5–45% B over 20 min, then a 0 min hold at 100% B; flow rate: 20 mL/min; column temperature: 25 °C. HPLC fractions with desired product mass were filtered under gravity through a cartridge containing PL-HCO<sub>3</sub> MP-resin (Agilent), washed with acetonitrile, and lyophilized. Liquid chromatography (LC) data were recorded on a Shimadzu LC-10AS liquid chromatograph using an SPD-10AV UV–VIS detector with mass spectrometry (MS) data determined using a Micromass Platform for LC in electrospray mode. Purities of final compounds were determined by HPLC/UPLC and were greater than 95%.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>S</i>)-3-((5-Iodopentyl)oxy)-2-methoxy-5-((2-(trimethylsilyl)ethoxy)methyl)-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,6a<i>H</i>)-dione (<b>4b</b>)</h3><div class="NLM_p last">To a suspension of <b>49</b> (250 mg, 0.55 mmol) and potassium carbonate (304 mg, 2.2 mmol) in DMSO (5 mL) was added 1,5-diiodopentane (891 mg, 2.75 mmol). The reaction was then stirred at room temperature for 2 h before it was diluted with EtOAc and washed with brine. The organic layer was separated, dried over sodium sulfate, and concentrated <i>in vacuo</i>. The crude product was purified by silica gel chromatography (CombiFlash, 12 g column, 0–10% MeOH/DCM) to give the title compound <b>4b</b> as a yellow oil (275 mg, 0.423 mmol, 77% yield). MS (C<sub>29</sub>H<sub>40</sub>IN<sub>2</sub>O<sub>5</sub>Si) <i>m</i>/<i>z</i>: 651 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.33–7.24 (m, 5H), 7.21 (s, 1H), 5.50 (d, <i>J</i> = 9.9 Hz, 1H), 5.15 (d, <i>J</i> = 15.4 Hz, 1H), 4.66 (d, <i>J</i> = 9.9 Hz, 1H), 4.41 (d, <i>J</i> = 15.4 Hz, 1H), 4.33–4.25 (m, 1H), 4.05 (d, <i>J</i> = 8.6 Hz, 2H), 3.89 (s, 3H), 3.80 (td, <i>J</i> = 9.6, 6.9 Hz, 1H), 3.72–3.62 (m, 1H), 3.56 (dd, <i>J</i> = 15.5, 7.4 Hz, 1H), 3.22 (t, <i>J</i> = 6.9 Hz, 2H), 3.00 (dd, <i>J</i> = 15.6, 6.4 Hz, 1H), 1.98–1.80 (m, 4H), 1.67–1.54 (m, 2H), 0.98 (m, 2H), 0.04 (s, 9H).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>S</i>)-2-Methoxy-3-((5-(((<i>S</i>)-7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)pentyl)oxy)-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one (<b>4</b>)</h3><div class="NLM_p">A suspension of <b>4b</b> (50 mg, 0.077 mmol), potassium carbonate (31.9 mg, 0.231 mmol), and <b>4c</b> (40.3 mg, 0.154 mmol) in DMF (1.5 mL) was heated at 50 °C for 2 h. The reaction was then cooled to room temperature and quenched with water. The resulting mixture was extracted with EtOAc (3×). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated <i>in vacuo</i>. The crude material was purified by silica gel chromatography (24 g column, 0–10% MeOH/DCM) to give the dimer <b>4d</b>. MS (C<sub>42</sub>H<sub>52</sub>N<sub>4</sub>O<sub>9</sub>Si) <i>m</i>/<i>z</i>: 785 (M + H)<sup>+</sup>. This was dissolved in DMF (0.5 mL) and cooled to 0 °C before sodium hydride (60% dispersion in mineral oil, 3.07 mg, 0.077 mmol) and (2-(chloromethoxy)ethyl)trimethylsilane (0.014 mL, 0.077 mmol) were added sequentially. The reaction was warmed to room temperature and stirred for 2 h. The reaction was then quenched with water, extracted with EtOAc, dried over sodium sulfate, and concentrated <i>in vacuo</i> to give <b>4e</b> as a white solid (14 mg, 0.015 mmol, 20% yield). MS (C<sub>48</sub>H<sub>67</sub>N<sub>4</sub>O<sub>10</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 915 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of compound <b>4e</b> (14 mg, 0.015 mmol) in THF/EtOH (1:1, 1 mL) at 0 °C was added a solution of lithium borohydride (101 μL, 0.202 mmol, 2 M in THF). The reaction was slowly warmed to room temperature and stirred for 15 min before it was quenched with brine. The resulting mixture was extracted with chloroform (3×). The organic layer was separated, dried over sodium sulfate, and concentrated <i>in vacuo</i>. The residue was then taken up in EtOH/chloroform (1:1, 2 mL). Silica gel (700 mg) was added, followed by water (0.6 mL). The resulting suspension was stirred at room temperature for 1 day and then filtered and washed with 10% MeOH/chloroform. The filtrate was concentrated and purified by preparative HPLC to give the title compound <b>4</b> as a white solid (0.92 mg, 1.330 μmol, 8.69% yield). MS (C<sub>36</sub>H<sub>39</sub>N<sub>4</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 623 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.69 (d, <i>J</i> = 4.4 Hz, 1H), 7.57–7.53 (m, 2H), 7.50 (d, <i>J</i> = 5.1 Hz, 1H), 7.41–7.32 (m, 4H), 6.82 (d, <i>J</i> = 1.5 Hz, 2H), 5.03 (d, <i>J</i> = 15.6 Hz, 1H), 4.59 (d, <i>J</i> = 15.6 Hz, 1H), 4.18–4.06 (m, 4H), 3.97 (s, 3H), 3.96 (s, 3H), 3.75 (d, <i>J</i> = 7.3 Hz, 4H), 3.61 (dt, <i>J</i> = 11.8, 7.8 Hz, 1H), 3.34–3.26 (m, 1H), 3.22–3.15 (m, 1H), 2.34 (br s, 2H), 2.11–2.06 (m, 1H), 2.01–1.94 (m, 4H), 1.71–1.66 (m, 2H).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>S</i>)-10-(Dimethylamino)-3-hydroxy-2-methoxy-5-((2-(trimethylsilyl)ethoxy)methyl)-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,12<i>H</i>)-dione (<b>5c</b>)</h3><div class="NLM_p last">To a solution of <b>72</b> (220 mg, 0.512 mmol) in MeOH (3 mL) and THF (3 mL) were added formaldehyde (37% aqueous solution, 0.572 mL, 7.68 mmol) and a few drops of acetic acid. The solution was stirred at room temperature for 10 min before sodium cyanoborohydride (129 mg, 2.049 mmol) was added. The reaction was then stirred at room temperature for 2 h before it was concentrated <i>in vacuo</i>. The crude material was purified by silica gel chromatography (24 g column, 0–10% MeOH/DCM) to give the dimethylamino compound <b>5a</b> (230 mg, 0.503 mmol, 98% yield). MS (C<sub>27</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub>) <i>m</i>/<i>z</i>: 458 (M + H)<sup>+</sup>. This was taken in DMF (5 mL), and sodium hydride was added (60% dispersion in mineral oil, 25.1 mg, 0.628 mmol) at 0 °C. The mixture was stirred for 15 min before (2-(chloromethoxy)ethyl)trimethylsilane (0.111 mL, 0.628 mmol) was added. The reaction was slowly warmed to room temperature and stirred overnight. The reaction was then quenched with water and extracted with EtOAc (3×). The combined organic layers were dried over sodium sulfate and concentrated <i>in vacuo</i>. The crude material was purified by silica gel chromatography (0–10% MeOH/DCM) to give the SEM-protected compound <b>5b</b>. MS (C<sub>33</sub>H<sub>42</sub>N<sub>3</sub>O<sub>5</sub>Si) <i>m</i>/<i>z</i>: 588 (M + H)<sup>+</sup>. This was suspended in EtOH/EtOAc (1:1, 10 mL) and combined with 10% Pd/C (20 mg). The mixture was purged with N<sub>2</sub> and then stirred under a balloon of H<sub>2</sub> for 4 h. The reaction was then filtered through a pad of Celite and concentrated <i>in vacuo</i>. The crude material was purified by silica gel chromatography (40 g column, 0–10% MeOH/DCM) to give compound <b>5c</b> (190 mg, 0.382 mmol, 76% yield). MS (C<sub>26</sub>H<sub>36</sub>N<sub>3</sub>O<sub>5</sub>Si) <i>m</i>/<i>z</i>: 498 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.45 (s, 1H), 7.21 (s, 1H), 7.18–7.10 (m, 1H), 6.69 (m, 2H), 5.51 (d, <i>J</i> = 9.9 Hz, 1H), 5.12 (d, <i>J</i> = 15.2 Hz, 1H), 4.65 (d, <i>J</i> = 10.1 Hz, 1H), 4.33 (d, <i>J</i> = 15.2 Hz, 1H), 4.24 (m, 1H), 3.91 (s, 3H), 3.79 (s, 1H), 3.72–3.63 (m, 1H), 3.52–3.40 (m, 1H), 2.93 (s, 6H), 1.05–0.89 (m, 2H), 0.03 (s, 9H).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>S</i>)-10-(Dimethylamino)-2-methoxy-3-((5-(((<i>S</i>)-7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)pentyl)oxy)-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one (<b>5</b>)</h3><div class="NLM_p last">To a solution of <b>5c</b> (17 mg, 0.034 mmol) and <b>5d</b> (22.12 mg, 0.038 mmol) in DMSO (1 mL) was added potassium carbonate (9.44 mg, 0.068 mmol) and stirred at room temperature for 14 h. The reaction was then diluted with EtOAc, washed with water and then brine, dried, and concentrated. The residue was purified by silica gel chromatography (24 g column, 0–10% MeOH/DCM) to give dimer <b>5e</b> (27 mg, 0.028 mmol, 82% yield). MS (C<sub>48</sub>H<sub>67</sub>N<sub>4</sub>O<sub>10</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 915 (M + H)<sup>+</sup>. This was dissolved in THF/EtOH (1:1, 1 mL) and cooled to 0 °C. A solution of LiBH<sub>4</sub> (0.342 mL, 0.683 mmol) in THF (2 M) was added dropwise. The resulting solution was stirred for 2 h and then quenched with water (1 mL). The reaction was then extracted with chloroform, dried over sodium sulfate, filtered, and concentrated. The residue was then taken up in chloroform/EtOH (1:1, 2 mL). Silica gel (0.8 g) was added, followed by water (0.6 mL) and stirred at room temperature for 1 day and then filtered, washing with 10% MeOH/chloroform. The filtrate was concentrated and purified by preparative HPLC to give <b>5</b> as a white solid (11 mg, 0.015 mmol, 43.5% yield). MS (C<sub>38</sub>H<sub>44</sub>N<sub>5</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 666 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.68 (d, <i>J</i> = 4.4 Hz, 1H), 7.54 (d, <i>J</i> = 1.8 Hz, 2H), 7.52 (d, <i>J</i> = 5.3 Hz, 1H), 7.23 (d, <i>J</i> = 8.8 Hz, 1H), 6.82 (d, <i>J</i> = 1.8 Hz, 2H), 6.73–6.65 (m, 2H), 4.97 (d, <i>J</i> = 15.4 Hz, 1H), 4.53 (d, <i>J</i> = 15.4 Hz, 1H), 4.29–4.03 (m, 4H), 3.96 (s, 3H), 3.92 (s, 3H), 3.84 (ddd, <i>J</i> = 11.7, 7.1, 4.5 Hz, 1H), 3.78–3.72 (m, 1H), 3.66–3.56 (m, 1H), 3.28–3.17 (m, 1H), 3.06 (dd, <i>J</i> = 15.4, 4.2 Hz, 1H), 3.01–2.95 (m, 6H), 2.34 (td, <i>J</i> = 6.7, 3.0 Hz, 2H), 2.16–1.90 (m, 6H), 1.78–1.62 (m, 3H).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>S</i>)-2-Methoxy-3-((5-(((<i>S</i>)-7-methoxy-2-methyl-5-oxo-5,11a-dihydro-1<i>H</i>-benzo[e]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)pentyl)oxy)-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one (<b>6</b>)</h3><div class="NLM_p">To a solution of <b>50</b> (200 mg, 0.381 mmol) and 1,5-diiodopentane (0.284 mL, 1.906 mmol) in DMF (2 mL) was added potassium carbonate (70 mg, 0.506 mmol) and stirred at room temperature for 40 min. The reaction mixture was purified by silica gel chromatography (40 g column, 30–100% EtOAc/hexane) to afford <b>6a</b> as a white solid (247 mg, 0.336 mmol, 88% yield). MS (C<sub>33</sub>H<sub>46</sub>IN<sub>2</sub>O<sub>6</sub>Si) <i>m</i>/<i>z</i>: 721 (M + H)<sup>+</sup>.</div><div class="NLM_p">To a solution of <b>6a</b> (116 mg, 0.161 mmol) and <b>6b</b> (66 mg, 0.139 mmol) in DMF (1.5 mL) was added potassium carbonate (40 mg, 0.289 mmol) and stirred at 60 °C for 3 h. The reaction mixture was diluted with EtOAc and washed with water and brine. Organics were dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by silica gel chromatography (40 g column, 0–100% EtOAc/hexane) to afford <b>6c</b> as a white solid (100 mg, 0.092 mmol, 66% yield). MS (C<sub>57</sub>H<sub>79</sub>N<sub>4</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1067 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <b>6c</b> (100 mg, 0.094 mmol) and pyrrolidine (0.027 mL, 0.328 mmol) in DCM (1.3 mL) was added Pd(PPh<sub>3</sub>)<sub>4</sub> (13.53 mg, 0.012 mmol) and allowed to stir at room temperature for 12 h. The reaction mixture was diluted with DCM, washed twice with saturated aqueous NH<sub>4</sub>Cl, and water. The organics were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated, and the residue was purified by preparative HPLC to obtain <b>6</b> as a white solid (25 mg, 0.038 mmol, 40.8% yield). MS (C<sub>37</sub>H<sub>39</sub>N<sub>4</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 635 (M + H)<sup>+</sup>.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>S</i>)-3-(3-(((2<i>R</i>,11a<i>S</i>)-2-Hydroxy-7-methoxy-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-2,3,5,10,11,11a-hexahydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)propoxy)-2-methoxy-5-((2-(trimethylsilyl)ethoxy)methyl)-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,6a<i>H</i>)-dione (<b>7d</b>)</h3><div class="NLM_p">To a solution of 1,3-dibromopropane <b>7a</b> (1.881 mL, 18.36 mmol) and (2<i>R</i>,11a<i>S</i>)-2,8-dihydroxy-7-methoxy-10-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepine-5,11(10<i>H</i>,11a<i>H</i>)-dione <b>7b</b> (1.5 g, 3.67 mmol) in DMSO (10 mL) was added K<sub>2</sub>CO<sub>3</sub> (1.522 g, 11.02 mmol). The resulting suspension was stirred at room temperature for 3 h. The reaction was then quenched with brine and extracted with EtOAc (3×). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The crude product was purified by silica gel chromatography (40 g column, 0–100% EtOAc/hexane) to give compound <b>7c</b> as a white solid (1.62 g, 3.06 mmol, 83% yield). MS (C<sub>22</sub>H<sub>34</sub>BrN<sub>2</sub>O<sub>6</sub>Si) <i>m</i>/<i>z</i>: 531 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <b>7c</b> (1 g, 1.889 mmol) and <b>49</b> (0.859 g, 1.889 mmol) in DMSO (10 mL) was added K<sub>2</sub>CO<sub>3</sub> (0.522 g, 3.78 mmol). The resulting suspension was stirred at room temperature for 4 h before it was quenched with water. The mixture was extracted with EtOAc (3×). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated <i>in vacuo</i>. The crude product was purified by silica gel chromatography (0–6% MeOH/DCM, 40 g column) to give <b>7d</b> as a white solid (1.6 g, 1.506 mmol, 80% yield). MS (C<sub>46</sub>H<sub>63</sub>N<sub>4</sub>O<sub>11</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 903 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.43–7.19 (m, 8H), 5.56–5.41 (m, 2H), 5.30 (s, 1H), 5.15 (d, <i>J</i> = 15.3 Hz, 1H), 4.79–4.66 (m, 2H), 4.69–4.60 (m, 2H), 4.42 (d, <i>J</i> = 15.3 Hz, 1H), 4.35–4.22 (m, 6H), 3.98–3.84 (m, 7H), 3.84–3.48 (m, 6H), 3.10–2.89 (m, 2H), 2.84 (dd, <i>J</i> = 19.0, 3.7 Hz, 1H), 2.42 (p, <i>J</i> = 6.0 Hz, 2H), 2.11 (m, 1H), 1.11–0.89 (m, 4H), 0.12 to −0.04 (m, 18H).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>S</i>)-7-Methoxy-8-(3-(((<i>S</i>)-2-methoxy-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy)methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)propoxy)-10-((2-(trimethylsilyl)ethoxy)methyl)-1,11a-dihydro-5<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepine-2,5,11(3<i>H</i>,10<i>H</i>)-trione (<b>7e</b>)</h3><div class="NLM_p last">To a solution of oxalyl chloride (0.233 mL, 2.66 mmol) in DCM (15 mL) at −78 °C was added DMSO (0.377 mL, 5.31 mmol) dropwise. Stirred for 15 min, then a solution of <b>7d</b> (1.6 g, 1.772 mmol) in DCM (15 mL) was added dropwise. Stirred for 10 min before a solution of triethylamine (1.481 mL, 10.63 mmol) in DCM (10 mL) was added dropwise. The resulting solution was stirred at −78 °C for 15 min and then slowly warmed to 0 °C. The reaction was then quenched with ice water and extracted with DCM. The organic layers were washed with brine, dried, concentrated, and purified by silica gel chromatography (0–8% MeOH/DCM, 40 g column) to give <b>7e</b> as a white solid (1.41 g, 1.565 mmol, 88% yield). MS (C<sub>46</sub>H<sub>61</sub>N<sub>4</sub>O<sub>11</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 901 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.43–7.19 (m, 8H), 5.53 (td, <i>J</i> = 11.5, 9.9 Hz, 2H), 5.32 (s, 1H), 5.17 (d, <i>J</i> = 15.3 Hz, 1H), 4.85–4.67 (m, 2H), 4.64 (dd, <i>J</i> = 9.9, 3.1 Hz, 3H), 4.43 (d, <i>J</i> = 15.3 Hz, 1H), 4.36–4.21 (m, 5H), 3.93 (s, 3H), 3.89 (s, 3H), 3.82–3.47 (m, 5H), 3.01 (dd, <i>J</i> = 15.5, 6.4 Hz, 1H), 2.91–2.73 (m, 1H), 2.44 (t, <i>J</i> = 6.0 Hz, 2H), 1.11–0.88 (m, 4H), 0.06 (s, 18H).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>S</i>)-3-(3-(((<i>S</i>)-2-(4-Aminophenyl)-7-methoxy-5-oxo-5,11a-dihydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)propoxy)-2-methoxy-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one (<b>7</b>)</h3><div class="NLM_p">To a solution of <b>7e</b> (1.4 g, 1.554 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added 2,6-lutidine (0.362 mL, 3.11 mmol). The reaction was then cooled to −78 °C before trifluoromethanesulfonic anhydride (0.526 g, 1.864 mmol) was added dropwise. The reaction was stirred at −78 °C for 30 min before it was allowed to warm to 0 °C and stirred at that temperature for 3 h. The reaction was then quenched with brine and extracted with DCM (3×). The combined organic layers were dried over sodium sulfate and concentrated. The crude product was purified by silica gel chromatography (0–100% EtOAc/hexane, 40 g column) to give <b>7f</b> (0.72 g, 0.697 mmol, 44.9% yield). MS (C<sub>47</sub>H<sub>60</sub>F<sub>3</sub>N<sub>4</sub>O<sub>13</sub>SSi<sub>2</sub>) <i>m</i>/<i>z</i>: 1033 (M + H)<sup>+</sup>.</div><div class="NLM_p">To a degassed solution of <b>7f</b> (78 mg, 0.075 mmol), PdCl<sub>2</sub>(dppf) (2.76 mg, 3.77 μmol), and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (19.85 mg, 0.091 mmol) in THF (2 mL) was added aqueous solution of tripotassium phosphate (0.377 mL, 0.377 mmol). The reaction was stirred under N<sub>2</sub> at 35 °C for 1 h. The reaction was then diluted with EtOAc, washed with brine, concentrated, and purified by silica gel chromatography (12 g column, 0–100% EtOAc/hexane) to give <b>7g</b> as a white solid (51 mg, 0.052 mmol, 69.2% yield). MS (C<sub>52</sub>H<sub>66</sub>N<sub>5</sub>O<sub>10</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 976 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <b>7g</b> (18 mg, 0.018 mmol) in THF (1 mL) at −78 °C was added lithium triethylhydroborate (0.184 mL, 0.184 mmol) (1 M in THF). The reaction was stirred at −78 °C for 1 h and then quenched with water. The mixture was warmed to room temperature and extracted with EtOAc. The crude product was then taken up in THF/EtOH (10 mL, 1:1), and aqueous HCOOH (0.05%, 8 mL) was added. The mixture was stirred at room temperature for 6 h, monitoring with neutral LCMS for disappearance of the SEM-hemi aminal. The mixture was then concentrated, neutralized with solid NaHCO<sub>3</sub>, and then extracted with CHCl<sub>3</sub>/MeOH (10:1, 3×). The combined organic layers were concentrated and purified by silica gel chromatography (24 g column, 0–10% MeOH/DCM) to give <b>7</b> as a white solid (5.2 mg, 6.84 μmol, 37.1% yield). MS (C<sub>40</sub>H<sub>38</sub>N<sub>5</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 684 (M + H)<sup>+</sup>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (<i>S</i>)-3-(Benzyloxy)-10-hydroxy-2-methoxy-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,6a<i>H</i>)-dione (<b>8c</b>)</h3><div class="NLM_p">To a solution of 4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid <b>53</b> (1.97 g, 6.51 mmol) in THF (30 mL) was added dropwise oxalyl chloride (1.09 mL, 12.5 mmol), followed by DMF (30 μL). The resulting solution was stirred at room temperature for 2 h before it was concentrated <i>in vacuo</i> to give the acid chloride as a yellow solid. The acid chloride was dissolved in THF (30 mL) and added dropwise to a solution of (<i>S</i>)-methyl 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate <b>8a</b> (1.6 g, 5.21 mmol) and triethylamine (2.9 mL, 20.8 mmol) in THF (20 mL) at 0 °C. The reaction was stirred at 0 °C for 2 h before it was quenched with water. The resulting mixture was extracted with EtOAc (3×). The combined organic layers were washed with brine, and then dried over sodium sulfate and concentrated <i>in vacuo</i>. The resulting mixture was then taken up in MeOH (50 mL). Potassium carbonate (1 g) was added. The resulting suspension was stirred at room temperature for 1 h before it was filtered through a pad of Celite and concentrated <i>in vacuo</i>. The crude product mixture was purified by silica gel chromatography (220 g column, 0–50% EtOAc/hexane in 15 min) to give the title compound <b>8b</b> (1.75 g, 68% yield). MS (C<sub>26</sub>H<sub>25</sub>N<sub>2</sub>O<sub>8</sub>) <i>m</i>/<i>z</i>: 493 (M + H)<sup>+</sup>.</div><div class="NLM_p last">A suspension of <b>8b</b> (1.75 g, 3.55 mmol), zinc (1.394 g, 21.32 mmol), and ammonium chloride (2.281 g, 42.6 mmol) in MeOH (10 mL) was heated at 50 °C overnight. The reaction was then filtered through a pad of Celite, washing with 20% MeOH/DCM. The filtrate was concentrated to give the title compound <b>8c</b> (1.25 g, 2.90 mmol, 82% yield). MS (C<sub>25</sub>H<sub>23</sub>N<sub>2</sub>O<sub>5</sub>) <i>m</i>/<i>z</i>: 431 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.25 (br s, 1H), 9.26 (s, 1H), 7.53–7.32 (m, 5H), 7.24 (s, 1H), 7.07 (d, <i>J</i> = 8.1 Hz, 1H), 6.79 (s, 1H), 6.71–6.60 (m, 2H), 5.08 (d, <i>J</i> = 4.0 Hz, 2H), 4.83 (d, <i>J</i> = 15.2 Hz, 1H), 4.22 (d, <i>J</i> = 15.4 Hz, 1H), 4.08 (t, <i>J</i> = 6.7 Hz, 1H), 3.76 (s, 3H), 3.16 (dd, <i>J</i> = 15.4, 6.8 Hz, 1H), 2.85 (dd, <i>J</i> = 15.1, 6.3 Hz, 1H).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (6a<i>S</i>)-3-(Benzyloxy)-2-methoxy-10-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-5-((2-(trimethylsilyl)ethoxy)methyl)-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,6a<i>H</i>)-dione (<b>8e</b>)</h3><div class="NLM_p">To a solution of <b>8c</b> (1.25 g, 2.9 mmol) in DCM (40 mL) were added PPTS (0.073 g, 0.29 mmol) and tetrahydropyran (2.84 mL, 29 mmol). The reaction was stirred at room temperature overnight and then quenched with saturated aqueous NaHCO<sub>3</sub> solution. The resulting mixture was extracted with DCM (3×). The combined organic layers were dried over sodium sulfate and concentrated <i>in vacuo</i>. The crude product mixture was purified by silica gel chromatography (40 g column 0–100% EtOAc/hexane) to give compound <b>8d</b> as a white solid (1.15 g, 2.235 mmol, 77% yield). MS (C<sub>30</sub>H<sub>31</sub>N<sub>2</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 515 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To an ice-cooled solution of <b>8d</b> (1.2 g, 2.332 mmol) in DMF (10 mL) was added sodium hydride (60% dispersion in mineral oil, 0.168 g, 2.80 mmol). The mixture was stirred at 0 °C for 15 min and then warmed to room temperature and stirred for 10 min before it was cooled back to 0 °C. (2-(Chloromethoxy)ethyl)trimethylsilane (0.496 mL, 2.80 mmol) was then added. The reaction was stirred at 0 °C for 30 min before it was then allowed to warm to room temperature and stirred for 1 h. The reaction was then quenched with brine. The resulting mixture was extracted with EtOAc (3×). The combined organic layers were dried over sodium sulfate and concentrated <i>in vacuo</i>. The crude product mixture was purified by silica gel chromatography (40 g column, 0–50% EtOAc/hexane) to give the title compound <b>8e</b> (875 mg, 1.357 mmol, 58.2%). MS (C<sub>36</sub>H<sub>45</sub>N<sub>2</sub>O<sub>7</sub>Si) <i>m</i>/<i>z</i>: 645 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.48–7.41 (m, 2H), 7.39–7.28 (m, 4H), 7.24 (s, 1H), 7.19 (d, <i>J</i> = 8.1 Hz, 1H), 7.02–6.92 (m, 2H), 5.51–5.32 (m, 2H), 5.20 (s, 2H), 5.12 (dd, <i>J</i> = 15.3, 3.2 Hz, 1H), 4.50 (dd, <i>J</i> = 9.8, 1.7 Hz, 1H), 4.33 (dd, <i>J</i> = 15.3, 5.2 Hz, 1H), 4.22 (ddd, <i>J</i> = 7.4, 6.5, 4.3 Hz, 1H), 3.91 (s, 4H), 3.76–3.56 (m, 3H), 3.47 (dd, <i>J</i> = 15.4, 7.7 Hz, 1H), 2.92 (dd, <i>J</i> = 15.4, 6.4 Hz, 1H), 2.03–1.92 (m, 1H), 1.88–1.81 (m, 2H), 1.74–1.57 (m, 3H), 0.97 (m, 2H), 0.09–0.01 (m, 9H).</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (<i>S</i>)-8-(3-(((<i>S</i>)-2,10-Dimethoxy-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy)methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)propoxy)-7-methoxy-10-((2-(trimethylsilyl)ethoxy)methyl)-1,11a-dihydro-5<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepine-2,5,11(3<i>H</i>,10<i>H</i>)-trione (<b>8i</b>)</h3><div class="NLM_p">A suspension of <b>8e</b> (875 mg, 1.357 mmol) and Pd/C (10%, 87 mg) in EtOAc (10 mL) was stirred under a balloon of H<sub>2</sub> at room temperature for 2 h. The reaction was then filtered through a pad of Celite and concentrated <i>in vacuo</i>. The crude product mixture was purified by silica gel chromatography (40 g column, 0–100% EtOAc/hexane) to give compound <b>8f</b> as a white solid (485 mg, 0.874 mmol, 64.4% yield). MS (C<sub>29</sub>H<sub>39</sub>N<sub>2</sub>O<sub>7</sub>Si) <i>m</i>/<i>z</i>: 555 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.33 (d, <i>J</i> = 0.7 Hz, 1H), 7.27 (s, 1H), 7.22 (d, <i>J</i> = 8.1 Hz, 1H), 7.04–6.95 (m, 2H), 6.01 (s, 1H), 5.46 (d, <i>J</i> = 9.7 Hz, 1H), 5.44–5.34 (m, 1H), 5.16 (dd, <i>J</i> = 15.3, 2.6 Hz, 1H), 4.71 (dd, <i>J</i> = 9.7, 1.8 Hz, 1H), 4.35 (dd, <i>J</i> = 15.3, 4.5 Hz, 1H), 4.25 (ddd, <i>J</i> = 7.7, 6.4, 4.0 Hz, 1H), 4.01–3.87 (m, 4H), 3.80–3.59 (m, 3H), 3.52 (dd, <i>J</i> = 15.5, 7.8 Hz, 1H), 2.95 (dd, <i>J</i> = 15.5, 6.4 Hz, 1H), 2.05–1.96 (m, 1H), 1.92–1.82 (m, 2H), 1.77–1.62 (m, 3H), 1.06–0.97 (m, 2H), 0.05 (s, 9H).</div><div class="NLM_p">To a solution of <b>8f</b> (100 mg, 0.180 mmol) and <b>7c</b> (117 mg, 0.198 mmol) in DMSO (2 mL) was added potassium carbonate (62.3 mg, 0.451 mmol). The mixture was stirred at room temperature for 16 h. The reaction was then diluted with EtOAc and washed sequentially with water and brine. The organic layer was separated, dried over sodium sulfate, and concentrated. The resulting mixture was taken up in MeOH (10 mL), and PPTS (20 mg) was added. The reaction was stirred at 40 °C for 1 h. The reaction was then concentrated, taken up in EtOAc, and washed with aqueous sodium bicarbonate and then brine. The organic layer was separated, dried over sodium sulfate, and concentrated <i>in vacuo</i>. The crude product was purified by silica gel chromatography (0–20% EtOAc/hexane, 24 g column) to give <b>8g</b> as a white solid (150 mg, 0.163 mmol, 91% yield). MS (C<sub>46</sub>H<sub>63</sub>N<sub>4</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 919 (M + H)<sup>+</sup>.</div><div class="NLM_p">To a solution of <b>8g</b> (150 mg, 0.163 mmol) in DMSO (2 mL) were added potassium carbonate (67.7 mg, 0.490 mmol) and iodomethane (46.3 mg, 0.326 mmol). The mixture was stirred at room temperature for 16 h. The reaction was then diluted with EtOAc and washed with water. The organic layer was dried over sodium sulfate and concentrated <i>in vacuo</i> to give <b>8h</b>. The crude material was used in the next step without further purification. MS (C<sub>47</sub>H<sub>65</sub>N<sub>4</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 933 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <b>8h</b> in DCM (804 μL) and DMSO (804 μL) 0 °C was added triethylamine (112 μL, 0.804 mmol), followed by sulfur trioxide pyridine complex (51.2 mg, 0.321 mmol). The reaction was allowed to warm to room temperature and stirred for 16 h. The reaction was then diluted with CH<sub>2</sub>Cl<sub>2</sub> (30 mL), washed sequentially with saturated aqueous NH<sub>4</sub>Cl (10 mL), H<sub>2</sub>O (2 × 10 mL), and saturated aqueous NaHCO<sub>3</sub> solution (10 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated <i>in vacuo</i>. The crude material was purified by silica gel chromatography (24 g column; gradient 0–100% EtOAc/CH<sub>2</sub>Cl<sub>2</sub>) to provide the title compound <b>8i</b> (112 mg, 0.084 mmol, 52.4% yield). MS (C<sub>47</sub>H<sub>63</sub>N<sub>4</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 931 (M + H)<sup>+</sup>.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (<i>S</i>)-3-((5-(((<i>S</i>)-2-(4-Aminophenyl)-7-methoxy-5-oxo-5,11a-dihydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)pentyl)oxy)-2,10-dimethoxy-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one (<b>8</b>)</h3><div class="NLM_p">To a solution of <b>8i</b> (112 mg, 0.120 mmol) in DCM (2 mL) was added 2,6-lutidine (0.028 mL, 0.241 mmol). The solution was cooled to −78 °C and triflic anhydride (0.030 mL, 0.180 mmol) was then added dropwise. The reaction was slowly warmed to 0 °C and stirred for 2 h. The reaction was then quenched with brine and extracted with DCM. The organic layer was separated, dried over sodium sulfate, and concentrated <i>in vacuo</i>. The crude product was purified by silica gel chromatography (24 g column, 0–10% MeOH/DCM) to give compound <b>8j</b> (81 mg, 0.076 mmol, 63.3% yield). MS (C<sub>48</sub>H<sub>62</sub>F<sub>3</sub>N<sub>4</sub>O<sub>14</sub>SSi<sub>2</sub>) <i>m</i>/<i>z</i>: 1063 (M + H)<sup>+</sup>.</div><div class="NLM_p">To a vial with a screw-cap top were added <b>8j</b> (75 mg, 0.071 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (18.54 mg, 0.085 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (2.58 mg, 3.53 μmol). The vial was degassed and backfilled with N<sub>2</sub>, and then THF (1411 μL) and a solution of aqueous K<sub>3</sub>PO<sub>4</sub> (0.5 M, 705 μL, 0.353 mmol) were added. The mixture was stirred under N<sub>2</sub> at 45 °C for 2 h. The reaction was then diluted with EtOAc and washed with brine. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated <i>in vacuo</i>. The crude material was purified by silica gel chromatography (12 g column; 0–100% EtOAc/hexane) to provide compound <b>8k</b> as a white solid (45 mg, 0.045 mmol, 63.4% yield). MS (C<sub>53</sub>H<sub>68</sub>N<sub>5</sub>O<sub>11</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1006 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.41 (s, 1H), 7.33 (s, 1H), 7.29–7.20 (m, 6H), 6.91–6.80 (m, 2H), 6.68 (d, <i>J</i> = 8.6 Hz, 2H), 5.51 (dd, <i>J</i> = 11.9, 10.0 Hz, 2H), 5.13 (d, <i>J</i> = 15.4 Hz, 1H), 4.75 (dd, <i>J</i> = 16.8, 10.0 Hz, 2H), 4.60 (dd, <i>J</i> = 10.6, 3.4 Hz, 1H), 4.39 (d, <i>J</i> = 15.3 Hz, 1H), 4.33–4.21 (m, 5H), 3.93 (s, 3H), 3.89 (s, 3H), 3.82 (s, 3H), 3.80–3.74 (m, 3H), 3.69 (m, 2H), 3.51 (dd, <i>J</i> = 15.5, 7.5 Hz, 1H), 3.12 (m, 1H), 3.03–2.87 (m, 1H), 2.44 (t, <i>J</i> = 5.9 Hz, 2H), 1.03–0.92 (m, 4H), 0.04 (s, 9H), 0.03 (s, 9H).</div><div class="NLM_p last">To a solution of <b>8k</b> (7 mg, 6.96 μmol) in THF (1 mL) at −78 °C was added dropwise a solution of lithium triethylborohydride (0.070 mL, 0.070 mmol, 1 M in THF). The reaction was stirred at −78 °C for 1 h before it was quenched with brine. The mixture was extracted with 10% MeOH/chloroform (3×). The combined organic layers were dried over sodium sulfate and concentrated <i>in vacuo</i>. The residue was taken up in THF/EtOH (1:1, 2 mL) and stirred with aqueous formic acid (0.05%, 1 mL) at room temperature for 2 h. The mixture was then neutralized with aqueous NaHCO<sub>3</sub> and extracted with chloroform (3×). The combined organic layers were concentrated and purified by silica gel chromatography (4 g column, 0–6% MeOH/DCM) to give the title compound <b>8</b> as a white solid (2.1 mg, 2.65 μmol, 38.1% yield). MS (C<sub>41</sub>H<sub>40</sub>N<sub>5</sub>O<sub>7</sub>) <i>m</i>/<i>z</i>: 714 (M + H)<sup>+</sup>.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (<i>S</i>)-10-Amino-2-methoxy-3-(3-(((<i>S</i>)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,11a-dihydro-1<i>H</i>-benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepin-8-yl)oxy)propoxy)-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one (<b>9</b>)</h3><div class="NLM_p">A vial was charged with <b>7c</b> (480 mg, 0.907 mmol), <b>51</b> (502 mg, 0.907 mmol), and K<sub>2</sub>CO<sub>3</sub> (125 mg, 0.907 mmol) in DMSO (4 mL) and stirred at room temperature for 5 h. The reaction was then diluted with EtOAc (30 mL), washed with brine, dried over sodium sulfate, concentrated, and purified by silica gel chromatography (40 g column, 0–10% MeOH/DCM) to give <b>9a</b> as a white solid (830 mg, 0.828 mmol, 91% yield). MS (C<sub>50</sub>H<sub>68</sub>N<sub>5</sub>O<sub>13</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1002 (M + H)<sup>+</sup>.</div><div class="NLM_p">To a solution of oxalyl chloride (0.068 mL, 0.778 mmol) in DCM (10 mL) at −78 °C was added DMSO (0.110 mL, 1.556 mmol) dropwise. Stirred for 15 min, then a solution of <b>9a</b> (0.52 g, 0.519 mmol) in DCM (5 mL) was added dropwise. The solution was stirred for 10 min before a solution of triethylamine (0.434 mL, 3.11 mmol) in DCM (3 mL) was added dropwise. The resulting solution was stirred at −78 °C for 15 min and then slowly warmed to 0 °C. The reaction was then quenched with ice water and extracted with DCM. The organic layers were washed with brine, dried, concentrated, and purified by silica gel chromatography (0–10% MeOH/DCM, 40 g column) to give <b>9b</b> as a white solid (0.41 g, 0.410 mmol, 79% yield). MS (C<sub>53</sub>H<sub>66</sub>N<sub>5</sub>O<sub>13</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1000 (M + H)<sup>+</sup>.</div><div class="NLM_p">To a solution of <b>9b</b> (410 mg, 0.410 mmol) in DCM (6 mL) was added 2,6-lutidine (0.143 mL, 1.230 mmol). The reaction was then cooled to −78 °C before trifluoromethanesulfonic anhydride (173 mg, 0.615 mmol) was added. The reaction was then slowly warmed to −10 °C and stirred for 20 min. The reaction was then quenched with brine, extracted with DCM, dried, concentrated, and purified by silica gel chromatography (0–10% MeOH/DCM, 40 g column) to give <b>9c</b> (330 mg, 0.248 mmol, 60.4% yield). MS (C<sub>51</sub>H<sub>65</sub>F<sub>3</sub>N<sub>5</sub>O<sub>15</sub>SSi<sub>2</sub>) <i>m</i>/<i>z</i>: 1132 (M + H)<sup>+</sup>.</div><div class="NLM_p"><b>9c</b> (500 mg, 0.442 mmol), (4-methoxyphenyl)boronic acid (134 mg, 0.883 mmol), and PdCl<sub>2</sub>(dppf) (32.3 mg, 0.044 mmol) were combined in a vial. THF (3 mL) was added. The solution was immediately purged with N<sub>2</sub>, and potassium phosphate (187 mg, 0.883 mmol) in water (1 mL) was then added. The solution was purged with N<sub>2</sub> again before it was heated to 35 °C for 2 h. The material was purified by silica gel chromatography (0–5% MeOH/DCM) to afford <b>9d</b> as a white solid (412 mg, 0.409 mmol, 93% yield). MS (C<sub>53</sub>H<sub>68</sub>N<sub>5</sub>O<sub>11</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1006 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <b>9d</b> (40 mg, 0.040 mmol) in THF (3 mL) at −78 °C was added superhydride (0.238 mL, 0.238 mmol) and allowed to stir at −78 °C for 1 h. The reaction was then warmed to room temperature and diluted with dichloromethane (10 mL) and water. The water layer was washed again with DCM (10 mL), and the organics were combined and concentrated. The residue was taken up in DCM/EtOH/water (1:2:1, 4 mL). To this was added silica gel (300 mg), and the reaction was stirred at room temperature for 3 days. The reaction was filtered to remove the silica gel and then concentrated to residue. The residue was purified by preparative HPLC to give the title compound <b>9</b> as a white solid (12.2 mg, 39% yield). MS (C<sub>41</sub>H<sub>40</sub>N<sub>5</sub>O<sub>7</sub>) <i>m</i>/<i>z</i>: 714 (M + H)<sup>+</sup>.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-(Propane-1,3-diylbis(oxy))bis(2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one) (<b>10</b>)</h3><div class="NLM_p">A suspension of <b>49</b> (52 mg, 0.11 mmol) and 1,3-dibromopropane (12 mg, 0.057 mmol) and potassium carbonate (47.4 mg, 0.34 mmol) in DMF (1 mL) were stirred at room temperature for 14 h. The reaction was then diluted with H<sub>2</sub>O and extracted with EtOAc (3×). The combined organic layers were washed with brine, dried over NaSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The crude product mixture was purified by silica gel chromatography (12 g column, 0–10% MeOH/DCM) to give compound <b>10b</b> (23 mg, 21% yield). MS (C<sub>51</sub>H<sub>65</sub>N<sub>4</sub>O<sub>10</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1049 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <b>10b</b> (22 mg, 0.023 mmol) in THF/EtOH (1:1, 1 mL) was added a solution of LiBH<sub>4</sub> in THF (2 M, 116 μL, 0.232 mmol) at 0 °C. The reaction was slowly warmed to room temperature and stirred for 15 min before it was quenched with brine. The resulting mixture was extracted with chloroform. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated <i>in vacuo</i>. The crude product was then taken up in EtOH/chloroform (1:1, 2 mL). Silica gel (700 mg) was added, followed by water (0.6 mL). The resulting suspension was stirred at room temperature for 24 h and then filtered, washing with 10% MeOH/chloroform. The filtrate was concentrated and purified by preparative HPLC to give <b>10</b> as a white solid (8.5 mg, 0.012 mmol, 50.3% yield). MS (C<sub>39</sub>H<sub>37</sub>N<sub>4</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 657 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.55 (s, 2H), 7.49 (d, <i>J</i> = 5.3 Hz, 2H), 7.42–7.31 (m, 8H), 6.82 (s, 2H), 5.03 (d, <i>J</i> = 15.6 Hz, 2H), 4.58 (d, <i>J</i> = 15.4 Hz, 2H), 4.26–4.04 (m, 4H), 4.00–3.92 (m, 8H), 3.37–3.25 (m, 2H), 3.21–3.10 (m, 2H), 2.02–1.90 (m, 4H), 1.70 (d, <i>J</i> = 7.3 Hz, 2H).</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (<i>S</i>)-10-Amino-2-methoxy-3-(3-(((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)propoxy)-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one (<b>11</b>)</h3><div class="NLM_p">To a solution of <b>49</b> (1 g, 2.200 mmol) in DMSO (5 mL) were added 1,3-dibromopropane (1.1 g, 5.45 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.608 g, 4.40 mmol). The reaction was stirred for 1 h and then quenched with water. The mixture was extracted with DCM (3×). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The crude product was purified by silica gel chromatography (0–100% EtOAc/hexane, 40 g column) to give <b>11a</b>. MS (C<sub>27</sub>H<sub>36</sub>BrN<sub>2</sub>O<sub>5</sub>Si) <i>m</i>/<i>z</i>: 575 (M + H)<sup>+</sup>.</div><div class="NLM_p">To a solution of <b>51</b> (77 mg, 0.139 mmol) in DMSO (0.5 mL) were added <b>11a</b> (80 mg, 0.139 mmol) and K<sub>2</sub>CO<sub>3</sub> (38.4 mg, 0.278 mmol). The reaction was stirred at room temperature for 1 h and then quenched with water. The mixture was extracted with DCM (3×). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated to provide <b>11b</b>. MS (C<sub>55</sub>H<sub>70</sub>N<sub>5</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1048 (M + H)<sup>+</sup>. This was then taken up in DCM (10 mL), and morpholine (0.121 mL, 1.391 mmol) was added. The solution was then purged with N<sub>2</sub> and cooled to 0 °C. Pd(Ph<sub>3</sub>P)<sub>4</sub> (4.82 mg, 4.17 μmol) was added. The reaction was then stirred for 2 h at 0 °C. The crude product was purified by silica gel chromatography (0–100% EtOAc/hexane, 40 g column) to give <b>11c</b> as a white solid (119 mg, 0.123 mmol, 89% yield). MS (C<sub>51</sub>H<sub>66</sub>N<sub>5</sub>O<sub>10</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 964 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <b>11c</b> (10 mg, 10.37 μmol) in THF (0.7 mL) at −78 °C was added superhydride (0.104 mL, 0.104 mmol). The reaction was stirred at −78 °C for 1 h before it was quenched with water. The mixture was then extracted with EtOAc. The combined organic layers were concentrated and treated with silica gel (0.7 g) in CHCl<sub>3</sub>–EtOH–water (1:1:1, 3 mL) at room temperature for 24 h and then filtered, washing with 10% MeOH/chloroform. The filtrate was concentrated and purified by preparative HPLC to give <b>11</b> as a white solid (3.1 mg, 4.15 μmol, 40% yield). MS (C<sub>39</sub>H<sub>38</sub>N<sub>5</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 672 (M + H)<sup>+</sup>.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-(Propane-1,3-diylbis(oxy))bis(10-amino-2-methoxy-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one) (<b>12</b>)</h3><div class="NLM_p">To a solution of <b>51</b> (158 mg, 0.285 mmol) in DMSO (1.5 mL) were added 1,3-dibromopropane (28.8 mg, 0.143 mmol) and K<sub>2</sub>CO<sub>3</sub> (79 mg, 0.571 mmol). The reaction was stirred for 1 h and then quenched with water. The mixture was extracted with DCM (3×). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The crude mixture was then taken up in DCM (4 mL), and morpholine (0.199 mL, 2.283 mmol) was added. The mixture was purged with N<sub>2</sub> and then cooled to 0 °C. Pd(Ph<sub>3</sub>P)<sub>4</sub> (9.89 mg, 8.56 μmol) was then added. The reaction was then stirred at 0 °C for 3 h and concentrated. The crude product was purified by silica gel chromatography (0–100% EtOAc/hexane, 40 g column) to give <b>12a</b> (105 mg, 0.107 mmol, 75% yield). MS (C<sub>51</sub>H<sub>67</sub>N<sub>6</sub>O<sub>10</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 979 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <b>12a</b> (15 mg, 0.015 mmol) in THF (0.7 mL) at −78 °C was added superhydride (0.153 mL, 0.153 mmol). The reaction was stirred at −78 °C for 1 h before it was quenched with water. The mixture was then extracted with EtOAc. The combined organic layers were dried and concentrated. The crude product was purified by preparative HPLC to give <b>12</b> as a white solid (4.2 mg, 5.50 μmol, 35.9% yield). MS (C<sub>39</sub>H<sub>39</sub>N<sub>6</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 687 (M + H)<sup>+</sup>.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-(Pentane-1,5-diylbis(oxy))bis(2-methoxy-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one) (<b>13</b>)</h3><div class="NLM_p">To a solution of <b>49</b> (50 mg, 0.110 mmol), 1,5-diiodopentane (17.82 mg, 0.055 mmol) in DMF (1 mL) was added K<sub>2</sub>CO<sub>3</sub> (15.20 mg, 0.110 mmol) and stirred at room temperature for 14 h. The reaction was then diluted with water, extracted with EtOAc, washed with brine, dried over sodium sulfate, concentrated, and purified on ISCO (12 g column, 0–10% MeOH/DCM) to give <b>13b</b> as a white solid (22 mg, 0.023 mmol, 20.47% yield). MS (C<sub>53</sub>H<sub>69</sub>N<sub>4</sub>O<sub>10</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 977 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <b>13b</b> (22 mg, 0.023 mmol) in THF/EtOH (1:1, 1 mL) was added LiBH<sub>4</sub> (225 μL, 0.450 mmol) in THF at 0 °C. The reaction was slowly warmed to room temperature and stirred for 15 min before it was quenched with brine, extracted with chloroform, dried, and concentrated. The resulting intermediate was then taken up in EtOH/chloroform (1:1, 2 mL). Silica gel (700 mg) was added, followed by water (0.6 mL). That was stirred at room temperature for 24 h and then filtered, washing with 10% MeOH/chloroform. The filtrate was concentrated and purified by preparative HPLC to give <b>13</b> as a white solid (7.5 mg, 9.86 μmol, 43.8% yield). MS (C<sub>41</sub>H<sub>41</sub>N<sub>4</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 685 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.55 (s, 1H), 7.49 (d, <i>J</i> = 5.3 Hz, 1H), 7.42–7.30 (m, 4H), 6.82 (s, 1H), 5.03 (d, <i>J</i> = 15.6 Hz, 1H), 4.58 (d, <i>J</i> = 15.4 Hz, 1H), 4.11 (d, <i>J</i> = 17.6 Hz, 2H), 4.01–3.91 (m, 4H), 3.36–3.24 (m, 1H), 3.22–3.13 (m, 1H), 2.02–1.91 (m, 2H), 1.70 (d, <i>J</i> = 7.3 Hz, 1H).</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Allyl ((<i>S</i>)-2-Methoxy-3-((5-(((<i>S</i>)-2-methoxy-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy)methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)pentyl)oxy)-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy)methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-10-yl)carbamate (<b>14a</b>)</h3><div class="NLM_p last">To a solution of <b>4b</b> (100 mg, 0.154 mmol) and <b>51</b> (68 mg, 0.123 mmol) in DMSO (3 mL) was added potassium carbonate (50.9 mg, 0.368 mmol). The resulting suspension was stirred at room temperature for 5 h. The reaction was then diluted with EtOAc, washed with brine, dried over sodium sulfate, and concentrated <i>in vacuo</i>. The crude material was purified by silica gel chromatography (CombiFlash, 12 g column, 0–10% MeOH/DCM) to give the title compound (124 mg, 0.115 mmol, 94% yield). MS (C<sub>57</sub>H<sub>74</sub>N<sub>5</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1076 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.30 (d, <i>J</i> = 0.9 Hz, 6H), 7.27–7.18 (m, 5H), 6.89 (s, 1H), 6.01–5.88 (m, 1H), 5.49 (dd, <i>J</i> = 9.9, 4.0 Hz, 2H), 5.34 (dd, <i>J</i> = 17.3, 1.4 Hz, 1H), 5.25 (dd, <i>J</i> = 10.3, 1.1 Hz, 1H), 5.18–5.04 (m, 2H), 4.71–4.62 (m, 4H), 4.40 (d, <i>J</i> = 15.4 Hz, 2H), 4.32–4.22 (m, 2H), 4.09–3.97 (m, 4H), 3.90–3.84 (m, 6H), 3.82–3.73 (m, 2H), 3.71–3.44 (m, 5H), 3.08–2.90 (m, 2H), 1.99–1.90 (m, 4H), 1.04–0.91 (m, 4H), 0.02 (s, 9H), 0.02 (s, 9H).</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (<i>S</i>)-10-Amino-2-methoxy-3-((5-(((<i>S</i>)-2-methoxy-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy)methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)pentyl)oxy)-5-((2-(trimethylsilyl)ethoxy)methyl)-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,6a<i>H</i>)-dione (<b>14b</b>)</h3><div class="NLM_p last">To a solution of <b>14a</b> (124 mg, 0.115 mmol) in DCM (6 mL) at 0 °C was added morpholine (0.080 mL, 0.922 mmol). After the reaction was purged with N<sub>2</sub>, Pd(Ph<sub>3</sub>P)<sub>4</sub> (13.31 mg, 0.012 mmol) was added. The reaction was slowly warmed to room temperature and stirred under N<sub>2</sub> for 2 h. The reaction was then concentrated and purified by silica gel chromatography (CombiFlash, 12 g column, 0–10% MeOH/DCM) to give the title compound <b>14b</b> as a white solid (90 mg, 0.091 mmol, 79% yield). MS (C<sub>53</sub>H<sub>70</sub>N<sub>5</sub>O<sub>10</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 992 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.74–7.64 (m, 1H), 7.62–7.44 (m, 1H), 7.37–7.25 (m, 7H), 7.22 (d, <i>J</i> = 2.3 Hz, 2H), 7.09 (d, <i>J</i> = 7.8 Hz, 1H), 6.63 (s, 1H), 5.52 (dd, <i>J</i> = 10.0, 4.1 Hz, 2H), 5.28–5.06 (m, 3H), 4.68 (dd, <i>J</i> = 10.0, 2.2 Hz, 2H), 4.43 (d, <i>J</i> = 15.3 Hz, 1H), 4.34–4.25 (m, 2H), 4.22 (dd, <i>J</i> = 7.7, 6.4 Hz, 1H), 4.16–4.00 (m, 4H), 3.90 (d, <i>J</i> = 0.8 Hz, 6H), 3.81 (m, 2H), 3.76–3.72 (m, 2H), 3.72–3.63 (m, 3H), 3.57 (dd, <i>J</i> = 15.5, 7.5 Hz, 1H), 3.47 (dd, <i>J</i> = 15.4, 7.7 Hz, 1H), 3.07–2.96 (m, 2H), 2.91 (dd, <i>J</i> = 15.4, 6.4 Hz, 1H), 2.63 (s, 1H), 2.47 (d, <i>J</i> = 4.4 Hz, 1H), 1.97 (p, <i>J</i> = 6.7 Hz, 4H), 1.71 (m, 2H), 1.07–0.89 (m, 4H), 0.05 (d, <i>J</i> = 0.8 Hz, 18H).</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (<i>S</i>)-10-Amino-2-methoxy-3-((5-(((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)pentyl)oxy)-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one (<b>14</b>)</h3><div class="NLM_p last">To a solution of <b>14b</b> (89 mg, 0.090 mmol) in THF (3 mL) at −78 °C was added superhydride (0.448 mL, 0.448 mmol, 1 M in THF). The reaction was stirred at −78 °C for 1 h and then quenched with water (1 mL) and extracted with chloroform (3×). The combined organic layers were dried over sodium sulfate, filtered, and concentrated <i>in vacuo</i>. The residue was then taken up in chloroform/EtOH (1:1, 2 mL). Silica gel (0.7 g) was added, followed by water (0.6 mL). The resulting suspension was stirred at room temperature for 1 day and then filtered and washed with 10% MeOH/chloroform. The filtrate was concentrated and purified by preparative HPLC to give the title compound <b>14</b> as a white solid (19 mg, 0.024 mmol, 27.2% yield). MS (C<sub>41</sub>H<sub>42</sub>N<sub>5</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 700 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.54 (d, <i>J</i> = 2.4 Hz, 2H), 7.50 (t, <i>J</i> = 4.7 Hz, 2H), 7.41–7.31 (m, 5H), 7.15 (d, <i>J</i> = 8.6 Hz, 1H), 6.81 (d, <i>J</i> = 1.8 Hz, 2H), 6.73–6.59 (m, 2H), 5.02 (d, <i>J</i> = 15.6 Hz, 1H), 4.92 (d, <i>J</i> = 15.4 Hz, 1H), 4.58 (d, <i>J</i> = 15.6 Hz, 1H), 4.47 (d, <i>J</i> = 15.4 Hz, 1H), 4.22–4.03 (m, 3H), 4.00–3.70 (m, 9H), 3.34–3.25 (m, 1H), 3.18 (dt, <i>J</i> = 15.4, 4.2 Hz, 2H), 3.09–3.00 (m, 1H), 2.03–1.92 (m, 4H), 1.76–1.63 (m, 2H).</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (<i>S</i>)-10-Amino-3-((5-(((<i>S</i>)-10-(dimethylamino)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)pentyl)oxy)-2-methoxy-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one (<b>15</b>)</h3><div class="NLM_p">In a flask were added 1,5-diiodopentane (0.276 mL, 1.852 mmol) and <b>51</b> (2.154 g, 3.89 mmol) in DMF (10 mL) with potassium carbonate (0.768 g, 5.56 mmol). The reaction was stirred at room temperature for 6 h and then quenched with water. This was extracted with ethyl acetate. The organics were concentrated to residue. The residue was purified by silica gel chromatography (0–100% ethyl acetate in hexanes) to give Alloc-dimer (2 g, 92% yield). MS (C<sub>61</sub>H<sub>79</sub>N<sub>6</sub>O<sub>14</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1175 (M + H)<sup>+</sup>. This was taken in DCM (3 mL) and treated with pyrrolidine (0.352 mL, 4.25 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.197 g, 0.170 mmol) at room temperature for 3 h. The reaction was poured into water and dichloromethane. The organic was collected and concentrated to residue. The residue was purified by silica gel chromatography (0–100% ethyl acetate in hexanes) to give diamine <b>15a</b> (1.1 g, 64.2%) as a white solid. MS (C<sub>53</sub>H<sub>71</sub>N<sub>6</sub>O<sub>10</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1007 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.76–7.64 (m, 4H), 7.63–7.53 (m, 2H), 7.53–7.45 (m, 4H), 7.36–7.26 (m, 3H), 7.22 (d, <i>J</i> = 3.5 Hz, 2H), 7.09 (d, <i>J</i> = 7.8 Hz, 2H), 6.63 (d, <i>J</i> = 7.1 Hz, 3H), 5.53 (dd, <i>J</i> = 9.9, 2.8 Hz, 2H), 5.10 (d, <i>J</i> = 15.2 Hz, 2H), 4.72–4.63 (m, 2H), 4.29 (d, <i>J</i> = 15.2 Hz, 2H), 4.26–4.17 (m, 2H), 4.16–3.99 (m, 4H), 3.95–3.84 (m, 6H), 3.81 (td, <i>J</i> = 9.6, 6.9 Hz, 2H), 3.76–3.59 (m, 4H), 3.47 (dd, <i>J</i> = 15.4, 7.8 Hz, 2H), 2.95–2.84 (m, 2H), 1.97 (p, <i>J</i> = 6.8 Hz, 4H), 1.79–1.54 (m, 4H), 1.06–0.91 (m, 4H), 0.06 (d, <i>J</i> = 2.6 Hz, 19H).</div><div class="NLM_p">In a vial was added <b>15a</b> (330 mg, 0.328 mmol) in THF (10 mL) with triethylamine (0.183 mL, 1.310 mmol). To this was added allyl chloroformate (0.035 mL, 0.328 mmol), and the reaction was allowed to stir at room temperature for 3 h. The reaction was quenched with water and extracted with dichloromethane. The organic layer was concentrated and purified by silica gel chromatography (0–10% MeOH/DCM) to give mono Alloc product (125 mg, 35% yield). MS (C<sub>57</sub>H<sub>75</sub>N<sub>6</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1091 (M + H)<sup>+</sup>. To this in MeOH (1 mL) and THF (1 mL) were added paraformaldehyde (16.51 mg, 0.550 mmol) and a few drops of acetic acid. The solution was stirred at room temperature for 10 min before sodium cyanoborohydride (27.6 mg, 0.440 mmol) was added slowly. The reaction was then stirred at room temperature overnight. The reaction was quenched with water and extracted with dichloromethane. The organic layer was concentrated. The residue was purified by silica gel chromatography (0–30% MeOH/DCM) to give dimethylamino compound (77 mg, 85% yield). MS (C<sub>59</sub>H<sub>79</sub>N<sub>6</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1120 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To the above material (50 mg, 0.045 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (5.16 mg, 4.47 μmol) in DCM (5 mL) was added pyrrolidine (0.011 mL, 0.134 mmol), and the reaction was stirred at room temperature overnight. The reaction was taken up in DCM and water. The organic was collected and purified by silica gel chromatography (0–40% MeOH/DCM) to give SEM-lactam <b>15b</b> (40 mg, 86%). MS (C<sub>55</sub>H<sub>75</sub>N<sub>6</sub>O<sub>10</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1035 (M + H)<sup>+</sup>. This was taken in THF (3 mL) and cooled to −78 °C in a dry ice/acetone bath. To the reaction was added superhydride (0.348 mL, 0.348 mmol), and the reaction was allowed to stir at −78 °C for 2 h. The reaction was quenched with water and extracted with dichloromethane. The organics were combined and concentrated to residue. The residue was taken up in DCM–EtOH–water (1:2:1, 8 mL). To this was added silica gel (300 mg), and the reaction was stirred at room temperature for 3 days. The reaction was then filtered to remove the silica gel and then concentrated to residue. The residue was purified by preparative HPLC to give <b>15</b> as a white solid. MS (C<sub>43</sub>H<sub>47</sub>N<sub>6</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 743 (M + H)<sup>+</sup>.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-((Oxybis(ethane-2,1-diyl))bis(oxy))bis(2-methoxy-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one) (<b>16</b>)</h3><div class="NLM_p">To a solution of <b>49</b> (50 mg, 0.110 mmol) and 1-iodo-2-(2-iodoethoxy)ethane <b>16a</b> (17.92 mg, 0.055 mmol) in DMSO (2 mL) was added K<sub>2</sub>CO<sub>3</sub> (22.80 mg, 0.165 mmol) and allowed to stir at room temperature overnight. The reaction was then diluted with EtOAc, washed with brine, dried, concentrated, and purified by silica gel chromatography (0–10% MeOH/DCM, 12 g column) to give <b>16b</b> (47 mg, 0.048 mmol, 87% yield). MS (C<sub>52</sub>H<sub>67</sub>N<sub>4</sub>O<sub>11</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 979 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <b>16b</b> (27 mg, 0.028 mmol) in THF (2 mL) at −78 °C was added superhydride (138 μL, 0.138 mmol, 1 M THF) dropwise. The resulting solution was stirred at −78 °C for 1 h. The reaction was then quenched with brine, warmed to room temperature, and extracted with chloroform. The organic layers were combined, dried, and concentrated. The residue was then dissolved in EtOH/chloroform (1:1, 2 mL), and silica gel (0.6 g) was added, followed by water (0.5 mL). The resulting slurry was stirred at room temperature for 36 h and then filtered, washing with 10% MeOH/chloroform. The filtrate was concentrated and purified by preparative HPLC to give <b>16</b> as a white solid (9.5 mg, 0.012 mmol, 45.2% yield). MS (C<sub>40</sub>H<sub>39</sub>N<sub>4</sub>O<sub>7</sub>) <i>m</i>/<i>z</i>: 687 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.55 (s, 2H), 7.49 (d, <i>J</i> = 5.3 Hz, 2H), 7.40–7.31 (m, 8H), 6.86 (s, 2H), 5.02 (d, <i>J</i> = 15.4 Hz, 2H), 4.58 (d, <i>J</i> = 15.4 Hz, 2H), 4.36–4.18 (m, 4H), 4.07–4.00 (m, 4H), 3.97–3.92 (m, 8H), 3.35–3.24 (m, 2H), 3.22–3.12 (m, 2H).</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> (((Allyloxy)carbonyl)azanediyl)bis(ethane-2,1-diyl)bis(4-methylbenzenesulfonate) (<b>17a</b>)</h3><div class="NLM_p">To a suspension of 2,2′-azanediyldiethanol (5 g, 47.6 mmol, Fluka) and K<sub>2</sub>CO<sub>3</sub> (6.57 g, 47.6 mmol) in acetonitrile (50 mL) at 0 °C was added allyl chloroformate (5.07 mL, 47.6 mmol) and allowed to stir at room temperature for 3 h, cooled to 0 °C, and quenched with water (200 mL). The mixture was extracted with EtOAc (3 × 100 mL), and the combined organic layers were washed with saturated NaHCO<sub>3</sub> solution (100 mL) and water (100 mL), followed by brine (100 mL). The organic layer was dried over MgSO<sub>4</sub> and concentrated to afford allyl bis(2-hydroxyethyl)carbamate as a pale yellow oil (2.55 g, 13.48 mmol, 28.3% yield). MS (C<sub>8</sub>H<sub>16</sub>NO<sub>4</sub>) <i>m</i>/<i>z</i>: 190 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 5.94 (m, 1H), 5.32 (dd, <i>J</i> = 17.6, 1.6 Hz, 1H), 5.24 (dd, <i>J</i> = 10.4, 1.2 Hz, 1H), 4.62 (d, <i>J</i> = 6.8 Hz, 2H), 3.84 (d, <i>J</i> = 12.4 Hz, 2H), 3.52 (s, 2H), 2.86 (s, 2H).</div><div class="NLM_p last">To a solution of allyl bis(2-hydroxyethyl)carbamate (600 mg, 3.17 mmol) and TEA (1.768 mL, 12.68 mmol) in DCM (5 mL) at 0 °C was added tosyl chloride (1814 mg, 9.51 mmol) in DCM (5 mL), and the mixture was allowed to stir at room temperature for 1 h. The reaction mixture was concentrated, and the resulting residue was purified by silica gel chromatography (CombiFlash, 80 g column, 0–70% EtOAc/hexane over 25 min) to give the title compound <b>17a</b> as a thick oil (854 mg, 54% yield). MS (C<sub>22</sub>H<sub>27</sub>NNaO<sub>8</sub>S<sub>2</sub>) <i>m</i>/<i>z</i>: 520 (M + Na)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.78 (m, 4H), 7.38 (m, 4H), 5.82 (m, 1H), 5.22 (m, 2H), 4.48 (m, 2H), 4.13 (m, 4H), 3.52 (m, 4H), 2.47 (s, 6H).</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Allyl Bis(2-(((<i>S</i>)-2-methoxy-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy)methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)ethyl)carbamate (<b>17b</b>)</h3><div class="NLM_p last">A solution of <b>49</b> (80 mg, 0.176 mmol), bis tosylate <b>17a</b> (39.8 mg, 0.08 mmol), and K<sub>2</sub>CO<sub>3</sub> (33.2 mg, 0.240 mmol) in DMSO (1.5 mL) was stirred at 50 °C for 19 h. The reaction mixture was poured into water (30 mL). The mixture was saturated with brine (10 mL) and extracted with EtOAc (3 × 15 mL), and the combined organic layers were concentrated. The resulting residue was purified by silica gel chromatography (CombiFlash, 24 g column, 0–100% EtOAc/hexane over 30 min) to give the Alloc dimer <b>17b</b> as a white solid (54 mg, 0.051 mmol, 63.5% yield). MS (C<sub>56</sub>H<sub>72</sub>N<sub>5</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1062 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.29–7.17 (m, 12H), 5.88 (m, 1H), 5.44 (d, <i>J</i> = 10.0 Hz, 2H), 5.29–5.11 (m, 4H), 4.70 (dd, <i>J</i> = 18.4, 10.0 Hz, 2H), 4.58 (dd, <i>J</i> = 4.4, 1.2 Hz, 2H), 4.40 (m, 2H), 4.22 (m, 6H), 3.88–3.51 (m, 16H), 2.99 (m, 2H), 0.94 (m, 4H), 0.00 (s, 18H).</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-((Azanediylbis(ethane-2,1-diyl))bis(oxy))bis(2-methoxy-5-((2-(trimethylsilyl)ethoxy)methyl)-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,6a<i>H</i>)-dione) (<b>17c</b>)</h3><div class="NLM_p last">To a solution of Alloc dimer <b>17b</b> (54 mg, 0.051 mmol) in THF (4 mL) were added morpholine (0.022 mL, 0.254 mmol) and Pd(Ph<sub>3</sub>P)<sub>4</sub> (2.94 mg, 2.54 μmol). The reaction mixture was stirred under a nitrogen atmosphere at room temperature for 2 h and concentrated. The resulting residue was purified by silica gel chromatography (CombiFlash, 24 g column, 0–8% MeOH/DCM) to afford compound <b>17c</b> as a white solid (35 mg, 70% yield). MS (C<sub>52</sub>H<sub>68</sub>N<sub>5</sub>O<sub>10</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 978 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.36–7.17 (m, 12H), 5.46 (d, <i>J</i> = 10.0 Hz, 2H), 5.12 (d, <i>J</i> = 15.3 Hz, 2H), 4.63 (d, <i>J</i> = 10.0 Hz, 2H), 4.38 (d, <i>J</i> = 15.3 Hz, 2H), 4.25 (dd, <i>J</i> = 7.4, 6.4 Hz, 2H), 4.15 (m, 4H), 3.84 (s, 6H), 3.74 (td, <i>J</i> = 9.7, 6.9 Hz, 2H), 3.63 (td, <i>J</i> = 9.7, 6.9 Hz, 2H), 3.53 (dd, <i>J</i> = 15.5, 7.4 Hz, 2H), 3.17 (t, <i>J</i> = 5.1 Hz, 4H), 2.97 (dd, <i>J</i> = 15.5, 6.4 Hz, 2H), 1.04–0.87 (m, 4H), 0.00 (s, 18H).</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-((Azanediylbis(ethane-2,1-diyl))bis(oxy))bis(2-methoxy-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one) (<b>17</b>)</h3><div class="NLM_p last">To a solution of compound <b>17c</b> (350 mg, 0.358 mmol) in THF (10 mL) was added superhydride (1.789 mL, 1.789 mmol) at −76 °C. The reaction mixture was stirred for 1 h, quenched with cold water (10 mL), and extracted with DCM (3 × 20 mL). The resulting residue was treated with DCM/EtOH/water (1:2:1 = 8 mL) and silica gel (2 g) at room temperature for 3 days. This mixture was filtered through a sintered funnel, and the silica gel was washed with DCM–MeOH (8:2, 100 mL). The filtrate was concentrated under high vacuum and purified on CombiFlash EZ Prep 50 g C18 column eluting with 0–50% acetonitrile/water (0.05% formic acid) over 20 min. Product fractions were filtered through a basic resin (PL-HCO<sub>3</sub> MP-Resin 1.8 mmol/g; Agilent) and washed with acetonitrile (5 mL). Lyophilization provided the title compound <b>17</b> as a white solid (102.5 mg, 0.142 mmol, 39.7% yield). MS (C<sub>40</sub>H<sub>40</sub>N<sub>5</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 686 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.45 (s, 2H), 7.39 (d, <i>J</i> = 5.2 Hz, 2H), 7.23 (m, 8H), 6.75 (s, 2H), 4.92 (d, <i>J</i> = 15.6 Hz, 2H), 4.47 (d, <i>J</i> = 15.6 Hz, 2H), 4.19 (m, 4H), 3.85 (m, 8H), 3.05–3.22 (m, 9H).</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> (<i>S</i>)-3-(2-Aminoethoxy)-2-methoxy-5-((2-(trimethylsilyl)ethoxy)methyl)-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,6a<i>H</i>)-dione (<b>18c</b>)</h3><div class="NLM_p">To a solution of benzyl(2-hydroxyethyl)carbamate (Aldrich, 0.781 g, 4 mmol) and triethylamine (1.115 mL, 8.00 mmol) in DCM (20 mL) was added tosyl chloride (0.915 g, 4.80 mmol). The reaction was stirred at room temperature for 1 h. The reaction was then concentrated and purified by silica gel chromatography (0–100% EtOAc/hexane, 40 g column) to give 2-(((benzyloxy)carbonyl)amino)ethyl 4-methylbenzenesulfonate <b>18a</b> (0.85 g, 2.43 mmol, 60.8% yield). MS (C<sub>17</sub>H<sub>20</sub>NO<sub>5</sub>S) <i>m</i>/<i>z</i>: 350 (M + H)<sup>+</sup>.</div><div class="NLM_p">To a solution of <b>49</b> (160 mg, 0.352 mmol) and <b>18a</b> (135 mg, 0.387 mmol) in DMF (3 mL) was added potassium carbonate (97 mg, 0.704 mmol). The resulting suspension was stirred at room temperature for 2 h. The reaction was then diluted with EtOAc and washed sequentially with aq LiCl and brine. The organic layer was separated, dried over sodium sulfate, and concentrated <i>in vacuo</i>. The crude material was purified by silica gel chromatography (0–10% MeOH/DCM, 24 g column) to give <b>18b</b>. MS (C<sub>34</sub>H<sub>42</sub>N<sub>3</sub>O<sub>7</sub>Si) <i>m</i>/<i>z</i>: 632 (M + H)<sup>+</sup>.</div><div class="NLM_p last">A suspension of <b>18b</b> and 10% Pd/C (25 mg) in MeOH (8 mL) was stirred under a balloon of H<sub>2</sub> at room temperature for 5 h. The reaction was then purged with N<sub>2</sub>, filtered through a pad of Celite, and concentrated to give <b>18c</b> (150 mg, 0.301 mmol, 86% yield). MS (C<sub>26</sub>H<sub>36</sub>N<sub>3</sub>O<sub>5</sub>Si) <i>m</i>/<i>z</i>: 498 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.65 (d, <i>J</i> = 8.2 Hz, 1H), 7.38–7.23 (m, 4H), 7.21 (s, 1H), 7.07 (d, <i>J</i> = 7.9 Hz, 1H), 6.90–6.64 (m, 3H), 5.41 (d, <i>J</i> = 10.2 Hz, 1H), 5.14 (d, <i>J</i> = 15.3 Hz, 1H), 4.76 (d, <i>J</i> = 10.1 Hz, 1H), 4.44–4.33 (m, 2H), 4.32–4.17 (m, 3H), 3.80 (s, 3H), 3.72–3.50 (m, 4H), 3.39–3.30 (m, 2H), 3.05–2.93 (m, 1H), 0.98–0.87 (m, 2H), 0.00 (s, 9H).</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 2-(((<i>S</i>)-2-Methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)-<i>N</i>-(2-(((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)ethyl)acetamide (<b>18</b>)</h3><div class="NLM_p">To a solution of <b>18c</b> (65 mg, 0.131 mmol) in DCM (2 mL) at 0 °C were added triethylamine (0.055 mL, 0.39 mmol) and 2-chloroacetyl chloride (22.13 mg, 0.196 mmol). The solution was stirred for 1 h and then diluted with DCM. The organic layer was washed with brine, dried over sodium sulfate, and concentrated <i>in vacuo</i> to give <b>18d</b>. MS (C<sub>28</sub>H<sub>37</sub>ClN<sub>3</sub>O<sub>6</sub>Si) <i>m</i>/<i>z</i>: 574 (M + H)<sup>+</sup>. This residue was combined with <b>49</b> (59.4 mg, 0.131 mmol) and treated with potassium carbonate (4.2 mg, 0.392 mmol) in DMSO (1 mL) at 50 °C for 4 h. After cooling to room temperature, the reaction was diluted with EtOAc and washed with brine. The organic layer was separated, dried over sodium sulfate, and concentrated <i>in vacuo</i>. The crude material was purified by silica gel chromatography (0–10% Me OH/DCM, 24 g column) to give the title compound <b>18e</b> (95 mg, 0.096 mmol, 73.3% yield). MS (C<sub>52</sub>H<sub>66</sub>N<sub>5</sub>O<sub>11</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 992 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <b>18e</b> (40 mg, 0.040 mmol) in THF (0.6 mL) at −78 °C was added a solution of lithium triethylborohydride (0.4 mL, 1 M in THF). The reaction was then stirred at −78 °C for 1 h before it was quenched with water (1 mL). The reaction was then extracted with chloroform (3×). The combined organic layers were dried over sodium sulfate, filtered, and concentrated <i>in vacuo</i>. The residue was then taken up in chloroform/EtOH (1:1, 2 mL). Silica gel (0.8 g) was added, followed by water (0.6 mL). The resulting suspension was stirred at room temperature for 1 day and then filtered, washing with 10% MeOH/chloroform. The filtrate was concentrated <i>in vacuo</i> and purified by preparative HPLC to give the title compound <b>18</b> as a white solid (11 mg, 0.014 mmol, 35.1% yield). MS (C<sub>40</sub>H<sub>38</sub>N<sub>5</sub>O<sub>7</sub>) <i>m</i>/<i>z</i>: 700 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.57 (d, <i>J</i> = 9.5 Hz, 2H), 7.48 (dd, <i>J</i> = 5.3, 0.9 Hz, 2H), 7.40–7.31 (m, 9H), 6.83 (d, <i>J</i> = 4.0 Hz, 2H), 5.01 (d, <i>J</i> = 15.6 Hz, 2H), 4.64–4.51 (m, 4H), 4.20 (td, <i>J</i> = 9.4, 5.0 Hz, 2H), 3.96 (s, 3H), 3.95 (s, 3H), 3.91–3.82 (m, 4H), 3.34–3.23 (m, 2H), 3.20–3.11 (m, 2H).</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> (<i>S</i>)-10-Hydroxy-2-methoxy-3-((5-(((<i>S</i>)-2-methoxy-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy) methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)pentyl)oxy)-5-((2-(trimethylsilyl)ethoxy)methyl)-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,12<i>H</i>)-dione (<b>19</b>)</h3><div class="NLM_p">To a solution of <b>4b</b> (135 mg, 0.208 mmol) and <b>8f</b> (110 mg, 0.198 mmol) in DMSO (3 mL) was added potassium carbonate (82 mg, 0.595 mmol). The resulting suspension was stirred at room temperature for 5 h. The reaction was then diluted with EtOAc and washed with water. The organic layer was separated, dried over sodium sulfate, and concentrated <i>in vacuo</i>. The residue was taken up in MeOH (10 mL), PPTS (15 mg) was added, and the reaction was stirred at 40 °C for 1 h. The reaction was then concentrated and purified by silica gel chromatography (0–100% EtOAc/hexane, 24 g column) to give the title compound <b>19a</b> (141 mg, 0.142 mmol, 71.6% yield). MS (C<sub>53</sub>H<sub>69</sub>N<sub>4</sub>O<sub>11</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 993 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.36–7.29 (m, 4H), 7.27–7.24 (m, 1H), 7.23–7.10 (m, 4H), 6.94 (d, <i>J</i> = 2.2 Hz, 1H), 6.79 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H), 5.51 (t, <i>J</i> = 9.6 Hz, 2H), 5.18 (dd, <i>J</i> = 19.4, 15.2 Hz, 2H), 4.69 (dd, <i>J</i> = 9.9, 7.5 Hz, 2H), 4.42 (d, <i>J</i> = 15.4 Hz, 1H), 4.37–4.26 (m, 2H), 4.22 (dd, <i>J</i> = 7.7, 6.6 Hz, 1H), 4.09–4.00 (m, 3H), 3.88 (d, <i>J</i> = 2.6 Hz, 6H), 3.80 (dd, <i>J</i> = 7.0, 4.6 Hz, 2H), 3.68 (dd, <i>J</i> = 6.8, 5.1 Hz, 2H), 3.60–3.43 (m, 2H), 3.10–2.82 (m, 2H), 2.00–1.87 (m, 4H), 1.69 (br s, 2H), 0.98 (td, <i>J</i> = 6.6, 3.3 Hz, 4H), 0.10–0.02 (m, 18H).</div><div class="NLM_p last">To a solution of <b>19a</b> (18 mg, 0.018 mmol) in THF (0.6 mL) at −78 °C was added a solution of lithium triethylborohydride (1 M in THF, 362 μL, 0.362 mmol). The reaction was stirred at −78 °C for 1 h before it was quenched with water (1 mL). The reaction was then extracted with chloroform (3×). The combined organic layers were dried over sodium sulfate, filtered, and concentrated <i>in vacuo</i>. The residue was then taken up in chloroform/EtOH (1:1, 2 mL). Silica gel (0.8 g) was added, followed by water (0.6 mL). The resulting suspension was stirred at room temperature for 1 day and then filtered, washing with 10% MeOH/chloroform. The filtrate was concentrated <i>in vacuo</i> and purified by preparative HPLC to give the title compound <b>19</b> as a white solid (4.8 mg, 6.16 μmol, 34.0% yield). MS (C<sub>41</sub>H<sub>41</sub>N<sub>4</sub>O<sub>7</sub>) <i>m</i>/<i>z</i>: 701 (M + H)<sup>+</sup>.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> (<i>S</i>)-2,10-Dimethoxy-3-((5-(((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)pentyl)oxy)-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one (<b>20</b>)</h3><div class="NLM_p last">To a solution of <b>19a</b> (18 mg, 0.018 mmol) in DMSO (0.5 mL) were added potassium carbonate (7.51 mg, 0.054 mmol) and iodomethane (2.53 mg, 0.054 mmol). The reaction was stirred at room temperature for 3 h before it was diluted with EtOAc and washed with water. The organic layer was separated, dried over sodium sulfate, and concentrated <i>in vacuo</i> to give <b>20a</b>. MS (C<sub>54</sub>H<sub>71</sub>N<sub>4</sub>O<sub>11</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1007 (M + H)<sup>+</sup>. The crude product was dissolved in THF (0.6 mL) and cooled to −78 °C. A solution of lithium triethylborohydride (0.4 mL, 1 M in THF) was added dropwise. The reaction was then stirred at −78 °C for 1 h before it was quenched with water (1 mL). The reaction was then extracted with chloroform (3×). The combined organic layers were dried over sodium sulfate, filtered, and concentrated <i>in vacuo</i>. The residue was then taken up in chloroform/EtOH (1:1, 2 mL). Silica gel (0.8 g) was added, followed by water (0.6 mL). The resulting suspension was stirred at room temperature for 1 day and then filtered, washing with 10% MeOH/chloroform. The filtrate was concentrated <i>in vacuo</i> and purified by preparative HPLC to give the title compound <b>20</b> (4.2 mg, 5.29 μmol, 29.2% yield). MS (C<sub>42</sub>H<sub>43</sub>N<sub>4</sub>O<sub>7</sub>) <i>m</i>/<i>z</i>: 715 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.55 (d, <i>J</i> = 1.6 Hz, 2H), 7.50 (d, <i>J</i> = 5.3 Hz, 2H), 7.41–7.30 (m, 5H), 6.94–6.86 (m, 2H), 6.81 (m, 1H), 5.01 (t, <i>J</i> = 14.9 Hz, 2H), 4.67–4.47 (m, 2H), 4.24–4.01 (m, 5H), 3.96 (s, 6H), 3.86 (s, 3H), 3.34–3.02 (m, 4H), 2.02–1.88 (m, 4H).</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> (<i>S</i>)-10-(2-Hydroxyethoxy)-2-methoxy-3-((5-(((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)pentyl)oxy)-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one (<b>21</b>)</h3><div class="NLM_p last">To a solution of <b>19a</b> (20 mg, 0.020 mmol) in DMF (0.8 mL) was added potassium carbonate (13.91 mg, 0.101 mmol), followed by 2-bromoethanol (7.55 mg, 0.060 mmol). The reaction was heated at 80 °C for 4 h, at which point LCMS showed full conversion to product. The reaction was then filtered and loaded onto a 24 g silica gel column and eluted with 0–100% EtOAc/hexane to give <b>21a</b>. MS (C<sub>55</sub>H<sub>73</sub>N<sub>4</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1037 (M + H)<sup>+</sup>. This was dissolved in THF (0.6 mL) and cooled to −78 °C. Superhydride (0.201 mL, 0.201 mmol) was added and stirred at −78 °C for 1 h. The reaction was quenched with water (1 mL) and extracted with chloroform, dried over sodium sulfate, filtered, and concentrated. The residue was taken up in chloroform/EtOH (1:1, 2 mL). Silica gel (0.8 g) was added, followed by water (∼0.6 mL) and stirred at room temperature for 1 day and then filtered, washing with 10% MeOH/chloroform. The filtrate was concentrated and purified by preparative HPLC to give <b>21</b> as a white solid (3.5 mg, 4.23 μmol, 21% yield over two steps). MS (C<sub>43</sub>H<sub>45</sub>N<sub>4</sub>O<sub>8</sub>) <i>m</i>/<i>z</i>: 745 (M + H)<sup>+</sup>.</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> (<i>S</i>)-2-Methoxy-3-((5-(((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)pentyl)oxy)-10-(2-(2-methoxyethoxy)ethoxy)-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one (<b>22</b>)</h3><div class="NLM_p last">To a solution of <b>19a</b> (18 mg, 0.018 mmol) and 1-bromo-2-(2-methoxyethoxy)ethane (3.32 mg, 0.018 mmol) in DMSO (0.5 mL) was added potassium carbonate (7.51 mg, 0.054 mmol) and stirred at room temperature for 3 h. The reaction was diluted with EtOAc, washed with water and then brine, dried, and concentrated to give <b>22a</b>. MS (C<sub>58</sub>H<sub>79</sub>N<sub>4</sub>O<sub>13</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1095 (M + H)<sup>+</sup>. This was dissolved in THF (0.6 mL) and cooled to −78 °C. Superhydride (0.4 mL, 1 M in THF) was then added and stirred at −78 °C for 1 h. The reaction was quenched with water (1 mL). The reaction was then extracted with chloroform, dried over sodium sulfate, filtered, and concentrated. The residue was then taken up in chloroform/EtOH (1:1, 2 mL). Silica gel (0.8 g) was added, followed by water (0.6 mL), stirred at room temperature for 1 day, and then filtered, washing with 10% MeOH/chloroform. The filtrate was concentrated and purified by preparative HPLC to give <b>22</b> as a white solid (3.1 mg, 3.47 μmol, 19.18% yield). MS (C<sub>46</sub>H<sub>51</sub>N<sub>4</sub>O<sub>9</sub>) <i>m</i>/<i>z</i>: 803 (M + H)<sup>+</sup>.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 2-Amino-<i>N</i>-((<i>S</i>)-2-methoxy-3-((5-(((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)pentyl)oxy)-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-10-yl)acetamide (<b>23</b>)</h3><div class="NLM_p last">To a solution of <b>14</b> (4.5 mg, 6.43 μmol), Fmoc-Gly-OH (3.82 mg, 0.013 mmol), and HATU (4.89 mg, 0.013 mmol) in DMF (0.5 mL) was added Hunig’s base (3.37 μL, 0.019 mmol). The reaction was stirred at room temperature for 4 h, and then piperidine (100 μL) was added. The resulting mixture was stirred at room temperature for 1 h and purified by preparative HPLC to give <b>23</b> as a white solid (0.94 mg, 1.180 μmol, 18.35% yield). MS (C<sub>43</sub>H<sub>45</sub>N<sub>6</sub>O<sub>7</sub>) <i>m</i>/<i>z</i>: 757 (M + H)<sup>+</sup>.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-((1,3-Phenylenebis(methylene))bis(oxy))bis(2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one) (<b>24</b>)</h3><div class="NLM_p">To a solution of <b>50</b> (68 mg, 0.130 mmol) and [1,3-bis(bromomethyl)benzene (17.10 mg, 0.065 mmol)] in acetone (0.4 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (42.2 mg, 0.130 mmol) and stirred at 40 °C for 1 h. That was quenched with 0.1 M citric acid and extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, concentrated, and purified by silica gel chromatography using EtOAc/hexane to give <b>24b</b> as a white solid (13.5 mg, 0.012 mmol, 18.09% yield). MS (C<sub>64</sub>H<sub>79</sub>N<sub>4</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1151 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <b>24b</b> (13.5 mg, 0.012 mmol) and pyrrolidine in DCM (0.698 mL, 0.029 mmol, 0.042 M) was added Pd(PPh<sub>3</sub>)<sub>4</sub> (2 mg, 1.731 μmol) and allowed to stir at room temperature for 30 min. That was diluted with DCM and washed with saturated ammonium chloride. The aqueous layer was re-extracted with DCM. Combined organic phases were dried over sodium sulfate, filtered, and concentrated. The residue was purified by preparative HPLC to give <b>24</b> as a white solid (5.18 mg, 58.4% yield). MS (C<sub>44</sub>H<sub>39</sub>N<sub>4</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 719 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.58 (s, 2H), 7.54–7.31 (m, 12H), 6.85 (s, 2H), 5.25 (d, <i>J</i> = 12.3 Hz, 2H), 5.18 (d, <i>J</i> = 12.4 Hz, 2H), 5.02 (d, <i>J</i> = 15.5 Hz, 2H), 4.58 (d, <i>J</i> = 15.5 Hz, 2H), 3.99 (s, 6H), 3.94 (m, 2H), 3.28 (dd, <i>J</i> = 15.4, 5.6 Hz, 2H), 3.17 (dd, <i>J</i> = 15.4, 4.2 Hz, 2H).</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-((1,4-Phenylenebis(methylene))bis(oxy))bis(2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one) (<b>25</b>)</h3><div class="NLM_p">To a solution of <b>50</b> (119 mg, 0.227 mmol) and 1,4-bis(bromomethyl)benzene <b>25a</b> (20 mg, 0.076 mmol) in DMF (2 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (74.1 mg, 0.227 mmol) and stirred at room temperature for 1 h. The crude material was purified on silica gel using MeOH/DCM to afford <b>25b</b> as a white solid (85 mg, 0.069 mmol, 91% yield). MS (C<sub>64</sub>H<sub>79</sub>N<sub>4</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1151 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.45–7.21 (m, 10H), 7.18 (s, 2H), 6.62–6.56 (m, 2H), 5.67 (ddt, <i>J</i> = 16.0, 10.3, 5.0 Hz, 2H), 5.20 (d, <i>J</i> = 9.6 Hz, 3H), 5.09 (dd, <i>J</i> = 26.7, 12.2 Hz, 6H), 4.98 (d, <i>J</i> = 17.0 Hz, 3H), 4.74 (d, <i>J</i> = 15.7 Hz, 3H), 4.49–4.39 (m, 2H), 4.30 (dd, <i>J</i> = 14.2, 6.5 Hz, 4H), 3.84 (s, 6H), 3.52 (s, 1H), 3.09 (dd, <i>J</i> = 15.4, 6.0 Hz, 2H), 0.83 (s, 18H), 0.07 (s, 12H).</div><div class="NLM_p last">The dimer <b>25b</b> (85 mg, 0.074 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>25</b> as a white solid (50 mg, 91% yield). MS (C<sub>44</sub>H<sub>3</sub>N<sub>4</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 719 (M + H)<sup>+</sup>.</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-((1,2-Phenylenebis(methylene))bis(oxy))bis(2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one) (<b>26</b>)</h3><div class="NLM_p">To a solution of <i>O</i>-xylylene dibromide <b>26a</b> (10 mg, 0.038 mmol) and <b>50</b> (59.6 mg, 0.114 mmol) in DMF (0.1 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (37.0 mg, 0.114 mmol), and the reaction was stirred at room temperature for 1 h. The crude material was purified on silica gel (30–100% acetone/DCM) to afford <b>26b</b> as a white solid (50 mg, 0.033 mmol, 88% yield). MS (C<sub>64</sub>H<sub>79</sub>N<sub>4</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1151 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.61–7.49 (m, 2H), 7.48–7.41 (m, 2H), 7.37 (d, <i>J</i> = 7.0 Hz, 2H), 7.34–7.22 (m, 6H), 7.17 (s, 1H), 6.67 (s, 1H), 5.69 (s, 1H), 5.20 (dd, <i>J</i> = 28.6, 10.5 Hz, 4H), 5.02 (q, <i>J</i> = 16.9, 12.9 Hz, 6H), 4.72 (d, <i>J</i> = 16.2 Hz, 2H), 4.56 (d, <i>J</i> = 15.9 Hz, 1H), 4.40 (m, 6H), 3.81 (s, 6H), 3.54–3.47 (m, 2H), 3.08 (dd, <i>J</i> = 15.2, 5.7 Hz, 2H), 2.93 (s, 1H), 0.70 (d, <i>J</i> = 6.4 Hz, 18H), 0.12–0.03 (m, 12H).</div><div class="NLM_p last">The dimer <b>26b</b> (16 mg, 0.014 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>26</b> as a white solid (4 mg, 5.45 μmol, 39.2% yield). MS (C<sub>44</sub>H<sub>39</sub>N<sub>4</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 719 (M + H)<sup>+</sup>.</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Allyl (3,5-Bis(hydroxymethyl)phenyl)carbamate (<b>27b</b>)</h3><div class="NLM_p last">A suspension of 5-nitro-<i>m</i>-xylene-alpha,alpha′-diol <b>27a</b> (1 g, 5.46 mmol, Aldrich) and 10% palladium on carbon (291 mg, 0.273 mmol) in methanol (50 mL) was stirred under a balloon of H<sub>2</sub> at room temperature for 2 h. The reaction was filtered through Celite and concentrated <i>in vacuo</i>. This was dissolved in THF (10 mL) and mixed with potassium carbonate (650 mg, 4.7 mmol). That was cooled to 0 °C, and allyl chloroformate (0.5 mL, 4.7 mmol) was added. The reaction was stirred at 0 °C for 30 min before it was allowed to warm to room temperature and stirred for 3 h. The reaction was then quenched with water and extracted with EtOAc (2×). The organic layer was dried and concentrated <i>in vacuo</i>. The crude product was purified by silica gel chromatography (40 g column, 0–100% EtOAc/DCM in 15 min) to give <b>27b</b> (200 mg, 21.5% yield). MS (C<sub>12</sub>H<sub>15</sub>NNaO<sub>4</sub>) <i>m</i>/<i>z</i>: 260 (M + Na)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.31 (s, 2H), 6.91 (s, 1H), 5.99 (ddt, <i>J</i> = 17.2, 10.6, 5.4 Hz, 1H), 5.36 (dq, <i>J</i> = 17.2, 1.6 Hz, 1H), 5.24 (dq, <i>J</i> = 10.6, 1.4 Hz, 1H), 5.13 (t, <i>J</i> = 5.7 Hz, 2H), 4.60 (dt, <i>J</i> = 5.4, 1.3 Hz, 2H), 4.44 (d, <i>J</i> = 5.5 Hz, 4H).</div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> (5-(((Allyloxy)carbonyl)amino)-1,3-phenylene)bis(methylene) Dimethanesulfonate (<b>27c</b>)</h3><div class="NLM_p last">A suspension of <b>27b</b> (462.5 mg, 1.949 mmol) and triethylamine (0.815 mL, 5.85 mmol) in DCM (20 mL) was cooled to −10 °C and treated with mesyl chloride (0.395 mL, 5.07 mmol). The reaction was stirred at −10 °C for 1 h before it was quenched with ice-cold water and extracted with DCM (2 × 10 mL). The organic layer was washed with ice-cold water, dried over sodium sulfate, and concentrated <i>in vacuo</i> to give the title compound <b>27c</b> (750 mg, 95% yield). MS (C<sub>14</sub>H<sub>20</sub>NO<sub>8</sub>S<sub>2</sub>) <i>m</i>/<i>z</i>: 394 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.52 (s, 2H), 7.15 (s, 1H), 7.04 (s, 1H), 6.09–5.87 (m, 1H), 5.39 (dd, <i>J</i> = 17.2, 1.5 Hz, 1H), 5.29 (dd, <i>J</i> = 10.3, 1.3 Hz, 1H), 5.21 (s, 4H), 4.69 (dt, <i>J</i> = 5.7, 1.2 Hz, 2H), 3.02 (s, 6H).</div></div><div id="sec5_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Allyl (3,5-Bis((((<i>S</i>)-2-methoxy-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy)methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)methyl)phenyl)carbamate (<b>27d</b>)</h3><div class="NLM_p last">A solution of <b>27c</b> (135 mg, 0.343 mmol) in DMSO (16 mL) was treated with <b>49</b> (312 mg, 0.686 mmol) and potassium carbonate (142 mg, 1.029 mmol) at room temperature for 2 h. The reaction was quenched with water and extracted with EtOAc (3×). The mixture was then dried and concentrated <i>in vacuo</i>. The crude product was purified by silica gel chromatography (40 g column, 0–100% EtOAc/hexane in 15 min) to give the title compound <b>27d</b> (250 mg, 66% yield). MS (C<sub>60</sub>H<sub>72</sub>N<sub>5</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1110 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.51 (s, 2H), 7.38–7.13 (m, 14H), 6.96–6.75 (m, 1H), 6.12–5.86 (m, 1H), 5.48 (d, <i>J</i> = 10.1 Hz, 2H), 5.43–5.32 (m, 1H), 5.32–5.23 (m, 1H), 5.23–4.99 (m, 6H), 4.74–4.53 (m, 4H), 4.41 (d, <i>J</i> = 15.2 Hz, 2H), 4.30 (d, <i>J</i> = 0.9 Hz, 2H), 3.96–3.83 (m, 6H), 3.81–3.46 (m, 6H), 2.98 (s, 2H), 1.14–0.85 (m, 4H), 0.13 to −0.08 (m, 18H).</div></div><div id="sec5_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-(((5-Amino-1,3-phenylene)bis(methylene))bis(oxy))bis(2-methoxy-5-((2-(trimethylsilyl)ethoxy)methyl)-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,6a<i>H</i>)-dione) (<b>27e</b>)</h3><div class="NLM_p last">To a solution of <b>27d</b> (200 mg, 0.180 mmol) in THF (5 mL) at 0 °C were added Pd(Ph<sub>3</sub>P)<sub>4</sub> (8.33 mg, 7.20 μmol) and morpholine (0.038 mL, 0.432 mmol). The reaction was stirred at 0 °C for 2 h. The reaction mixture was quenched with saturated aqueous ammonium chloride (5 mL) and extracted with EtOAc (10 mL). The organic layer was washed with saturated aqueous NaHCO<sub>3</sub> and then brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified by silica gel chromatography (40 g column, 0–10% methanol/DCM in 15 min) to give the title compound <b>27e</b> (160 mg, 87% yield). MS (C<sub>56</sub>H<sub>68</sub>N<sub>5</sub>O<sub>10</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1026 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.38–7.30 (m, 6H), 7.28 (d, <i>J</i> = 5.1 Hz, 7H), 6.92–6.85 (m, 1H), 6.76 (d, <i>J</i> = 1.1 Hz, 2H), 5.47 (d, <i>J</i> = 10.1 Hz, 2H), 5.18 (d, <i>J</i> = 15.2 Hz, 2H), 5.08 (d, <i>J</i> = 8.6 Hz, 4H), 4.65 (d, <i>J</i> = 10.1 Hz, 2H), 4.42 (d, <i>J</i> = 15.4 Hz, 2H), 4.30 (d, <i>J</i> = 0.9 Hz, 2H), 3.92 (s, 6H), 3.82–3.50 (m, 8H), 3.09–2.94 (m, 2H), 1.11–0.88 (m, 4H), 0.10–0.03 (m, 18H).</div></div><div id="sec5_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-(((5-Amino-1,3-phenylene)bis(methylene))bis(oxy))bis(2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one) (<b>27</b>)</h3><div class="NLM_p last">To a solution of <b>27e</b> (22 mg, 0.021 mmol) in THF (233 μL) and EtOH (233 μL) at 0 °C was added a solution of lithium borohydride (214 μL, 0.429 mmol) (2 M in THF). The reaction was slowly warmed to room temperature and stirred at room temperature for 2 h. The reaction was quenched with water and extracted with chloroform (2×) and then chloroform/MeOH (2×). The combined organic extracts were dried over sodium sulfate and concentrated <i>in vacuo</i>. The residue was dissolved in chloroform/EtOH/water (1:1:1, 2 mL), silica gel (0.7 g) was added, and the reaction was stirred at room temperature for 3 days. The reaction mixture was filtered through a Celite plug and washed with chloroform, and the solution was concentrated. The residue was purified by preparative HPLC to give the title compound <b>27</b> as a pale yellow solid (8.1 mg, 46.3% yield). MS (C<sub>44</sub>H<sub>40</sub>N<sub>5</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 734 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.57 (s, 2H), 7.47 (d, <i>J</i> = 5.3 Hz, 2H), 7.43–7.30 (m, 8H), 6.99–6.79 (m, 2H), 6.73 (s, 2H), 5.40–4.90 (m, 8H), 4.59 (d, <i>J</i> = 15.4 Hz, 2H), 4.17–3.85 (m, 8H), 3.39–3.05 (m, 4H).</div></div><div id="sec5_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-(((5-Azido-1,3-phenylene)bis(methylene))bis(oxy))bis(2-methoxy-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one) (<b>28</b>)</h3><div class="NLM_p">A suspension of (5-azido-1,3-phenylene)dimethanol<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> (0.25 g, 1.40 mmol) and triethylamine (0.58 mL, 4.19 mmol) in DCM (5 mL) was cooled on an ice–water bath and treated with mesyl chloride (0.25 mL, 3.2 mmol). The reaction mixture was stirred at the same temperature for 2 h and then quenched by the addition of water. The layers of the biphasic mixture were separated, and the aqueous layer was extracted again with a portion of DCM. The combined organics were washed with cold dilute HCl (0.05 N), followed by brine and then dried over sodium sulfate. Evaporation of the solvent afforded mesylate <b>28a</b> as a white solid, which was used without further purification (0.425 g, 91% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.25 (s, 1H), 7.11 (s, 2H), 5.29–5.18 (m, 4H), 3.05 (s, 6H).</div><div class="NLM_p">A suspension of phenol <b>50</b> (94 mg, 0.18 mmol), mesylate <b>28a</b> (30 mg, 0.089 mmol), and cesium carbonate (73 mg, 0.22 mmol) in acetone (0.4 mL) was stirred at 40 °C for 1 h. The mixture was quenched with 0.1 M citric acid and extracted thrice with ethyl acetate. The combined organics were washed with brine and dried over sodium sulfate, filtered, and evaporated. The mixture was purified by silica gel chromatography (30–80% ethyl acetate in hexanes) to afford dimer <b>28b</b> (82.6 mg, 77% yield). MS (C<sub>64</sub>H<sub>78</sub>N<sub>7</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1192 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Dimer <b>28b</b> (41.3 mg, 0.035 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>28</b> as a white solid (7.08 mg, 26% yield). HRMS (ESI<sup>+</sup>): calcd (C<sub>44</sub>H<sub>38</sub>N<sub>7</sub>O<sub>6</sub>) (M + H)<sup>+</sup>, 760.2878; found, 760.2872.</div></div><div id="sec5_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Allyl (6a<i>S</i>)-3,6-Dihydroxy-2-methoxy-14-oxo-6,6a,7,12-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-5(14<i>H</i>)-carboxylate (<b>29b</b>)</h3><div class="NLM_p last">To a solution of <b>66</b> (600 mg, 1.059 mmol) in DMF–water (50:1, 5 mL) was added LiOAc (69.9 mg, 1.059 mmol) and stirred at room temperature overnight. The mixture was quenched with 0.1 M citric acid and extracted thrice with ethyl acetate. The combined organics were washed with brine and dried over sodium sulfate, filtered, and evaporated to afford <b>29b</b> as a white solid (410 mg, 0.999 mmol, 94% yield). MS (C<sub>22</sub>H<sub>23</sub>N<sub>2</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 411 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.35–7.23 (m, 13H), 6.77 (s, 2H), 5.92 (s, 2H), 5.81 (ddt, <i>J</i> = 17.5, 10.8, 5.5 Hz, 2H), 5.37–5.29 (m, 2H), 5.20–5.12 (m, 4H), 4.84 (d, <i>J</i> = 15.6 Hz, 2H), 4.68–4.55 (m, 4H), 4.46 (d, <i>J</i> = 13.2 Hz, 2H), 4.15 (q, <i>J</i> = 7.1 Hz, 3H), 3.97 (s, 6H), 3.73 (ddd, <i>J</i> = 9.8, 5.7, 3.8 Hz, 2H), 3.34 (s, 1H), 3.18 (dd, <i>J</i> = 15.4, 3.9 Hz, 2H), 3.10 (dd, <i>J</i> = 15.3, 5.7 Hz, 2H).</div></div><div id="sec5_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Diallyl 3,3′-(((5-(Bromomethyl)-1,3-phenylene)bis(methylene))bis(oxy))(6a<i>S</i>,6a′<i>S</i>)-bis(6-hydroxy-2-methoxy-14-oxo-6,6a,7,12-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-5(14<i>H</i>)-carboxylate) (<b>29c</b>)</h3><div class="NLM_p last">To a mixture of <b>29b</b> (120 mg, 0.291 mmol) and cesium carbonate (100 mg, 0.306 mmol) in DMF (729 μL) was added 1,3,5-tris(bromomethyl)benzene <b>29a</b> (52 mg, 0.146 mmol) and stirred at room temperature for 2 h. The mixture was quenched with 0.1 M citric acid and extracted thrice with ethyl acetate. The combined organics were washed with brine and dried over sodium sulfate, filtered, and evaporated. The mixture was purified by silica gel chromatography, eluting with ethyl acetate/hexanes to afford dimer <b>29c</b> (36 mg, 24% yield). MS (C<sub>53</sub>H<sub>51</sub>BrN<sub>4</sub>NaO<sub>12</sub>) <i>m</i>/<i>z</i>: 1039 (M + Na)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.39 (d, <i>J</i> = 15.4 Hz, 3H), 7.30 (d, <i>J</i> = 3.6 Hz, 10H), 6.64 (s, 1H), 5.68 (s, 1H), 5.31 (s, 3H), 5.19–5.02 (m, 8H), 4.82 (dd, <i>J</i> = 15.7, 5.1 Hz, 2H), 4.59 (d, <i>J</i> = 15.4 Hz, 2H), 4.53–4.34 (m, 6H), 3.96 (d, <i>J</i> = 6.1 Hz, 6H), 3.81 (s, 1H), 3.73–3.66 (m, 2H), 3.11 (m, 4H).</div></div><div id="sec5_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-(((5-(Azidomethyl)-1,3-phenylene)bis(methylene))bis(oxy))bis(2-methoxy-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one) (<b>29</b>)</h3><div class="NLM_p last">To a solution of <b>29c</b> (30 mg, 0.030 mmol) in DMF (0.1 mL) was added sodium azide (19.20 mg, 0.295 mmol) and stirred at room temperature overnight. That was worked-up with EtOAc/water. The organic layer was dried over sodium sulfate and concentrated to afford <b>29d</b>. This was deprotected using a procedure similar to compound <b>24</b> to afford <b>29</b> as a white solid (8 mg, 32% yield). MS (C<sub>45</sub>H<sub>40</sub>N<sub>7</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 774 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.68–7.16 (m, 13H), 7.10 (d, <i>J</i> = 3.5 Hz, 1H), 6.95 (d, <i>J</i> = 6.0 Hz, 1H), 6.68 (s, 1H), 5.90 (s, 1H), 5.36 (s, 1H), 5.30–4.97 (m, 4H), 4.82 (d, <i>J</i> = 15.5 Hz, 1H), 4.70–4.41 (m, 4H), 4.27 (s, 1H), 3.83 (s, 3H), 3.71 (s, 3H), 3.59 (d, <i>J</i> = 24.3 Hz, 2H), 3.26 (s, 1H), 3.17–2.87 (m, 3H).</div></div><div id="sec5_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-((Pyridine-2,6-diylbis(methylene))bis(oxy))bis(2-methoxy-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one) (<b>30</b>)</h3><div class="NLM_p">A suspension <b>50</b> (60 mg, 0.114 mmol), 2,6-bis(bromomethyl)pyridine <b>30a</b>, (15 mg, 0.057 mmol) and cesium carbonate (37 mg, 0.114 mmol) in acetone (0.4 mL) was stirred at 40 °C for 1 h. The reaction was quenched with 0.1 M citric acid and extracted thrice with ethyl acetate. The combined organics were washed with brine and dried over sodium sulfate, filtered, and evaporated. The mixture was purified by silica gel chromatography, eluting with a gradient from 30 to 80% ethyl acetate in hexanes to afford dimer <b>30b</b> (36.2 mg, 55% yield). MS (C<sub>63</sub>H<sub>78</sub>N<sub>5</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1153 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Dimer <b>30b</b> (36 mg, 0.031 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>30</b> as a white powder (13.4 mg, 56% yield). HRMS (ESI<sup>+</sup>): calcd (C<sub>43</sub>H<sub>38</sub>N<sub>5</sub>O<sub>6</sub>) (M + H)<sup>+</sup>, 720.2817; found, 720.2808. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.79–7.68 (m, 2H), 7.60 (s, 3H), 7.48 (t, <i>J</i> = 6.1 Hz, 5H), 7.41–7.30 (m, 7H), 6.87 (s, 2H), 5.34 (d, <i>J</i> = 1.8 Hz, 4H), 5.02 (d, <i>J</i> = 15.5 Hz, 2H), 4.60 (d, <i>J</i> = 15.5 Hz, 2H), 4.02 (s, 6H), 3.98–3.91 (m, 2H), 3.29 (dd, <i>J</i> = 15.4, 5.6 Hz, 2H), 3.17 (dd, <i>J</i> = 15.4, 4.3 Hz, 2H).</div></div><div id="sec5_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-((Pyridine-3,5-diylbis(methylene))bis(oxy))bis(2-methoxy-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one) (<b>31</b>)</h3><div class="NLM_p">To a solution of <b>50</b> (100 mg, 0.191 mmol), pyridine-3,5-diyldimethanol <b>31a</b> (26.5 mg, 0.191 mmol), and polymer-bound triphenylphosphine (200 mg, 0.629 mmol) in THF (2 mL) was added DIAD (0.122 mL, 0.629 mmol). The reaction was stirred at room temperature for 1.5 h. The solvent was removed, and the mixture was purified by silica gel chromatography (30–100% EtOAc/hexane) to afford <b>31b</b> as a white solid (55 mg, 0.029 mmol, 15.02% yield). MS (C<sub>63</sub>H<sub>77</sub>N<sub>5</sub>NaO<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1174 (M + Na)<sup>+</sup>.</div><div class="NLM_p last">The dimer <b>31b</b> (15 mg, 0.013 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>31</b> (2 mg, 2.64 μmol, 20.28% yield) as a white solid. MS (C<sub>43</sub>H<sub>38</sub>N<sub>5</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 720 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.68 (d, <i>J</i> = 2.2 Hz, 2H), 8.03–7.95 (m, 1H), 7.51 (dd, <i>J</i> = 5.2, 3.6 Hz, 1H), 7.48–7.39 (m, 2H), 7.36 (dd, <i>J</i> = 10.6, 6.9 Hz, 3H), 7.32–7.17 (m, 6H), 7.12 (d, <i>J</i> = 6.6 Hz, 1H), 6.71 (d, <i>J</i> = 5.3 Hz, 1H), 5.92 (s, 1H), 5.39 (d, <i>J</i> = 9.2 Hz, 1H), 5.32 (d, <i>J</i> = 12.4 Hz, 1H), 5.27–5.19 (m, 1H), 5.18–5.04 (m, 3H), 4.83 (d, <i>J</i> = 15.3 Hz, 1H), 4.64 (d, <i>J</i> = 15.4 Hz, 1H), 4.50 (d, <i>J</i> = 15.3 Hz, 1H), 4.29 (d, <i>J</i> = 9.3 Hz, 1H), 3.92–3.86 (m, 1H), 3.84 (d, <i>J</i> = 4.0 Hz, 2H), 3.72 (d, <i>J</i> = 4.2 Hz, 6H), 3.67–3.61 (m, 1H), 3.57 (dt, <i>J</i> = 9.7, 4.9 Hz, 1H), 3.13–2.95 (m, 5H).</div></div><div id="sec5_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-((Pyridine-2,4-diylbis(methylene))bis(oxy))bis(2-methoxy-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one) (<b>32</b>)</h3><div class="NLM_p last">A suspension of phenol <b>29b</b> (170 mg, 0.414 mmol), 2,4-bis(bromomethyl)pyridine <b>32a</b> (50 mg, 0.189 mmol), and cesium carbonate (170 mg, 0.522 mmol) in DMF (1.0 mL) was stirred at room temperature for 1 h. The mixture was quenched with water (20 mL) and filtered. The precipitate was washed with diethyl ether and air-dried. The material was purified by silica gel chromatography, eluting with a gradient from 5 to 50% acetone in dichloromethane to afford <b>32b</b> (134 mg, 0.138 mmol, 73% yield). MS (C<sub>51</sub>H<sub>50</sub>N<sub>5</sub>O<sub>12</sub>) <i>m</i>/<i>z</i>: 924 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.59 (d, <i>J</i> = 5.0 Hz, 1H), 7.61 (s, 1H), 7.42 (s, 1H), 7.39–7.23 (m, 8H), 7.16 (d, <i>J</i> = 5.7 Hz, 2H), 6.90 (d, <i>J</i> = 10.3 Hz, 2H), 6.59 (s, 1H), 5.76 (s, 4H), 5.66 (s, 2H), 5.32–5.08 (m, 6H), 5.08–4.84 (m, 4H), 4.69 (d, <i>J</i> = 15.6 Hz, 2H), 4.49–4.26 (m, 6H), 3.85 (s, 3H), 3.84 (s, 3H), 3.48 (s, 2H), 3.04 (m, 4H). Dimer <b>32b</b> (36 mg, 0.031 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>32</b> as a white powder (16.0 mg, 65% yield). MS (C<sub>43</sub>H<sub>38</sub>N<sub>5</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 720 (M + H)<sup>+</sup>.</div></div><div id="sec5_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> (<i>S</i>)-3-((6-(Bromomethyl)pyridin-2-yl)methoxy)-2-methoxy-5-((2-(trimethylsilyl)ethoxy)methyl)-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,6a<i>H</i>)-dione (<b>33a</b>)</h3><div class="NLM_p last">To a solution of <b>49</b> (1.830 g, 4.03 mmol) in DMF (20 mL) was added 2,6-bis(bromomethyl)pyridine <b>30a</b> (3.2 g, 12.08 mmol), followed by potassium carbonate (1.669 g, 12.08 mmol). The reaction was allowed to stir at room temperature overnight and then poured into water (50 mL). The reaction mixture was extracted with ethyl acetate and washed with brine. The organic layer was concentrated and purified by silica gel chromatography (0–100% ethyl acetate in hexanes) to obtain <b>33a</b> as a white solid (2.3 g, 89% yield). MS (C<sub>31</sub>H<sub>37</sub>BrN<sub>3</sub>O<sub>5</sub>Si) <i>m</i>/<i>z</i>: 640 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.77 (t, <i>J</i> = 7.8 Hz, 1H), 7.51 (d, <i>J</i> = 7.8 Hz, 1H), 7.42 (d, <i>J</i> = 7.8 Hz, 1H), 7.36 (s, 1H), 7.34–7.22 (m, 5H), 5.43 (d, <i>J</i> = 9.9 Hz, 1H), 5.31 (s, 2H), 5.18 (d, <i>J</i> = 15.3 Hz, 1H), 4.66 (d, <i>J</i> = 9.9 Hz, 1H), 4.58 (s, 2H), 4.41 (d, <i>J</i> = 15.3 Hz, 1H), 4.28 (dd, <i>J</i> = 7.6, 6.4 Hz, 1H), 3.95 (s, 3H), 3.75–3.50 (m, 3H), 3.06–2.99 (m, 1H), 1.05–0.88 (m, 2H), 0.05 (s, 9H).</div></div><div id="sec5_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Allyl ((<i>S</i>)-2-Methoxy-3-((6-((((<i>S</i>)-2-methoxy-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy)methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)methyl)pyridin-2-yl)methoxy)-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy)methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-10-yl)carbamate (<b>33b</b>)</h3><div class="NLM_p last">To a solution of <b>33a</b> (2.1 g, 3.29 mmol) and <b>51</b> (1.517 g, 2.74 mmol) in DMF (10 mL) was added potassium carbonate (1.136 g, 8.22 mmol) and stirred at room temperature overnight. The reaction was poured into dichloromethane and water. The organic was collected and concentrated. The residue was purified by silica gel chromatography (0–100% ethyl acetate in hexanes) to give <b>33b</b> as a white solid (2.4 g, 79% yield). MS (C<sub>59</sub>H<sub>71</sub>N<sub>6</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1111 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.79 (t, <i>J</i> = 7.8 Hz, 1H), 7.53 (d, <i>J</i> = 7.8 Hz, 2H), 7.39–7.21 (m, 11H), 6.94 (s, 1H), 5.97 (ddt, <i>J</i> = 17.2, 10.4, 5.7 Hz, 1H), 5.48–5.37 (m, 2H), 5.34 (q, <i>J</i> = 1.6 Hz, 1H), 5.28 (d, <i>J</i> = 1.4 Hz, 3H), 5.25 (dd, <i>J</i> = 2.9, 1.6 Hz, 1H), 5.17 (d, <i>J</i> = 15.3 Hz, 1H), 5.11 (d, <i>J</i> = 15.4 Hz, 1H), 4.72–4.62 (m, 3H), 4.40 (d, <i>J</i> = 15.3 Hz, 2H), 4.32–4.21 (m, 2H), 3.93 (s, 6H), 3.76–3.43 (m, 6H), 1.01–0.86 (m, 4H), 0.05 (s, 18H).</div></div><div id="sec5_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> (<i>S</i>)-10-Amino-2-methoxy-3-((6-((((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)methyl)pyridin-2-yl)methoxy)-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one (<b>33</b>)</h3><div class="NLM_p">To a solution of <b>33b</b> (850 mg, 0.765 mmol) in DCM (10 mL) was added tetrakis(triphenylphosphine)palladium(0) (88 mg, 0.076 mmol) and pyrrolidine (0.158 mL, 1.912 mmol). The reaction was stirred at room temperature for 1 h and poured into water and dichloromethane. The organic was collected and concentrated. The residue was purified by silica gel chromatography (0–30% MeOH in DCM) to give <b>33c</b> as a white solid (500 mg, 63.6% yield).</div><div class="NLM_p last">To a solution of <b>33c</b> (26 mg, 0.025 mmol) in THF (1 mL) at −76 °C was added superhydride (0.127 mL, 0.127 mmol) and stirred for 1 h. The reaction was quenched with cold water (1 mL) and extracted with DCM (3 × 10 mL). The organic layer was concentrated and treated with DCM/EtOH/water (1:2:1 = 4 mL) and silica gel (1 g) for 3 days. This mixture was filtered through a sintered funnel, and the silica gel was washed with DCM–MeOH (8:2, 100 mL). The filtrate was concentrated under high vacuum and purified by silica gel chromatography (0–10% MeOH/DCM) to provide <b>33</b> as a white solid (16 mg, 0.021 mmol, 82% yield). MS (C<sub>43</sub>H<sub>39</sub>N<sub>6</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 735 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.64 (t, <i>J</i> = 7.8 Hz, 2H), 7.48 (m, 3H), 7.38 (d, <i>J</i> = 7.7 Hz, 5H), 7.31–7.18 (m, 6H), 7.03 (d, <i>J</i> = 7.5 Hz, 1H), 6.76 (s, 2H), 6.54 (s, 2H), 5.22 (s, 4H), 4.91 (d, <i>J</i> = 15.5 Hz, 2H), 4.80 (d, <i>J</i> = 15.5 Hz, 2H), 4.48 (d, <i>J</i> = 15.5 Hz, 2H), 4.36 (d, <i>J</i> = 15.4 Hz, 2H), 3.90 (s, 6H), 3.87–3.80 (m, 3H), 3.77 (s, 2H), 3.17 (m, 2H), 3.11–3.01 (m, 4H), 2.91 (m, 3H).</div></div><div id="sec5_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Methyl 2,6-Bis(bromomethyl)isonicotinate (<b>34a</b>)</h3><div class="NLM_p last">To a suspension of methyl 2,6-bis(hydroxymethyl)isonicotinate<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> (0.5 g, 2.54 mmol) and triethylamine (1.060 mL, 7.61 mmol) in DCM (10 mL) was added mesyl chloride (0.454 mL, 5.83 mmol) at 0 °C. The reaction was stirred at 0 °C for 2 h. The reaction was then quenched with water, extracted with DCM, washed with aqueous HCl (0.1 N) and then brine, dried over sodium sulfate, and concentrated. The residue was dissolved in DMF (5 mL) and stirred with sodium bromide (1.3 g, 12.70 mmol) at room temperature for 40 min. That was diluted with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered, and concentrated to give <b>34a</b> (730 mg, 2.260 mmol, 89% yield). MS (C<sub>9</sub>H<sub>10</sub>Br<sub>2</sub>NO<sub>2</sub>) <i>m</i>/<i>z</i>: 322 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.95 (s, 2H), 4.61 (s, 4H), 4.06–3.94 (m, 3H).</div></div><div id="sec5_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Methyl 2,6-Bis((((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)methyl)isonicotinate (<b>34</b>)</h3><div class="NLM_p last">To a mixture of <b>29b</b> (103 mg, 0.50 mmol) and cesium carbonate (81 mg, 0.25 mmol) in DMF (500 μL) was added <b>34a</b> (32.3 mg, 0.1 mmol) and stirred at room temperature for 1 h. The mixture was quenched with 0.1 M citric acid and extracted thrice with ethyl acetate. The combined organics were washed with brine and dried over sodium sulfate, filtered, and evaporated. The mixture was purified by silica gel chromatography, eluting with ethyl acetate/hexanes to afford <b>34b</b> as a white solid (67.2 mg, 0.068 mmol, 68.4% yield). MS (C<sub>53</sub>H<sub>52</sub>N<sub>5</sub>O<sub>14</sub>) <i>m</i>/<i>z</i>: 982 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.01 (s, 1H), 7.92 (s, 1H), 7.30 (m, 12H), 6.61 (d, <i>J</i> = 27.2 Hz, 1H), 5.66 (m, 2H), 5.30 (m, 6H), 5.16–4.93 (m, 4H), 4.81 (t, <i>J</i> = 17.5 Hz, 3H), 4.60 (t, <i>J</i> = 17.1 Hz, 2H), 4.42 (m, 5H), 4.08–3.89 (m, 9H), 3.74–3.61 (m, 2H), 3.09 (m, 4H). Dimer <b>34b</b> (22 mg, 0.022 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>34</b> as a white solid (9.32 mg, 53.5% yield). MS (C<sub>45</sub>H<sub>40</sub>N<sub>5</sub>O<sub>8</sub>) <i>m</i>/<i>z</i>: 778 (M + H)<sup>+</sup>.</div></div><div id="sec5_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-(((4-Chloropyridine-2,6-diyl)bis(methylene))bis(oxy))bis(2-methoxy-7,12-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(6a<i>H</i>)-one) (<b>35</b>)</h3><div class="NLM_p">To a mixture of <b>29b</b> (123 mg, 0.3 mmol) and cesium carbonate (150 mg, 0.46 mmol) in DMF (500 μL) was added 2,6-bis(bromomethyl)-4-chloropyridine <b>35a</b> (90 mg, 0.3 mmol) and stirred at room temperature for 2.5 h. The mixture was quenched with 0.1 M citric acid and extracted thrice with ethyl acetate. The combined organics were washed with brine and dried over sodium sulfate, filtered, and evaporated. The mixture was purified by silica gel chromatography, eluting with 0–10% MeOH/DCM to afford <b>35b</b> (72 mg, 0.075 mmol, 24.99 yield). MS (C<sub>51</sub>H<sub>49</sub>ClN<sub>5</sub>O<sub>12</sub>) <i>m</i>/<i>z</i>: 958 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Dimer <b>35b</b> (25 mg, 0.026 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>35</b> as a white solid (13.7 mg, 66.2% yield). MS (C<sub>43</sub>H<sub>37</sub>ClN<sub>5</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 754 (M + H)<sup>+</sup>.</div></div><div id="sec5_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-(((4-Methoxypyridine-2,6-diyl)bis(methylene))bis(oxy))bis(2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one) (<b>36</b>)</h3><div class="NLM_p">To a solution of dimethyl 4-methoxypyridine-2,6-dicarboxylate<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (0.45 g, 1.998 mmol) in ethanol (20 mL) was added LiBH<sub>4</sub> (0.261 g, 16.07 mmol), and the reaction was stirred at room temperature for 5 h. The reaction was quenched with acetic acid (2 mL, 35 mmol), stirred for 10 min, concentrated, and purified by silica gel chromatography using MeOH/DCM to give (4-methoxypyridine-2,6-diyl)dimethanol (210 mg, 1.241 mmol, 62.1% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 6.87 (s, 2H), 5.33 (t, <i>J</i> = 5.5 Hz, 2H), 4.47 (d, <i>J</i> = 4.9 Hz, 4H), 3.84 (s, 3H). This was converted to <b>36a</b> following <b>34a</b> procedure (0.155 g, 39% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.92 (s, 2H), 4.51 (s, 4H), 3.91 (s, 3H).</div><div class="NLM_p">A mixture of <b>36a</b> (29.5 mg, 0.3 mmol), <b>29b</b> (103 mg, 0.25 mmol), and cesium carbonate (81 mg, 0.46 mmol) in DMF (500 μL) was added at room temperature for 2.5 h. The mixture was quenched with 0.1 M citric acid and extracted thrice with ethyl acetate. The combined organics were washed with brine and dried over sodium sulfate, filtered, and evaporated. The mixture was purified by silica gel chromatography, eluting with 0–10% MeOH/DCM to afford <b>36b</b> (79.4 mg, 0.083 mmol, 83% yield). MS (C<sub>52</sub>H<sub>52</sub>N<sub>5</sub>O<sub>13</sub>) <i>m</i>/<i>z</i>: 954 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Dimer <b>36b</b> (20 mg, 0.021 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>36</b> as a white powder (13.35 mg, 0.017 mmol, 81% yield). MS (C<sub>44</sub>H<sub>40</sub>N<sub>5</sub>O<sub>7</sub>) <i>m</i>/<i>z</i>: 750 (M + H)<sup>+</sup>.</div></div><div id="sec5_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-(((4-Hydroxypyridine-2,6-diyl)bis(methylene))bis(oxy))bis(2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one) (<b>37</b>)</h3><div class="NLM_p">To a mixture of <b>29b</b> (103 mg, 0.25 mmol) and cesium carbonate (81 mg, 0.25 mmol) in DMF (500 μL) was added 4-(allyloxy)-2,6-bis(bromomethyl)pyridine <b>37a</b> (32.1 mg, 0.1 mmol) and stirred at room temperature for 2.5 h. The mixture was quenched with 0.1 M citric acid and extracted thrice with ethyl acetate. The combined organics were washed with brine and dried over sodium sulfate, filtered, and evaporated. The mixture was purified by silica gel chromatography, eluting with 0–10% MeOH/DCM to afford <b>37b</b> as a white solid (64.4 mg, 0.066 mmol, 65.7% yield). MS (C<sub>54</sub>H<sub>54</sub>N<sub>5</sub>O<sub>13</sub>) <i>m</i>/<i>z</i>: 980 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Dimer <b>37b</b> (20 mg, 0.021 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>37</b> as a white solid (3.73 mg, 4.82 μmol, 23.60% yield). MS (C<sub>43</sub>H<sub>38</sub>N<sub>5</sub>O<sub>7</sub>) <i>m</i>/<i>z</i>: 736 (M + H)<sup>+</sup>.</div></div><div id="sec5_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-(((4-(Hydroxymethyl)pyridine-2,6-diyl)bis(methylene))bis(oxy))bis(2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one) (<b>38</b>)</h3><div class="NLM_p">To a suspension of (4-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)pyridine-2,6-diyl)dimethanol (120 mg, 0.423 mmol) and TEA (0.177 mL, 1.270 mmol) in DCM (3 mL) was added mesyl chloride (0.082 mL, 1.058 mmol) at 0 °C. The reaction was stirred at 0 °C for 1 h. The reaction was then quenched with water, extracted with DCM, washed with cold aqueous HCl (0.05 N) and then brine, dried over sodium sulfate, and concentrated to give (4-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)pyridine-2,6-diyl)bis(methylene) dimethanesulfonate <b>38a</b> as an orange oil (186 mg, 90% yield). MS (C<sub>16</sub>H<sub>30</sub>NO<sub>7</sub>S<sub>2</sub>Si) <i>m</i>/<i>z</i>: 440 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.50 (d, <i>J</i> = 11.6 Hz, 2H), 5.75 (s, 2H), 5.33 (s, 4H), 3.85 (s, 3H), 3.16 (s, 3H), 0.93 (d, <i>J</i> = 5.7 Hz, 9H), 0.36 (s, 3H), 0.10 (s, 3H).</div><div class="NLM_p">To a solution of <b>38a</b> (25 mg, 0.057 mmol) and <b>50</b> (90 mg, 0.171 mmol) in DMF (0.3 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (85 mg, 0.261 mmol) and stirred at room temperature for 1 h. The crude material was purified by silica gel chromatography (30–100% acetone/DCM) to afford <b>38b</b> (70 mg, 0.053 mmol, 93% yield). MS (C<sub>70</sub>H<sub>94</sub>N<sub>5</sub>O<sub>13</sub>Si<sub>3</sub>) <i>m</i>/<i>z</i>: 1296 (M + H)<sup>+</sup>.</div><div class="NLM_p">To a solution of <b>38b</b> (40 mg, 0.031 mmol) in THF (0.3 mL) was added TBAF (0.037 mL, 0.037 mmol) and stirred at room temperature for 30 min, quenched with saturated ammonium chloride, extracted with ethyl acetate (3×), dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (20–50% acetone/DCM) and preparative HPLC to afford <b>38c</b> (14 mg, 0.014 mmol, 46.6% yield). MS (C<sub>52</sub>H<sub>52</sub>N<sub>5</sub>O<sub>13</sub>) <i>m</i>/<i>z</i>: 954 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Dimer <b>38c</b> (14 mg, 0.015 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>38</b> as a white solid (5 mg, 43% yield). MS (C<sub>44</sub>H<sub>40</sub>N<sub>5</sub>O<sub>7</sub>) <i>m</i>/<i>z</i>: 750 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.55–7.19 (m, 13H), 7.14 (d, <i>J</i> = 10.0 Hz, 1H), 7.00–6.91 (m, 1H), 5.62–5.45 (m, 1H), 5.33–5.18 (m, 3H), 5.18–5.07 (m, 1H), 4.82 (d, <i>J</i> = 15.2 Hz, 1H), 4.67–4.49 (m, 4H), 3.87 (s, 6H), 3.76 (s, 1H), 3.67 (s, 1H), 3.28 (t, <i>J</i> = 10.0 Hz, 4H), 3.14–2.95 (m, 2H).</div></div><div id="sec5_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> (3-Methoxypyridine-2,6-diyl)bis(methylene) Dimethanesulfonate (<b>39a</b>)</h3><div class="NLM_p last">To a suspension of (3-methoxypyridine-2,6-diyl)dimethanol (90 mg, 0.532 mmol) and TEA (0.185 mL, 1.330 mmol) in DCM (3 mL) was added mesyl chloride (0.095 mL, 1.224 mmol) at 0 °C. The reaction was stirred at 0 °C for 1 h. The reaction was then quenched with water, extracted with DCM, washed with cold aqueous HCl (0.05 N) and then brine, dried over sodium sulfate, and concentrated to give the crude mesylate as an orange oil. The residue was purified by silica gel chromatography (20–100% ethyl acetate/hexane) to afford <b>39a</b> (87 mg, 0.241 mmol, 45.2% yield). MS (C<sub>10</sub>H<sub>16</sub>NO<sub>7</sub>S<sub>2</sub>) <i>m</i>/<i>z</i>: 326 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.63 (s, 2H), 5.32–5.28 (m, 2H), 5.28–5.24 (m, 2H), 3.90 (s, 3H), 3.26 (s, 3H), 3.24 (s, 3H).</div></div><div id="sec5_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> (6<i>R</i>,6a<i>R</i>)-Allyl 3-((6-((((6<i>S</i>,6a<i>S</i>)-5-((Allyloxy)carbonyl)-6-((<i>tert</i>-butyldimethylsilyl)oxy)-2-methoxy-14-oxo-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)methyl)-3-methoxypyridin-2-yl)methoxy)-6-((<i>tert</i>-butyldimethylsilyl)oxy)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-5(6<i>H</i>)-carboxylate (<b>39b</b>)</h3><div class="NLM_p last">To a solution of <b>39a</b> (20 mg, 0.061 mmol) and <b>50</b> (97 mg, 0.184 mmol) in DMF (0.3 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (60.1 mg, 0.184 mmol) and stirred at room temperature for 3 h. The crude material was purified by silica gel chromatography (2–10% MeOH–DCM) to afford <b>39b</b> (67 mg, 0.048 mmol, 77% yield). MS (C<sub>64</sub>H<sub>80</sub>N<sub>5</sub>O<sub>13</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1182 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.59 (d, <i>J</i> = 8.7 Hz, 1H), 7.55–7.46 (m, 1H), 7.37 (s, 2H), 7.28 (q, <i>J</i> = 8.9, 7.2 Hz, 6H), 7.16 (d, <i>J</i> = 11.4 Hz, 2H), 6.68 (s, 1H), 6.53 (s, 1H), 5.65 (s, 1H), 5.20 (dd, <i>J</i> = 22.7, 9.3 Hz, 2H), 5.11–4.98 (m, 6H), 4.92 (d, <i>J</i> = 18.3 Hz, 1H), 4.74 (d, <i>J</i> = 16.0 Hz, 2H), 4.51–4.37 (m, 2H), 4.32 (d, <i>J</i> = 17.7 Hz, 4H), 3.87 (s, 3H), 3.81 (d, <i>J</i> = 7.2 Hz, 6H), 3.51 (s, 1H), 3.14–3.05 (m, 2H), 0.90–0.78 (m, 18H), 0.07 (m, 9H).</div></div><div id="sec5_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-(((3-Methoxypyridine-2,6-diyl)bis(methylene))bis(oxy))bis(2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one) (<b>39</b>)</h3><div class="NLM_p last">Dimer <b>39b</b> (20 mg, 0.017 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>39</b> as a white solid (3 mg, 22% yield). MS (C<sub>44</sub>H<sub>40</sub>N<sub>5</sub>O<sub>7</sub>) <i>m</i>/<i>z</i>: 750 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.66–7.17 (m, 12H), 7.14–6.92 (m, 2H), 6.74 (d, <i>J</i> = 7.6 Hz, 1H), 6.68 (d, <i>J</i> = 2.0 Hz, 1H), 5.35 (s, 1H), 5.28–4.94 (m, 4H), 4.82 (d, <i>J</i> = 15.3 Hz, 1H), 4.64 (dd, <i>J</i> = 15.1, 3.9 Hz, 1H), 4.53 (dd, <i>J</i> = 25.5, 15.2 Hz, 2H), 4.33–4.24 (m, 1H), 3.86 (m, 6H), 3.80 (s, 3H), 3.74 (d, <i>J</i> = 2.4 Hz, 2H), 3.67 (d, <i>J</i> = 12.3 Hz, 2H), 3.61–3.49 (m, 2H), 3.12–2.93 (m, 4H).</div></div><div id="sec5_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-((Pyrazine-2,6-diylbis(methylene))bis(oxy))bis(2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one) (<b>40</b>)</h3><div class="NLM_p">A mixture of 2,6-dimethylpyrazine (200 mg, 1.849 mmol), <i>N</i>-bromosuccinimide (700 mg, 3.93 mmol), and AIBN (20 mg, 0.122 mmol) in CCl<sub>4</sub> (3 mL) was heated in a microwave vial at 80 °C for 6 h. The crude material was purified by silica gel chromatography (30–100% ethyl acetate/hexane) to afford 2,6-bis(bromomethyl)pyrazine <b>40a</b> (22 mg, 0.083 mmol, 4.47% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.64 (s, 2H), 4.55 (s, 4H).</div><div class="NLM_p">To a solution of <b>40a</b> (22 mg, 0.083 mmol) and <b>50</b> (100 mg, 0.190 mmol) in DMF (3 mL) was added potassium carbonate (23 mg, 0.165 mmol) and stirred at room temperature for 16 h. The crude material was dry loaded (Celite) and purified by silica gel chromatography (2–10% MeOH/DCM) to afford <b>40b</b> (75 mg, 0.062 mmol, 74.7% yield). MS (C<sub>62</sub>H<sub>77</sub>N<sub>6</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1154 (M + H)<sup>+</sup>.</div><div class="NLM_p last">The dimer <b>40b</b> (35 mg, 0.030 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>40</b> as a white solid (3 mg, 4.08 μmol, 13.44% yield). MS (C<sub>42</sub>H<sub>37</sub>N<sub>6</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 721 (M + H)<sup>+</sup>.</div></div><div id="sec5_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-((Pyrazine-2,5-diylbis(methylene))bis(oxy))bis(2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one) (<b>41</b>)</h3><div class="NLM_p">A mixture of 2,5-dimethylpyrazine (200 mg, 1.849 mmol), <i>N</i>-bromosuccinimide (700 mg, 3.93 mmol) and AIBN (20 mg, 0.122 mmol) in CCl<sub>4</sub> (3 mL) was heated in a microwave vial at 80 °C for 2.5 h. The crude material was purified by silica gel chromatography (30–100% ethyl acetate/hexane) to afford 2,5-bis(bromomethyl)pyrazine <b>41a</b> (83 mg, 0.297 mmol, 16.03% yield). MS (C<sub>6</sub>H<sub>7</sub>Br<sub>2</sub>N<sub>2</sub>) <i>m</i>/<i>z</i>: 266 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.67 (s, 2H), 4.56 (s, 4H).</div><div class="NLM_p">To a solution of 2,5-bis(bromomethyl)pyrazine <b>41a</b> (25 mg, 0.094 mmol) and <b>50</b> (113 mg, 0.216 mmol) in DMF (3 mL) was added potassium carbonate (26 mg, 0.188 mmol) and stirred at room temperature for 16 h. The crude material was dry loaded (Celite) and purified by silica gel chromatography (2–10% MeOH/DCM) to afford <b>41b</b> (115 mg, 0.091 mmol, 97% yield). MS (C<sub>62</sub>H<sub>77</sub>N<sub>6</sub>O<sub>12</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1154 (M + H)<sup>+</sup>.</div><div class="NLM_p last">The dimer <b>41b</b> (60 mg, 0.052 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>41</b> as a white solid (10 mg, 0.013 mmol, 25.6% yield). MS (C<sub>42</sub>H<sub>37</sub>N<sub>6</sub>O<sub>6</sub>) <i>m</i>/<i>z</i>: 721 (M + H)<sup>+</sup>.</div></div><div id="sec5_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-((Furan-2,5-diylbis(methylene))bis(oxy))bis(2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one) (<b>42</b>)</h3><div class="NLM_p">To a solution of <b>50</b> (100 mg, 0.191 mmol), 2,5-furandimethanol <b>42a</b> (20 mg, 0.156 mmol), and triphenylphosphine (100 mg, 0.381 mmol) in THF (2 mL) was added DIAD (0.074 mL, 0.381 mmol) and stirred at room temperature for 1.5 h. The solvent was removed, and the mixture was purified by silica gel chromatography (30–100% ethyl acetate/hexane) to afford <b>42b</b> (15 mg, 0.012 mmol, 7.58% yield). MS (C<sub>62</sub>H<sub>77</sub>N<sub>4</sub>O<sub>13</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1141 (M + H)<sup>+</sup>.</div><div class="NLM_p last">The dimer <b>42b</b> (15 mg, 0.013 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>42</b> as a white solid (4 mg, 5.08 μmol, 38.7% yield). MS (C<sub>42</sub>H<sub>37</sub>N<sub>4</sub>O<sub>7</sub>) <i>m</i>/<i>z</i>: 709 (M + H)<sup>+</sup>.</div></div><div id="sec5_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> (6a<i>S</i>,6a′<i>S</i>)-3,3′-((Thiophene-2,5-diylbis(methylene))bis(oxy))bis(2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-14(12<i>H</i>)-one) (<b>43</b>)</h3><div class="NLM_p">To a solution of 2,5-bis(chloromethyl)thiophene <b>43a</b> (50 mg, 0.276 mmol) and <b>50</b> (300 mg, 0.572 mmol) in DMF (0.5 mL) was added K<sub>2</sub>CO<sub>3</sub> (95 mg, 0.690 mmol), and the reaction was stirred at 40 °C for 3 h. The crude material was dry loaded (Celite) and purified by silica gel chromatography (25–100% EtOAc/hexane) to afford <b>43b</b> (135 mg, 0.117 mmol, 42.2% yield). MS (C<sub>62</sub>H<sub>77</sub>N<sub>4</sub>O<sub>12</sub>SSi<sub>2</sub>) <i>m</i>/<i>z</i>: 1157 (M + H)<sup>+</sup>.</div><div class="NLM_p last">The dimer <b>43b</b> (130 mg, 0.112 mmol) was deprotected using a procedure similar to compound <b>24</b> to afford <b>43</b> as a white solid (35 mg, 0.046 mmol, 41.3% yield). MS (C<sub>42</sub>H<sub>37</sub>N<sub>4</sub>O<sub>6</sub>S) <i>m</i>/<i>z</i>: 725 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.43–7.13 (m, 16H), 5.37–5.17 (m, 4H), 4.59–4.47 (m, 4H), 3.97 (d, <i>J</i> = 9.1 Hz, 2H), 3.83 (s, 2H), 3.72 (s, 6H), 3.66–3.55 (m, 2H).</div></div><div id="sec5_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> 1-(3-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)propanamido)-<i>N</i>-((<i>S</i>)-1-(((<i>S</i>)-1-(((<i>S</i>)-2-methoxy-3-((5-(((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)pentyl)oxy)-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-10-yl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-amide (<b>44</b>)</h3><div class="NLM_p last">To a solution compound <b>79</b> (9.6 mg, 0.010 mmol) and 2,6-lutidine (2.152 mg, 0.020 mmol) in DMSO (0.7 mL) was added MAL-dPEG8-NHS ester (13.85 mg, 0.020 mmol in 100 μL of DMSO). The reaction mixture was stirred at room temperature for 1 h and purified by preparative HPLC to give compound <b>44</b> as a white solid (9.4 mg, 5.53 μmol, 55% yield). MS (C<sub>78</sub>H<sub>104</sub>N<sub>11</sub>O<sub>21</sub>) <i>m</i>/<i>z</i>: 1531 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.88 (s, 1H), 8.03 (s, 1H), 7.91 (s, 1H), 7.79 (d, <i>J</i> = 8.8 Hz, 1H), 7.55–7.04 (m, 9H), 6.97 (s, 2H), 6.91 (s, 1H), 6.75 (s, 1H), 6.46 (s, 1H), 5.90 (s, 1H), 5.77 (s, 1H), 5.34 (s, 2H), 5.24 (d, <i>J</i> = 9.7 Hz, 1H), 4.54 (d, <i>J</i> = 15.4 Hz, 1H), 4.43 (q, <i>J</i> = 15.9 Hz, 2H), 4.31 (s, 1H), 4.16 (q, <i>J</i> = 8.8, 7.4 Hz, 1H), 4.00 (s, 1H), 3.87 (s, 4H), 3.73 (s, 1H), 3.61 (s, 4H), 3.52 (d, <i>J</i> = 11.3 Hz, 3H), 3.41 (s, 25H), 3.23 (s, 9H), 3.17–1.85 (m, 14H), 1.72 (m, 6H), 1.48 (m, 4H), 0.77 (m, 6H).</div></div><div id="sec5_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> 4-((<i>S</i>)-2-((<i>S</i>)-2-(6-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl Bis(2-(((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)ethyl)carbamate (<b>45</b>)</h3><div class="NLM_p last">To a solution of <b>80</b> (10 mg, 0.014 mmol) and payload <b>17</b> (13.01 mg, 0.019 mmol) in DMSO (0.5 mL) was added Hunig’s base (7.10 μL, 0.041 mmol) and stirred at room temperature for 16 h. The reaction mixture was purified by preparative HPLC to obtain <b>45</b> as a white solid (5.6 mg, 4.36 μmol, 32.2% yield). MS (C<sub>69</sub>H<sub>78</sub>N<sub>11</sub>O<sub>14</sub>) <i>m</i>/<i>z</i>: 1284 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.01 (s, 1H), 8.11 (d, <i>J</i> = 7.2 Hz, 2H), 7.82 (d, <i>J</i> = 8.8 Hz, 2H), 7.57 (d, <i>J</i> = 8.4 Hz, 2H), 7.31 (m, 11 H), 7.07 (d, <i>J</i> = 12.8 Hz, 1H), 6.99 (s, 2H), 6.86 (m, 1H), 6.53 (s, 1H), 6.00 (s, 1H), 5.42 (s, 2H), 5.02 (s, 2H), 4.88 (d, <i>J</i> = 15.6 Hz, 4H), 4.19–4.65 (m, 10H), 3.78 (m, 11H), 3.01 (m, 4H), 2.14 (m, 2H), 1.96 (m, 1H), 1.18–1.70 (m, 9H), 0.83 (m, 6H).</div></div><div id="sec5_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> 4-((2<i>S</i>,5<i>S</i>)-15-Amino-5-isopropyl-4,7-dioxo-2-(3-ureidopropyl)-10,13-dioxa-3,6-diazapentadecanamido)benzyl Bis(2-(((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)ethyl)carbamate (<b>46</b>)</h3><div class="NLM_p last">To a solution of 1-(9<i>H</i>-fluoren-9-yl)-3-oxo-2,7,10-trioxa-4-azatridecan-13-oic acid (61.9 mg, 0.155 mmol) and HATU (58.9 mg, 0.155 mmol) in DMF (0.9 mL) was added 2,6-lutidine (0.028 mL, 0.238 mmol) and allowed to stir at room temperature for 1.5 h. LCMS showed the formation of HATU activated ester. Then, <b>84</b> (130 mg, 0.119 mmol) in DMF (0.9 mL) was added and allowed to stir at room temperature for 30 min. LCMS showed complete conversion to the amide. Diethylamine (0.2 mL, 1.914 mmol) was added, and the reaction mixture was stirred at room temperature for 1 h and injected directly onto CombiFlash EZ Prep 150 g C18 column and eluted with 0–50% acetonitrile/water (0.05% formic acid) over 40 min. Fractions with the product mass were filtered through a basic resin (PL-HCO<sub>3</sub> MP-Resin 1.8 mmol/g; Agilent) and lyophilized to provide <b>46</b> as a white solid (35.7 mg, 0.026 mmol, 22.05% yield). MS (C<sub>66</sub>H<sub>80</sub>N<sub>11</sub>O<sub>14</sub>) <i>m</i>/<i>z</i>: 1251 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.89 (s, 1H), 8.06 (d, <i>J</i> = 7.5 Hz, 2H), 7.96–7.66 (m, 2H), 7.66–7.29 (m, 3H), 7.29–6.90 (m, 11H), 6.84–6.18 (m, 3H), 6.11–5.76 (m, 2H), 5.35 (d, <i>J</i> = 9.6 Hz, 2H), 5.22 (s, 2H), 4.95 (s, 3H), 4.71–4.35 (m, 5H), 4.35–3.83 (m, 14H), 3.49 (s, 20H), 2.94 (s, 5H), 2.66 (s, 2H), 2.40–2.14 (m, 2H), 1.90 (d, <i>J</i> = 6.7 Hz, 1H), 1.81–0.96 (m, 4H), 0.79 (m, 6H).</div></div><div id="sec5_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> 4-((17<i>S</i>,20<i>S</i>)-1-Amino-17-isopropyl-15,18-dioxo-20-(3-ureidopropyl)-3,6,9,12-tetraoxa-16,19-diazahenicosanamido)benzyl Bis(2-(((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)ethyl)carbamate (<b>47</b>)</h3><div class="NLM_p last">To a solution of <b>83</b> (118 mg, 0.085 mmol) in THF (3 mL) was added 2,5-dioxopyrrolidin-1-yl 1-(9<i>H</i>-fluoren-9-yl)-3-oxo-2,7,10,13,16-pentaoxa-4-azanonadecan-19-oate (90 mg, 0.153 mmol), and the mixture was allowed to stir at room temperature for 1 h. Piperidine (0.3 mL, 3.03 mmol) was added to the reaction mixture and stirred at room temperature for 1 h. The solution was injected directly on to CombiFlash EZ Prep 150 g C18 column and eluting with 0–100% acetonitrile/water (0.1% TFA) over 30 min. Fractions with product mass were lyophilized to obtain <b>85</b> as a white solid (72 mg, 0.041 mmol, 48.4% yield). MS (C<sub>82</sub>H<sub>116</sub>N<sub>11</sub>O<sub>20</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1631 (M + H)<sup>+</sup>. This was dissolved in THF (2 mL) and treated with superhydride (0.41 mL, 0.41 mmol) at −78 °C for 1 h. The reaction was quenched with cold water (0.5 mL) and allowed to warm to room temperature. The reaction mixture was then injected directly on to CombiFlash EZ Prep 150 g C18 column and eluting with water/acetonitrile (0.1% TFA) over 20 min. Forty percent acetonitrile/water (0.1% TFA) fractions were filtered through a basic resin (PL-HCO<sub>3</sub> MP-Resin 1.8 mmol/g; Agilent) and washed with acetonitrile (5 mL). Lyophilization provided the title compound <b>47</b> as a white solid (19 mg, 29.9% yield). MS (C<sub>70</sub>H<sub>88</sub>N<sub>11</sub>O<sub>16</sub>) <i>m</i>/<i>z</i>: 1339 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.02 (s, 1H), 8.14 (d, <i>J</i> = 7.2 Hz, 1H), 7.89 (d, <i>J</i> = 8.0 Hz, 1H), 7.57 (d, <i>J</i> = 8.4 Hz, 2H), 7.29 (m, 9 H), 7.09 (m, 2H), 6.53 (m, 2H), 6.01 (br s, 1H), 5.42 (s, 2H), 5.31 (s, 1H), 5.03 (s, 2H), 4.07–4.65 (m, 10H), 3.48–3.73 (m, 24H), 3.01 (m, 6H), 2.69 (m, 2H), 1.96 (m, 1H), 1.38–1.69 (m, 4H), 0.85 (m, 6H).</div></div><div id="sec5_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> 4-((29<i>S</i>,32<i>S</i>)-1-Amino-29-isopropyl-27,30-dioxo-32-(3-ureidopropyl)-3,6,9,12,15,18,21,24-octaoxa-28,31-diazatritriacontanamido)benzyl Bis(2-(((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)ethyl)carbamate (<b>48</b>)</h3><div class="NLM_p last">To a solution of compound <b>84</b> (84 mg, 0.077 mmol) in DMF (1 mL) were added 2,3,5,6-tetrafluorophenyl 1-(9<i>H</i>-fluoren-9-yl)-3-oxo-2,7,10,13,16,19,22,25,28-nonaoxa-4-azahentriacontan-31-oate (68.7 mg, 0.085 mmol) and 2,6-lutidine (0.018 mL, 0.154 mmol). The reaction mixture was allowed to stir at room temperature for 2 h, and piperidine (0.1 mL, 1.010 mmol) was added. The mixture was stirred at room temperature for 1 h and injected directly on to CombiFlash EZ Prep 150 g C18 column and eluted with acetonitrile/water (0.05% formic acid) over 30 min. Thirty-eight percent acetonitrile/water fractions were filtered through a basic resin (PL-HCO<sub>3</sub> MP-Resin 1.8 mmol/g; Agilent) and washed with acetonitrile (5 mL). Lyophilization provided compound <b>48</b> as a white solid (24.4 mg, 0.015 mmol, 19.88% yield). MS (C<sub>78</sub>H<sub>104</sub>N<sub>11</sub>O<sub>20</sub>) <i>m</i>/<i>z</i>: 1514 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.70 (s, 1H), 10.23 (s, 1H), 9.99 (s, 1H), 8.12 (d, <i>J</i> = 6.4 Hz, 1H), 7.95 (d, <i>J</i> = 7.2 Hz, 1H), 7.87 (d, <i>J</i> = 8.4 Hz, 2H), 7.77 (m, 2H), 7.57 (m, 4 H), 7.29 (m, 8H), 7.08 (m, 1H), 6.57–6.86 (m, 2H), 6.01 (br s, 1H), 5.76 (s, 1H), 5.63 (m, 1H), 5.42 (br s, 1H), 5.38 (dd, 5.6, 1.6 Hz, 1H), 5.02 (br s, 2H), 4.83 (m, 1H), 4.63 (m, 2H), 4.40 (m, 2H), 4.18 (m, 5H), 3.76 (m, 10H), 3.60 (m, 9H), 3.51 (m, 14H), 3.27 (m, 1H), 3.18 (s, 2H), 2.99 (m, 6H), 2.43 (m, 2H) 2.15 (m, 1H), 1.96 (m, 2H), 1.35–1.85 (m, 10H), 0.84 (m, 6H).</div></div><div id="sec5_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> (<i>S</i>)-3-Hydroxy-2-methoxy-5-((2-(trimethylsilyl)ethoxy)methyl)-6a,7-dihydrobenzo[5,6][1,4]diazepino [1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,12<i>H</i>)-dione (<b>49</b>)</h3><div class="NLM_p last">A suspension of <b>58</b> (4.68 g, 8.59 mmol) and Pd/C (10%, 0.457 g) in ethanol (10 mL) was stirred under a balloon of H<sub>2</sub> at room temperature for 3 h. The reaction was filtered through Celite, washed with ethanol, and concentrated <i>in vacuo</i>. The crude product mixture was purified by silica gel chromatography (CombiFlash, 120 g column, 0–100% EtOAc/DCM in 15 min) to give the title compound <b>49</b> as a white solid (3.23 g, 83% yield). MS (C<sub>24</sub>H<sub>31</sub>N<sub>2</sub>O<sub>5</sub>Si) <i>m</i>/<i>z</i>: 455 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.40–7.21 (m, 5H), 5.97 (s, 1H), 5.46 (d, <i>J</i> = 9.7 Hz, 1H), 5.18 (d, <i>J</i> = 15.4 Hz, 1H), 4.72 (d, <i>J</i> = 9.7 Hz, 1H), 4.58–4.24 (m, 2H), 3.95 (s, 3H), 3.83–3.44 (m, 3H), 3.14–2.88 (m, 1H), 0.99 (t, <i>J</i> = 8.0 Hz, 2H), 0.14 (s, 9H).</div></div><div id="sec5_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> Allyl (6<i>S</i>,6a<i>S</i>)-6-((<i>tert</i>-Butyldimethylsilyl)oxy)-3-hydroxy-2-methoxy-14-oxo-6,6a,7,12-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-5(14<i>H</i>)-carboxylate (<b>50</b>)</h3><div class="NLM_p last">Silyl ether <b>67</b> (907 mg, 1.332 mmol) was dissolved in DMF (5 mL) and water (0.1 mL). Lithium acetate (88 mg, 1.332 mmol) was added, and the mixture was stirred at room temperature overnight. Most of the DMF was evaporated under a stream of nitrogen. The residue was diluted with EtOAc and washed with 0.1 M citric acid (2×) then once with brine. The organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to dryness. The residue was purified by silica gel chromatography (30–70% EtOAc/hexanes) to afford phenol <b>50</b> as a white solid (707.4 mg, 1.107 mmol, 83% yield). MS (C<sub>28</sub>H<sub>37</sub>N<sub>2</sub>O<sub>6</sub>Si) <i>m</i>/<i>z</i>: 525.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.39–7.17 (m, 6H), 5.95 (s, 1H), 5.76 (m, 1H), 5.42 (d, <i>J</i> = 9.5 Hz, 1H), 5.16–5.02 (m, 2H), 4.83 (d, <i>J</i> = 15.6 Hz, 1H), 4.67–4.45 (m, 2H), 4.43–4.30 (m, 1H), 3.98 (s, 3H), 3.65 (m, 1H), 3.04 (d, <i>J</i> = 4.7 Hz, 2H), 0.93 (s, 9H), 0.15 (d, <i>J</i> = 5.8 Hz, 6H).</div></div><div id="sec5_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> (<i>S</i>)-Allyl (3-Hydroxy-2-methoxy-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy)methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-10-yl)carbamate (<b>51</b>)</h3><div class="NLM_p last">To a solution of <b>75</b> (500 mg, 1.065 mmol) in THF (3 mL) at 0 °C was added triethylamine (0.742 mL, 5.32 mmol). Allyl chloroformate (513 mg, 4.26 mmol) was added dropwise, and the resulting solution was stirred at 0 °C for 2 h. The reaction was then diluted with MeOH (5 mL), and aqueous LiOH (2 mL, 2 N) was added. The resulting mixture was stirred at room temperature for 16 h. The reaction was then diluted with EtOAc and washed with brine. The organic layer was separated, dried over sodium sulfate, and concentrated <i>in vacuo</i>. The crude product mixture was purified by silica gel chromatography (CombiFlash, 24 g column, 0–10% MeOH/DCM) to give the title compound <b>51</b> as a white solid (440 mg, 0.795 mmol, 74.6% yield). MS (C<sub>28</sub>H<sub>36</sub>N<sub>3</sub>O<sub>7</sub>Si) <i>m</i>/<i>z</i>: 554 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.38–7.30 (m, 3H), 7.27–7.21 (m, 2H), 6.96 (s, 1H), 6.28 (s, 1H), 6.02–5.89 (m, 1H), 5.44 (d, <i>J</i> = 9.8 Hz, 1H), 5.35 (dq, <i>J</i> = 17.2, 1.5 Hz, 1H), 5.26 (dq, <i>J</i> = 10.4, 1.3 Hz, 1H), 5.10 (d, <i>J</i> = 15.4 Hz, 1H), 4.70 (d, <i>J</i> = 9.8 Hz, 1H), 4.66 (d, <i>J</i> = 5.1 Hz, 2H), 4.40 (d, <i>J</i> = 15.4 Hz, 1H), 4.31–4.23 (m, 1H), 3.91 (s, 3H), 3.79–3.58 (m, 2H), 3.51 (dd, <i>J</i> = 15.6, 7.3 Hz, 1H), 2.96 (dd, <i>J</i> = 15.5, 6.4 Hz, 1H), 1.07–0.95 (m, 2H), 0.03 (s, 9H).</div></div><div id="sec5_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> 4-(Benzyloxy)-5-methoxy-2-nitrobenzoic Acid (<b>53</b>)</h3><div class="NLM_p last">To a solution of methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate <b>52</b> (15 g, 47.3 mmol, Harve Chem) in THF (350 mL) was added a solution of aqueous NaOH (56.7 mL, 142 mmol, 2.5 M). The reaction was stirred at 50 °C for 5 h. The reaction was cooled to room temperature and then concentrated <i>in vacuo</i> to remove THF. The remaining aqueous layer was acidified with aqueous HCl (6 N) until pH = 2. The resulting yellow precipitate was filtered, washed with water, and dried under vacuum to give the title compound (14.32 g, 100% yield). MS (C<sub>15</sub>H<sub>14</sub>NO<sub>6</sub>) <i>m</i>/<i>z</i>: 304 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): δ 7.60 (s, 1H), 7.53–7.45 (m, 2H), 7.45–7.31 (m, 3H), 7.29 (s, 1H), 5.23 (s, 2H), 3.98 (s, 3H).</div></div><div id="sec5_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> (<i>S</i>)-Benzyl 2-(4-(Benzyloxy)-5-methoxy-2-nitrobenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (<b>55</b>)</h3><div class="NLM_p last">To a solution of 4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid <b>53</b> (3.5 g, 11.54 mmol) in THF (150 mL) was added dropwise oxalyl chloride (1.212 mL, 13.85 mmol), followed by DMF (50 μL). The resulting solution was stirred at room temperature for 2 h before it was concentrated <i>in vacuo</i> to give the acid chloride as a yellow solid. The acid chloride was dissolved in THF (35 mL) and added dropwise to a solution of (<i>S</i>)-benzyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate <i>p</i>-toluenesulfonic acid salt <b>54</b> (5.58 g, 12.70 mmol, Accela) and triethylamine (4.83 mL, 34.6 mmol) in THF (80 mL) at 0 °C. The reaction was stirred at room temperature for 4 h before it was quenched with water and concentrated to remove THF. The resulting mixture was extracted with EtOAc (3×). The combined organic layers were washed with saturated aqueous NaHCO<sub>3</sub>, then brine, and then dried over sodium sulfate and concentrated <i>in vacuo</i>. The crude product mixture was purified by silica gel chromatography (CombiFlash, 80 g column, 0–100% EtOAc/DCM in 15 min) to give the title compound <b>55</b> (6.25 g, 98% yield). MS (C<sub>32</sub>H<sub>29</sub>N<sub>2</sub>O<sub>7</sub>) <i>m</i>/<i>z</i>: 553 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.95–7.72 (m, 1H), 7.57–7.35 (m, 5H), 7.34–7.0 (m, 8H), 7.14–6.98 (m, 1H), 6.94–6.69 (m, 1H), 5.39–5.19 (m, 2H), 5.19–5.08 (m, 1H), 4.99 (q, <i>J</i> = 12.4 Hz, 1H), 4.75 (d, <i>J</i> = 17.4 Hz, 1H), 4.65–4.40 (m, 2H), 4.28 (d, <i>J</i> = 15.6 Hz, 1H), 3.86 (br s, 3H), 3.71 (s, 1H), 3.50–3.18 (m, 1H).</div></div><div id="sec5_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> (<i>S</i>)-3-(Benzyloxy)-2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,12<i>H</i>)-dione (<b>56</b>)</h3><div class="NLM_p last">A suspension of (<i>S</i>)-benzyl 2-(4-(benzyloxy)-5-methoxy-2-nitrobenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate <b>55</b> (6.25 g, 11.31 mmol), zinc (4.44 g, 67.9 mmol), and ammonium chloride (7.26 g, 136 mmol) in MeOH (50 mL) was heated at 50 °C for 16 h. The reaction was cooled to room temperature and diluted with MeOH. The resulting mixture was filtered through a pad of Celite, washing successively with EtOAc, DCM, and methanol. The filtrate was combined and concentrated <i>in vacuo</i>. The crude product mixture was purified by silica gel chromatography (CombiFlash, 120 g column, 0–100% EtOAc/DCM in 15 min) to give the title compound <b>56</b> (4.5 g, 96% yield). MS (C<sub>25</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub>) <i>m</i>/<i>z</i>: 415 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.49–7.40 (m, 4H), 7.32 (br s, 6H), 6.45 (s, 1H), 5.19 (s, 2H), 5.13 (d, <i>J</i> = 15.4 Hz, 1H), 4.47 (d, <i>J</i> = 15.2 Hz, 1H), 4.21 (t, <i>J</i> = 6.7 Hz, 1H), 3.93 (s, 3H), 3.52 (dd, <i>J</i> = 15.4, 7.0 Hz, 1H), 3.02 (dd, <i>J</i> = 15.4, 6.4 Hz, 1H).</div></div><div id="sec5_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> (<i>S</i>)-3-(Benzyloxy)-2-methoxy-5-((2-(trimethylsilyl)ethoxy)methyl)-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,12<i>H</i>)-dione (<b>58</b>)</h3><div class="NLM_p last">A solution of <b>56</b> (4.5 g, 10.86 mmol) in DMF (54.3 mL) was cooled to 0 °C before sodium hydride (60% dispersion in mineral oil, 0.54 g, 13.57 mmol) was added batch wise. The resulting mixture was stirred for 30 min before (2-(chloromethoxy)ethyl)trimethylsilane <b>57</b> (2.31 mL, 13.03 mmol) was added. The reaction was warmed to room temperature and stirred for 1 h before it was quenched with water. The resulting mixture was extracted with EtOAc (3×). The combined organic layers were dried over sodium sulfate and concentrated <i>in vacuo</i>. The crude product mixture was purified by silica gel chromatography (CombiFlash, 80 g column, 0–50% EtOAc/DCM in 15 min) to give the title compound <b>58</b> as a white solid (4.60 g, 78% yield). MS (C<sub>31</sub>H<sub>37</sub>N<sub>2</sub>O<sub>5</sub>Si) <i>m</i>/<i>z</i>: 545 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.59–7.41 (m, 2H), 7.40–7.21 (m, 9H), 5.43 (d, <i>J</i> = 9.9 Hz, 1H), 5.21 (s, 2H), 5.14 (d, <i>J</i> = 15.2 Hz, 1H), 4.50 (d, <i>J</i> = 9.7 Hz, 1H), 4.41 (d, <i>J</i> = 15.2 Hz, 1H), 4.33–4.16 (m, 1H), 4.13 (d, <i>J</i> = 7.3 Hz, 1H), 3.92 (s, 3H), 3.82–3.46 (m, 3H), 3.06–2.84 (m, 1H), 1.26 (t, <i>J</i> = 7.2 Hz, 1H), 0.97 (ddd, <i>J</i> = 9.9, 6.8, 2.6 Hz, 2H), 0.10–0.01 (m, 9H).</div></div><div id="sec5_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> (<i>S</i>)-3-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-1,2,3,4-tetrahydroisoquinoline (<b>60</b>)</h3><div class="NLM_p last">TBS-Cl (55.4 g, 368 mmol) was added to a stirred solution of (<i>S</i>)-(1,2,3,4-tetrahydroisoquinolin-3-yl)methanol <b>59</b> (50.0 g, 306 mmol) and imidazole (27.1 g, 398 mmol) in acetonitrile (375 mL) under nitrogen at room temperature. The mixture was stirred for 1.5 h at room temperature, then filtered, and washed with acetonitrile. The filtrate was concentrated under reduced pressure. The residue was diluted with ethyl acetate and water. The organic layer was washed with water (3 × 200 mL) and dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified by CombiFlash on neutral alumina using 2–4% ethyl acetate in hexanes to provide <b>60</b> (60.0 g, 207 mmol, 67.5% yield) as a pale-yellow oil. MS (C<sub>16</sub>H<sub>28</sub>NOSi) <i>m</i>/<i>z</i>: 278 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.19–6.96 (m, 4H), 4.10 (s, 2H), 3.78 (dd, <i>J</i> = 9.8, 4.0 Hz, 1H), 3.63 (dd, <i>J</i> = 9.8, 6.8 Hz, 1H), 3.04 (m, 1H), 2.67 (m, 2H), 0.93 (s, 9H), 0.11 (s, 6H).</div></div><div id="sec5_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> (<i>S</i>)-(3-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)(5-methoxy-2-nitro-4-((triisopropylsilyl)oxy)phenyl)methanone (<b>62</b>)</h3><div class="NLM_p last">A flask was charged with 5-methoxy-2-nitro-4-((triisopropylsilyl)oxy)benzoic acid <b>61</b> (9.0 g, 24.36 mmol) and HATU (10.19 g, 26.8 mmol) in DCM (100 mL) at 0 °C. The reaction mixture was stirred for 10 min and treated with DIPEA (4.68 mL, 26.8 mmol) and amine <b>60</b> (7.43 g, 26.8 mmol). The reaction was stirred at 0 °C for 3 h and then at room temperature for 24 h. The reaction mixture was poured into saturated aqueous NH<sub>4</sub>Cl and DCM. The organic phase was collected and concentrated to a residue. The residue was purified by silica gel chromatography (10–30% EtOAc in hexanes) to afford amide <b>62</b> as a light tan oil (10.15 g, 66% yield). MS (C<sub>33</sub>H<sub>53</sub>N<sub>2</sub>O<sub>6</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 629 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.62, (s, 1H), 7.21 (m, 4H), 6.97 (m, 1H), 5.18 (d, <i>J</i> = 17.6 Hz, 1H), 4.78 (br s, 1H), 4.31 (d, <i>J</i> = 17.6 Hz, 1H), 3.92 (s, 3H), 3.32–3.72 (m, 2H), 3.03 (m, 1H), 2.82 (m, 1H), 1.30 (m, 3H), 1.07 (m, 18H), 0.84 (s, 9H), −0.02 (s, 6H).</div></div><div id="sec5_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> (<i>S</i>)-(2-Amino-5-methoxy-4-((triisopropylsilyl)oxy)phenyl)(3-(((<i>tert</i>-butyldimethylsilyl)oxy)methyl)-3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)methanone (<b>63</b>)</h3><div class="NLM_p last">A solution of amide <b>62</b> (10.1 g, 16.06 mmol) in MeOH (200 mL) was cooled to 0 °C, and NH<sub>4</sub>Cl (4.29 g, 80 mmol) and zinc dust (5.25 g, 80 mmol) were added. The resulting green suspension was stirred at 0 °C for 45 min and then allowed to warm to room temperature overnight. The reaction mixture was filtered through a Celite pad (washing with MeOH), and the filtrate was concentrated to a residue. The residue was taken up in DCM and loaded onto a silica gel pad. This was flushed with 50% EtOAc in hexanes to afford aniline <b>63</b> (8.02 g, 83% yield). MS (C<sub>33</sub>H<sub>55</sub>N<sub>2</sub>O<sub>4</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 599 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.14 (m, 4H), 6.72 (s, 1H), 6.31 (s, 1H), 4.30–5.10 (m, 2H), 4.06 (s, 2H), 3.72 (s, 3H), 3.67 (m, 2H), 3.15 (dd, <i>J</i> = 16.0, 6.0 Hz, 1H), 2.83 (d, <i>J</i> = 16.0 Hz, 1H), 1.29 (m, 3H), 1.10 (m, 18H), 0.84 (s, 9H), −0.02 (s, 6H).</div></div><div id="sec5_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> Allyl (<i>S</i>)-(2-(3-(((<i>tert</i>-Butyldimethylsilyl)oxy)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-4-methoxy-5-((triisopropylsilyl)oxy)phenyl)carbamate (<b>64</b>)</h3><div class="NLM_p last">Aniline <b>63</b> (2.5 g, 4.17 mmol) was dissolved in DCM (50 mL), and pyridine (0.878 mL, 10.85 mmol) was added. The mixture was cooled to −78 °C and allyl chloroformate (0.579 mL, 5.43 mmol) was added. The reaction mixture was maintained at this temperature for 1 h and then allowed to warm to room temperature. The reaction mixture was poured into saturated aqueous NH<sub>4</sub>Cl and DCM. The mixture was extracted with DCM and purified by silica gel chromatography (10–50% EtOAc/hexanes) to afford carbamate <b>64</b> (2.5 g, 88% yield). MS (C<sub>37</sub>H<sub>59</sub>N<sub>2</sub>O<sub>6</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 683 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.20 (br s, 1H), 7.80 (s, 1H), 7.19 (m, 3H), 6.80 (s, 1H), 5.92 (m, 1H), 5.26 (dd, <i>J</i> = 42.5, 13.7 Hz, 2H), 4.60 (s, 2H), 4.40 (m, 1H), 3.78 (s, 3H), 3.70 (br s, 1H), 3.14 (m, 1H), 2.85 (m, 1H), 1.31 (m, 3H), 1.12 (m, 18H), 0.84 (s, 9H), −0.02 (s, 6H).</div></div><div id="sec5_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> Allyl (<i>S</i>)-(2-(3-(Hydroxymethyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-4-methoxy-5-((triisopropylsilyl)oxy)phenyl)carbamate (<b>65</b>)</h3><div class="NLM_p last">Carbamate <b>64</b> (1.372 g, 2.009 mmol) was dissolved in MeOH (20 mL), and 10% concentrated HCl in MeOH (2 mL, 6.58 mmol) was added. The mixture was aged for 20 min and quenched with NaHCO<sub>3</sub> (0.591 g, 7.03 mmol) in water. The mixture was diluted with water and extracted 4× with DCM. The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. Purification by silica gel chromatography (10–50% EtOAc/hexanes) afforded alcohol <b>65</b> (963 mg, 84% yield). MS (C<sub>31</sub>H<sub>45</sub>N<sub>2</sub>O<sub>6</sub>Si) <i>m</i>/<i>z</i>: 569 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.90 (s, 1H), 7.66 (s, 1H), 7.27–7.12 (m, 3H), 6.76 (s, 1H), 6.02–5.85 (m, 1H), 5.32 (dq, <i>J</i> = 10.3, 1.3 Hz, 1H), 5.22 (dq, <i>J</i> = 10.3, 1.3 Hz, 1H), 4.62 (dt, <i>J</i> = 5.7, 1.5 Hz, 2H), 4.41 (d, <i>J</i> = 16.8 Hz, 1H), 3.77 (s, 3H), 3.70 (s, 2H), 3.19 (dd, <i>J</i> = 16.5, 6.4 Hz, 1H), 2.77 (br s, 1H), 1.58 (s, 7H), 1.30 (m, 3H), 1.14 (d, <i>J</i> = 7.4 Hz, 18H).</div></div><div id="sec5_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> Allyl (6<i>S</i>,6a<i>S</i>)-6-Hydroxy-2-methoxy-14-oxo-3-((triisopropylsilyl)oxy)-6,6a,7,12-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-5(14<i>H</i>)-carboxylate (<b>66</b>)</h3><div class="NLM_p last">Oxalyl chloride (2 M, 1.450 mL, 2.90 mmol) was dissolved in DCM (30 mL), and then, the mixture was cooled to −78 °C in a dry ice/acetone bath. To this was added DMSO (0.515 mL, 7.25 mmol, dissolved in 2 mL of DCM to prevent freezing during addition), and the temperature was maintained at −78 °C. After 20 min, alcohol <b>65</b> (1.65 g, 2.90 mmol) dissolved in DCM (10 mL) was added to the reaction. This was allowed to stir for an additional 30 min, followed by addition of NEt<sub>3</sub> (2.022 mL, 14.50 mmol). After 10 min, the reaction was allowed to warm up to room temperature, quenched with saturated NH<sub>4</sub>Cl, and extracted with DCM (2×). The organic phases were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to residue. The residue was purified by silica gel chromatography (30–100% EtOAc in hexanes) to afford aminal <b>66</b> as a white solid (1.51 g, 92% yield). MS (C<sub>31</sub>H<sub>43</sub>N<sub>2</sub>O<sub>6</sub>Si) <i>m</i>/<i>z</i>: 567 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.39–7.24 (m, 5H), 7.22 (s, 1H), 6.67 (s, 1H), 5.75 (dd, <i>J</i> = 11.2, 5.6 Hz, 1H), 5.31 (dd, <i>J</i> = 9.5, 4.0 Hz, 1H), 5.22–5.07 (m, 2H), 4.84 (d, <i>J</i> = 15.8 Hz, 1H), 4.64–4.49 (m, 2H), 4.44 (d, <i>J</i> = 5.3 Hz, 1H), 3.87 (s, 3H), 3.77–3.61 (m, 1H), 3.28–3.01 (m, 3H), 1.34–1.18 (m, 3H), 1.09 (dd, <i>J</i> = 7.4, 2.6 Hz, 18H).</div></div><div id="sec5_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122"> Allyl (6<i>S</i>,6a<i>S</i>)-6-((<i>tert</i>-Butyldimethylsilyl)oxy)-2-methoxy-14-oxo-3-((triisopropylsilyl)oxy)-6,6a,7,12-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-5(14<i>H</i>)-carboxylate (<b>67</b>)</h3><div class="NLM_p last">Aminal <b>66</b> (776 mg, 1.369 mmol) was dissolved in DCM (12 mL), and 2,6-lutidine (0.638 mL, 5.48 mmol) was added. The mixture was cooled on an ice bath, and <i>tert</i>-butyldimethylsilyl trifluoromethanesulfonate (TBSOTf, 0.943 mL, 4.11 mmol) was added. The mixture was aged for 30 min, diluted with DCM, quenched with saturated NaHCO<sub>3</sub> solution, and extracted twice with DCM. The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to dryness. The residue was purified by silica gel chromatography (10–30% EtOAc/hexanes) to afford silyl ether <b>67</b> (907.6 mg, 1.333 mmol, 97% yield). MS (C<sub>37</sub>H<sub>57</sub>N<sub>2</sub>O<sub>6</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 681 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.36–7.18 (m, 6H), 6.67 (s, 1H), 5.74 (m, 1H), 5.39 (d, <i>J</i> = 9.4 Hz, 1H), 5.17–5.10 (m, 1H), 5.10 (d, <i>J</i> = 1.5 Hz, 1H), 4.84 (d, <i>J</i> = 15.7 Hz, 1H), 4.62–4.46 (m, 2H), 4.30 (dd, <i>J</i> = 13.3, 5.7 Hz, 1H), 3.89 (s, 3H), 3.63 (dt, <i>J</i> = 9.3, 4.6 Hz, 1H), 3.05 (d, <i>J</i> = 4.8 Hz, 2H), 1.33–1.21 (m, 3H), 1.10 (dd, <i>J</i> = 7.4, 3.6 Hz, 18H), 0.93 (s, 9H), 0.14 (d, <i>J</i> = 14.6 Hz, 6H).</div></div><div id="sec5_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123"> Ethyl (<i>S</i>)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylate (<b>69</b>)</h3><div class="NLM_p last">To a suspension of (<i>S</i>)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid <b>68</b> (9.2 g, 51.9 mmol) in EtOH (180 mL) was added sulfuric acid (4.15 mL, 78 mmol) dropwise at room temperature. The resulting mixture was heated at 80 °C under a nitrogen stream for 20 h. After 4 h, the reaction mixture turned into a clear solution. The reaction mixture was cooled to room temperature and concentrated <i>in vacuo</i>, and the residue was basified with 1 N NaOH solution carefully to pH = 8–9. The residue was extracted with ethyl acetate. The organic layer was separated, combined and washed with brine, and dried over MgSO<sub>4</sub>. The filtrate was concentrated <i>in vacuo</i> to produce a pale-yellow oil. To the solution of the above oil in DCM (20 mL), HCl (14.93 mL, 59.7 mmol, 4.0 M solution in dioxane) was added slowly within an ice bath to make the HCl salt. The mixture was stirred at room temperature for 20 min. White solid precipitated out during addition, and the slurry was concentrated <i>in vacuo</i> to give <b>69</b> as a light pink solid (8.8 g, 83% yield). MS (C<sub>12</sub>H<sub>16</sub>NO<sub>2</sub>) <i>m</i>/<i>z</i>: 206 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.22–7.01 (m, 4H), 4.27 (q, <i>J</i> = 7.2 Hz, 2H), 4.21–4.06 (m, 2H), 3.75 (dd, <i>J</i> = 10.2, 4.7 Hz, 1H), 3.11 (dd, <i>J</i> = 16.2, 4.6 Hz, 1H), 2.98 (dd, <i>J</i> = 16.3, 10.2 Hz, 1H), 2.06 (d, <i>J</i> = 5.8 Hz, 1H), 1.34 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec5_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> Ethyl (<i>S</i>)-7-Nitro-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (<b>70</b>)</h3><div class="NLM_p last">(<i>S</i>)-Ethyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate <b>69</b> (50 g, 244 mmol) was added slowly to concentrated H<sub>2</sub>SO<sub>4</sub> (195 mL, 3654 mmol) maintained at a temperature of −5 °C, and concentrated nitric acid (36.5 mL, 816 mmol) was then added dropwise over 45 min. The reaction mixture was stirred at this temperature for 1 h, slowly poured onto ice water (5 L), and basified with solid Na<sub>2</sub>CO<sub>3</sub> (∼900 g). The mixture was diluted with water and extracted with ethyl acetate (3 × 4 L). The organic layer was washed with water (2 L) and brine (1 L), dried over sodium sulfate, and concentrated to give a mixture of mono and dinitro products. The mixture was purified by silica gel chromatography (25–30% EtOAc in hexanes) to obtain <b>70</b> as an orange color solid (60 g, 221 mmol, 91% yield). MS (C<sub>12</sub>H<sub>15</sub>N<sub>2</sub>O<sub>4</sub>) <i>m</i>/<i>z</i>: 251 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.02 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.95 (d, <i>J</i> = 2.3 Hz, 1H), 7.30 (d, <i>J</i> = 8.6 Hz, 1H), 4.27 (q, <i>J</i> = 7.1 Hz, 2H), 4.24–4.12 (m, 2H), 3.79 (dd, <i>J</i> = 9.4, 4.7 Hz, 1H), 3.22 (dd, <i>J</i> = 17.1, 4.8 Hz, 1H), 3.14–3.00 (m, 1H), 2.19 (s, 1H), 1.34 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec5_86" class="NLM_sec NLM_sec_level_2"><div id="ac_i125" class="anchor-spacer"></div><h3 class="article-section__title" id="_i125"> (<i>S</i>)-Ethyl 2-(4-(Benzyloxy)-5-methoxy-2-nitrobenzoyl)-7-nitro-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (<b>71</b>)</h3><div class="NLM_p last">To a solution of 4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid <b>53</b> (2.13 g, 7.03 mmol) in THF (30 mL) was added dropwise oxalyl chloride (1.34 mL, 15.3 mmol), followed by DMF (30 μL). The resulting solution was stirred at room temperature for 2 h before it was concentrated <i>in vacuo</i> to give the acid chloride as a yellow solid. The acid chloride was dissolved in THF (30 mL) and added dropwise to a solution of (<i>S</i>)-ethyl 7-nitro-1,2,3,4-tetrahydroisoquinoline-3-carboxylate <b>70</b> (1.6 g, 6.39 mmol) and triethylamine (2.67 mL, 19.2 mmol) in THF (20 mL) at 0 °C. The reaction solution was slowly warmed to room temperature and stirred for 30 min. The reaction was then quenched with water and concentrated to remove THF. The resulting mixture was extracted with EtOAc (3×). The combined organic layers were washed with saturated aqueous NaHCO<sub>3</sub> and then brine and then dried over sodium sulfate and concentrated <i>in vacuo</i>. The crude product mixture was purified by silica gel chromatography (CombiFlash, 80 g column, 0–100% EtOAc/hexane in 15 min) to give the title compound <b>71</b> (2.66 g, 78% yield). MS (C<sub>27</sub>H<sub>26</sub>N<sub>3</sub>O<sub>9</sub>) <i>m</i>/<i>z</i>: 536 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.28 (s, 1H), 8.07 (m, 2H), 7.89 (d, <i>J</i> = 8.8 Hz, 1H), 7.56 (m, 5H), 6.93 (br s, 1H), 5.35 (m, 1H), 5.28 (m, 2H), 4.58 (m, 2H), 4.09 (m, 2H), 3.91 (m, 3H), 3.37 (s, 1H), 1.08 (m, 3H).</div></div><div id="sec5_87" class="NLM_sec NLM_sec_level_2"><div id="ac_i126" class="anchor-spacer"></div><h3 class="article-section__title" id="_i126"> (<i>S</i>)-10-Amino-3-(benzyloxy)-2-methoxy-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,12<i>H</i>)-dione (<b>72</b>)</h3><div class="NLM_p last">A suspension of <b>71</b> (1.75 g, 3.55 mmol), zinc (1.394 g, 21.32 mmol), and ammonium chloride (2.281 g, 42.6 mmol) in MeOH (10 mL) was heated at 50 °C overnight. The reaction was then filtered through a pad of Celite, washing with copious amount of 20% MeOH in DCM. The filtrate was concentrated to give the title compound <b>72</b> as a white solid (1.25 g, 2.90 mmol, 82% yield). MS (C<sub>25</sub>H<sub>24</sub>N<sub>3</sub>O<sub>4</sub>) <i>m</i>/<i>z</i>: 430 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.26 (br s, 1H), 7.53–7.31 (m, 6H), 7.24 (s, 1H), 6.92 (d, <i>J</i> = 7.9 Hz, 1H), 6.78 (s, 1H), 6.50–6.41 (m, 2H), 5.07 (d, <i>J</i> = 4.6 Hz, 2H), 5.00–4.88 (m, 2H), 4.84 (d, <i>J</i> = 15.0 Hz, 1H), 4.09 (d, <i>J</i> = 15.0 Hz, 1H), 4.01 (t, <i>J</i> = 6.9 Hz, 1H), 3.75 (s, 3H), 3.12 (dd, <i>J</i> = 15.3, 7.6 Hz, 1H), 2.78 (dd, <i>J</i> = 15.2, 6.2 Hz, 1H).</div></div><div id="sec5_88" class="NLM_sec NLM_sec_level_2"><div id="ac_i127" class="anchor-spacer"></div><h3 class="article-section__title" id="_i127"> (<i>S</i>)-3-(Benzyloxy)-2-methoxy-10-(tritylamino)-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,12<i>H</i>)-dione (<b>73</b>)</h3><div class="NLM_p last">To a solution of <b>72</b> (1.6 g, 3.73 mmol) and trityl chloride (1.246 g, 4.47 mmol) in DCM (10 mL) was added triethylamine (0.779 mL, 5.59 mmol). The reaction was stirred at room temperature for 3 h and then concentrated. The crude product mixture was purified by silica gel chromatography (CombiFlash, 80 g column, 0–50% EtOAc/hexane) to give the title compound <b>73</b> as a white solid (2.2 g, 3.27 mmol, 88% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.01 (s, 1H), 7.50–7.12 (m, 22H), 6.77 (d, <i>J</i> = 8.4 Hz, 1H), 6.47–6.34 (m, 2H), 6.16 (dd, <i>J</i> = 8.1, 2.4 Hz, 1H), 5.02 (br, 1H), 4.91 (d, <i>J</i> = 15.2 Hz, 1H), 4.18–4.09 (m, 2H), 4.05 (t, <i>J</i> = 6.9 Hz, 1H), 3.92 (s, 3H), 3.28 (dd, <i>J</i> = 15.4, 7.7 Hz, 1H), 2.75 (dd, <i>J</i> = 15.4, 6.4 Hz, 1H).</div></div><div id="sec5_89" class="NLM_sec NLM_sec_level_2"><div id="ac_i128" class="anchor-spacer"></div><h3 class="article-section__title" id="_i128"> (<i>S</i>)-3-(Benzyloxy)-2-methoxy-5-((2-(trimethylsilyl)ethoxy)methyl)-10-(tritylamino)-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,12<i>H</i>)-dione (<b>74</b>)</h3><div class="NLM_p last">To a solution of <b>73</b> (2.2 g, 3.27 mmol) in DMF (15 mL) at 0 °C was added sodium hydride (60% dispersion in mineral oil, 0.236 g, 3.93 mmol). The mixture was stirred for 30 min before (2-(chloromethoxy)ethyl)trimethylsilane (0.697 mL, 3.93 mmol) was added. The reaction was stirred at 0 °C for 2 h before it was quenched with brine. The reaction mixture was extracted with EtOAc (3×). The combined organic layers were dried over sodium sulfate and concentrated <i>in vacuo</i>. The crude product mixture was purified by silica gel chromatography (CombiFlash, 40 g column, 0–50% EtOAc/hexane) to give the title compound <b>74</b> as a white solid (2.1 g, 2.62 mmol, 80% yield). MS (C<sub>31</sub>H<sub>38</sub>N<sub>3</sub>O<sub>5</sub>Si) <i>m</i>/<i>z</i>: 560 (M – trityl + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.48–7.42 (m, 2H), 7.41–7.32 (m, 9H), 7.31–7.18 (m, 11H), 6.77 (d, <i>J</i> = 8.1 Hz, 1H), 6.38 (d, <i>J</i> = 2.2 Hz, 1H), 6.19 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 5.45 (d, <i>J</i> = 9.7 Hz, 1H), 5.21 (s, 2H), 5.08–4.92 (m, 2H), 4.49 (d, <i>J</i> = 9.7 Hz, 1H), 4.13–4.08 (m, 1H), 4.02 (d, <i>J</i> = 15.2 Hz, 1H), 3.93 (s, 3H), 3.71 (td, <i>J</i> = 9.6, 7.0 Hz, 1H), 3.61 (td, <i>J</i> = 9.6, 7.2 Hz, 1H), 3.36 (dd, <i>J</i> = 15.5, 8.3 Hz, 1H), 2.72 (dd, <i>J</i> = 15.5, 6.5 Hz, 1H), 1.05–0.92 (m, 2H), 0.06 (s, 9H).</div></div><div id="sec5_90" class="NLM_sec NLM_sec_level_2"><div id="ac_i129" class="anchor-spacer"></div><h3 class="article-section__title" id="_i129"> (<i>S</i>)-10-Amino-3-hydroxy-2-methoxy-5-((2-(trimethylsilyl)ethoxy)methyl)-6a,7-dihydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinoline-6,14(5<i>H</i>,12<i>H</i>)-dione (<b>75</b>)</h3><div class="NLM_p last">A suspension of <b>74</b> (950 mg, 1.18 mmol) and Pd/C (10%, 200 mg) in EtOAc (20 mL) was stirred under a balloon of H<sub>2</sub> for 2 days. The reaction was then filtered through a pad of Celite, washing with EtOAc and then MeOH. The combined filtrate was concentrated and purified by silica gel chromatography (CombiFlash, 40 g column, 0–100% EtOAc/hexane) to give the title compound <b>75</b> as a white solid (510 mg, 1.08 mmol, 90% yield). MS (C<sub>24</sub>H<sub>32</sub>N<sub>3</sub>O<sub>5</sub>Si) <i>m</i>/<i>z</i>: 470 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.33 (s, 1H), 7.27 (s, 1H), 7.09 (d, <i>J</i> = 8.6 Hz, 1H), 6.67–6.54 (m, 2H), 6.02 (s, 1H), 5.47 (d, <i>J</i> = 9.7 Hz, 1H), 5.11 (d, <i>J</i> = 15.2 Hz, 1H), 4.71 (d, <i>J</i> = 9.7 Hz, 1H), 4.29 (d, <i>J</i> = 15.2 Hz, 1H), 4.22 (dd, <i>J</i> = 7.7, 6.5 Hz, 1H), 3.94 (s, 3H), 3.79–3.60 (m, 4H), 3.47 (dd, <i>J</i> = 15.4, 7.7 Hz, 1H), 2.90 (dd, <i>J</i> = 15.5, 6.4 Hz, 1H), 1.09–0.94 (m, 2H), 0.05 (s, 9H).</div></div><div id="sec5_91" class="NLM_sec NLM_sec_level_2"><div id="ac_i130" class="anchor-spacer"></div><h3 class="article-section__title" id="_i130"> (9<i>H</i>-Fluoren-9-yl)methyl ((<i>S</i>)-1-(((<i>S</i>)-1-(((<i>S</i>)-2-Methoxy-3-((5-(((<i>S</i>)-2-methoxy-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy)methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)pentyl)oxy)-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy)methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-10-yl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (<b>77</b>)</h3><div class="NLM_p last">(<i>S</i>)-2-((<i>S</i>)-2-((((9<i>H</i>-Fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanoic acid <b>76</b> (67.6 mg, 0.136 mmol) and HATU (51.7 mg, 0.136 mmol) were combined in a vial and cooled to 0 °C. DMF (1 mL) was added, and the mixture was stirred at 0 °C for 10 min at which point everything was in solution. 2,6-Lutidine (0.021 mL, 0.181 mmol) was added, and then mixture was treated with compound <b>14b</b> (90 mg, 0.091 mmol). The reaction was then slowly warmed to room temperature and stirred for 1 h. Aqueous LiCl was added to the reaction, and the mixture was extracted with ethyl acetate. The organic layer was washed with aqueous LiCl and brine, then dried, and concentrated. The residue was purified by silica gel chromatography (CombiFlash, 40 g column, 0–10% MeOH/DCM) to give the title compound <b>77</b> as a white solid (95 mg, 0.065 mmol, 71.2% yield). MS (C<sub>79</sub>H<sub>100</sub>N<sub>9</sub>O<sub>15</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1470 (M + H)<sup>+</sup>.</div></div><div id="sec5_92" class="NLM_sec NLM_sec_level_2"><div id="ac_i131" class="anchor-spacer"></div><h3 class="article-section__title" id="_i131"> (<i>S</i>)-2-((<i>S</i>)-2-Amino-3-methylbutanamido)-<i>N</i>-((<i>S</i>)-2-methoxy-3-((5-(((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)pentyl)oxy)-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-10-yl)-5-ureidopentanamide (<b>79</b>)</h3><div class="NLM_p last">To a solution of compound <b>77</b> (95 mg, 0.065 mmol) in THF (2 mL) was added piperidine (0.13 mL) and allowed to stir at room temperature for 2 h. The reaction was then concentrated and purified by silica gel chromatography (CombiFlash, 12 g column, 50–100% EtOAc/hexane over 3 min, then 20% 2 N NH<sub>3</sub> in MeOH/DCM over 10 min) to give <b>78</b> as a white solid (52 mg, 0.042 mmol, 64.5% yield). MS (C<sub>64</sub>H<sub>90</sub>N<sub>9</sub>O<sub>13</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1249 (M + H)<sup>+</sup>. This was dissolved in THF (2 mL) and cooled to −78 °C. A solution of superhydride (0.2 mL, 0.2 mmol) in THF (1 M) was added dropwise. The resulting reaction mixture was stirred at −78 °C for 1 h, quenched with brine, warmed to room temperature, and extracted with chloroform. The organic layers were combined, dried, and concentrated. The residue was then dissolved in EtOH/chloroform (1:1, 2 mL), and silica gel (0.6 g) was added, followed by water (0.5 mL). The resulting slurry was stirred at room temperature for 36 h and then filtered, washing with 20% MeOH/chloroform. The filtrate was combined, concentrated, and then purified by preparative HPLC to give compound <b>79</b> as a white solid (21 mg, 0.022 mmol, 54.8% yield). MS (C<sub>52</sub>H<sub>62</sub>N<sub>9</sub>O<sub>9</sub>) <i>m</i>/<i>z</i>: 956 (M + H)<sup>+</sup>.</div></div><div id="sec5_93" class="NLM_sec NLM_sec_level_2"><div id="ac_i132" class="anchor-spacer"></div><h3 class="article-section__title" id="_i132"> 4-((<i>S</i>)-2-((<i>S</i>)-2-((((9<i>H</i>-Fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanamido)benzyl Bis(2-(((<i>S</i>)-2-methoxy-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy)methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)ethyl)carbamate (<b>82</b>)</h3><div class="NLM_p last">To a solution of <b>17c</b> (850 mg, 0.869 mmol) and <b>81</b> (666 mg, 0.869 mmol) in NMP (7 mL) was added Hunig’s base (0.228 mL, 1.303 mmol) and allowed to stir at room temperature overnight. The crude reaction was directly purified by silica gel chromatography (120 g column, 0–10% MeOH/DCM over 45 min) to provide <b>82</b> as a white solid (0.8 g, 57% yield). MS (C<sub>86</sub>H<sub>105</sub>N<sub>10</sub>O<sub>17</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1606 (M + H)<sup>+</sup>.</div></div><div id="sec5_94" class="NLM_sec NLM_sec_level_2"><div id="ac_i133" class="anchor-spacer"></div><h3 class="article-section__title" id="_i133"> 4-((<i>S</i>)-2-((<i>S</i>)-2-Amino-3-methylbutanamido)-5-ureidopentanamido)benzyl Bis(2-(((<i>S</i>)-2-methoxy-6,14-dioxo-5-((2-(trimethylsilyl)ethoxy)methyl)-5,6,6a,7,12,14-hexahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)ethyl)carbamate (<b>83</b>)</h3><div class="NLM_p last">To a solution of <b>82</b> (0.7 g, 0.436 mmol) in THF (5 mL) was added piperidine (0.5 mL, 5.05 mmol) and allowed to stir at room temperature for 30 min. The reaction mixture was concentrated and purified by silica gel chromatography (80 g column, 0–30% MeOH/DCM over 40 min) to provide <b>83</b> as a white solid (0.475 g, 0.343 mmol, 79% yield). MS (C<sub>71</sub>H<sub>95</sub>N<sub>10</sub>O<sub>15</sub>Si<sub>2</sub>) <i>m</i>/<i>z</i>: 1383.6 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.11 (s, 2H), 8.13 (s, 2H), 7.57 (d, <i>J</i> = 8.4 Hz, 2H), 7.23 (m, 14 H), 5.96 (t, <i>J</i> = 5.6 Hz, 2H), 5.76 (s, 1H). 5.39 (s, 4H), 5.26 (t, <i>J</i> = 6.0 Hz, 4H), 5.08 (dd, <i>J</i> = 22.0, 10.4 Hz, 4H), 5.01 (s, 2H), 4.92 (d, <i>J</i> = 15.6 Hz, 4H), 4.47 (m, 2H), 4.31 (m, 5H), 4.21 (m, 5 H), 4.10 (q, <i>J</i> = 5.2 Hz, 2H), 3.76 (m, 10 H), 3.18 (d, <i>J</i> = 5.2 Hz, 2H), 3.03 (m, 6H), 2.68 (m, 2H), 2.34 (m, 2H), 1.93 (m, 3H), 1.50–1.70 (m, 6H), 1.39 (m, 5H), 0.88 (d, <i>J</i> = 6.8 Hz, 3H), 0.78 (d, <i>J</i> = 6.8 Hz, 3H), 0.74 (m, 9H), 0.09 (m, 9H).</div></div><div id="sec5_95" class="NLM_sec NLM_sec_level_2"><div id="ac_i134" class="anchor-spacer"></div><h3 class="article-section__title" id="_i134"> 4-((<i>S</i>)-2-((<i>S</i>)-2-Amino-3-methylbutanamido)-5-ureidopentanamido)benzyl Bis(2-(((<i>S</i>)-2-methoxy-14-oxo-6a,7,12,14-tetrahydrobenzo[5,6][1,4]diazepino[1,2-<i>b</i>]isoquinolin-3-yl)oxy)ethyl)carbamate (<b>84</b>)</h3><div class="NLM_p last">To a solution of <b>83</b> (975 mg, 0.705 mmol) in THF (10 mL) at −76 °C was added superhydride (3.52 mL, 3.52 mmol). The reaction mixture was stirred for 1 h, quenched with cold water (1 mL), and concentrated. The resulting residue was treated with DCM/EtOH/water (1:2:1 = 8 mL) and silica gel (1 g) at room temperature for 3 days. This mixture was filtered through a sintered funnel and the silica gel was washed with DCM–MeOH (8:2, 100 mL). The filtrate was concentrated under high vacuum and purified by silica gel chromatography (0–20% MeOH/DCM over 15 min) to provide <b>84</b> as a white solid (422 mg, 0.387 mmol, 54.9% yield). MS (C<sub>59</sub>H<sub>67</sub>N<sub>10</sub>O<sub>11</sub>) <i>m</i>/<i>z</i>: 1091.6 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.98 (br s, 1H), 10.20 (s, 1H), 8.70 (m, 1H), 8.11 (br s, 2H), 7.95 (d, <i>J</i> = 7.2 Hz, 1H), 7.05–7.53 (m, 14 H), 6.85 (m, 1H), 6.58 (m, 1H), 6.32 (m, 1H), 6.04 (m, 1H), 5.49 (s, 1H), 5.01 (m, 2H), 4.80 (m, 1H), 4.51 (m, 3H), 4.20 (m, 2H), 3.76 (m, 10 H), 3.49 (m, 3H), 2.98 (m, 3H), 2.77 (m, 2H), 2.08 (m, 1H), 1.40–1.80 (m, 4H), 0.94 (m, 6H).</div></div><div id="sec5_96" class="NLM_sec NLM_sec_level_2"><div id="ac_i135" class="anchor-spacer"></div><h3 class="article-section__title" id="_i135"> Molecular Modeling</h3><div class="NLM_p last">The 8-Mer duplex DNA was built and optimized using the program Quanta from Polygen Corporation. Owing to the selectivity of PBD class of payloads toward the GC-rich sequences, we chose to use GCGCGCGC 8-mer sequence for molecular modeling studies. Payloads were hand-docked into the DNA models and optimized using Maestro from Schrödinger suite of programs.</div></div><div id="sec5_97" class="NLM_sec NLM_sec_level_2"><div id="ac_i136" class="anchor-spacer"></div><h3 class="article-section__title" id="_i136"> Heterogeneous Lysine Conjugation</h3><div class="NLM_p last">The conjugation of anti-mesothelin antibody and drug component were performed as follows. The antibody at 5 mg/mL in 20 mM sodium phosphate, 50 mM NaCl, 100 μM DTPA, pH 7.5 was thiolated with a 35-fold molar excess of 2-IT. The thiolation reaction was allowed to proceed for 1 h at room temperature with continuous mixing. The antibody was buffer exchanged into conjugation buffer (50 mM HEPES, 5 mM glycine, 2 mM DTPA, pH 5.5) via a PD10 column (Sephadex G-25). The concentration of the thiolated antibody was determined at 280 nm. The number of thiols per antibody was found to be 5, as measured by the dithiodipyridine assay. Thiolated antibody (6.38 mL) was first diluted with equal volume of propylene glycol. Equal molar of linker-payload <b>45</b> per thiol (5 mM DMSO solution) was then added to the thiolated antibody and reacted for 1.5 h at room temperature. <i>N</i>-Ethyl maleimide (49.2 μL of 100 mM stock, 10 equiv) was added and reacted for 1 h at room temperature. The sample was 0.2 μm sterile filtered. Sartorius VivaFlow Hydrosart 30 kDa TFF was used to buffer exchange. The membrane was first rinsed with WFI and then with preformulation buffer (20 g/L Sorbitol, 10 g/L Glycine, 15% acetonitrile, pH 5) prior to the buffer exchange. The filtered sample underwent sixfold volume exchange (90 mL) with preformulation buffer. After that, the sample underwent 10-fold volume exchange (150 mL) with formulation buffer (20 g/L Sorbitol, 10 g/L Glycine, pH 5). A total of 8.1 mL of ADC was recovered from the cassette. The conjugate was then 0.2 μm sterile filtered. The concentration and DAR were determined by measuring absorbance at 280 and 310 nm. The concentration was found to be 1.3 mg/mL with a DAR of 3.0. Endotoxin was measured to be 2.81 EU/mg. SEC analysis showed 4.7% (by 220 nm) of aggregate post buffer exchange. Yield is 10.5 mg with recovery of 65%.</div></div><div id="sec5_98" class="NLM_sec NLM_sec_level_2"><div id="ac_i137" class="anchor-spacer"></div><h3 class="article-section__title" id="_i137"> Site-Specific Conjugation</h3><div class="NLM_p last">To a solution of meso N297A antibody (8.5 mg, 58 nmol) in 20 mM Tris, 50 mM NaCl, pH 8.0 buffer (1.7 mL) were added linker-payload <b>46</b> (580 nmol, 20 mM DMSO solution) and BTGase enzyme (14.5 nmol) and gentle mixing was maintained at 37 °C for 18–20 h. The sample was loaded onto MabSelect Sure column (GE Health Sciences) and eluted with 10 mM succinic acid, 20 mM glycine, pH 3.1. The elutions were immediately neutralized with 1 M Tris–HCl, pH 8.0 (4:1 ratio of elution buffer/neutralizing buffer). The fraction was buffer exchanged into formulation buffer using a Slide-A-Lyzer 30 kDa cutoff dialysis membrane. The concentration and DAR were determined by measuring absorbance at 280 and 310 nm. The concentration was found to be 1.1 mg/mL with a DAR of 1.9. Endotoxin was measured to be <1 EU/mg. SEC analysis showed 1.2% (by 220 nm) of aggregate post buffer exchange. Yield is 5.8 mg with recovery of 68%.</div></div><div id="sec5_99" class="NLM_sec NLM_sec_level_2"><div id="ac_i138" class="anchor-spacer"></div><h3 class="article-section__title" id="_i138"> Cathepsin B Enzyme Assay</h3><div class="NLM_p">ADC samples were diluted with 25 mM MES, 0.5 mM EDTA (pH 5.5) buffer to achieve a final concentration of 0.1 mg/mL. The disulfide bonds in ADCs were then reduced by addition of 10 mM of cysteamine HCl and incubation at 37 °C for 30 min. After reduction, 0.3 units of human liver cathepsin B enzyme (Millipore Sigma) was added, and the samples were incubated at 37 °C for an additional 4 h. A negative control was included for each of the samples, where incubations were carried out without the addition of the enzyme. After 4 h, a 10 μL aliquot was taken and the digestion was stopped by addition of 190 μL of 0.1% formic acid in methanol-acetonitrile (3:1). The samples were then held at −20 °C for 1 h to ensure protein precipitation and centrifuged at 14,000 rpm for 15 min. The supernatant was transferred and analyzed by LC–MS/MS. The concentration of payload cleaved by cathepsin B is accurately determined using the standard curve of payload spiked in digestion buffer, followed by the same sample preparation steps as described above.</div><div class="NLM_p last">LC–MS/MS analysis was performed on a Shimadzu Nexera UPLC connected to an AB Sciex API 4000 Triple Quadrupole MS system. The supernatant (5 μL) was injected onto an Acquity UPLC BEH-C18 column (2.1 × 50 mm, 1.7 μm) held at 60 °C. The mobile phase consisted of 0.1% formic acid in water (Solvent A) and 0.1% formic acid in acetonitrile (Solvent B). The flow rate was 0.5 mL/min with the following gradient: 0–1 min, held at 20% B; 1–3.5 min, linear ramp to 70% B; 3.5–3.6 min, fast ramp to 95% B; 3.6–4.6 min, held at 95% B; 4.6–5 min, ramp down to 20% B; 5–6.5 min, equilibration at 20% B. The MS parameters were as follows: curtain gas = 25 psi, ion source gas 1 = 30 psi, ion source gas 2 = 40 psi, ion spray voltage = 5000 V, source temperature = 500 °C. MRM transition for the payload <b>17</b> was <i>m</i>/<i>z</i> 686.4 → 309.3 (DP = 151 V, CXP = 22 V, EP = 10 V, CE = 51 V) with a dwell time of 200 ms.</div></div><div id="sec5_100" class="NLM_sec NLM_sec_level_2"><div id="ac_i139" class="anchor-spacer"></div><h3 class="article-section__title" id="_i139"> Serum Stability of ADCs</h3><div class="NLM_p last">ADCs were spiked into BALB/c mouse serum to achieve a final concentration of 0.1 mg/mL. The samples were incubated at 37 °C, and a 20 μL aliquot was taken at 0, 4, and 24 h post incubation and immediately frozen at −20 °C. To each of these aliquots, 80 μL of 0.1% formic acid in methanol–acetonitrile (3:1) was added and held at −20 °C for 1 h to ensure protein precipitation. The samples were then centrifuged at 14,000 rpm for 15 min, and the supernatant was transferred and analyzed by LC–MS/MS to quantify the released payload. The concentration of payload released in mouse serum is accurately determined using the standard curve of payload spiked in mouse serum, followed by protein precipitation. Furthermore, a parallel experiment where the payload was spiked and incubated up to 24 h in mouse serum and subsequently processed as described above was conducted to determine any recovery bias of released payload from the mouse serum. The LC and MS parameters were same as described in the cathepsin B assay section.</div></div><div id="sec5_101" class="NLM_sec NLM_sec_level_2"><div id="ac_i140" class="anchor-spacer"></div><h3 class="article-section__title" id="_i140"> In Vitro Cytotoxicity</h3><div class="NLM_p last">CellTiter-Glo cell viability kits (Promega, Madison, WI) were used to detect the viability (ATP content) of cells. Cells were cultured to ∼50–70% confluency and harvested using 0.25% trypsin, and cells were seeded at 1 × 10<sup>3</sup> cells/well in 96-well plates for 3 h for ATP CellTiter<sup>Glo</sup> assays. Serial dilutions (1:3) of compounds were added to the wells. Plates were allowed to incubate for 72 h. A CellTiter<sup>Glo</sup> cell viability kit from Promega was used to measure the ATP content of cells treated with compounds following the manufacturer’s instructions. After 15 min of incubation with CellTiter-Glo at ambient temperature, the plates were read on a GloMax 96 Microplate Luminometer (Promega, Madison, WI) within 30 min. A decrease in the ATP content is a measure of decrease in cellular viability. The IC<sub>50</sub> value, the concentration at which an agent reduces cell viability by 50% of the maximum effect, was determined using PRISM software, version 5.0 (GraphPad Software, La Jolla, CA, USA).</div></div><div id="sec5_102" class="NLM_sec NLM_sec_level_2"><div id="ac_i141" class="anchor-spacer"></div><h3 class="article-section__title" id="_i141"> In Vivo Efficacy</h3><div class="NLM_p last">The efficacies of Mesothelin- or FucGM1-ADCs were evaluated in xenograft models of N87 human gastric tumors or H187 small cell lung tumors, respectively (from ATCC). All cell lines were cultured in RPMI-1640 supplemented with 10% FBS (Gibco). To establish a subcutaneous xenograft model for an in vivo efficacy study, female C.B-17 SCID mice, 7- to 9-weeks of age (from Charles River Laboratories), were each inoculated in the flank area with the tumor cells (5 million cells in 0.2 mL of RPMI-1640 media with 50% Matrigel from Corning). When tumors reached desired volumes, the tumor-bearing mice were randomized based on their individual tumor and given a single dose by iv injection of the ADC (typically <i>N</i> = 8–12 per treatment cohort). Tumor volumes, body weights, and clinical observations were recorded twice per week. Tumor caliper measurements were converted into tumor volumes using the formula: 1/2 × length × width × height. Results were plotted as mean tumor volume ± SEM of each group over time. Mice were humanely euthanized when the tumor volume exceeded 2000 mm<sup>3</sup> or bodyweight loss exceeded 20% of the initial study weight. All mouse experiments were carried out in accordance to protocols approved by the Bristol Myers Squibb Animal Care and Use Committee and accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. All mice were maintained under specific pathogen-free conditions following the National Research Council’s “Guide for the Care and Use of Laboratory Animals,” 8th edition.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i142"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01385" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16221" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16221" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01385?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01385</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">LC traces of compounds <b>17</b>, <b>45</b>, and <b>46</b> and LCMS analysis of DNA cross-linking adduct with compound <b>27</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01385/suppl_file/jm0c01385_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">PDB file for the molecular model displayed in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01385/suppl_file/jm0c01385_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings of new compounds in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01385/suppl_file/jm0c01385_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01385/suppl_file/jm0c01385_si_001.pdf">jm0c01385_si_001.pdf (305.18 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01385/suppl_file/jm0c01385_si_002.pdb">jm0c01385_si_002.pdb (63.09 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01385/suppl_file/jm0c01385_si_003.csv">jm0c01385_si_003.csv (7.12 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01385" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58705" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58705" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Naidu S. Chowdari</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8795-2570" title="Orcid link">http://orcid.org/0000-0001-8795-2570</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7f110c1c1710081b1e0d163f18121e1613511c1012"><span class="__cf_email__" data-cfemail="c5abb6a6adaab2a1a4b7ac85a2a8a4aca9eba6aaa8">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Zhang</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1857-1883" title="Orcid link">http://orcid.org/0000-0003-1857-1883</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ivar McDonald</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Walter Johnson</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David R. Langley</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Prasanna Sivaprakasam</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Mate</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tram Huynh</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Srikanth Kotapati</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2302-5350" title="Orcid link">http://orcid.org/0000-0003-2302-5350</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Madhura Deshpande</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chin Pan</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Menezes</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yichong Wang</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chetana Rao</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ganapathy Sarma</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bethanne M. Warrack</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vangipuram S. Rangan</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sung Mei-Chen</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pina Cardarelli</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shrikant Deshpande</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Passmore</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Rampulla</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arvind Mathur</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Borzilleri</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arvind Rajpal</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregory Vite</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sanjeev Gangwar</span> - <span class="hlFld-Affiliation affiliation">Bristol
Myers Squibb Research & Early Development, 700 Bay Road, Redwood City, California 94063, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i144">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87416" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87416" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank Mary Huber, Wisely Wu, Lourdes Thevanayagam, Aarti Jashnani, Paul Ponath, Bing Chen, Eilene Kwok, Ayesha Nazeer, and Yi-Xin Li for their help and scientific discussions; the Department of Discovery Synthesis at the Biocon Bristol Myers Squibb R&D Center for their synthesis support; and Catherine Bolger for editorial support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody–drug conjugate</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">2-(trimethylsilyl)ethoxymethyl</p></td></tr><tr><td class="NLM_term">Alloc</td><td class="NLM_def"><p class="first last">allyloxycabonyl</p></td></tr><tr><td class="NLM_term">Fmoc</td><td class="NLM_def"><p class="first last">fluorenylmethyloxycarbonyl</p></td></tr><tr><td class="NLM_term">TBS</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilyl</p></td></tr><tr><td class="NLM_term">TIPS</td><td class="NLM_def"><p class="first last">triisopropylsilyl</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyranyl</p></td></tr><tr><td class="NLM_term">Cbz</td><td class="NLM_def"><p class="first last">chlorobenzyloxy</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">UPLC</td><td class="NLM_def"><p class="first last">ultra performance liquid chromatography</p></td></tr><tr><td class="NLM_term">MES</td><td class="NLM_def"><p class="first last">2-morpholinoethanesulfonic acid</p></td></tr><tr><td class="NLM_term">EDTA</td><td class="NLM_def"><p class="first last">ethylenediaminetetraacetic acid</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i146">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21806" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21806" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 33 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, C. Q.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates for personalized treatment of solid tumors</span>. <i>Adv. Therapy</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1035</span>, <span class="refDoi"> DOI: 10.1007/s12325-017-0519-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1007%2Fs12325-017-0519-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=28361465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltl2isbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=1015-1035&author=J.+M.+Lambertauthor=C.+Q.+Morris&title=Antibody-drug+conjugates+for+personalized+treatment+of+solid+tumors&doi=10.1007%2Fs12325-017-0519-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review</span></div><div class="casAuthors">Lambert, John M.; Morris, Charles Q.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1015-1035</span>CODEN:
                <span class="NLM_cas:coden">ADTHE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-238X</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">Attaching a cytotoxic "payload" to an antibody to form an antibody-drug conjugate (ADC) provides a mechanism for selective delivery of the cytotoxic agent to cancer cells via the specific binding of the antibody to cancer-selective cell surface mols.  The first ADC to receive marketing authorization was gemtuzumab ozogamicin, which comprises an anti-CD33 antibody conjugated to a highly potent DNA-targeting antibiotic, calicheamicin, approved in 2000 for treating acute myeloid leukemia.  It was withdrawn from the US market in 2010 following an unsuccessful confirmatory trial.  The development of two classes of highly potent microtubule-disrupting agents, maytansinoids and auristatins, as payloads for ADCs resulted in approval of brentuximab vedotin in 2011 for treating Hodgkin lymphoma and anaplastic large cell lymphoma, and approval of ado-trastuzumab emtansine in 2013 for treating HER2-pos. breast cancer.  Their success stimulated much research into the ADC approach, with >60 ADCs currently in clin. evaluation, mostly targeting solid tumors.  Five ADCs have advanced into pivotal clin. trials for treating various solid tumors-platinum-resistant ovarian cancer, mesothelioma, triple-neg. breast cancer, glioblastoma, and small cell lung cancer.  The level of target expression is a key parameter in predicting the likelihood of patient benefit for all these ADCs, as well as for the approved compd., ado-trastuzumab emtansine.  The development of a patient selection strategy linked to target expression on the tumor is thus critically important for identifying the population appropriate for receiving treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFGOQG-cRY8bVg90H21EOLACvtfcHk0li4PtfNx3ZxQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltl2isbk%253D&md5=42789949f7bbb6d2764af4072632f905</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs12325-017-0519-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-017-0519-6%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DMorris%26aufirst%3DC.%2BQ.%26atitle%3DAntibody-drug%2520conjugates%2520for%2520personalized%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DAdv.%2520Therapy%26date%3D2017%26volume%3D34%26spage%3D1015%26epage%3D1035%26doi%3D10.1007%2Fs12325-017-0519-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, E. L.</span></span> <span> </span><span class="NLM_article-title">The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1038/nbt.2289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1038%2Fnbt.2289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=22781692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFCqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=631-637&author=P.+D.+Senterauthor=E.+L.+Sievers&title=The+discovery+and+development+of+brentuximab+vedotin+for+use+in+relapsed+Hodgkin+lymphoma+and+systemic+anaplastic+large+cell+lymphoma&doi=10.1038%2Fnbt.2289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma</span></div><div class="casAuthors">Senter, Peter D.; Sievers, Eric L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">631-637</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Progress was made recently in developing antibody-drug conjugates (ADCs) that can selectively deliver cancer drugs to tumor cells.  In principle, the idea is simple: by attaching drugs to tumor-seeking antibodies, target cells will be killed and nontarget cells will be spared.  In practice, many parameters needed to be addressed to develop safe and effective ADCs, including the expression profiles of tumor vs. normal tissues, the potency of the drug, the linker attaching the drug and placement of the drug on the antibody, and the pharmacokinetic and stability profiles of the resulting ADC.  All these issues had been taken into account in developing brentuximab vedotin (Adcetris), an ADC that recently received accelerated approval by the US Food and Drug Administration for the treatment of relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).  Research is under way to extend the applications of brentuximab vedotin and to advance the field by developing other ADCs with new linker and conjugation strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyPib6JxGsSrVg90H21EOLACvtfcHk0lhRHtc-EFjMGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFCqtbw%253D&md5=6940eb8178e8c8c150a7b21361e23234</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2289%26sid%3Dliteratum%253Aachs%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DSievers%26aufirst%3DE.%2BL.%26atitle%3DThe%2520discovery%2520and%2520development%2520of%2520brentuximab%2520vedotin%2520for%2520use%2520in%2520relapsed%2520Hodgkin%2520lymphoma%2520and%2520systemic%2520anaplastic%2520large%2520cell%2520lymphoma%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D631%26epage%3D637%26doi%3D10.1038%2Fnbt.2289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welslau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guardino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackwell, K.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab Emtansine for HER2-positive advanced breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1783</span>– <span class="NLM_lpage">1791</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1209124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1056%2Fnejmoa1209124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=23020162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1783-1791&author=S.+Vermaauthor=D.+Milesauthor=L.+Gianniauthor=I.+E.+Kropauthor=M.+Welslauauthor=J.+Baselgaauthor=M.+Pegramauthor=D.-Y.+Ohauthor=V.+Di%C3%A9rasauthor=E.+Guardinoauthor=L.+Fangauthor=M.+W.+Luauthor=S.+Olsenauthor=K.+Blackwell&title=Trastuzumab+Emtansine+for+HER2-positive+advanced+breast+cancer&doi=10.1056%2Fnejmoa1209124"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine for HER2-positive advanced breast cancer</span></div><div class="casAuthors">Verma, Sunil; Miles, David; Gianni, Luca; Krop, Ian E.; Welslau, Manfred; Baselga, Jose; Pegram, Mark; Oh, Do-Youn; Dieras, Veronique; Guardino, Ellie; Fang, Liang; Lu, Michael W.; Olsen, Steven; Blackwell, Kim</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1783-1791</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.  The antibody and the cytotoxic agent are conjugated by means of a stable linker.  METHODS: We randomly assigned patients with HER2-pos. advanced breast cancer, who had previously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine.  The primary end points were progression-free survival (as assessed by independent review), overall survival, and safety.  Secondary end points included progression-free survival (investigator-assessed), the objective response rate, and the time to symptom progression.  Two interim analyses of overall survival were conducted.  RESULTS: Among 991 randomly assigned patients, median progression-free survival as assessed by independent review was 9.6 mo with T-DM1 vs. 6.4 mo with lapatinib plus capecitabine (hazard ratio for progression or death from any cause, 0.65; 95% confidence interval [CI], 0.55 to 0.77; P<0.001), and median overall survival at the second interim anal. crossed the stopping boundary for efficacy (30.9 mo vs. 25.1 mo; hazard ratio for death from any cause, 0.68; 95% CI, 0.55 to 0.85; P<0.001).  The objective response rate was higher with T-DM1 (43.6%, vs. 30.8% with lapatinib plus capecitabine; P<0.001); results for all addnl. secondary end points favored T-DM1.  Rates of grade 3 or above were higher with lapatinib plus capecitabine than with T-DM1 (57% vs. 41%).  The incidences of thrombocytopenia and increased serum aminotransferase levels were higher with T-DM1, whereas the incidences of diarrhea, nausea, vomiting, and palmar-plantar erythrodysesthesia were higher with lapatinib plus capecitabine.  CONCLUSIONS: T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-pos. advanced breast cancer previously treated with trastuzumab and a taxane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGRhxRQ7JSJrVg90H21EOLACvtfcHk0lhRHtc-EFjMGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M&md5=3be5bac27a81b530442dc8a6b4a1f82e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1209124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1209124%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DGianni%26aufirst%3DL.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DWelslau%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DGuardino%26aufirst%3DE.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DS.%26aulast%3DBlackwell%26aufirst%3DK.%26atitle%3DTrastuzumab%2520Emtansine%2520for%2520HER2-positive%2520advanced%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1783%26epage%3D1791%26doi%3D10.1056%2Fnejmoa1209124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suciu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selleslag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venditti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voso, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fabritiis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagemeijer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoloni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramadan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemze, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Witte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, F.</span></span> <span> </span><span class="NLM_article-title">Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">972</span>– <span class="NLM_lpage">979</span>, <span class="refDoi"> DOI: 10.1200/jco.2015.64.0060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1200%2FJCO.2015.64.0060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=26811524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A280%3ADC%252BC28nkt12itw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=972-979&author=S.+Amadoriauthor=S.+Suciuauthor=D.+Selleslagauthor=F.+Aversaauthor=G.+Gaidanoauthor=M.+Mussoauthor=L.+Anninoauthor=A.+Vendittiauthor=M.+T.+Vosoauthor=C.+Mazzoneauthor=D.+Magroauthor=P.+De+Fabritiisauthor=P.+Muusauthor=G.+Alimenaauthor=M.+Manciniauthor=A.+Hagemeijerauthor=F.+Paoloniauthor=M.+Vignettiauthor=P.+Faziauthor=L.+Meertauthor=S.+M.+Ramadanauthor=R.+Willemzeauthor=T.+de+Witteauthor=F.+Baron&title=Gemtuzumab+ozogamicin+versus+best+supportive+care+in+older+patients+with+newly+diagnosed+acute+myeloid+leukemia+unsuitable+for+intensive+chemotherapy&doi=10.1200%2Fjco.2015.64.0060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial</span></div><div class="casAuthors">Amadori Sergio; Suciu Stefan; Selleslag Dominik; Aversa Franco; Gaidano Gianluca; Musso Maurizio; Annino Luciana; Venditti Adriano; Voso Maria Teresa; Mazzone Carla; Magro Domenico; De Fabritiis Paolo; Muus Petra; Alimena Giuliana; Mancini Marco; Hagemeijer Anne; Paoloni Francesca; Vignetti Marco; Fazi Paola; Meert Liv; Ramadan Safaa Mahmoud; Willemze Roel; de Witte Theo; Baron Frederic</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">972-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care (BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid leukemia unsuitable for intensive chemotherapy.  PATIENTS AND METHODS:  In this trial, patients at least 61 years old were centrally randomized (1:1) to receive either a single induction course of GO (6 mg/m(2) on day 1 and 3 mg/m(2) on day 8) or BSC.  Patients who did not progress after GO induction could receive up to eight monthly infusions of the immunoconjugate at 2 mg/m(2).  Randomization was stratified by age, WHO performance score, CD33 expression status, and center.  The primary end point was overall survival (OS) by intention-to-treat analysis.  RESULTS:  A total of 237 patients were randomly assigned (118 to GO and 119 to BSC).  The median OS was 4.9 months (95% CI, 4.2 to 6.8 months) in the GO group and 3.6 months (95% CI, 2.6 to 4.2 months) in the BSC group (hazard ratio, 0.69; 95% CI, 0.53 to 0.90; P = .005); the 1-year OS rate was 24.3% with GO and 9.7% with BSC.  The OS benefit with GO was consistent across most subgroups, and was especially apparent in patients with high CD33 expression status, in those with favorable/intermediate cytogenetic risk profile, and in women.  Overall, complete remission (CR [complete remission] + CRi [CR with incomplete recovery of peripheral blood counts]) occurred in 30 of 111 (27%) GO recipients.  The rates of serious adverse events (AEs) were similar in the two groups, and no excess mortality from AEs was observed with GO.  CONCLUSION:  First-line monotherapy with low-dose GO, as compared with BSC, significantly improved OS in older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy.  No unexpected AEs were identified and toxicity was manageable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQq1EguFmpL0eIHSmpohpd0fW6udTcc2eZej4X-sFTqArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nkt12itw%253D%253D&md5=43d7a399ece0fc79ad921ce9cfe226ac</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.64.0060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.64.0060%26sid%3Dliteratum%253Aachs%26aulast%3DAmadori%26aufirst%3DS.%26aulast%3DSuciu%26aufirst%3DS.%26aulast%3DSelleslag%26aufirst%3DD.%26aulast%3DAversa%26aufirst%3DF.%26aulast%3DGaidano%26aufirst%3DG.%26aulast%3DMusso%26aufirst%3DM.%26aulast%3DAnnino%26aufirst%3DL.%26aulast%3DVenditti%26aufirst%3DA.%26aulast%3DVoso%26aufirst%3DM.%2BT.%26aulast%3DMazzone%26aufirst%3DC.%26aulast%3DMagro%26aufirst%3DD.%26aulast%3DDe%2BFabritiis%26aufirst%3DP.%26aulast%3DMuus%26aufirst%3DP.%26aulast%3DAlimena%26aufirst%3DG.%26aulast%3DMancini%26aufirst%3DM.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DPaoloni%26aufirst%3DF.%26aulast%3DVignetti%26aufirst%3DM.%26aulast%3DFazi%26aufirst%3DP.%26aulast%3DMeert%26aufirst%3DL.%26aulast%3DRamadan%26aufirst%3DS.%2BM.%26aulast%3DWillemze%26aufirst%3DR.%26aulast%3Dde%2BWitte%26aufirst%3DT.%26aulast%3DBaron%26aufirst%3DF.%26atitle%3DGemtuzumab%2520ozogamicin%2520versus%2520best%2520supportive%2520care%2520in%2520older%2520patients%2520with%2520newly%2520diagnosed%2520acute%2520myeloid%2520leukemia%2520unsuitable%2520for%2520intensive%2520chemotherapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D972%26epage%3D979%26doi%3D10.1200%2Fjco.2015.64.0060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Inotuzumab ozogamicin: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1603</span>– <span class="NLM_lpage">1610</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0802-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1007%2Fs40265-017-0802-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=28819740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlGktL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1603-1610&author=Y.+N.+Lamb&title=Inotuzumab+ozogamicin%3A+First+global+approval&doi=10.1007%2Fs40265-017-0802-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Inotuzumab Ozogamicin: First Global Approval</span></div><div class="casAuthors">Lamb, Yvette N.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1603-1610</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">I.v. inotuzumab ozogamicin (Besponsa; Pfizer) is an anti-CD22 monoclonal antibody-calicheamicin conjugate that binds to CD22-expressing tumor cells.  Upon binding, the complex is internalized and the cytotoxic calicheamicin deriv. is released inside the cell, inducing double-strand DNA breakage and subsequent cell death.  In June 2017, the EMA granted inotuzumab ozogamicin approval as monotherapy for the treatment of adults with relapsed or refractory CD22-pos. B-cell precursor acute lymphoblastic leukemia (ALL).  The use of inotuzumab ozogamicin in adult patients with Philadelphia chromosome-pos., relapsed or refractory CD22-pos. B-cell precursor ALL is restricted to those who have failed treatment with at least one tyrosine kinase inhibitor.  Inotuzumab ozogamicin was granted priority review for the treatment of relapsed or refractory B-cell precursor ALL by the US FDA in Feb. 2017.  In the USA, a phase III trial evaluating inotuzumab ozogamicin in combination with frontline chemotherapy in adults with newly diagnosed B-cell ALL has recently been initiated and inotuzumab ozogamicin is under phase II evaluation in childhood CD22-pos. B-cell ALL.  Inotuzumab ozogamicin combination therapies are also being evaluated in the phase I/II or II setting in ALL and chronic myeloid leukemia and in the phase I setting in Burkitt's lymphoma.  This article summarizes the milestones in the development of inotuzumab ozogamicin leading to this first approval for ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSHnoFMpPaqbVg90H21EOLACvtfcHk0ljaSLGuyOuvuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlGktL3P&md5=76c6dbf41181e769901bbc313aabdb20</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0802-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0802-5%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DInotuzumab%2520ozogamicin%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1603%26epage%3D1610%26doi%3D10.1007%2Fs40265-017-0802-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sehn, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamdar, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assouline, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozcan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penuel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulson, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matasar, M. J.</span></span> <span> </span><span class="NLM_article-title">Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1200/jco.19.00172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1200%2FJCO.19.00172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=31693429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslSktb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=155-165&author=L.+H.+Sehnauthor=A.+F.+Herreraauthor=C.+R.+Flowersauthor=M.+K.+Kamdarauthor=A.+McMillanauthor=M.+Hertzbergauthor=S.+Assoulineauthor=T.+M.+Kimauthor=W.+S.+Kimauthor=M.+Ozcanauthor=J.+Hirataauthor=E.+Penuelauthor=J.+N.+Paulsonauthor=J.+Chengauthor=G.+Kuauthor=M.+J.+Matasar&title=Polatuzumab+vedotin+in+relapsed+or+refractory+diffuse+large+B-cell+lymphoma&doi=10.1200%2Fjco.19.00172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma</span></div><div class="casAuthors">Sehn, Laurie H.; Herrera, Alex F.; Flowers, Christopher R.; Kaar, Manali K.; McMillan, Andrew; Hertzberg, Mark; Assouline, Sarit; Kim, Tae Min; Kim, Won Seog; Ozcan, Muhit; Hirata, Jamie; Penuel, Elicia; Paulson, Joseph N.; Cheng, Ji; Ku, Grace; Matasar, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-176</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, with limited treatment options.  The antibody-drug conjugate polatuzumab vedotin targets CD79b, a B-cell receptor component.  Safety and efficacy of polatuzumab vedotin with bendamustine and obinutuzumab (pola-BG) was evaluated in a single-arm cohort.  Polatuzumab vedotin combined with bendamustine and rituximab (pola-BR) was compared with bendamustine and rituximab (BR) in a randomly assigned cohort of patients with transplantation-ineligible R/R DLBCL (primary end point: independent review committee [IRC] assessed complete response [CR] rate at the end of treatment).  Duration of response, progression-free survival (PFS), and overall survival (OS) were analyzed using Kaplan-Meier and Cox regression methods.  Pola-BG and pola-BR had a tolerable safety profile.  The phase Ib/II pola-BG cohort (n = 27) had a CR rate of 29.6% and a median OS of 10.8 mo (median follow-up, 27.0 mo).  In the randomly assigned cohort (n = 80; 40 per arm), pola-BR patients had a significantly higher IRC-assessed CR rate (40.0% v 17.5%; P = .026) and longer IRC-assessed PFS (median, 9.5 v 3.7 mo; hazard ratio [HR], 0.36, 95% CI, 0.21 to 0.63; P < .001) and OS (median, 12.4 v 4.7 mo; HR, 0.42; 95% CI, 0.24 to 0.75; P = .002; median follow-up, 22.3 mo).  Pola-BR patients had higher rates of grade 3-4 neutropenia (46.2% v 33.3%), anemia (28.2% v 17.9%), and thrombocytopenia (41% v 23.1%), but similar grade 3-4 infections (23.1% v 20.5%), vs. the BR group.  Peripheral neuropathy assocd. with polatuzumab vedotin (43.6% of patients) was grade 1-2 and resolved in most patients.  Polatuzumab vedotin combined with BR resulted in a significantly higher CR rate and reduced the risk of death by 58% compared with BR in patients with transplantation-ineligible R/R DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUa_nOL1QFFLVg90H21EOLACvtfcHk0ljaSLGuyOuvuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslSktb3L&md5=3e8d91c5458d187b189615090441f029</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2FJCO.19.00172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.19.00172%26sid%3Dliteratum%253Aachs%26aulast%3DSehn%26aufirst%3DL.%2BH.%26aulast%3DHerrera%26aufirst%3DA.%2BF.%26aulast%3DFlowers%26aufirst%3DC.%2BR.%26aulast%3DKamdar%26aufirst%3DM.%2BK.%26aulast%3DMcMillan%26aufirst%3DA.%26aulast%3DHertzberg%26aufirst%3DM.%26aulast%3DAssouline%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DOzcan%26aufirst%3DM.%26aulast%3DHirata%26aufirst%3DJ.%26aulast%3DPenuel%26aufirst%3DE.%26aulast%3DPaulson%26aufirst%3DJ.%2BN.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DKu%26aufirst%3DG.%26aulast%3DMatasar%26aufirst%3DM.%2BJ.%26atitle%3DPolatuzumab%2520vedotin%2520in%2520relapsed%2520or%2520refractory%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26spage%3D155%26epage%3D165%26doi%3D10.1200%2Fjco.19.00172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruether, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaig, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baranda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plimack, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milowsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartner, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melhem-Bertrandt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrylak, D. P.</span></span> <span> </span><span class="NLM_article-title">EV-101: A phase 1 study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1041</span>– <span class="NLM_lpage">1049</span>, <span class="refDoi"> DOI: 10.1200/jco.19.02044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1200%2FJCO.19.02044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=32031899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVSjsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=1041-1049&author=J.+Rosenbergauthor=S.+S.+Sridharauthor=J.+Zhangauthor=D.+Smithauthor=D.+Ruetherauthor=T.+W.+Flaigauthor=J.+Barandaauthor=J.+Langauthor=E.+R.+Plimackauthor=R.+Sanghaauthor=E.+I.+Heathauthor=J.+Merchanauthor=D.+I.+Quinnauthor=S.+Srinivasauthor=M.+Milowskyauthor=C.+Wuauthor=E.+M.+Gartnerauthor=P.+Zuoauthor=A.+Melhem-Bertrandtauthor=D.+P.+Petrylak&title=EV-101%3A+A+phase+1+study+of+single-agent+enfortumab+vedotin+in+patients+with+nectin-4-positive+solid+tumors%2C+including+metastatic+urothelial+carcinoma&doi=10.1200%2Fjco.19.02044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma</span></div><div class="casAuthors">Rosenberg, Jonathan; Sridhar, Srikala S.; Zhang, Jingsong; Smith, David; Ruether, Dean; Flaig, Thomas W.; Baranda, Joaquina; Lang, Joshua; Plimack, Elizabeth R.; Sangha, Randeep; Heath, Elisabeth I.; Merchan, Jamie; Quinn, David I.; Srinivas, Sandy; Milowsky, Matthew; Wu, Chunzhang; Gartner, Elaina M.; Zuo, Peiying; Melhem-Bertrandt, Amal; Petrylak, Daniel P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1041-1051</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose to assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV), a novel investigational antibody-drug conjugate that delivers the microtubule-disrupting agent, monomethyl auristatin E, to cells that express Nectin-4.  Methods EV-101 is a phase I dose escalation/expansion study that enrolled patients with Nectin-4-expressing solid tumors (eg, metastatic urothelial carcinoma [mUC]) who progressed on ≥ 1 prior chemotherapy regimen and/or programmed death-1 receptor/programmed death ligand-1 [PD-(L)1] inhibitor, including a cohort of patients with mUC who received prior anti-PD-(L)1 therapy.  Patients received escalating doses of EV up to 1.25 mg/kg on days 1, 8, and 15 of every 28-day cycle.  Primary objectives were evaluation of safety/tolerability and pharmacokinetics; antitumor activity was a secondary objective.  Results Enrolled patients with mUC (n = 155) were heavily pretreated, with 96% having prior platinum-based chemotherapy and 29% receiving ≥ 3 lines of prior treatment.  Maximum tolerated dose of EV was not established; however, the recommended phase II dose was identified as 1.25 mg/kg.  Rash, peripheral neuropathy, fatigue, alopecia, and nausea were the most common treatment-related adverse events (TRAEs); the most common TRAEs were grade 1-2 in severity.  Among the 112 patients with mUC treated with single-agent EV 1.25 mg/kg, the investigator-assessed confirmed objective response rate (ORR) was 43%, and duration of response was 7.4 mo.  Median overall survival (OS) was 12.3 mo, and the OS rate at 1 yr was 51.8%.  Similar ORR and estd. median OS were obsd. in patients ≥ 75 years of age with and without prior anti-PD-(L)1 treatment, liver metastases, or upper-tract disease.  Conclusion Single-agent EV was generally well tolerated and provided clin. meaningful and durable responses in patients with mUC; survival data are encouraging.  A pivotal phase II and a confirmatory phase III study are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosZiEQO7bO-7Vg90H21EOLACvtfcHk0ljaSLGuyOuvuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVSjsb7K&md5=371071def1de7c83ffda412e8df9fb59</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1200%2FJCO.19.02044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.19.02044%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DJ.%26aulast%3DSridhar%26aufirst%3DS.%2BS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRuether%26aufirst%3DD.%26aulast%3DFlaig%26aufirst%3DT.%2BW.%26aulast%3DBaranda%26aufirst%3DJ.%26aulast%3DLang%26aufirst%3DJ.%26aulast%3DPlimack%26aufirst%3DE.%2BR.%26aulast%3DSangha%26aufirst%3DR.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DMerchan%26aufirst%3DJ.%26aulast%3DQuinn%26aufirst%3DD.%2BI.%26aulast%3DSrinivas%26aufirst%3DS.%26aulast%3DMilowsky%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DGartner%26aufirst%3DE.%2BM.%26aulast%3DZuo%26aufirst%3DP.%26aulast%3DMelhem-Bertrandt%26aufirst%3DA.%26aulast%3DPetrylak%26aufirst%3DD.%2BP.%26atitle%3DEV-101%253A%2520A%2520phase%25201%2520study%2520of%2520single-agent%2520enfortumab%2520vedotin%2520in%2520patients%2520with%2520nectin-4-positive%2520solid%2520tumors%252C%2520including%2520metastatic%2520urothelial%2520carcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26spage%3D1041%26epage%3D1049%26doi%3D10.1200%2Fjco.19.02044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nooka, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdallah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callander, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lendvai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sborov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvannasankha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnulf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortum, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Otero, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usmani, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quach, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorhees, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piontek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dettman, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposti, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opalinska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A. D.</span></span> <span> </span><span class="NLM_article-title">Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAM-2): a two-arm, randomized, open-label, phase 2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/s1470-2045(19)30788-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1016%2FS1470-2045%2819%2930788-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=31859245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVajtLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=207-221&author=S.+Lonialauthor=H.+C.+Leeauthor=A.+Badrosauthor=S.+Trudelauthor=A.+K.+Nookaauthor=A.+Chariauthor=A.+Abdallahauthor=N.+Callanderauthor=N.+Lendvaiauthor=D.+Sborovauthor=A.+Suvannasankhaauthor=K.+Weiselauthor=L.+Karlinauthor=E.+Libbyauthor=B.+Arnulfauthor=T.+Faconauthor=C.+Hulinauthor=K.+M.+Kortumauthor=P.+Rodriguez-Oteroauthor=S.+Z.+Usmaniauthor=P.+Hariauthor=R.+Bazauthor=H.+Quachauthor=P.+Moreauauthor=P.+M.+Voorheesauthor=I.+Guptaauthor=A.+Hoosauthor=E.+Zhiauthor=J.+Baronauthor=T.+Piontekauthor=E.+Lewisauthor=R.+C.+Jewellauthor=E.+J.+Dettmanauthor=R.+Popatauthor=S.+D.+Espostiauthor=J.+Opalinskaauthor=P.+Richardsonauthor=A.+D.+Cohen&title=Belantamab+mafodotin+for+relapsed+or+refractory+multiple+myeloma+%28DREAM-2%29%3A+a+two-arm%2C+randomized%2C+open-label%2C+phase+2+study&doi=10.1016%2Fs1470-2045%2819%2930788-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study</span></div><div class="casAuthors">Lonial, Sagar; Lee, Hans C.; Badros, Ashraf; Trudel, Suzanne; Nooka, Ajay K.; Chari, Ajai; Abdallah, Al-Ola; Callander, Natalie; Lendvai, Nikoletta; Sborov, Douglas; Suvannasankha, Attaya; Weisel, Katja; Karlin, Lionel; Libby, Edward; Arnulf, Bertrand; Facon, Thierry; Hulin, Cyrille; Kortum, K. Martin; Rodriguez-Otero, Paula; Usmani, Saad Z.; Hari, Parameswaran; Baz, Rachid; Quach, Hang; Moreau, Philippe; Voorhees, Peter M.; Gupta, Ira; Hoos, Axel; Zhi, Eric; Baron, January; Piontek, Trisha; Lewis, Eric; Jewell, Roxanne C.; Dettman, Elisha J.; Popat, Rakesh; Esposti, Simona Degli; Opalinska, Joanna; Richardson, Paul; Cohen, Adam D.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-221</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma.  We further investigated the safety and activity of belantamab mafodotin in the DREAMM-2 study.  DREAMM-2 is an open-label, two-arm, phase 2 study done at 58 multiple myeloma specialty centers in eight countries.  Patients (aged ≥18 years) with relapsed or refractory multiple myeloma with disease progression after three or more lines of therapy and who were refractory to immunomodulatory drugs and proteasome inhibitors, and refractory or intolerant (or both) to an anti-CD38 monoclonal antibody with an Eastern Cooperative Oncol. Group performance status of 0-2 were recruited, centrally randomly assigned (1:1) with permuted blocks (block size 4), and stratified by previous lines of therapy (≤4 vs >4) and cytogenetic features to receive 2·5 mg/kg or 3·4 mg/kg belantamab mafodotin via i.v. infusion every 3 wk on day 1 of each cycle until disease progression or unacceptable toxicity.  The intention-to-treat population comprised all randomised patients, regardless of treatment administration.  The safety population comprised all patients who received at least one dose of belantamab mafodotin.  The primary outcome was the proportion of randomly assigned patients in the intention-to-treat population who achieved an overall response, as assessed by an independent review committee.  This study is registered with ClinicalTrials.gov, NCT03525678, and is ongoing.  Between June 18, 2018, and Jan 2, 2019, 293 patients were screened and 196 were included in the intention-to-treat population (97 in the 2·5 mg/kg cohort and 99 in the 3·4 mg/kg cohort).  As of June 21, 2019 (the primary anal. data cutoff date), 30 (31%; 97·5% CI 20·8-42·6) of 97 patients in the 2·5 mg/kg cohort and 34 (34%; 23·9-46·0) of 99 patients in the 3·4 mg/kg cohort achieved an overall response.  The most common grade 3-4 adverse events in the safety population were keratopathy (in 26 [27%] of 95 patients in the 2·5 mg/kg cohort and 21 [21%] of 99 patients in the 3·4 mg/kg cohort), thrombocytopenia (19 [20%] and 33 [33%]), and anemia (19 [20%] and 25 [25%]); 38 (40%) of 95 patients in the 2·5 mg/kg cohort and 47 (47%) of 99 in the 3·4 mg/kg cohort reported serious adverse events.  Two deaths were potentially treatment related (one case of sepsis in the 2·5 mg/kg cohort and one case of haemophagocytic lymphohistiocytosis in the 3·4 mg/kg cohort).  Single-agent belantamab mafodotin shows anti-myeloma activity with a manageable safety profile in patients with relapsed or refractory multiple myeloma.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX5xuk-7bebbVg90H21EOLACvtfcHk0lgJgRZuYi6HHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVajtLjN&md5=cef83b6e32d56ef8410f339855314db1</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930788-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930788-0%26sid%3Dliteratum%253Aachs%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DH.%2BC.%26aulast%3DBadros%26aufirst%3DA.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DNooka%26aufirst%3DA.%2BK.%26aulast%3DChari%26aufirst%3DA.%26aulast%3DAbdallah%26aufirst%3DA.%26aulast%3DCallander%26aufirst%3DN.%26aulast%3DLendvai%26aufirst%3DN.%26aulast%3DSborov%26aufirst%3DD.%26aulast%3DSuvannasankha%26aufirst%3DA.%26aulast%3DWeisel%26aufirst%3DK.%26aulast%3DKarlin%26aufirst%3DL.%26aulast%3DLibby%26aufirst%3DE.%26aulast%3DArnulf%26aufirst%3DB.%26aulast%3DFacon%26aufirst%3DT.%26aulast%3DHulin%26aufirst%3DC.%26aulast%3DKortum%26aufirst%3DK.%2BM.%26aulast%3DRodriguez-Otero%26aufirst%3DP.%26aulast%3DUsmani%26aufirst%3DS.%2BZ.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DBaz%26aufirst%3DR.%26aulast%3DQuach%26aufirst%3DH.%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DVoorhees%26aufirst%3DP.%2BM.%26aulast%3DGupta%26aufirst%3DI.%26aulast%3DHoos%26aufirst%3DA.%26aulast%3DZhi%26aufirst%3DE.%26aulast%3DBaron%26aufirst%3DJ.%26aulast%3DPiontek%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DE.%26aulast%3DJewell%26aufirst%3DR.%2BC.%26aulast%3DDettman%26aufirst%3DE.%2BJ.%26aulast%3DPopat%26aufirst%3DR.%26aulast%3DEsposti%26aufirst%3DS.%2BD.%26aulast%3DOpalinska%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DCohen%26aufirst%3DA.%2BD.%26atitle%3DBelantamab%2520mafodotin%2520for%2520relapsed%2520or%2520refractory%2520multiple%2520myeloma%2520%2528DREAM-2%2529%253A%2520a%2520two-arm%252C%2520randomized%252C%2520open-label%252C%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2020%26volume%3D21%26spage%3D207%26epage%3D221%26doi%3D10.1016%2Fs1470-2045%2819%2930788-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahdat, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isakoff, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shaughnessy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroose, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santin, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweidan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washkowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinsky, K.</span></span> <span> </span><span class="NLM_article-title">Dacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1814213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1056%2FNEJMoa1814213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=30786188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvVSjs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=741-751&author=A.+Bardiaauthor=I.+A.+Mayerauthor=L.+T.+Vahdatauthor=S.+M.+Tolaneyauthor=S.+J.+Isakoffauthor=J.+R.+Diamondauthor=J.+O%E2%80%99Shaughnessyauthor=R.+L.+Morooseauthor=A.+D.+Santinauthor=V.+G.+Abramsonauthor=N.+C.+Shahauthor=H.+S.+Rugoauthor=D.+M.+Goldenbergauthor=A.+M.+Sweidanauthor=R.+Iannoneauthor=S.+Washkowitzauthor=R.+M.+Sharkeyauthor=W.+A.+Wegenerauthor=K.+Kalinsky&title=Dacituzumab+govitecan-hziy+in+refractory+metastatic+triple-negative+breast+cancer&doi=10.1056%2Fnejmoa1814213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer</span></div><div class="casAuthors">Bardia, A.; Mayer, I. A.; Vahdat, L. T.; Tolaney, S. M.; Isakoff, S. J.; Diamond, J. R.; O'Shaughnessy, J.; Moroose, R. L.; Santin, A. D.; Abramson, V. G.; Shah, N. C.; Rugo, H. S.; Goldenberg, D. M.; Sweidan, A. M.; Iannone, R.; Washkowitz, S.; Sharkey, R. M.; Wegener, W. A.; Kalinsky, K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">741-751</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Std. chemotherapy is assocd. with low response rates and short progression-free survival among patients with pretreated metastatic triple-neg. breast cancer.  Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker.  Sacituzumab govitecan-hziy enables delivery of high concns. of SN-38 to tumors.  Methods We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy i.v. on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects.  A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kg of body wt. after receiving at least two previous anticancer therapies for metastatic triple-neg. breast cancer.  The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clin. benefit rate (defined as a complete or partial response or stable disease for at least 6 mo); progression-free survival; and overall survival.  Post hoc analyses detd. the response rate and duration, which were assessed by blinded independent central review. results The 108 patients with triple-neg. breast cancer had received a median of 3 previous therapies (range, 2 to 10).  Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events.  Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia.  The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 mo (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 mo, resp.  The clin. benefit rate was 45.4%.  Median progression-free survival was 5.5 mo (95% CI, 4.1 to 6.3), and overall survival was 13.0 mo (95% CI, 11.2 to 13.7).  Conclusions Sacituzumab govitecan-hziy was assocd. with durable objective responses in patients with heavily pretreated metastatic triple-neg. breast cancer.  Myelotoxic effects were the main adverse reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAgQWEPOcqfrVg90H21EOLACvtfcHk0lgJgRZuYi6HHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvVSjs7w%253D&md5=75edc2c274aef0ab90dd2aaf230dabac</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1814213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1814213%26sid%3Dliteratum%253Aachs%26aulast%3DBardia%26aufirst%3DA.%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DVahdat%26aufirst%3DL.%2BT.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DIsakoff%26aufirst%3DS.%2BJ.%26aulast%3DDiamond%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DMoroose%26aufirst%3DR.%2BL.%26aulast%3DSantin%26aufirst%3DA.%2BD.%26aulast%3DAbramson%26aufirst%3DV.%2BG.%26aulast%3DShah%26aufirst%3DN.%2BC.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26aulast%3DSweidan%26aufirst%3DA.%2BM.%26aulast%3DIannone%26aufirst%3DR.%26aulast%3DWashkowitz%26aufirst%3DS.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DWegener%26aufirst%3DW.%2BA.%26aulast%3DKalinsky%26aufirst%3DK.%26atitle%3DDacituzumab%2520govitecan-hziy%2520in%2520refractory%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26spage%3D741%26epage%3D751%26doi%3D10.1056%2Fnejmoa1814213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurutani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denduluri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab deruxtecan in previously treated HER2-positive breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1914510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1056%2FNEJMoa1914510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=31825192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlChur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=610-621&author=S.+Modiauthor=C.+Sauraauthor=T.+Yamashitaauthor=Y.+H.+Parkauthor=S.-B.+Kimauthor=K.+Tamuraauthor=F.+Andreauthor=H.+Iwataauthor=Y.+Itoauthor=J.+Tsurutaniauthor=J.+Sohnauthor=N.+Denduluriauthor=C.+Perrinauthor=K.+Aogiauthor=E.+Tokunagaauthor=S.-A.+Imauthor=K.+S.+Leeauthor=S.+A.+Hurvitzauthor=J.+Cortesauthor=C.+Leeauthor=S.+Chenauthor=L.+Zhangauthor=J.+Shahidiauthor=A.+Yverauthor=I.+Krop&title=Trastuzumab+deruxtecan+in+previously+treated+HER2-positive+breast+cancer&doi=10.1056%2Fnejmoa1914510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab deruxtecan in previously treated HER2-positive breast cancer</span></div><div class="casAuthors">Modi, S.; Saura, C.; Yamashita, T.; Park, Y. H.; Kim, S.-B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; Sohn, J.; Denduluri, N.; Perrin, C.; Aogi, K.; Tokunaga, E.; Im, S.-A.; Lee, K. S.; Hurvitz, S. A.; Cortes, J.; Lee, C.; Chen, S.; Zhang, L.; Shahidi, J.; Yver, A.; Krop, I.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">610-621</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathol. documented HER2-pos. metastatic breast cancer who had received previous treatment with trastuzumab emtansine.  In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose.  Key secondary end points were the disease-control rate, clin.-benefit rate, duration of response and progression-free survival, and safety. results Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kg of body wt.).  During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%).  On independent adjudication, the trial drug was assocd. with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). conclusions Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-pos. metastatic breast cancer.  In addn. to nausea and myelosuppression, interstitial lung disease was obsd. in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Uc2NDB76h7Vg90H21EOLACvtfcHk0lgsSmCrnRKoTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlChur8%253D&md5=0b142802a47c4f50f0b2cdc82f22ce87</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1914510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1914510%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DS.%26aulast%3DSaura%26aufirst%3DC.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DKim%26aufirst%3DS.-B.%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DTsurutani%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DJ.%26aulast%3DDenduluri%26aufirst%3DN.%26aulast%3DPerrin%26aufirst%3DC.%26aulast%3DAogi%26aufirst%3DK.%26aulast%3DTokunaga%26aufirst%3DE.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShahidi%26aufirst%3DJ.%26aulast%3DYver%26aufirst%3DA.%26aulast%3DKrop%26aufirst%3DI.%26atitle%3DTrastuzumab%2520deruxtecan%2520in%2520previously%2520treated%2520HER2-positive%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D610%26epage%3D621%26doi%3D10.1056%2Fnejmoa1914510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chowdari, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprakasam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sufi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derwin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passmore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangan, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardarelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangwar, S.</span></span> <span> </span><span class="NLM_article-title">Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">466</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1016%2Fj.bmcl.2018.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=30579797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFygu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=466-470&author=N.+S.+Chowdariauthor=C.+Panauthor=C.+Raoauthor=D.+R.+Langleyauthor=P.+Sivaprakasamauthor=B.+Sufiauthor=D.+Derwinauthor=Y.+Wangauthor=E.+Kwokauthor=D.+Passmoreauthor=V.+S.+Ranganauthor=S.+Deshpandeauthor=P.+Cardarelliauthor=G.+Viteauthor=S.+Gangwar&title=Uncialamycin+as+a+novel+payload+for+antibody+drug+conjugate+%28ADC%29+based+targeted+cancer+therapy&doi=10.1016%2Fj.bmcl.2018.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy</span></div><div class="casAuthors">Chowdari, Naidu S.; Pan, Chin; Rao, Chetana; Langley, David R.; Sivaprakasam, Prasanna; Sufi, Bilal; Derwin, Daniel; Wang, Yichong; Kwok, Eilene; Passmore, David; Rangan, Vangipuram S.; Deshpande, Shrikant; Cardarelli, Pina; Vite, Gregory; Gangwar, Sanjeev</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">466-470</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Uncialamycin analogs were evaluated as potential cytotoxic agents in an antibody-drug conjugate (ADC) approach to treating human cancer.  These analogs were synthesized using Hauser annulations of substituted phthalides as a key step.  A highly potent uncialamycin analog 3c with a valine-citrulline dipeptide linker was conjugated to an anti-mesothelin monoclonal antibody (mAb) through lysines to generate a meso-13 conjugate.  This conjugate demonstrated subnanomolar potency (IC50 = 0.88 nM, H226 cell line) in in vitro cytotoxicity expts. with good immunol. specificity to mesothelin-pos. lung cancer cell lines.  The potency and mechanism of action of this uncialamycin class of enediyne antitumor antibiotics make them attractive payloads in ADC-based cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqBfRZz2Cfk7Vg90H21EOLACvtfcHk0lgsSmCrnRKoTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFygu7rJ&md5=371237eb33fc1f2dd6230a8649d75233</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DChowdari%26aufirst%3DN.%2BS.%26aulast%3DPan%26aufirst%3DC.%26aulast%3DRao%26aufirst%3DC.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DSivaprakasam%26aufirst%3DP.%26aulast%3DSufi%26aufirst%3DB.%26aulast%3DDerwin%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKwok%26aufirst%3DE.%26aulast%3DPassmore%26aufirst%3DD.%26aulast%3DRangan%26aufirst%3DV.%2BS.%26aulast%3DDeshpande%26aufirst%3DS.%26aulast%3DCardarelli%26aufirst%3DP.%26aulast%3DVite%26aufirst%3DG.%26aulast%3DGangwar%26aufirst%3DS.%26atitle%3DUncialamycin%2520as%2520a%2520novel%2520payload%2520for%2520antibody%2520drug%2520conjugate%2520%2528ADC%2529%2520based%2520targeted%2520cancer%2520therapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D466%26epage%3D470%26doi%3D10.1016%2Fj.bmcl.2018.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span> <span> </span><span class="NLM_article-title">The development of pyrrolobenzodiazepines as antitumour agents</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">744</span>, <span class="refDoi"> DOI: 10.1517/13543784.2011.573477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1517%2F13543784.2011.573477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=21457108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVSktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=733-744&author=J.+A.+Hartley&title=The+development+of+pyrrolobenzodiazepines+as+antitumour+agents&doi=10.1517%2F13543784.2011.573477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The development of pyrrolobenzodiazepines as antitumour agents</span></div><div class="casAuthors">Hartley, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">733-744</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: DNA interacting agents play a major role in cancer chemotherapy, either as single agents, in combination drug regimens, or as components of novel targeted therapies.  The search for more selective and efficacious drugs that can deliver crit. DNA damage with minimal side effects continues.  Areas covered: The development of the pyrrolobenzodiazepines (PBDs) from their discovery as natural products in the 1960s, through synthetic PBD monomers, PBD hybrids and conjugates, and PBD dimers is described.  The latter mols. are capable of forming sequence selective, non-distorting and potently cytotoxic DNA interstrand cross-links in the minor groove of DNA.  In particular, the development of PBD dimer SJG-136 (SG2000), currently in Phase II clin. trials, is presented.  Potential future cancer therapeutic applications of PBDs, including their use as components of targeting strategies, are also discussed.  Expert opinion: The culmination of over four decades of study on structure--activity relationships of PBDs has led to a detailed understanding of how to introduce structural modification to enhance biol. activity and potency.  The challenge for the next phase in the development of the PBDs is to harness this activity and potency in a new generation of cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi0QG1axF_kLVg90H21EOLACvtfcHk0lgmrZFWG3Myvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVSktbc%253D&md5=bb7cf4096261862fe33b22f49c16c137</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.573477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.573477%26sid%3Dliteratum%253Aachs%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520development%2520of%2520pyrrolobenzodiazepines%2520as%2520antitumour%2520agents%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D733%26epage%3D744%26doi%3D10.1517%2F13543784.2011.573477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mantaj, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span> <span> </span><span class="NLM_article-title">From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs)</span>. <i>Angew. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1002/anie.201510610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1002%2Fanie.201510610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVGitrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=462-488&author=J.+Mantajauthor=P.+J.+M.+Jacksonauthor=K.+M.+Rahmanauthor=D.+E.+Thurston&title=From+anthramycin+to+pyrrolobenzodiazepine+%28PBD%29-containing+antibody-drug+conjugates+%28ADCs%29&doi=10.1002%2Fanie.201510610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)</span></div><div class="casAuthors">Mantaj, Julia; Jackson, Paul J. M.; Rahman, Khondaker M.; Thurston, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">462-488</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a family of sequence-selective DNA minor-groove binding agents that form a covalent aminal bond between their C11-position and the C2-NH2 groups of guanine bases.  The first example of a PBD monomer, the natural product anthramycin, was discovered in the 1960s, and the best known PBD dimer, SJG-136 (also known as SG2000, NSC 694501 or BN2629), was synthesized in the 1990s and has recently completed Phase II clin. trials in patients with leukemia and ovarian cancer.  More recently, PBD dimer analogs are being attached to tumor-targeting antibodies to create antibody-drug conjugates (ADCs), a no. of which are now in clin. trials, with many others in pre-clin. development.  This Review maps the development from anthramycin to the first PBD dimers, and then to PBD-contg. ADCs, and explores both structure-activity relationships (SARs) and the biol. of PBDs, and the strategies for their use as payloads for ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9tjTimo4Cv7Vg90H21EOLACvtfcHk0lgmrZFWG3Myvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVGitrnO&md5=8a87ad3c033b2a20798c861accba46a6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fanie.201510610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201510610%26sid%3Dliteratum%253Aachs%26aulast%3DMantaj%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DP.%2BJ.%2BM.%26aulast%3DRahman%26aufirst%3DK.%2BM.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DFrom%2520anthramycin%2520to%2520pyrrolobenzodiazepine%2520%2528PBD%2529-containing%2520antibody-drug%2520conjugates%2520%2528ADCs%2529%26jtitle%3DAngew.%2520Chem.%26date%3D2017%26volume%3D56%26spage%3D462%26epage%3D488%26doi%3D10.1002%2Fanie.201510610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiske, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholas, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okeley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1256</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1021/bc400217g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc400217g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFKjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=1256-1263&author=S.+C.+Jeffreyauthor=P.+J.+Burkeauthor=R.+P.+Lyonauthor=D.+W.+Meyerauthor=D.+Sussmanauthor=M.+Andersonauthor=J.+H.+Hunterauthor=C.+I.+Leiskeauthor=J.+B.+Miyamotoauthor=N.+D.+Nicholasauthor=N.+M.+Okeleyauthor=R.+J.+Sandersonauthor=I.+J.+Stoneauthor=W.+Zengauthor=S.+J.+Gregsonauthor=L.+Mastersonauthor=A.+C.+Tiberghienauthor=P.+W.+Howardauthor=D.+E.+Thurstonauthor=C.-L.+Lawauthor=P.+D.+Senter&title=A+potent+anti-CD70+antibody-drug+conjugate+combining+a+dimeric+pyrrolobenzodiazepine+drug+with+site-specific+conjugation+technology&doi=10.1021%2Fbc400217g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology</span></div><div class="casAuthors">Jeffrey, Scott C.; Burke, Patrick J.; Lyon, Robert P.; Meyer, David W.; Sussman, Django; Anderson, Martha; Hunter, Joshua H.; Leiske, Chris I.; Miyamoto, Jamie B.; Nicholas, Nicole D.; Okeley, Nicole M.; Sanderson, Russell J.; Stone, Ivan J.; Zeng, Weiping; Gregson, Stephen J.; Masterson, Luke; Tiberghien, Arnaud C.; Howard, Philip W.; Thurston, David E.; Law, Che-Leung; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1256-1263</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A highly cytotoxic DNA crosslinking pyrrolobenzodiazepine (PBD) dimer with a valine-alanine dipeptide linker was conjugated to the anti-CD70 h1F6 mAb either through endogenous interchain cysteines or, site-specifically, through engineered cysteines at position 239 of the heavy chains.  The h1F6239C-PBD conjugation strategy proved to be superior to interchain cysteine conjugation, affording an antibody-drug conjugate (ADC) with high uniformity in drug-loading and low levels of aggregation.  In vitro cytotoxicity expts. demonstrated that the h1F6239C-PBD was potent and immunol. specific on CD70-pos. renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL) cell lines.  The conjugate was resistant to drug loss in plasma and in circulation, and had a pharmacokinetic profile closely matching that of the parental h1F6239C antibody capped with N-ethylmaleimide (NEM).  Evaluation in CD70-pos. RCC and NHL mouse xenograft models showed pronounced antitumor activities at single or weekly doses as low as 0.1 mg/kg of ADC.  The ADC was tolerated at 2.5 mg/kg.  These results demonstrate that PBDs can be effectively used for antibody-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVruNGtWHpsbVg90H21EOLACvtfcHk0lgmrZFWG3Myvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFKjs7c%253D&md5=31841b0267e41ae861eaf05240c97b15</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fbc400217g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc400217g%26sid%3Dliteratum%253Aachs%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DMeyer%26aufirst%3DD.%2BW.%26aulast%3DSussman%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DJ.%2BH.%26aulast%3DLeiske%26aufirst%3DC.%2BI.%26aulast%3DMiyamoto%26aufirst%3DJ.%2BB.%26aulast%3DNicholas%26aufirst%3DN.%2BD.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DStone%26aufirst%3DI.%2BJ.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26aulast%3DLaw%26aufirst%3DC.-L.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DA%2520potent%2520anti-CD70%2520antibody-drug%2520conjugate%2520combining%2520a%2520dimeric%2520pyrrolobenzodiazepine%2520drug%2520with%2520site-specific%2520conjugation%2520technology%26jtitle%3DBioconjugate%2520Chem.%26date%3D2013%26volume%3D24%26spage%3D1256%26epage%3D1263%26doi%3D10.1021%2Fbc400217g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankovich, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bheddah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escarpe, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laysang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Molina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pysz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slingerland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torgov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foord, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jassem, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badzio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czapiewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harpole, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowlati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massion, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travis, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietanza, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stull, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dylla, S. J.</span></span> <span> </span><span class="NLM_article-title">A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">302ra136</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aac9459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1126%2Fscitranslmed.aac9459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=26311731" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=302ra136&author=L.+R.+Saundersauthor=A.+J.+Bankovichauthor=W.+C.+Andersonauthor=M.+A.+Aujayauthor=S.+Bheddahauthor=K.+Blackauthor=R.+Desaiauthor=P.+A.+Escarpeauthor=J.+Hamplauthor=A.+Laysangauthor=D.+Liuauthor=J.+Lopez-Molinaauthor=M.+Miltonauthor=A.+Parkauthor=M.+A.+Pyszauthor=H.+Shaoauthor=B.+Slingerlandauthor=M.+Torgovauthor=S.+A.+Williamsauthor=O.+Foordauthor=P.+Howardauthor=J.+Jassemauthor=A.+Badzioauthor=P.+Czapiewskiauthor=D.+H.+Harpoleauthor=A.+Dowlatiauthor=P.+P.+Massionauthor=W.+D.+Travisauthor=M.+C.+Pietanzaauthor=J.+T.+Poirierauthor=C.+M.+Rudinauthor=R.+A.+Stullauthor=S.+J.+Dylla&title=A+DLL3-targeted+antibody-drug+conjugate+eradicates+high-grade+pulmonary+neuroendocrine+tumor-initiating+cells+in+vivo&doi=10.1126%2Fscitranslmed.aac9459"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aac9459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aac9459%26sid%3Dliteratum%253Aachs%26aulast%3DSaunders%26aufirst%3DL.%2BR.%26aulast%3DBankovich%26aufirst%3DA.%2BJ.%26aulast%3DAnderson%26aufirst%3DW.%2BC.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBheddah%26aufirst%3DS.%26aulast%3DBlack%26aufirst%3DK.%26aulast%3DDesai%26aufirst%3DR.%26aulast%3DEscarpe%26aufirst%3DP.%2BA.%26aulast%3DHampl%26aufirst%3DJ.%26aulast%3DLaysang%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DLopez-Molina%26aufirst%3DJ.%26aulast%3DMilton%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DA.%26aulast%3DPysz%26aufirst%3DM.%2BA.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DSlingerland%26aufirst%3DB.%26aulast%3DTorgov%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%2BA.%26aulast%3DFoord%26aufirst%3DO.%26aulast%3DHoward%26aufirst%3DP.%26aulast%3DJassem%26aufirst%3DJ.%26aulast%3DBadzio%26aufirst%3DA.%26aulast%3DCzapiewski%26aufirst%3DP.%26aulast%3DHarpole%26aufirst%3DD.%2BH.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DMassion%26aufirst%3DP.%2BP.%26aulast%3DTravis%26aufirst%3DW.%2BD.%26aulast%3DPietanza%26aufirst%3DM.%2BC.%26aulast%3DPoirier%26aufirst%3DJ.%2BT.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DStull%26aufirst%3DR.%2BA.%26aulast%3DDylla%26aufirst%3DS.%2BJ.%26atitle%3DA%2520DLL3-targeted%2520antibody-drug%2520conjugate%2520eradicates%2520high-grade%2520pulmonary%2520neuroendocrine%2520tumor-initiating%2520cells%2520in%2520vivo%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26spage%3D302ra136%26doi%3D10.1126%2Fscitranslmed.aac9459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishkin, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteman, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovtun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audette, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modafferi, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinkas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldmacher, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span> <span> </span><span class="NLM_article-title">A new class of antibody–drug conjugates with potent DNA alkylating activity</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1870</span>– <span class="NLM_lpage">1878</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-16-0184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1158%2F1535-7163.MCT-16-0184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=27216304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oks77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=1870-1878&author=M.+L.+Millerauthor=N.+E.+Fishkinauthor=W.+Liauthor=K.+R.+Whitemanauthor=Y.+Kovtunauthor=E.+E.+Reidauthor=K.+E.+Archerauthor=E.+K.+Maloneyauthor=C.+A.+Audetteauthor=M.+F.+Mayoauthor=A.+Wilhelmauthor=H.+A.+Modafferiauthor=R.+Singhauthor=J.+Pinkasauthor=V.+Goldmacherauthor=J.+M.+Lambertauthor=R.+V.+J.+Chari&title=A+new+class+of+antibody%E2%80%93drug+conjugates+with+potent+DNA+alkylating+activity&doi=10.1158%2F1535-7163.mct-16-0184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity</span></div><div class="casAuthors">Miller, Michael L.; Fishkin, Nathan E.; Li, Wei; Whiteman, Kathleen R.; Kovtun, Yelena; Reid, Emily E.; Archer, Katie E.; Maloney, Erin K.; Audette, Charlene A.; Mayo, Michele F.; Wilhelm, Alan; Modafferi, Holly A.; Singh, Rajeeva; Pinkas, Jan; Goldmacher, Victor; Lambert, John M.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1870-1878</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The promise of tumor-selective delivery of cytotoxic agents in the form of antibody-drug conjugates (ADC) has now been realized, evidenced by the approval of two ADCs, both of which incorporate highly cytotoxic tubulin-interacting agents, for cancer therapy.  An ongoing challenge remains in identifying potent agents with alternative mechanisms of cell killing that can provide ADCs with high therapeutic indexes and favorable tolerability.  Here, we describe the development of a new class of potent DNA alkylating agents that meets these objectives.  Through chem. design, we changed the mechanism of action of our novel DNA crosslinking agent to a monofunctional DNA alkylator.  This modification, coupled with linker optimization, generated ADCs that were well tolerated in mice and demonstrated robust antitumor activity in multiple tumor models at doses 1.5% to 3.5% of maximally tolerated levels.  These properties underscore the considerable potential of these purpose-created, unique DNA-interacting conjugates for broadening the clin. application of ADC technol.  Mol Cancer Ther; 15(8); 1870-8. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt5MUcMyl9MbVg90H21EOLACvtfcHk0lgjJuyk0hjWFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oks77F&md5=39217fa47540ea33e2c7c25d57daa19c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0184%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DFishkin%26aufirst%3DN.%2BE.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DReid%26aufirst%3DE.%2BE.%26aulast%3DArcher%26aufirst%3DK.%2BE.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DMayo%26aufirst%3DM.%2BF.%26aulast%3DWilhelm%26aufirst%3DA.%26aulast%3DModafferi%26aufirst%3DH.%2BA.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DPinkas%26aufirst%3DJ.%26aulast%3DGoldmacher%26aufirst%3DV.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26atitle%3DA%2520new%2520class%2520of%2520antibody%25E2%2580%2593drug%2520conjugates%2520with%2520potent%2520DNA%2520alkylating%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D1870%26epage%3D1878%26doi%3D10.1158%2F1535-7163.mct-16-0184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">McDonald, I. M.</span>; <span class="NLM_string-name">Chowdari, N. S.</span>; <span class="NLM_string-name">Tram, H.</span>; <span class="NLM_string-name">Borzilleri, R. M.</span>; <span class="NLM_string-name">Gangwar, S.</span></span> <span> </span><span class="NLM_article-title">Benzodiazepine Dimers, Conjugates Thereof, and Methods of Making and Using</span>. U.S. Patent <span class="NLM_patent">9,527,871 B2</span>, Dec 27, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Zhang&author=I.+M.+McDonald&author=N.+S.+Chowdari&author=H.+Tram&author=R.+M.+Borzilleri&author=S.+Gangwar&title=Benzodiazepine+Dimers%2C+Conjugates+Thereof%2C+and+Methods+of+Making+and+Using"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DBenzodiazepine%2520Dimers%252C%2520Conjugates%2520Thereof%252C%2520and%2520Methods%2520of%2520Making%2520and%2520Using%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I. M.</span>; <span class="NLM_string-name">Chowdari, N. S.</span>; <span class="NLM_string-name">Johnson, W. J.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Borzilleri, R. M.</span>; <span class="NLM_string-name">Gangwar, S.</span></span> <span> </span><span class="NLM_article-title">Heteroarylene-bridged Benzodiazepine Dimers, Conjugates Thereof, and Methods of Making and Using</span>. U.S. Patent <span class="NLM_patent">9,526,801 B2</span>, Dec 27, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=I.+M.+McDonald&author=N.+S.+Chowdari&author=W.+J.+Johnson&author=Y.+Zhang&author=R.+M.+Borzilleri&author=S.+Gangwar&title=Heteroarylene-bridged+Benzodiazepine+Dimers%2C+Conjugates+Thereof%2C+and+Methods+of+Making+and+Using"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonald%26aufirst%3DI.%2BM.%26atitle%3DHeteroarylene-bridged%2520Benzodiazepine%2520Dimers%252C%2520Conjugates%2520Thereof%252C%2520and%2520Methods%2520of%2520Making%2520and%2520Using%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jammalamadaka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borkin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrado, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of isoquinolidinobenzodiazepine dimers, a novel class of antibody–drug conjugate payload</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00436</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00436" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaqsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=56-60&author=S.+W.+Smithauthor=V.+Jammalamadakaauthor=D.+Borkinauthor=J.+Zhuauthor=S.+J.+Degradoauthor=J.+Luauthor=J.+Huangauthor=Y.-P.+Jiangauthor=N.+Jainauthor=J.+R.+Junutula&title=Design+and+synthesis+of+isoquinolidinobenzodiazepine+dimers%2C+a+novel+class+of+antibody%E2%80%93drug+conjugate+payload&doi=10.1021%2Facsmedchemlett.7b00436"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Isoquinolidinobenzodiazepine Dimers, a Novel Class of Antibody-Drug Conjugate Payload</span></div><div class="casAuthors">Smith, Sean W.; Jammalamadaka, Vasu; Borkin, Dmitry; Zhu, Jianyu; Degrado, Sylvia J.; Lu, Jennifer; Huang, Jianqing; Jiang, Ying-Ping; Jain, Nareshkumar; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-60</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) represent an important class of emerging cancer therapeutics.  Recent ADC development efforts highlighted the use of pyrrolobenzodiazepine (PBD) dimer payload for the treatment of several cancers.  The authors identified the isoquinolidinobenzodiazepine (IQB) payload (D211), a new class of PBD dimer family of DNA damaging payloads.  The authors have successfully synthesized all three IQB stereoisomers, exptl. showed that the purified (S,S)-D211 isomer is functionally more active than (R,R)-D221 and (S,R)-D231 isomers by >50,000-fold and ∼200-fold, resp.  The authors also synthesized a linker-payload (D212) that uses (S,S)-D211 payload with a cathepsin cleavable linker, a hydrophilic PEG8 spacer, and a thiol reactive maleimide.  Homogeneous ADCs generated using D212 linker-payload exhibited ideal physicochem. properties, and anti-CD33 ADC displayed a robust target-specific potency on AML cell lines.  D212 linker-payload described here can be used for developing novel ADC therapeutics for targeted cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbr6bg3ED4NLVg90H21EOLACvtfcHk0lgWwbnxpb0d7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaqsL%252FP&md5=50142e330f23c1c2fc8e51abb4bb4d41</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00436%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DS.%2BW.%26aulast%3DJammalamadaka%26aufirst%3DV.%26aulast%3DBorkin%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DDegrado%26aufirst%3DS.%2BJ.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.-P.%26aulast%3DJain%26aufirst%3DN.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520isoquinolidinobenzodiazepine%2520dimers%252C%2520a%2520novel%2520class%2520of%2520antibody%25E2%2580%2593drug%2520conjugate%2520payload%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D56%26epage%3D60%26doi%3D10.1021%2Facsmedchemlett.7b00436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kothakonda, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, D. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a novel tetrahydroisoquinolino[2,1-c][1,4]benzodiazepine ring system with DNA recognition potential</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4371</span>– <span class="NLM_lpage">4373</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1016%2Fj.bmcl.2004.07.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=4371-4373&author=K.+K.+Kothakondaauthor=D.+S.+Bose&title=Synthesis+of+a+novel+tetrahydroisoquinolino%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepine+ring+system+with+DNA+recognition+potential&doi=10.1016%2Fj.bmcl.2004.07.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DKothakonda%26aufirst%3DK.%2BK.%26aulast%3DBose%26aufirst%3DD.%2BS.%26atitle%3DSynthesis%2520of%2520a%2520novel%2520tetrahydroisoquinolino%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepine%2520ring%2520system%2520with%2520DNA%2520recognition%2520potential%26jtitle%3DTetrahedron%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D4371%26epage%3D4373%26doi%3D10.1016%2Fj.bmcl.2004.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, C. R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laughton, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shnyder, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loadman, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5442</span>– <span class="NLM_lpage">5461</span>, <span class="refDoi"> DOI: 10.1021/jm051199z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051199z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvVaksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5442-5461&author=G.+Wellsauthor=C.+R.+H.+Martinauthor=P.+W.+Howardauthor=Z.+A.+Sandsauthor=C.+A.+Laughtonauthor=A.+Tiberghienauthor=C.+K.+Wooauthor=L.+A.+Mastersonauthor=M.+J.+Stephensonauthor=J.+A.+Hartleyauthor=T.+C.+Jenkinsauthor=S.+D.+Shnyderauthor=P.+M.+Loadmanauthor=M.+J.+Waringauthor=D.+E.+Thurston&title=Design%2C+synthesis%2C+and+biophysical+and+biological+evaluation+of+a+series+of+pyrrolobenzodiazepine-poly%28N-methylpyrrole%29+conjugates&doi=10.1021%2Fjm051199z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biophysical and Biological Evaluation of a Series of Pyrrolobenzodiazepine-Poly(N-methylpyrrole) Conjugates</span></div><div class="casAuthors">Wells, Geoff; Martin, Christopher R. H.; Howard, Philip W.; Sands, Zara A.; Laughton, Charles A.; Tiberghien, Arnaud; Woo, Chi Kit; Masterson, Luke A.; Stephenson, Marissa J.; Hartley, John A.; Jenkins, Terence C.; Shnyder, Steven D.; Loadman, Paul M.; Waring, Michael J.; Thurston, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5442-5461</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of six Me ester-terminated C8-linked pyrrolobenzodiazepine (PBD)-poly(N-methylpyrrole) conjugates has been synthesized and their DNA interaction evaluated by thermal denaturation, DNA footprinting, and in vitro transcription stop assays.  The synergistic effect of attaching a PBD unit to a polypyrrole fragment is illustrated by the large increase in DNA binding affinity (up to 50-fold) compared to the individual PBD and pyrrole components.  The conjugates were found to bind mainly to identical DNA sequences but with apparent binding site widths increasing with mol. length and the majority of sites conforming to the consensus motif 5'-XGXWz (z = 3±1; W = A or T; X = any base but preferably a purine).  They also provided robust sequence-selective blockade of transcription at sites corresponding approx. to their DNA footprints.  The conjugates were shown to have good cellular/nuclear penetration properties, and a degree of correlation between cytotoxicity and DNA-binding affinity was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0EDeZEws47rVg90H21EOLACvtfcHk0lgWwbnxpb0d7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvVaksrk%253D&md5=ba74219df193a55a984edd07635e731a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm051199z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051199z%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DC.%2BR.%2BH.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DSands%26aufirst%3DZ.%2BA.%26aulast%3DLaughton%26aufirst%3DC.%2BA.%26aulast%3DTiberghien%26aufirst%3DA.%26aulast%3DWoo%26aufirst%3DC.%2BK.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DStephenson%26aufirst%3DM.%2BJ.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DJenkins%26aufirst%3DT.%2BC.%26aulast%3DShnyder%26aufirst%3DS.%2BD.%26aulast%3DLoadman%26aufirst%3DP.%2BM.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biophysical%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520pyrrolobenzodiazepine-poly%2528N-methylpyrrole%2529%2520conjugates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5442%26epage%3D5461%26doi%3D10.1021%2Fjm051199z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guille, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span> <span> </span><span class="NLM_article-title">Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8′ ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Dimers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1161</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1021/jm030897l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030897l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFWhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1161-1174&author=S.+J.+Gregsonauthor=P.+W.+Howardauthor=D.+R.+Gullickauthor=A.+Hamaguchiauthor=K.+E.+Corcoranauthor=N.+A.+Brooksauthor=J.+A.+Hartleyauthor=T.+C.+Jenkinsauthor=S.+Patelauthor=M.+J.+Guilleauthor=D.+E.+Thurston&title=Linker+length+modulates+DNA+cross-linking+reactivity+and+cytotoxic+potency+of+C8%2FC8%E2%80%B2+ether-linked+C2-exo-unsaturated+pyrrolo%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepine+%28PBD%29+Dimers&doi=10.1021%2Fjm030897l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Linker Length Modulates DNA Cross-Linking Reactivity and Cytotoxic Potency of C8/C8' Ether-Linked C2-exo-Unsaturated Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Dimers</span></div><div class="casAuthors">Gregson, Stephen J.; Howard, Philip W.; Gullick, Darren R.; Hamaguchi, Anzu; Corcoran, Kathryn E.; Brooks, Natalie A.; Hartley, John A.; Jenkins, Terence C.; Patel, Sejal; Guille, Matthew J.; Thurston, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1161-1174</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A C2/C2'-exo-unsatd. pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimer (DRG-16) with a C8-O(CH2)nO-C8' diether linkage (n = 5) has been synthesized that shows markedly superior in vitro cytotoxic potency (e.g., >3400-fold in IGROV1 ovarian cells) and interstrand DNA crosslinking reactivity (>10-fold) compared to the shorter homolog (SJG-136; n = 3).  In contrast, for the C-ring unsubstituted series, the corresponding n = 5 dimer is generally less cytotoxic and has a lower interstrand crosslinking reactivity compared to its shorter n = 3 homolog.  Dimer DRG-16 cross-links DNA with >10-fold efficiency compared to 4a, and also inhibits the activity of the restriction endonuclease BamH1 more efficiently.  The C2-exo-unsatd. PBD dimers 4a,b are not only more effective than their C-ring satd. counterparts in terms of induced ΔTm shift, but they also exert this effect more rapidly.  Mol. modeling shows a rank order of DRG-16 (n = 5) > SJG-136 (n = 3) in terms of binding energy toward duplexes contg. embedded target 5'-GAT1-2C cross-link sequences, reflecting the superior fit of the C2-exo-unsatd. rather than satd. C-rings of the PBD dimers.  A novel synthesis of core synthetic building blocks for PBD dimers via stepwise Mitsunobu reaction and nitration with Cu(NO3)2 is also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv_FYScSSSFLVg90H21EOLACvtfcHk0likyBwr1426Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFWhsQ%253D%253D&md5=ed9b4a4a43930d3316188bbd9e50401b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm030897l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030897l%26sid%3Dliteratum%253Aachs%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DGullick%26aufirst%3DD.%2BR.%26aulast%3DHamaguchi%26aufirst%3DA.%26aulast%3DCorcoran%26aufirst%3DK.%2BE.%26aulast%3DBrooks%26aufirst%3DN.%2BA.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DJenkins%26aufirst%3DT.%2BC.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DGuille%26aufirst%3DM.%2BJ.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DLinker%2520length%2520modulates%2520DNA%2520cross-linking%2520reactivity%2520and%2520cytotoxic%2520potency%2520of%2520C8%252FC8%25E2%2580%25B2%2520ether-linked%2520C2-exo-unsaturated%2520pyrrolo%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepine%2520%2528PBD%2529%2520Dimers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1161%26epage%3D1174%26doi%3D10.1021%2Fjm030897l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terret, J. A.</span>; <span class="NLM_string-name">Pogue, S. L.</span>; <span class="NLM_string-name">Toy, K.</span>; <span class="NLM_string-name">Yang, L.</span>; <span class="NLM_string-name">Rao, C. R.</span>; <span class="NLM_string-name">Chen, B.</span></span> <span> </span><span class="NLM_article-title">Human Antibodies That Bind Mesothelin, and Uses Thereof</span>. U.S. Patent <span class="NLM_patent">8,425,904 B2</span>, Apr 23, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+A.+Terret&author=S.+L.+Pogue&author=K.+Toy&author=L.+Yang&author=C.+R.+Rao&author=B.+Chen&title=Human+Antibodies+That+Bind+Mesothelin%2C+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTerret%26aufirst%3DJ.%2BA.%26atitle%3DHuman%2520Antibodies%2520That%2520Bind%2520Mesothelin%252C%2520and%2520Uses%2520Thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, K.</span></span> <span> </span><span class="NLM_article-title">Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>211</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/s0378-5173(00)00590-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1016%2FS0378-5173%2800%2900590-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=11137340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BD3MXosl2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=2000&pages=67-78&author=C.+Weberauthor=S.+Reissauthor=K.+Langer&title=Preparation+of+surface+modified+protein+nanoparticles+by+introduction+of+sulfhydryl+groups&doi=10.1016%2Fs0378-5173%2800%2900590-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups</span></div><div class="casAuthors">Weber, C.; Reiss, S.; Langer, K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">67-78</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The objective of the present study was to establish several methods for the introduction of thiol groups onto the surface of human serum albumin (HSA) nanoparticles.  Besides the ε-amino groups of lysine, the carboxyl groups of aspartic and glutaminic acid, and the carbonyl groups of the crosslinker glutaraldehyde, sulfhydryl groups are possible targets for the covalent linkage of drugs to particle surfaces.  In principle, the thiol groups were introduced by the reaction with dithiothreitol (DDT) or 2-iminothiolane, by quenching reactive aldehyde residues with cystaminium dichloride or by coupling L-cysteine and cystaminium dichloride by the aq. carbodiimide reaction.  The resulting nanoparticulate systems were characterized concerning the no. of available sulfhydryl groups, particle size and particle d.  It was shown, that by variation of the reaction conditions, e.g., the concn. of the coupling reagent or the sulfhydryl contg. component as well as the reaction time, the proposed methods enabled the prepn. of HSA nanoparticles with a well defined surface characteristic.  Stability studies showed that the introduced thiol groups were relatively stable and lost their reactivity with a half-life of 28.2 days independently of the method used for the sulfhydryl group introduction.  Besides the quantification of free sulfhydryl groups the covalent attachment of cystaminium dichloride by the carbodiimide reaction was used to calc. the amt. of free carboxyl groups on the surface of the nanoparticles.  The toxicity of the modified nanoparticles was evaluated in cell culture expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcGF665AynEbVg90H21EOLACvtfcHk0likyBwr1426Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXosl2htQ%253D%253D&md5=dd3551dce604511d54d6c9cc661da6aa</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0378-5173%2800%2900590-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5173%252800%252900590-1%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DC.%26aulast%3DReiss%26aufirst%3DS.%26aulast%3DLanger%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520surface%2520modified%2520protein%2520nanoparticles%2520by%2520introduction%2520of%2520sulfhydryl%2520groups%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2000%26volume%3D211%26spage%3D67%26epage%3D78%26doi%3D10.1016%2Fs0378-5173%2800%2900590-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strop, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaria, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foletti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasa-Moreno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorywalska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farias, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pios, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dushin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navaratnam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajpal, A.</span></span> <span> </span><span class="NLM_article-title">Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">694</span>– <span class="NLM_lpage">696</span>, <span class="refDoi"> DOI: 10.1038/nbt.3274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1038%2Fnbt.3274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=26154005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ensLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=694-696&author=P.+Stropauthor=K.+Delariaauthor=D.+Folettiauthor=J.+M.+Wittauthor=A.+Hasa-Morenoauthor=K.+Poulsenauthor=M.+G.+Casasauthor=M.+Dorywalskaauthor=S.+Fariasauthor=A.+Piosauthor=V.+Luiauthor=R.+Dushinauthor=D.+Zhouauthor=T.+Navaratnamauthor=T.-T.+Tranauthor=J.+Suttonauthor=K.+C.+Lindquistauthor=B.+Hanauthor=S.-H.+Liuauthor=D.+L.+Sheltonauthor=J.+Ponsauthor=A.+Rajpal&title=Site-specific+conjugation+improves+therapeutic+index+of+antibody+drug+conjugates+with+high+drug+loading&doi=10.1038%2Fnbt.3274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading</span></div><div class="casAuthors">Strop, Pavel; Delaria, Kathy; Foletti, Davide; Witt, Jody Melton; Hasa-Moreno, Adela; Poulsen, Kris; Casas, Meritxell Galindo; Dorywalska, Magdalena; Farias, Santiago; Pios, Ariel; Lui, Victor; Dushin, Russell; Zhou, Dahui; Navaratnam, Thayalan; Tran, Thomas-Toan; Sutton, Janette; Lindquist, Kevin C.; Han, Bora; Liu, Shu-Hui; Shelton, David L.; Pons, Jaume; Rajpal, Arvind</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">694-696</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt9y4CtErWAbVg90H21EOLACvtfcHk0likyBwr1426Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ensLbK&md5=43b6c9f702e02a91887c3f27a5ab7353</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnbt.3274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.3274%26sid%3Dliteratum%253Aachs%26aulast%3DStrop%26aufirst%3DP.%26aulast%3DDelaria%26aufirst%3DK.%26aulast%3DFoletti%26aufirst%3DD.%26aulast%3DWitt%26aufirst%3DJ.%2BM.%26aulast%3DHasa-Moreno%26aufirst%3DA.%26aulast%3DPoulsen%26aufirst%3DK.%26aulast%3DCasas%26aufirst%3DM.%2BG.%26aulast%3DDorywalska%26aufirst%3DM.%26aulast%3DFarias%26aufirst%3DS.%26aulast%3DPios%26aufirst%3DA.%26aulast%3DLui%26aufirst%3DV.%26aulast%3DDushin%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DNavaratnam%26aufirst%3DT.%26aulast%3DTran%26aufirst%3DT.-T.%26aulast%3DSutton%26aufirst%3DJ.%26aulast%3DLindquist%26aufirst%3DK.%2BC.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DS.-H.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DPons%26aufirst%3DJ.%26aulast%3DRajpal%26aufirst%3DA.%26atitle%3DSite-specific%2520conjugation%2520improves%2520therapeutic%2520index%2520of%2520antibody%2520drug%2520conjugates%2520with%2520high%2520drug%2520loading%26jtitle%3DNat.%2520Biotechnol.%26date%3D2015%26volume%3D33%26spage%3D694%26epage%3D696%26doi%3D10.1038%2Fnbt.3274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strop, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorywalska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaria, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dushin, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farias, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdiche, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekaran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krimm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dilley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaparro-Riggers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filzen, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajpal, A.</span></span> <span> </span><span class="NLM_article-title">Location matters: Site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1016%2Fj.chembiol.2013.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=23438745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=161-167&author=P.+Stropauthor=S.-H.+Liuauthor=M.+Dorywalskaauthor=K.+Delariaauthor=R.+G.+Dushinauthor=T.-T.+Tranauthor=W.-H.+Hoauthor=S.+Fariasauthor=M.+G.+Casasauthor=Y.+Abdicheauthor=D.+Zhouauthor=R.+Chandrasekaranauthor=C.+Samainauthor=C.+Looauthor=A.+Rossiauthor=M.+Rickertauthor=S.+Krimmauthor=T.+Wongauthor=S.+M.+Chinauthor=J.+Yuauthor=J.+Dilleyauthor=J.+Chaparro-Riggersauthor=G.+F.+Filzenauthor=C.+J.+O%E2%80%99Donnellauthor=F.+Wangauthor=J.+S.+Myersauthor=J.+Ponsauthor=D.+L.+Sheltonauthor=A.+Rajpal&title=Location+matters%3A+Site+of+conjugation+modulates+stability+and+pharmacokinetics+of+antibody+drug+conjugates&doi=10.1016%2Fj.chembiol.2013.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates</span></div><div class="casAuthors">Strop, Pavel; Liu, Shu-Hui; Dorywalska, Magdalena; Delaria, Kathy; Dushin, Russell G.; Tran, Thomas-Toan; Ho, Wei-Hsien; Farias, Santiago; Casas, Meritxell Galindo; Abdiche, Yasmina; Zhou, Dahui; Chandrasekaran, Ramalakshmi; Samain, Caroline; Loo, Carole; Rossi, Andrea; Rickert, Mathias; Krimm, Stellanie; Wong, Teresa; Chin, Sherman Michael; Yu, Jessica; Dilley, Jeanette; Chaparro-Riggers, Javier; Filzen, Gary F.; O'Donnell, Christopher J.; Wang, Fang; Myers, Jeremy S.; Pons, Jaume; Shelton, David L.; Rajpal, Arvind</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-167</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Antibody drug conjugates (ADCs) are a therapeutic class offering promise for cancer therapy.  The attachment of cytotoxic drugs to antibodies can result in an effective therapy with better safety potential than nontargeted cytotoxics.  To understand the role of conjugation site, we developed an enzymic method for site-specific antibody drug conjugation using microbial transglutaminase.  This allowed us to attach diverse compds. at multiple positions and investigate how the site influences stability, toxicity, and efficacy.  We show that the conjugation site has significant impact on ADC stability and pharmacokinetics in a species-dependent manner.  These differences can be directly attributed to the position of the linkage rather than the chem. instability, as was obsd. with a maleimide linkage.  With this method, it is possible to produce homogeneous ADCs and tune their properties to maximize the therapeutic window.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIo4ZEVMFX2LVg90H21EOLACvtfcHk0livswur0xh2Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWht74%253D&md5=0b419848b5fd4dfa4863a29de0555cf4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DStrop%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DS.-H.%26aulast%3DDorywalska%26aufirst%3DM.%26aulast%3DDelaria%26aufirst%3DK.%26aulast%3DDushin%26aufirst%3DR.%2BG.%26aulast%3DTran%26aufirst%3DT.-T.%26aulast%3DHo%26aufirst%3DW.-H.%26aulast%3DFarias%26aufirst%3DS.%26aulast%3DCasas%26aufirst%3DM.%2BG.%26aulast%3DAbdiche%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DChandrasekaran%26aufirst%3DR.%26aulast%3DSamain%26aufirst%3DC.%26aulast%3DLoo%26aufirst%3DC.%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DRickert%26aufirst%3DM.%26aulast%3DKrimm%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DChin%26aufirst%3DS.%2BM.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DDilley%26aufirst%3DJ.%26aulast%3DChaparro-Riggers%26aufirst%3DJ.%26aulast%3DFilzen%26aufirst%3DG.%2BF.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMyers%26aufirst%3DJ.%2BS.%26aulast%3DPons%26aufirst%3DJ.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DRajpal%26aufirst%3DA.%26atitle%3DLocation%2520matters%253A%2520Site%2520of%2520conjugation%2520modulates%2520stability%2520and%2520pharmacokinetics%2520of%2520antibody%2520drug%2520conjugates%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D161%26epage%3D167%26doi%3D10.1016%2Fj.chembiol.2013.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, I. S.</span></span> <span> </span><span class="NLM_article-title">CD70 as a therapeutic target in human malignancies</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1517/14728222.12.3.341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1517%2F14728222.12.3.341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=18269343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslKqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=341-351&author=I.+S.+Grewal&title=CD70+as+a+therapeutic+target+in+human+malignancies&doi=10.1517%2F14728222.12.3.341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">CD70 as a therapeutic target in human malignancies</span></div><div class="casAuthors">Grewal, Iqbal S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-351</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Expression of CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T and B lymphocytes and mature dendritic cells.  CD70 has also been detected on hematol. tumors and on carcinomas.  The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics.  Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clin. candidates.  Anti-CD70 antibodies for therapeutic use have been developed and used to validate CD70 as a target for cancers.  Antibodies are also used as a vehicle to deliver potent cytotoxic drugs to target CD70+malignant cells.  Both unconjugated antibodies and antibody-drug conjugates targeting CD70 have been tested in animal models of human cancers.  To describe the expression of CD70 in cancer cells and the development of antibody-based therapies against CD70.  A review of the available literature.  Humanized anti-CD70 antibodies have shown significant antitumor activity in preclin. xenograft models of cancer.  Addnl., anti-CD70 antibody-drug conjugates exhibit potent antitumor activity in solid tumor xenograft models, confirming increased therapeutic efficacy through cytotoxic drug delivery.  Thus, preclin. animal models have provided strong evidence that targeting CD70 either with unconjugated antibodies or with antibody-drug conjugates represents a promising approach to treat human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAVG1bz-F3nrVg90H21EOLACvtfcHk0livswur0xh2Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslKqu7g%253D&md5=576c0320d4f2683e0be9956a158a802e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1517%2F14728222.12.3.341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.12.3.341%26sid%3Dliteratum%253Aachs%26aulast%3DGrewal%26aufirst%3DI.%2BS.%26atitle%3DCD70%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520malignancies%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2008%26volume%3D12%26spage%3D341%26epage%3D351%26doi%3D10.1517%2F14728222.12.3.341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ponath, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyasu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strachan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBlanc, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangan, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristea, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardarelli, P. M.</span></span> <span> </span><span class="NLM_article-title">A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5178</span>– <span class="NLM_lpage">5189</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-18-0018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1158%2F1078-0432.CCR-18-0018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=30021910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsl2gsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=5178-5189&author=P.+Ponathauthor=D.+Menezesauthor=C.+Panauthor=B.+Chenauthor=M.+Oyasuauthor=D.+Strachanauthor=H.+LeBlancauthor=H.+Sunauthor=X.-T.+Wangauthor=V.+S.+Ranganauthor=S.+Deshpandeauthor=S.+Cristeaauthor=K.-S.+Parkauthor=J.+Sageauthor=P.+M.+Cardarelli&title=A+novel%2C+fully+human+anti-fucosyl-GM1+antibody+demonstrates+potent+in+vitro+and+in+vivo+antitumor+activity+in+preclinical+models+of+small+cell+lung+cancer&doi=10.1158%2F1078-0432.ccr-18-0018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer</span></div><div class="casAuthors">Ponath, Paul; Menezes, Daniel; Pan, Chin; Chen, Bing; Oyasu, Miho; Strachan, Debbie; LeBlanc, Heidi; Sun, Huadong; Wang, Xi-Tao; Rangan, Vangipuram S.; Deshpande, Shrikant; Cristea, Sandra; Park, Kwon-Sik; Sage, Julien; Cardarelli, Pina M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5178-5189</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The ganglioside fucosyl-GM1 (FucGM1) is a tumor-assocd. antigen expressed in a large percentage of human small cell lung cancer (SCLC) tumors, but absent in most normal adult tissues, making it a promising target in immuno-oncol.  This study was undertaken to evaluate the preclin. efficacy of BMS-986012, a novel, nonfucosylated, fully human IgG1 antibody that binds specifically to FucGM1.  Exptl. Design: The antitumor activity of BMS-986012 was evaluated in in vitro assays using SCLC cells and in mouse xenograft and syngeneic tumor models, with and without chemotherapeutic agents and checkpoint inhibitors.  Results: BMS-986012 showed a high binding affinity for FcγRIIIa (CD16), which resulted in enhanced antibody-dependent cellular cytotoxicity (ADCC) against FucGM1-expressing tumor cell lines.  BMS-986012-mediated tumor cell killing was also obsd. in complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP) assays.  In several mouse SCLC models, BMS-986012 demonstrated efficacy and was well tolerated.  In the DMS79 xenograft model, tumor regression was achieved with BMS-986012 doses of 0.3 mg/kg and greater; antitumor activity was enhanced when BMS-986012 was combined with std.-of-care cisplatin or etoposide.  In a syngeneic model, tumors derived from a genetically engineered model of SCLC were treated with BMS-986012 or anti-FucGM1 with a mouse IgG2a Fc and their responses evaluated; when BMS-986012 was combined with anti-PD-1 or anti-CD137 antibody, therapeutic responses significantly improved.  Conclusions: Single-agent BMS-986012 demonstrated robust antitumor activity, with the addn. of chemotherapeutic or immunomodulatory agents further inhibiting SCLC growth in the same models.  These preclin. data supported evaluation of BMS-986012 in a phase I clin. trial of patients with relapsed, refractory SCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2I3l3szsPmrVg90H21EOLACvtfcHk0ljh3kSE8LCMAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsl2gsr4%253D&md5=3f60f55d89c41e28135b612619038520</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-0018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-0018%26sid%3Dliteratum%253Aachs%26aulast%3DPonath%26aufirst%3DP.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DOyasu%26aufirst%3DM.%26aulast%3DStrachan%26aufirst%3DD.%26aulast%3DLeBlanc%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.-T.%26aulast%3DRangan%26aufirst%3DV.%2BS.%26aulast%3DDeshpande%26aufirst%3DS.%26aulast%3DCristea%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DK.-S.%26aulast%3DSage%26aufirst%3DJ.%26aulast%3DCardarelli%26aufirst%3DP.%2BM.%26atitle%3DA%2520novel%252C%2520fully%2520human%2520anti-fucosyl-GM1%2520antibody%2520demonstrates%2520potent%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activity%2520in%2520preclinical%2520models%2520of%2520small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D5178%26epage%3D5189%26doi%3D10.1158%2F1078-0432.ccr-18-0018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastalerz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton King, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstead, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasch, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P. A.</span></span> <span> </span><span class="NLM_article-title">Doxorubicin immunoconjugates containing bivalent, lysosomal cleavable linkages</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1529</span>– <span class="NLM_lpage">1532</span>, <span class="refDoi"> DOI: 10.1016/s0960-894x(02)00194-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1016%2FS0960-894X%2802%2900194-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=12031335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjsl2ltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=1529-1532&author=G.+M.+Dubowchikauthor=S.+Radiaauthor=H.+Mastalerzauthor=M.+A.+Walkerauthor=R.+A.+Firestoneauthor=H.+Dalton+Kingauthor=S.+J.+Hofsteadauthor=D.+Willnerauthor=S.+J.+Laschauthor=P.+A.+Trail&title=Doxorubicin+immunoconjugates+containing+bivalent%2C+lysosomal+cleavable+linkages&doi=10.1016%2Fs0960-894x%2802%2900194-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages</span></div><div class="casAuthors">Dubowchik, Gene M.; Radia, Shilpa; Mastalerz, Harold; Walker, Michael A.; Firestone, Raymond A.; King, H. Dalton; Hofstead, Sandra J.; Willner, David; Lasch, Shirley J.; Trail, Pamela A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1529-1532</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Bivalent doxorubicin (DOX)-dipeptides were prepd. and conjugated to the monoclonal antibody BR96.  The dipeptides are cleaved by lysosomal proteases following internalization of the resulting immunoconjugates.  Conjugate I (R = BR96) demonstrated antigen-specific in vitro tumor cell killing activity (IC50=0.2 μM) that was equipotent to DOX with a near doubling of drug mols./MAb.  Size exclusion chromatog. showed I to be a noncovalent dimer that was formed immediately upon conjugation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriP8-FshjnXLVg90H21EOLACvtfcHk0ljh3kSE8LCMAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjsl2ltr8%253D&md5=6a7dc51aa0d83a17ab9dc97e4705d886</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900194-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900194-4%26sid%3Dliteratum%253Aachs%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DRadia%26aufirst%3DS.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DWalker%26aufirst%3DM.%2BA.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26aulast%3DDalton%2BKing%26aufirst%3DH.%26aulast%3DHofstead%26aufirst%3DS.%2BJ.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DLasch%26aufirst%3DS.%2BJ.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DDoxorubicin%2520immunoconjugates%2520containing%2520bivalent%252C%2520lysosomal%2520cleavable%2520linkages%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D1529%26epage%3D1532%26doi%3D10.1016%2Fs0960-894x%2802%2900194-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donnel, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangwar, S.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic pyrrolobenzodiazepine dimers as antibody-drug conjugate payloads</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">5267</span>– <span class="NLM_lpage">5271</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1016%2Fj.bmcl.2017.10.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=29102228" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=5267-5271&author=A.+F.+Donnelauthor=Y.+Zhangauthor=D.+D.+Weiauthor=A.+J.+Tebbenauthor=H.+L.+Perezauthor=G.+M.+Schroederauthor=C.+Panauthor=C.+Raoauthor=R.+M.+Borzilleriauthor=G.+D.+Viteauthor=S.+Gangwar&title=Macrocyclic+pyrrolobenzodiazepine+dimers+as+antibody-drug+conjugate+payloads&doi=10.1016%2Fj.bmcl.2017.10.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DDonnel%26aufirst%3DA.%2BF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DD.%2BD.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DPerez%26aufirst%3DH.%2BL.%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DPan%26aufirst%3DC.%26aulast%3DRao%26aufirst%3DC.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DGangwar%26aufirst%3DS.%26atitle%3DMacrocyclic%2520pyrrolobenzodiazepine%2520dimers%2520as%2520antibody-drug%2520conjugate%2520payloads%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D5267%26epage%3D5271%26doi%3D10.1016%2Fj.bmcl.2017.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, J.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of Tesirine, a clinical antibody–drug conjugate pyrrolobenzodiazepine dimer payload</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00062</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00062" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFSgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=983-987&author=A.+C.+Tiberghienauthor=J.-N.+Levyauthor=L.+A.+Mastersonauthor=N.+V.+Patelauthor=L.+R.+Adamsauthor=S.+Corbettauthor=D.+G.+Williamsauthor=J.+A.+Hartleyauthor=P.+W.+Howard&title=Design+and+synthesis+of+Tesirine%2C+a+clinical+antibody%E2%80%93drug+conjugate+pyrrolobenzodiazepine+dimer+payload&doi=10.1021%2Facsmedchemlett.6b00062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload</span></div><div class="casAuthors">Tiberghien, Arnaud C.; Levy, Jean-Noel; Masterson, Luke A.; Patel, Neki V.; Adams, Lauren R.; Corbett, Simon; Williams, David G.; Hartley, John A.; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">983-987</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyrrolobenzodiazepine dimers are an emerging class of warhead in the field of antibody-drug conjugates (ADCs).  Tesirine (SG3249) was designed to combine potent antitumor activity with desirable physicochem. properties such as favorable hydrophobicity and improved conjugation characteristics.  One of the reactive imines was capped with a cathepsin B-cleavable valine-alanine linker.  A robust synthetic route was developed to allow the prodn. of tesirine on clin. scale, employing a flexible, convergent strategy.  Tesirine was evaluated in vitro both in stochastic and engineered ADC constructs and was confirmed as a potent and versatile payload.  The conjugation of tesirine to anti-DLL3 rovalpituzumab has resulted in rovalpituzumab-tesirine (Rova-T), currently under evaluation for the treatment of small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYid7RNts7s7Vg90H21EOLACvtfcHk0ljh3kSE8LCMAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFSgu70%253D&md5=7e4bbdd55b944ff712f01d31d58c0d13</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00062%26sid%3Dliteratum%253Aachs%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DLevy%26aufirst%3DJ.-N.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DPatel%26aufirst%3DN.%2BV.%26aulast%3DAdams%26aufirst%3DL.%2BR.%26aulast%3DCorbett%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DD.%2BG.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520Tesirine%252C%2520a%2520clinical%2520antibody%25E2%2580%2593drug%2520conjugate%2520pyrrolobenzodiazepine%2520dimer%2520payload%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D983%26epage%3D987%26doi%3D10.1021%2Facsmedchemlett.6b00062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neelarapu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzle, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velaparthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunsteiner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blond, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petukhov, P. A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4350</span>– <span class="NLM_lpage">4364</span>, <span class="refDoi"> DOI: 10.1021/jm2001025</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2001025" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntVemsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4350-4364&author=R.+Neelarapuauthor=D.+L.+Holzleauthor=S.+Velaparthiauthor=H.+Baiauthor=M.+Brunsteinerauthor=S.+Y.+Blondauthor=P.+A.+Petukhov&title=Design%2C+synthesis%2C+docking%2C+and+biological+evaluation+of+novel+diazide-containing+isoxazole-+and+pyrazole-based+histone+deacetylase+probes&doi=10.1021%2Fjm2001025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Docking, and Biological Evaluation of Novel Diazide-Containing Isoxazole- and Pyrazole-Based Histone Deacetylase Probes</span></div><div class="casAuthors">Neelarapu, Raghupathi; Holzle, Denise L.; Velaparthi, Subash; Bai, He; Brunsteiner, Michael; Blond, Sylvie Y.; Petukhov, Pavel A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4350-4364</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, docking, and biol. evaluation of novel potent HDAC3 and HDAC8 isoxazole- and pyrazole-based diazide probes suitable for binding ensemble profiling with photoaffinity labeling (BEProFL) expts. in cells is described.  Both the isoxazole- and pyrazole-based probes exhibit low nanomolar inhibitory activity against HDAC3 and HDAC8, resp.  The pyrazole-based probe I appears to be one of the most active HDAC8 inhibitors reported in the literature with an IC50 of 17 nM.  Our docking studies suggest that unlike the isoxazole-based ligands the pyrazole-based ligands are flexible enough to occupy the second binding site of HDAC8.  Probes/inhibitors II, III (R = H, N3) and I exerted the antiproliferative and neuroprotective activities at micromolar concns. through inhibition of nuclear HDACs, indicating that they are cell permeable and the presence of an azide or a diazide group does not interfere with the neuroprotection properties, or enhance cellular cytotoxicity, or affect cell permeability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhXV9jmEswzLVg90H21EOLACvtfcHk0lj0GNOwCZNxwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntVemsbw%253D&md5=274a01467ab7108b87dd6634562f4635</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm2001025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2001025%26sid%3Dliteratum%253Aachs%26aulast%3DNeelarapu%26aufirst%3DR.%26aulast%3DHolzle%26aufirst%3DD.%2BL.%26aulast%3DVelaparthi%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DH.%26aulast%3DBrunsteiner%26aufirst%3DM.%26aulast%3DBlond%26aufirst%3DS.%2BY.%26aulast%3DPetukhov%26aufirst%3DP.%2BA.%26atitle%3DDesign%252C%2520synthesis%252C%2520docking%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520diazide-containing%2520isoxazole-%2520and%2520pyrazole-based%2520histone%2520deacetylase%2520probes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4350%26epage%3D4364%26doi%3D10.1021%2Fjm2001025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, J. G. H.</span>; <span class="NLM_string-name">Wentzel, M.</span>; <span class="NLM_string-name">Knoetze, S.</span></span> <span> </span><span class="NLM_article-title">Aromatic Compounds and Metal Complexes Thereof</span>. <span class="NLM_patent">WO 2012153253 A2</span>, Nov 15, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+G.+H.+Perez&author=M.+Wentzel&author=S.+Knoetze&title=Aromatic+Compounds+and+Metal+Complexes+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DJ.%2BG.%2BH.%26atitle%3DAromatic%2520Compounds%2520and%2520Metal%2520Complexes%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howáth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köntös, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerencsér, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszthy, P.</span></span> <span> </span><span class="NLM_article-title">A new efficient method for the preparation of 2,6-pyridinedimethylditosylates from dimethyl 2,6-pyridinedicarboxylates</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3719</span>– <span class="NLM_lpage">3731</span>, <span class="refDoi"> DOI: 10.1080/00397919908086011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1080%2F00397919908086011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1999&pages=3719-3731&author=G.+How%C3%A1thauthor=C.+Rusaauthor=Z.+K%C3%B6nt%C3%B6sauthor=J.+Gerencs%C3%A9rauthor=P.+Huszthy&title=A+new+efficient+method+for+the+preparation+of+2%2C6-pyridinedimethylditosylates+from+dimethyl+2%2C6-pyridinedicarboxylates&doi=10.1080%2F00397919908086011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1080%2F00397919908086011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397919908086011%26sid%3Dliteratum%253Aachs%26aulast%3DHow%25C3%25A1th%26aufirst%3DG.%26aulast%3DRusa%26aufirst%3DC.%26aulast%3DK%25C3%25B6nt%25C3%25B6s%26aufirst%3DZ.%26aulast%3DGerencs%25C3%25A9r%26aufirst%3DJ.%26aulast%3DHuszthy%26aufirst%3DP.%26atitle%3DA%2520new%2520efficient%2520method%2520for%2520the%2520preparation%2520of%25202%252C6-pyridinedimethylditosylates%2520from%2520dimethyl%25202%252C6-pyridinedicarboxylates%26jtitle%3DSynth.%2520Commun.%26date%3D1999%26volume%3D29%26spage%3D3719%26epage%3D3731%26doi%3D10.1080%2F00397919908086011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">David J. Newman</span>. </span><span class="cited-content_cbyCitation_article-title">Natural Product Based Antibody Drug Conjugates: Clinical Status as of November 9, 2020. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2021,</strong> <em>84 </em>
                                    (3)
                                     , 917-931. <a href="https://doi.org/10.1021/acs.jnatprod.1c00065" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.1c00065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.1c00065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.1c00065%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DNatural%252BProduct%252BBased%252BAntibody%252BDrug%252BConjugates%25253A%252BClinical%252BStatus%252Bas%252Bof%252BNovember%252B9%25252C%252B2020%26aulast%3DNewman%26aufirst%3DDavid%2BJ.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D19012021%26date%3D26022021%26volume%3D84%26issue%3D3%26spage%3D917%26epage%3D931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Prasanna Sivaprakasam, Ivar McDonald, Christiana Iwuagwu, Naidu S. Chowdari, Kevin M. Peese, David R. Langley, Heng Cheng, Michael R. Luzung, Michael A. Schmidt, Bin Zheng, Yichen Tan, Patricia Cho, Souvik Rakshit, Thirumalai Lakshminarasimhan, Sivakrishna Guturi, Kishorekumar Kanagavel, Umamaheswararao Kanusu, Ankita G. Niyogi, Somprabha Sidhar, Rajappa Vaidyanathan, Martin D. Eastgate, Srikanth Kotapati, Madhura Deshpande, Chin Pan, Pina M. Cardarelli, Chunshan Xie, Chetana Rao, Patrick Holder, Ganapathy Sarma, Gregory Vite, <span class="NLM_string-name hlFld-ContribAuthor">Sanjeev Gangwar</span>. </span><span class="cited-content_cbyCitation_article-title">DNA-Model-Based Design and Execution of Some Fused Benzodiazepine Hybrid Payloads for Antibody–Drug Conjugate Modality. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (3)
                                     , 404-412. <a href="https://doi.org/10.1021/acsmedchemlett.0c00578" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00578</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00578%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDNA-Model-Based%252BDesign%252Band%252BExecution%252Bof%252BSome%252BFused%252BBenzodiazepine%252BHybrid%252BPayloads%252Bfor%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252BModality%26aulast%3DSivaprakasam%26aufirst%3DPrasanna%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D31102020%26date%3D27012021%26date%3D10022021%26volume%3D12%26issue%3D3%26spage%3D404%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saba  Farooq</span>, <span class="hlFld-ContribAuthor ">Zainab  Ngaini</span>. </span><span class="cited-content_cbyCitation_article-title">Chalcone derived benzoheterodiazepines for medicinal applications:
              A Two‐pot
              and
              one‐pot
              synthetic approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2021,</strong> <em>24 </em><a href="https://doi.org/10.1002/jhet.4337" title="DOI URL">https://doi.org/10.1002/jhet.4337</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.4337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.4337%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DChalcone%252Bderived%252Bbenzoheterodiazepines%252Bfor%252Bmedicinal%252Bapplications%25253A%252BA%252BTwo%2525E2%252580%252590pot%252Band%252Bone%2525E2%252580%252590pot%252Bsynthetic%252Bapproach%26aulast%3DFarooq%26aufirst%3DSaba%26date%3D2021%26date%3D2021%26volume%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0041.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of benzodiazepine-based dimers and monomers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Putative binding model of compound <b>13</b> illustrating the formation of interstrand covalent cross-linking in an 8-mer duplex DNA and ligand overlay of compounds <b>24</b>, <b>25</b>, and <b>26</b>. (A) Surface representation of compound <b>13</b> (green carbon) bound to DNA. Compound <b>13</b> fits snugly in the DNA minor groove because of its high shape complementarity. (B) Specific interactions exhibited by compound <b>13</b> are highlighted. Compound <b>13</b> is hypothesized to make covalent bonds with the exocyclic N2 amino groups of guanines on both strands through its C11/C11′ reactive centers. The hydrogen bonds between the N10/N10′ of compound <b>13</b> and carbonyl oxygens on C2 of cytosines (adjacent to the covalently modified guanines) are denoted as yellow dotted lines. The inset in B shows the nucleotide sequence of the 8-mer duplex DNA and the putative cross-linking and hydrogen bonding sites of compound <b>13</b> (magenta guanines and cyan cytosines, respectively). (C) Ligand overlay of optimized structures of compounds <b>24</b> (green), <b>25</b> (magenta), and <b>26</b> (blue). The green arc shows the angle of curvature provided by the central phenyl spacer to the two monomeric payload units in compound <b>24</b>. The magenta curve shows the slightly flattened corresponding angle of curvature in compound <b>25</b>. The blue curve shows the highly contracted angle of curvature in compound <b>26</b>. The 1,3-, 1,4-, and 1,2-attachment points in the central phenyl spacer for the two monomeric payload units create moderate to significant differences in the overall angle of curvatures in compounds <b>24</b>, <b>25</b>, and <b>26</b> to complement the curvature of the DNA minor groove. The figure was prepared using Pymol (The PyMOL Molecular Graphics System, Versions 1.6.1.0 and 2.0 Schrödinger, LLC).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures of ADCs <b>44–48</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plasma PK disposition of heterogeneous ADC-<b>45</b> (A) and site-specific ADC-<b>46</b> (B). Concentration of total ADC and unconjugated antibodies in plasma was determined with an ELISA-based quantitative assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Percent body weight change from randomization of wild-type BALB/c mice treated with 0.005, 0.02, and 0.05 μmol/kg single dose of anti-Meso-<b>45</b>. (B) In vivo antitumor activity of the anti-Meso-<b>45</b> in N87 gastric xenograft cancer model in SCID mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Percent body weight change from randomization after a single administration of 0.05 μmol/kg of site-specific anti-mesothelin ADCs with varying PEG lengths in the N87 gastric tumor xenograft model in SCID mice. (B) In vivo antitumor activity of site-specific anti-mesothelin ADC-<b>46</b> in the N87 xenograft model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) In vivo antitumor activity of anti-FucGM1-<b>45</b> ADC in the H187 SCLC xenograft model. (B) In vivo antitumor activity of anti-FucGM1-<b>45</b> ADC vs site-specific anti-FucGM1-<b>46</b> ADC in the H187 SCLC xenograft model in SCID mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Monomers and spacers employed in this work.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Retrosynthetic Analysis of Benzodiazepine Dimers</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of SEM Monomer <b>49</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaOH, THF–water, 50 °C, 5 h, 100%; (b) (1) (COCl)<sub>2</sub>, THF, DMF, rt, 2 h; (2) <b>54</b>, Et<sub>3</sub>N, THF, 4 h, 98%; (c) Zn, NH<sub>4</sub>Cl, MeOH, 50 °C, 16 h, 96%; (d) <b>57</b>, NaH, DMF, rt, 1 h, 78%; (d) 10% Pd/C, H<sub>2</sub>, EtOH, rt, 3 h, 83%.</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Alloc Monomer <b>50</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TBSCl, imidazole, CH<sub>3</sub>CN, rt, 1.5 h, 68%; (b) <b>61</b>, HATU, DCM, <i>i</i>-Pr<sub>2</sub>NEt, rt, 24 h, 66%; (c) Zn, NH<sub>4</sub>Cl, MeOH, rt, 24 h, 83%; (d) allyl chloroformate, pyridine, DCM, −78 °C to rt, 1 h, 88%; (e) HCl, MeOH, 20 min, rt, 84%; (f) (COCl)<sub>2</sub>, DMSO, DCM, −78 °C to rt, 30 min, 92%; (g) TBS-OTf, 2,6-lutidine, 0 °C, 30 min, 97%; (h) LiOAc, DMF–water, rt, 16 h, 71%.</p></p></figure><figure data-id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Monomer <b>51</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) H<sub>2</sub>SO<sub>4</sub>, EtOH, 80 °C, 20 h, 83%; (b) H<sub>2</sub>SO<sub>4</sub>, HNO<sub>3</sub>, −5 °C, 30 min, 91%; (c) (1) <b>53</b>, (COCl)<sub>2</sub>, THF, DMF, rt, 2 h; (2) <b>70</b>, Et<sub>3</sub>N, THF, rt, 30 min, 78%; (d) Zn, NH<sub>4</sub>Cl, MeOH, 50 °C, 16 h, 82%; (e) Trityl-Cl, Et<sub>3</sub>N, DCM, rt, 3 h, 88%; (f) SEM-Cl, NaH, DMF, 0 °C to rt, 2 h, 80%; (g) 10% Pd/C, H<sub>2</sub>, EtOAc, rt, 2 days, 90%; (h) (1) allyl chloroformate, Et<sub>3</sub>N, 0 °C, 2 h; (2) LiOH, MeOH–water, rt, 16 h, 75%.</p></p></figure><figure data-id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Payload <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 2 h, 77%; (b) <b>4c</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C, 2 h; (c) SEM-Cl, NaH, DMF, 0 °C to rt, 2 h, 20%; (d) (1) LiBH<sub>4</sub>, THF, −78 °C, 1 h; (2) Silica gel, CHCl<sub>3</sub>–EtOH–water, 24 h, 9%.</p></p></figure><figure data-id="sch6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Payload <b>5</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>72</b>, NaBH<sub>3</sub>CN, formaldehyde, AcOH, THF, rt, 2 h, 98%; (b) SEM-Cl, NaH, DMF, rt, 16 h; (c) 10% Pd/C, H<sub>2</sub>, EtOH/EtOAc, rt, 4 h, 76%; (d) <b>5d</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 14 h, 82%; (e) (1) LiBH<sub>4</sub>, THF, −78 °C, 2 h; (2) Silica gel, CHCl<sub>3</sub>–EtOH–water, 24 h, 44%.</p></p></figure><figure data-id="sch7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Payload <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1,5-diiodopentane, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 40 min, 88%; (b) <b>6b</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C, 3 h, 66%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, rt, 12 h, 41%.</p></p></figure><figure data-id="sch8" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Payload <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>7a</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 3 h, 83%; (b) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 4 h, 80%; (c) (COCl)<sub>2</sub>, DMSO, Et<sub>3</sub>N, DCM, −78 to 0 °C, 15 min, 88%; (d) Tf<sub>2</sub>O, 2,6-lutidine, DCM, −78 to −30 °C, 3 h, 45%; (e) 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, PdCl<sub>2</sub>(dppf), 35 °C, 1 h, 69%; (f) (1) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h; (2) HCO<sub>2</sub>H, THF–EtOH–water, rt, 6 h, 37%.</p></p></figure><figure data-id="sch9" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Payload <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) <b>53</b>, (COCl)<sub>2</sub>, THF, rt, 2 h; (2) <b>8a</b>, Et<sub>3</sub>N, 0 °C, 2 h, 68%; (b) Zn, NH<sub>4</sub>Cl, MeOH, 50 °C, 16 h, 82%; (c) THP, PPTS, THF, rt, 16 h, 77%; (d) SEM-Cl, NaH, DMF, rt, 1 h, 58%; (e) 10% Pd/C, H<sub>2</sub>, EtOAc, rt, 2 h, 64%; (f) <b>7c</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 16 h, 91%; (g) MeI, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 16 h; (h) Pyr-SO<sub>3</sub>, DCM, rt, 16 h, 52%; (i) Tf<sub>2</sub>O, 2,6-lutidine, DCM, −78 to 0 °C, 2 h, 63%; (j) 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, PdCl<sub>2</sub>(dppf), K<sub>3</sub>PO<sub>4</sub>, THF, 45 °C, 2 h, 63%; (f) (1) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h; (2) HCO<sub>2</sub>H, THF–EtOH–water, rt, 2 h, 38%.</p></p></figure><figure data-id="sch10" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0019.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Payload <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>7c</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 5 h, 91%; (b) (COCl)<sub>2</sub>, DMSO, Et<sub>3</sub>N, DCM, −78 to 0 °C, 15 min, 79%; (c) Tf<sub>2</sub>O, 2,6-lutidine, DCM, −78 to −10 °C, 20 min, 60%; (d) (4-methoxyphenyl)boronic acid, PdCl<sub>2</sub>(dppf), K<sub>3</sub>PO<sub>4</sub>, THF, 35 °C, 2 h, 93%; (e) (1) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h; (2) Silica gel, CHCl<sub>3</sub>–EtOH–water, 3 days, 39%.</p></p></figure><figure data-id="sch11" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0020.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Payloads <b>10</b>, <b>13</b>, <b>16</b>, and <b>17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>; (b) Pd(PPh<sub>3</sub>)<sub>4</sub>, morpholine, THF, rt, 2 h, 70%; (c) (1) LiBH<sub>4</sub> or LiEt<sub>3</sub>BH; (2) Silica gel, CHCl<sub>3</sub>–EtOH–water.</p></p></figure><figure data-id="sch12" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0021.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of Payloads <b>11</b>, <b>14</b>, and <b>19–23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 1–2 h; (b) <b>51</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 1–5 h; <b>19a</b>: (1) <b>8f</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 5 h (2) PPTS, MeOH, 40 °C, 1 h, 72%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, morpholine, DCM, 2 h; (d) MeI, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 3 h; (e) 2-bromoethanol, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 4 h; (f) 1-bromo-2-(2-methoxyethoxy)ethane, K<sub>2</sub>CO<sub>3</sub>, DMSO, rt, 3 h; (g) (1) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h; (2) silica gel, CHCl<sub>3</sub>–EtOH–water, 24 h. (h) (1) Fmoc-Gly-OH, HATU, <i>i</i>-Pr<sub>2</sub>NEt, DMF, rt, 4 h; (2) piperidine, DMF, rt, 1 h.</p></p></figure><figure data-id="sch13" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0022.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of Payloads <b>12</b>, <b>15</b>, and <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 2 h; (b) 10% Pd/C, H<sub>2</sub>, MeOH, rt, 5 h, 86%; (c) ClCH<sub>2</sub>COCl, Et<sub>3</sub>N, DCM, rt, 1 h; (d) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>, DMSO, 50 °C, 4 h, 73%; (e) (1) <b>51</b>, K<sub>2</sub>CO<sub>3</sub>, rt, 1–6 h; (2) Pd(PPh<sub>3</sub>)<sub>4</sub>, morpholine, DCM; (f) (1) Alloc-Cl, Et<sub>3</sub>N, THF, rt, 3 h, 85%; (2) NaBH<sub>3</sub>CN, formaldehyde, AcOH, MeOH/THF, rt, 15 h, 85%; (3) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, 15 h, 86%; (g) (1) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h; (2) silica gel, CHCl<sub>3</sub>–EtOH–water, rt, 24 h.</p></p></figure><figure data-id="sch14" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0023.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Synthesis of Payloads <b>24</b>, <b>28</b>, and <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LiOAc, DMF/water, rt, 15 h, 94%; (b) <b>29a</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 2 h; (c) <b>50</b>, Cs<sub>2</sub>CO<sub>3</sub>, acetone, 40 °C, 1 h; (d) NaN<sub>3</sub>, DMF, rt, 15 h; (e) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, rt, 30–90 min.</p></p></figure><figure data-id="sch15" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0024.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Synthesis of Payloads <b>25</b> and <b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>50</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (b) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, rt, 1.5 h.</p></p></figure><figure data-id="sch16" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0025.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of Payload <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>50</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 1 h; 88% (b) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, rt, 1.5 h, 39%.</p></p></figure><figure data-id="sch17" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0026.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of Payloads <b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) 10% Pd/C, H<sub>2</sub>, MeOH, rt, 5 h; (2) Alloc-Cl, K<sub>2</sub>CO<sub>3</sub>, THF, rt, 3 h, 22%; (b) mesyl chloride, Et<sub>3</sub>N, −10 °C, 1 h, 95%; (c) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 2 h; 66% (d) Pd(PPh<sub>3</sub>)<sub>4</sub>, morpholine, DCM, 0 °C, 2 h, 87%; (e) (1) LiBH<sub>4</sub>, THF/EtOH, rt, 2 h; (2) silica gel, CHCl<sub>3</sub>–EtOH–water, rt, 3 days, 46%.</p></p></figure><figure data-id="sch18" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0027.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Synthesis of Payloads <b>30</b> and <b>34–38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>50</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 1 h (b) <b>29b</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 1–2.5 h (c) TBAF, THF, rt, 30 min; (d) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, rt, 30 min.</p></p></figure><figure data-id="sch19" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0028.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Synthesis of Payloads <b>31</b>, <b>32</b>, <b>39</b>, and <b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>50</b>, DIAD, PPh<sub>3</sub>, THF, rt, 1.5 h, 15%; (b) <b>29b</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 1 h, 73%; (c) <b>50</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt; (d) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, rt, 30 min.</p></p></figure><figure data-id="sch20" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0029.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Synthesis of Payload <b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>49</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 16 h, 89%; (b) <b>50</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, 16 h, 79%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, rt, 1 h, 64%; (2) silica gel, CHCl<sub>3</sub>–EtOH–water, rt, 3 days, 82%.</p></p></figure><figure data-id="sch21" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0030.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Synthesis of Payloads <b>42</b> and <b>43</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>50</b>, DIAD, PPh<sub>3</sub>, THF, rt, 1.5 h, 8%; (b) <b>50</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, 40 °C, 3 h, 42%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, pyrrolidine, DCM, rt, 1 h.</p></p></figure><figure data-id="sch22" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0031.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Synthesis of Linker-Payload <b>44</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>14b</b>, HATU, DMF, 2,6-lutidine, rt, 1 h, 71%; (b) piperidine, THF, rt, 2 h, 65%; (c) (1) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h; (2) silica gel, CHCl<sub>3</sub>–EtOH–water, rt, 36 h, 55%; (d) MAL-dPEG8-NHS ester, 2,6-lutidine, DMSO, rt, 1 h, 55%.</p></p></figure><figure data-id="sch23" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0032.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Synthesis of Linker-Payload <b>45</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>17</b>, <i>i</i>-Pr<sub>2</sub>NEt, DMSO, rt, 16 h, 32%.</p></p></figure><figure data-id="sch24" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/medium/jm0c01385_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0033.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Synthesis of Linker-Payload <b>46</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01385/20201120/images/large/jm0c01385_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01385&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <b>17c</b>, <i>i</i>-Pr<sub>2</sub>NEt, NMP, rt, 16 h, 57%; (b) piperidine, THF, rt, 30 min, 79%; (c) (1) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h; (2) silica gel, DCM–EtOH–water, rt, 3 days, 55%; (d) (1) Fmoc-PEG<sub><i>n</i></sub>-acid, HATU, 2,6-lutidine, DMF, rt, 2 h; (2) Et<sub>2</sub>NH, DMF, rt, 1 h, 22%. (e) Fmoc-PEG4-OSu, THF, rt, 1 h, 48%; (f) LiEt<sub>3</sub>BH, THF, −78 °C, 1 h, 30%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i146">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50277" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50277" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 33 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, C. Q.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates for personalized treatment of solid tumors</span>. <i>Adv. Therapy</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1035</span>, <span class="refDoi"> DOI: 10.1007/s12325-017-0519-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1007%2Fs12325-017-0519-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=28361465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltl2isbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=1015-1035&author=J.+M.+Lambertauthor=C.+Q.+Morris&title=Antibody-drug+conjugates+for+personalized+treatment+of+solid+tumors&doi=10.1007%2Fs12325-017-0519-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review</span></div><div class="casAuthors">Lambert, John M.; Morris, Charles Q.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1015-1035</span>CODEN:
                <span class="NLM_cas:coden">ADTHE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-238X</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">Attaching a cytotoxic "payload" to an antibody to form an antibody-drug conjugate (ADC) provides a mechanism for selective delivery of the cytotoxic agent to cancer cells via the specific binding of the antibody to cancer-selective cell surface mols.  The first ADC to receive marketing authorization was gemtuzumab ozogamicin, which comprises an anti-CD33 antibody conjugated to a highly potent DNA-targeting antibiotic, calicheamicin, approved in 2000 for treating acute myeloid leukemia.  It was withdrawn from the US market in 2010 following an unsuccessful confirmatory trial.  The development of two classes of highly potent microtubule-disrupting agents, maytansinoids and auristatins, as payloads for ADCs resulted in approval of brentuximab vedotin in 2011 for treating Hodgkin lymphoma and anaplastic large cell lymphoma, and approval of ado-trastuzumab emtansine in 2013 for treating HER2-pos. breast cancer.  Their success stimulated much research into the ADC approach, with >60 ADCs currently in clin. evaluation, mostly targeting solid tumors.  Five ADCs have advanced into pivotal clin. trials for treating various solid tumors-platinum-resistant ovarian cancer, mesothelioma, triple-neg. breast cancer, glioblastoma, and small cell lung cancer.  The level of target expression is a key parameter in predicting the likelihood of patient benefit for all these ADCs, as well as for the approved compd., ado-trastuzumab emtansine.  The development of a patient selection strategy linked to target expression on the tumor is thus critically important for identifying the population appropriate for receiving treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFGOQG-cRY8bVg90H21EOLACvtfcHk0lh99YWKclSknw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltl2isbk%253D&md5=42789949f7bbb6d2764af4072632f905</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs12325-017-0519-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-017-0519-6%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DMorris%26aufirst%3DC.%2BQ.%26atitle%3DAntibody-drug%2520conjugates%2520for%2520personalized%2520treatment%2520of%2520solid%2520tumors%26jtitle%3DAdv.%2520Therapy%26date%3D2017%26volume%3D34%26spage%3D1015%26epage%3D1035%26doi%3D10.1007%2Fs12325-017-0519-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, E. L.</span></span> <span> </span><span class="NLM_article-title">The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1038/nbt.2289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1038%2Fnbt.2289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=22781692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFCqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=631-637&author=P.+D.+Senterauthor=E.+L.+Sievers&title=The+discovery+and+development+of+brentuximab+vedotin+for+use+in+relapsed+Hodgkin+lymphoma+and+systemic+anaplastic+large+cell+lymphoma&doi=10.1038%2Fnbt.2289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma</span></div><div class="casAuthors">Senter, Peter D.; Sievers, Eric L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">631-637</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Progress was made recently in developing antibody-drug conjugates (ADCs) that can selectively deliver cancer drugs to tumor cells.  In principle, the idea is simple: by attaching drugs to tumor-seeking antibodies, target cells will be killed and nontarget cells will be spared.  In practice, many parameters needed to be addressed to develop safe and effective ADCs, including the expression profiles of tumor vs. normal tissues, the potency of the drug, the linker attaching the drug and placement of the drug on the antibody, and the pharmacokinetic and stability profiles of the resulting ADC.  All these issues had been taken into account in developing brentuximab vedotin (Adcetris), an ADC that recently received accelerated approval by the US Food and Drug Administration for the treatment of relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).  Research is under way to extend the applications of brentuximab vedotin and to advance the field by developing other ADCs with new linker and conjugation strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyPib6JxGsSrVg90H21EOLACvtfcHk0ljfOYu3dtNWYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFCqtbw%253D&md5=6940eb8178e8c8c150a7b21361e23234</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2289%26sid%3Dliteratum%253Aachs%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DSievers%26aufirst%3DE.%2BL.%26atitle%3DThe%2520discovery%2520and%2520development%2520of%2520brentuximab%2520vedotin%2520for%2520use%2520in%2520relapsed%2520Hodgkin%2520lymphoma%2520and%2520systemic%2520anaplastic%2520large%2520cell%2520lymphoma%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D631%26epage%3D637%26doi%3D10.1038%2Fnbt.2289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welslau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guardino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackwell, K.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab Emtansine for HER2-positive advanced breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1783</span>– <span class="NLM_lpage">1791</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1209124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1056%2Fnejmoa1209124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=23020162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1783-1791&author=S.+Vermaauthor=D.+Milesauthor=L.+Gianniauthor=I.+E.+Kropauthor=M.+Welslauauthor=J.+Baselgaauthor=M.+Pegramauthor=D.-Y.+Ohauthor=V.+Di%C3%A9rasauthor=E.+Guardinoauthor=L.+Fangauthor=M.+W.+Luauthor=S.+Olsenauthor=K.+Blackwell&title=Trastuzumab+Emtansine+for+HER2-positive+advanced+breast+cancer&doi=10.1056%2Fnejmoa1209124"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine for HER2-positive advanced breast cancer</span></div><div class="casAuthors">Verma, Sunil; Miles, David; Gianni, Luca; Krop, Ian E.; Welslau, Manfred; Baselga, Jose; Pegram, Mark; Oh, Do-Youn; Dieras, Veronique; Guardino, Ellie; Fang, Liang; Lu, Michael W.; Olsen, Steven; Blackwell, Kim</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1783-1791</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.  The antibody and the cytotoxic agent are conjugated by means of a stable linker.  METHODS: We randomly assigned patients with HER2-pos. advanced breast cancer, who had previously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine.  The primary end points were progression-free survival (as assessed by independent review), overall survival, and safety.  Secondary end points included progression-free survival (investigator-assessed), the objective response rate, and the time to symptom progression.  Two interim analyses of overall survival were conducted.  RESULTS: Among 991 randomly assigned patients, median progression-free survival as assessed by independent review was 9.6 mo with T-DM1 vs. 6.4 mo with lapatinib plus capecitabine (hazard ratio for progression or death from any cause, 0.65; 95% confidence interval [CI], 0.55 to 0.77; P<0.001), and median overall survival at the second interim anal. crossed the stopping boundary for efficacy (30.9 mo vs. 25.1 mo; hazard ratio for death from any cause, 0.68; 95% CI, 0.55 to 0.85; P<0.001).  The objective response rate was higher with T-DM1 (43.6%, vs. 30.8% with lapatinib plus capecitabine; P<0.001); results for all addnl. secondary end points favored T-DM1.  Rates of grade 3 or above were higher with lapatinib plus capecitabine than with T-DM1 (57% vs. 41%).  The incidences of thrombocytopenia and increased serum aminotransferase levels were higher with T-DM1, whereas the incidences of diarrhea, nausea, vomiting, and palmar-plantar erythrodysesthesia were higher with lapatinib plus capecitabine.  CONCLUSIONS: T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-pos. advanced breast cancer previously treated with trastuzumab and a taxane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGRhxRQ7JSJrVg90H21EOLACvtfcHk0ljfOYu3dtNWYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ekt73M&md5=3be5bac27a81b530442dc8a6b4a1f82e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1209124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1209124%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DGianni%26aufirst%3DL.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DWelslau%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26aulast%3DGuardino%26aufirst%3DE.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DS.%26aulast%3DBlackwell%26aufirst%3DK.%26atitle%3DTrastuzumab%2520Emtansine%2520for%2520HER2-positive%2520advanced%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1783%26epage%3D1791%26doi%3D10.1056%2Fnejmoa1209124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suciu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selleslag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venditti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voso, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fabritiis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagemeijer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoloni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramadan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemze, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Witte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, F.</span></span> <span> </span><span class="NLM_article-title">Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">972</span>– <span class="NLM_lpage">979</span>, <span class="refDoi"> DOI: 10.1200/jco.2015.64.0060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1200%2FJCO.2015.64.0060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=26811524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A280%3ADC%252BC28nkt12itw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=972-979&author=S.+Amadoriauthor=S.+Suciuauthor=D.+Selleslagauthor=F.+Aversaauthor=G.+Gaidanoauthor=M.+Mussoauthor=L.+Anninoauthor=A.+Vendittiauthor=M.+T.+Vosoauthor=C.+Mazzoneauthor=D.+Magroauthor=P.+De+Fabritiisauthor=P.+Muusauthor=G.+Alimenaauthor=M.+Manciniauthor=A.+Hagemeijerauthor=F.+Paoloniauthor=M.+Vignettiauthor=P.+Faziauthor=L.+Meertauthor=S.+M.+Ramadanauthor=R.+Willemzeauthor=T.+de+Witteauthor=F.+Baron&title=Gemtuzumab+ozogamicin+versus+best+supportive+care+in+older+patients+with+newly+diagnosed+acute+myeloid+leukemia+unsuitable+for+intensive+chemotherapy&doi=10.1200%2Fjco.2015.64.0060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial</span></div><div class="casAuthors">Amadori Sergio; Suciu Stefan; Selleslag Dominik; Aversa Franco; Gaidano Gianluca; Musso Maurizio; Annino Luciana; Venditti Adriano; Voso Maria Teresa; Mazzone Carla; Magro Domenico; De Fabritiis Paolo; Muus Petra; Alimena Giuliana; Mancini Marco; Hagemeijer Anne; Paoloni Francesca; Vignetti Marco; Fazi Paola; Meert Liv; Ramadan Safaa Mahmoud; Willemze Roel; de Witte Theo; Baron Frederic</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">972-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care (BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid leukemia unsuitable for intensive chemotherapy.  PATIENTS AND METHODS:  In this trial, patients at least 61 years old were centrally randomized (1:1) to receive either a single induction course of GO (6 mg/m(2) on day 1 and 3 mg/m(2) on day 8) or BSC.  Patients who did not progress after GO induction could receive up to eight monthly infusions of the immunoconjugate at 2 mg/m(2).  Randomization was stratified by age, WHO performance score, CD33 expression status, and center.  The primary end point was overall survival (OS) by intention-to-treat analysis.  RESULTS:  A total of 237 patients were randomly assigned (118 to GO and 119 to BSC).  The median OS was 4.9 months (95% CI, 4.2 to 6.8 months) in the GO group and 3.6 months (95% CI, 2.6 to 4.2 months) in the BSC group (hazard ratio, 0.69; 95% CI, 0.53 to 0.90; P = .005); the 1-year OS rate was 24.3% with GO and 9.7% with BSC.  The OS benefit with GO was consistent across most subgroups, and was especially apparent in patients with high CD33 expression status, in those with favorable/intermediate cytogenetic risk profile, and in women.  Overall, complete remission (CR [complete remission] + CRi [CR with incomplete recovery of peripheral blood counts]) occurred in 30 of 111 (27%) GO recipients.  The rates of serious adverse events (AEs) were similar in the two groups, and no excess mortality from AEs was observed with GO.  CONCLUSION:  First-line monotherapy with low-dose GO, as compared with BSC, significantly improved OS in older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy.  No unexpected AEs were identified and toxicity was manageable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQq1EguFmpL0eIHSmpohpd0fW6udTcc2eZx_m2he1YIN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nkt12itw%253D%253D&md5=43d7a399ece0fc79ad921ce9cfe226ac</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.64.0060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.64.0060%26sid%3Dliteratum%253Aachs%26aulast%3DAmadori%26aufirst%3DS.%26aulast%3DSuciu%26aufirst%3DS.%26aulast%3DSelleslag%26aufirst%3DD.%26aulast%3DAversa%26aufirst%3DF.%26aulast%3DGaidano%26aufirst%3DG.%26aulast%3DMusso%26aufirst%3DM.%26aulast%3DAnnino%26aufirst%3DL.%26aulast%3DVenditti%26aufirst%3DA.%26aulast%3DVoso%26aufirst%3DM.%2BT.%26aulast%3DMazzone%26aufirst%3DC.%26aulast%3DMagro%26aufirst%3DD.%26aulast%3DDe%2BFabritiis%26aufirst%3DP.%26aulast%3DMuus%26aufirst%3DP.%26aulast%3DAlimena%26aufirst%3DG.%26aulast%3DMancini%26aufirst%3DM.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DPaoloni%26aufirst%3DF.%26aulast%3DVignetti%26aufirst%3DM.%26aulast%3DFazi%26aufirst%3DP.%26aulast%3DMeert%26aufirst%3DL.%26aulast%3DRamadan%26aufirst%3DS.%2BM.%26aulast%3DWillemze%26aufirst%3DR.%26aulast%3Dde%2BWitte%26aufirst%3DT.%26aulast%3DBaron%26aufirst%3DF.%26atitle%3DGemtuzumab%2520ozogamicin%2520versus%2520best%2520supportive%2520care%2520in%2520older%2520patients%2520with%2520newly%2520diagnosed%2520acute%2520myeloid%2520leukemia%2520unsuitable%2520for%2520intensive%2520chemotherapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D972%26epage%3D979%26doi%3D10.1200%2Fjco.2015.64.0060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Inotuzumab ozogamicin: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1603</span>– <span class="NLM_lpage">1610</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0802-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1007%2Fs40265-017-0802-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=28819740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlGktL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1603-1610&author=Y.+N.+Lamb&title=Inotuzumab+ozogamicin%3A+First+global+approval&doi=10.1007%2Fs40265-017-0802-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Inotuzumab Ozogamicin: First Global Approval</span></div><div class="casAuthors">Lamb, Yvette N.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1603-1610</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">I.v. inotuzumab ozogamicin (Besponsa; Pfizer) is an anti-CD22 monoclonal antibody-calicheamicin conjugate that binds to CD22-expressing tumor cells.  Upon binding, the complex is internalized and the cytotoxic calicheamicin deriv. is released inside the cell, inducing double-strand DNA breakage and subsequent cell death.  In June 2017, the EMA granted inotuzumab ozogamicin approval as monotherapy for the treatment of adults with relapsed or refractory CD22-pos. B-cell precursor acute lymphoblastic leukemia (ALL).  The use of inotuzumab ozogamicin in adult patients with Philadelphia chromosome-pos., relapsed or refractory CD22-pos. B-cell precursor ALL is restricted to those who have failed treatment with at least one tyrosine kinase inhibitor.  Inotuzumab ozogamicin was granted priority review for the treatment of relapsed or refractory B-cell precursor ALL by the US FDA in Feb. 2017.  In the USA, a phase III trial evaluating inotuzumab ozogamicin in combination with frontline chemotherapy in adults with newly diagnosed B-cell ALL has recently been initiated and inotuzumab ozogamicin is under phase II evaluation in childhood CD22-pos. B-cell ALL.  Inotuzumab ozogamicin combination therapies are also being evaluated in the phase I/II or II setting in ALL and chronic myeloid leukemia and in the phase I setting in Burkitt's lymphoma.  This article summarizes the milestones in the development of inotuzumab ozogamicin leading to this first approval for ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSHnoFMpPaqbVg90H21EOLACvtfcHk0ljDb2-Bmm_Vmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlGktL3P&md5=76c6dbf41181e769901bbc313aabdb20</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0802-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0802-5%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DInotuzumab%2520ozogamicin%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D1603%26epage%3D1610%26doi%3D10.1007%2Fs40265-017-0802-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sehn, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamdar, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertzberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assouline, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozcan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penuel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulson, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matasar, M. J.</span></span> <span> </span><span class="NLM_article-title">Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1200/jco.19.00172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1200%2FJCO.19.00172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=31693429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslSktb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=155-165&author=L.+H.+Sehnauthor=A.+F.+Herreraauthor=C.+R.+Flowersauthor=M.+K.+Kamdarauthor=A.+McMillanauthor=M.+Hertzbergauthor=S.+Assoulineauthor=T.+M.+Kimauthor=W.+S.+Kimauthor=M.+Ozcanauthor=J.+Hirataauthor=E.+Penuelauthor=J.+N.+Paulsonauthor=J.+Chengauthor=G.+Kuauthor=M.+J.+Matasar&title=Polatuzumab+vedotin+in+relapsed+or+refractory+diffuse+large+B-cell+lymphoma&doi=10.1200%2Fjco.19.00172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma</span></div><div class="casAuthors">Sehn, Laurie H.; Herrera, Alex F.; Flowers, Christopher R.; Kaar, Manali K.; McMillan, Andrew; Hertzberg, Mark; Assouline, Sarit; Kim, Tae Min; Kim, Won Seog; Ozcan, Muhit; Hirata, Jamie; Penuel, Elicia; Paulson, Joseph N.; Cheng, Ji; Ku, Grace; Matasar, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-176</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, with limited treatment options.  The antibody-drug conjugate polatuzumab vedotin targets CD79b, a B-cell receptor component.  Safety and efficacy of polatuzumab vedotin with bendamustine and obinutuzumab (pola-BG) was evaluated in a single-arm cohort.  Polatuzumab vedotin combined with bendamustine and rituximab (pola-BR) was compared with bendamustine and rituximab (BR) in a randomly assigned cohort of patients with transplantation-ineligible R/R DLBCL (primary end point: independent review committee [IRC] assessed complete response [CR] rate at the end of treatment).  Duration of response, progression-free survival (PFS), and overall survival (OS) were analyzed using Kaplan-Meier and Cox regression methods.  Pola-BG and pola-BR had a tolerable safety profile.  The phase Ib/II pola-BG cohort (n = 27) had a CR rate of 29.6% and a median OS of 10.8 mo (median follow-up, 27.0 mo).  In the randomly assigned cohort (n = 80; 40 per arm), pola-BR patients had a significantly higher IRC-assessed CR rate (40.0% v 17.5%; P = .026) and longer IRC-assessed PFS (median, 9.5 v 3.7 mo; hazard ratio [HR], 0.36, 95% CI, 0.21 to 0.63; P < .001) and OS (median, 12.4 v 4.7 mo; HR, 0.42; 95% CI, 0.24 to 0.75; P = .002; median follow-up, 22.3 mo).  Pola-BR patients had higher rates of grade 3-4 neutropenia (46.2% v 33.3%), anemia (28.2% v 17.9%), and thrombocytopenia (41% v 23.1%), but similar grade 3-4 infections (23.1% v 20.5%), vs. the BR group.  Peripheral neuropathy assocd. with polatuzumab vedotin (43.6% of patients) was grade 1-2 and resolved in most patients.  Polatuzumab vedotin combined with BR resulted in a significantly higher CR rate and reduced the risk of death by 58% compared with BR in patients with transplantation-ineligible R/R DLBCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUa_nOL1QFFLVg90H21EOLACvtfcHk0ljDb2-Bmm_Vmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslSktb3L&md5=3e8d91c5458d187b189615090441f029</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2FJCO.19.00172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.19.00172%26sid%3Dliteratum%253Aachs%26aulast%3DSehn%26aufirst%3DL.%2BH.%26aulast%3DHerrera%26aufirst%3DA.%2BF.%26aulast%3DFlowers%26aufirst%3DC.%2BR.%26aulast%3DKamdar%26aufirst%3DM.%2BK.%26aulast%3DMcMillan%26aufirst%3DA.%26aulast%3DHertzberg%26aufirst%3DM.%26aulast%3DAssouline%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DOzcan%26aufirst%3DM.%26aulast%3DHirata%26aufirst%3DJ.%26aulast%3DPenuel%26aufirst%3DE.%26aulast%3DPaulson%26aufirst%3DJ.%2BN.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DKu%26aufirst%3DG.%26aulast%3DMatasar%26aufirst%3DM.%2BJ.%26atitle%3DPolatuzumab%2520vedotin%2520in%2520relapsed%2520or%2520refractory%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26spage%3D155%26epage%3D165%26doi%3D10.1200%2Fjco.19.00172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruether, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaig, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baranda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plimack, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milowsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartner, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melhem-Bertrandt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrylak, D. P.</span></span> <span> </span><span class="NLM_article-title">EV-101: A phase 1 study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1041</span>– <span class="NLM_lpage">1049</span>, <span class="refDoi"> DOI: 10.1200/jco.19.02044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1200%2FJCO.19.02044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=32031899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVSjsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=1041-1049&author=J.+Rosenbergauthor=S.+S.+Sridharauthor=J.+Zhangauthor=D.+Smithauthor=D.+Ruetherauthor=T.+W.+Flaigauthor=J.+Barandaauthor=J.+Langauthor=E.+R.+Plimackauthor=R.+Sanghaauthor=E.+I.+Heathauthor=J.+Merchanauthor=D.+I.+Quinnauthor=S.+Srinivasauthor=M.+Milowskyauthor=C.+Wuauthor=E.+M.+Gartnerauthor=P.+Zuoauthor=A.+Melhem-Bertrandtauthor=D.+P.+Petrylak&title=EV-101%3A+A+phase+1+study+of+single-agent+enfortumab+vedotin+in+patients+with+nectin-4-positive+solid+tumors%2C+including+metastatic+urothelial+carcinoma&doi=10.1200%2Fjco.19.02044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma</span></div><div class="casAuthors">Rosenberg, Jonathan; Sridhar, Srikala S.; Zhang, Jingsong; Smith, David; Ruether, Dean; Flaig, Thomas W.; Baranda, Joaquina; Lang, Joshua; Plimack, Elizabeth R.; Sangha, Randeep; Heath, Elisabeth I.; Merchan, Jamie; Quinn, David I.; Srinivas, Sandy; Milowsky, Matthew; Wu, Chunzhang; Gartner, Elaina M.; Zuo, Peiying; Melhem-Bertrandt, Amal; Petrylak, Daniel P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1041-1051</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose to assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV), a novel investigational antibody-drug conjugate that delivers the microtubule-disrupting agent, monomethyl auristatin E, to cells that express Nectin-4.  Methods EV-101 is a phase I dose escalation/expansion study that enrolled patients with Nectin-4-expressing solid tumors (eg, metastatic urothelial carcinoma [mUC]) who progressed on ≥ 1 prior chemotherapy regimen and/or programmed death-1 receptor/programmed death ligand-1 [PD-(L)1] inhibitor, including a cohort of patients with mUC who received prior anti-PD-(L)1 therapy.  Patients received escalating doses of EV up to 1.25 mg/kg on days 1, 8, and 15 of every 28-day cycle.  Primary objectives were evaluation of safety/tolerability and pharmacokinetics; antitumor activity was a secondary objective.  Results Enrolled patients with mUC (n = 155) were heavily pretreated, with 96% having prior platinum-based chemotherapy and 29% receiving ≥ 3 lines of prior treatment.  Maximum tolerated dose of EV was not established; however, the recommended phase II dose was identified as 1.25 mg/kg.  Rash, peripheral neuropathy, fatigue, alopecia, and nausea were the most common treatment-related adverse events (TRAEs); the most common TRAEs were grade 1-2 in severity.  Among the 112 patients with mUC treated with single-agent EV 1.25 mg/kg, the investigator-assessed confirmed objective response rate (ORR) was 43%, and duration of response was 7.4 mo.  Median overall survival (OS) was 12.3 mo, and the OS rate at 1 yr was 51.8%.  Similar ORR and estd. median OS were obsd. in patients ≥ 75 years of age with and without prior anti-PD-(L)1 treatment, liver metastases, or upper-tract disease.  Conclusion Single-agent EV was generally well tolerated and provided clin. meaningful and durable responses in patients with mUC; survival data are encouraging.  A pivotal phase II and a confirmatory phase III study are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosZiEQO7bO-7Vg90H21EOLACvtfcHk0ljp9CW7nIihvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVSjsb7K&md5=371071def1de7c83ffda412e8df9fb59</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1200%2FJCO.19.02044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.19.02044%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DJ.%26aulast%3DSridhar%26aufirst%3DS.%2BS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRuether%26aufirst%3DD.%26aulast%3DFlaig%26aufirst%3DT.%2BW.%26aulast%3DBaranda%26aufirst%3DJ.%26aulast%3DLang%26aufirst%3DJ.%26aulast%3DPlimack%26aufirst%3DE.%2BR.%26aulast%3DSangha%26aufirst%3DR.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DMerchan%26aufirst%3DJ.%26aulast%3DQuinn%26aufirst%3DD.%2BI.%26aulast%3DSrinivas%26aufirst%3DS.%26aulast%3DMilowsky%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DGartner%26aufirst%3DE.%2BM.%26aulast%3DZuo%26aufirst%3DP.%26aulast%3DMelhem-Bertrandt%26aufirst%3DA.%26aulast%3DPetrylak%26aufirst%3DD.%2BP.%26atitle%3DEV-101%253A%2520A%2520phase%25201%2520study%2520of%2520single-agent%2520enfortumab%2520vedotin%2520in%2520patients%2520with%2520nectin-4-positive%2520solid%2520tumors%252C%2520including%2520metastatic%2520urothelial%2520carcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26spage%3D1041%26epage%3D1049%26doi%3D10.1200%2Fjco.19.02044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nooka, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdallah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callander, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lendvai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sborov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvannasankha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnulf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortum, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Otero, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usmani, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quach, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorhees, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piontek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dettman, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposti, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opalinska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A. D.</span></span> <span> </span><span class="NLM_article-title">Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAM-2): a two-arm, randomized, open-label, phase 2 study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/s1470-2045(19)30788-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1016%2FS1470-2045%2819%2930788-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=31859245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVajtLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=207-221&author=S.+Lonialauthor=H.+C.+Leeauthor=A.+Badrosauthor=S.+Trudelauthor=A.+K.+Nookaauthor=A.+Chariauthor=A.+Abdallahauthor=N.+Callanderauthor=N.+Lendvaiauthor=D.+Sborovauthor=A.+Suvannasankhaauthor=K.+Weiselauthor=L.+Karlinauthor=E.+Libbyauthor=B.+Arnulfauthor=T.+Faconauthor=C.+Hulinauthor=K.+M.+Kortumauthor=P.+Rodriguez-Oteroauthor=S.+Z.+Usmaniauthor=P.+Hariauthor=R.+Bazauthor=H.+Quachauthor=P.+Moreauauthor=P.+M.+Voorheesauthor=I.+Guptaauthor=A.+Hoosauthor=E.+Zhiauthor=J.+Baronauthor=T.+Piontekauthor=E.+Lewisauthor=R.+C.+Jewellauthor=E.+J.+Dettmanauthor=R.+Popatauthor=S.+D.+Espostiauthor=J.+Opalinskaauthor=P.+Richardsonauthor=A.+D.+Cohen&title=Belantamab+mafodotin+for+relapsed+or+refractory+multiple+myeloma+%28DREAM-2%29%3A+a+two-arm%2C+randomized%2C+open-label%2C+phase+2+study&doi=10.1016%2Fs1470-2045%2819%2930788-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study</span></div><div class="casAuthors">Lonial, Sagar; Lee, Hans C.; Badros, Ashraf; Trudel, Suzanne; Nooka, Ajay K.; Chari, Ajai; Abdallah, Al-Ola; Callander, Natalie; Lendvai, Nikoletta; Sborov, Douglas; Suvannasankha, Attaya; Weisel, Katja; Karlin, Lionel; Libby, Edward; Arnulf, Bertrand; Facon, Thierry; Hulin, Cyrille; Kortum, K. Martin; Rodriguez-Otero, Paula; Usmani, Saad Z.; Hari, Parameswaran; Baz, Rachid; Quach, Hang; Moreau, Philippe; Voorhees, Peter M.; Gupta, Ira; Hoos, Axel; Zhi, Eric; Baron, January; Piontek, Trisha; Lewis, Eric; Jewell, Roxanne C.; Dettman, Elisha J.; Popat, Rakesh; Esposti, Simona Degli; Opalinska, Joanna; Richardson, Paul; Cohen, Adam D.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-221</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma.  We further investigated the safety and activity of belantamab mafodotin in the DREAMM-2 study.  DREAMM-2 is an open-label, two-arm, phase 2 study done at 58 multiple myeloma specialty centers in eight countries.  Patients (aged ≥18 years) with relapsed or refractory multiple myeloma with disease progression after three or more lines of therapy and who were refractory to immunomodulatory drugs and proteasome inhibitors, and refractory or intolerant (or both) to an anti-CD38 monoclonal antibody with an Eastern Cooperative Oncol. Group performance status of 0-2 were recruited, centrally randomly assigned (1:1) with permuted blocks (block size 4), and stratified by previous lines of therapy (≤4 vs >4) and cytogenetic features to receive 2·5 mg/kg or 3·4 mg/kg belantamab mafodotin via i.v. infusion every 3 wk on day 1 of each cycle until disease progression or unacceptable toxicity.  The intention-to-treat population comprised all randomised patients, regardless of treatment administration.  The safety population comprised all patients who received at least one dose of belantamab mafodotin.  The primary outcome was the proportion of randomly assigned patients in the intention-to-treat population who achieved an overall response, as assessed by an independent review committee.  This study is registered with ClinicalTrials.gov, NCT03525678, and is ongoing.  Between June 18, 2018, and Jan 2, 2019, 293 patients were screened and 196 were included in the intention-to-treat population (97 in the 2·5 mg/kg cohort and 99 in the 3·4 mg/kg cohort).  As of June 21, 2019 (the primary anal. data cutoff date), 30 (31%; 97·5% CI 20·8-42·6) of 97 patients in the 2·5 mg/kg cohort and 34 (34%; 23·9-46·0) of 99 patients in the 3·4 mg/kg cohort achieved an overall response.  The most common grade 3-4 adverse events in the safety population were keratopathy (in 26 [27%] of 95 patients in the 2·5 mg/kg cohort and 21 [21%] of 99 patients in the 3·4 mg/kg cohort), thrombocytopenia (19 [20%] and 33 [33%]), and anemia (19 [20%] and 25 [25%]); 38 (40%) of 95 patients in the 2·5 mg/kg cohort and 47 (47%) of 99 in the 3·4 mg/kg cohort reported serious adverse events.  Two deaths were potentially treatment related (one case of sepsis in the 2·5 mg/kg cohort and one case of haemophagocytic lymphohistiocytosis in the 3·4 mg/kg cohort).  Single-agent belantamab mafodotin shows anti-myeloma activity with a manageable safety profile in patients with relapsed or refractory multiple myeloma.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX5xuk-7bebbVg90H21EOLACvtfcHk0ljp9CW7nIihvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVajtLjN&md5=cef83b6e32d56ef8410f339855314db1</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930788-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930788-0%26sid%3Dliteratum%253Aachs%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DH.%2BC.%26aulast%3DBadros%26aufirst%3DA.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DNooka%26aufirst%3DA.%2BK.%26aulast%3DChari%26aufirst%3DA.%26aulast%3DAbdallah%26aufirst%3DA.%26aulast%3DCallander%26aufirst%3DN.%26aulast%3DLendvai%26aufirst%3DN.%26aulast%3DSborov%26aufirst%3DD.%26aulast%3DSuvannasankha%26aufirst%3DA.%26aulast%3DWeisel%26aufirst%3DK.%26aulast%3DKarlin%26aufirst%3DL.%26aulast%3DLibby%26aufirst%3DE.%26aulast%3DArnulf%26aufirst%3DB.%26aulast%3DFacon%26aufirst%3DT.%26aulast%3DHulin%26aufirst%3DC.%26aulast%3DKortum%26aufirst%3DK.%2BM.%26aulast%3DRodriguez-Otero%26aufirst%3DP.%26aulast%3DUsmani%26aufirst%3DS.%2BZ.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DBaz%26aufirst%3DR.%26aulast%3DQuach%26aufirst%3DH.%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DVoorhees%26aufirst%3DP.%2BM.%26aulast%3DGupta%26aufirst%3DI.%26aulast%3DHoos%26aufirst%3DA.%26aulast%3DZhi%26aufirst%3DE.%26aulast%3DBaron%26aufirst%3DJ.%26aulast%3DPiontek%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DE.%26aulast%3DJewell%26aufirst%3DR.%2BC.%26aulast%3DDettman%26aufirst%3DE.%2BJ.%26aulast%3DPopat%26aufirst%3DR.%26aulast%3DEsposti%26aufirst%3DS.%2BD.%26aulast%3DOpalinska%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DCohen%26aufirst%3DA.%2BD.%26atitle%3DBelantamab%2520mafodotin%2520for%2520relapsed%2520or%2520refractory%2520multiple%2520myeloma%2520%2528DREAM-2%2529%253A%2520a%2520two-arm%252C%2520randomized%252C%2520open-label%252C%2520phase%25202%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2020%26volume%3D21%26spage%3D207%26epage%3D221%26doi%3D10.1016%2Fs1470-2045%2819%2930788-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahdat, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isakoff, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shaughnessy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroose, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santin, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweidan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iannone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washkowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinsky, K.</span></span> <span> </span><span class="NLM_article-title">Dacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1814213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1056%2FNEJMoa1814213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=30786188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvVSjs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=741-751&author=A.+Bardiaauthor=I.+A.+Mayerauthor=L.+T.+Vahdatauthor=S.+M.+Tolaneyauthor=S.+J.+Isakoffauthor=J.+R.+Diamondauthor=J.+O%E2%80%99Shaughnessyauthor=R.+L.+Morooseauthor=A.+D.+Santinauthor=V.+G.+Abramsonauthor=N.+C.+Shahauthor=H.+S.+Rugoauthor=D.+M.+Goldenbergauthor=A.+M.+Sweidanauthor=R.+Iannoneauthor=S.+Washkowitzauthor=R.+M.+Sharkeyauthor=W.+A.+Wegenerauthor=K.+Kalinsky&title=Dacituzumab+govitecan-hziy+in+refractory+metastatic+triple-negative+breast+cancer&doi=10.1056%2Fnejmoa1814213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer</span></div><div class="casAuthors">Bardia, A.; Mayer, I. A.; Vahdat, L. T.; Tolaney, S. M.; Isakoff, S. J.; Diamond, J. R.; O'Shaughnessy, J.; Moroose, R. L.; Santin, A. D.; Abramson, V. G.; Shah, N. C.; Rugo, H. S.; Goldenberg, D. M.; Sweidan, A. M.; Iannone, R.; Washkowitz, S.; Sharkey, R. M.; Wegener, W. A.; Kalinsky, K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">741-751</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Std. chemotherapy is assocd. with low response rates and short progression-free survival among patients with pretreated metastatic triple-neg. breast cancer.  Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker.  Sacituzumab govitecan-hziy enables delivery of high concns. of SN-38 to tumors.  Methods We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy i.v. on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects.  A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kg of body wt. after receiving at least two previous anticancer therapies for metastatic triple-neg. breast cancer.  The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clin. benefit rate (defined as a complete or partial response or stable disease for at least 6 mo); progression-free survival; and overall survival.  Post hoc analyses detd. the response rate and duration, which were assessed by blinded independent central review. results The 108 patients with triple-neg. breast cancer had received a median of 3 previous therapies (range, 2 to 10).  Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events.  Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia.  The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 mo (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 mo, resp.  The clin. benefit rate was 45.4%.  Median progression-free survival was 5.5 mo (95% CI, 4.1 to 6.3), and overall survival was 13.0 mo (95% CI, 11.2 to 13.7).  Conclusions Sacituzumab govitecan-hziy was assocd. with durable objective responses in patients with heavily pretreated metastatic triple-neg. breast cancer.  Myelotoxic effects were the main adverse reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAgQWEPOcqfrVg90H21EOLACvtfcHk0liJJzHFfNLqsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvVSjs7w%253D&md5=75edc2c274aef0ab90dd2aaf230dabac</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1814213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1814213%26sid%3Dliteratum%253Aachs%26aulast%3DBardia%26aufirst%3DA.%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DVahdat%26aufirst%3DL.%2BT.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DIsakoff%26aufirst%3DS.%2BJ.%26aulast%3DDiamond%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DMoroose%26aufirst%3DR.%2BL.%26aulast%3DSantin%26aufirst%3DA.%2BD.%26aulast%3DAbramson%26aufirst%3DV.%2BG.%26aulast%3DShah%26aufirst%3DN.%2BC.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26aulast%3DSweidan%26aufirst%3DA.%2BM.%26aulast%3DIannone%26aufirst%3DR.%26aulast%3DWashkowitz%26aufirst%3DS.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DWegener%26aufirst%3DW.%2BA.%26aulast%3DKalinsky%26aufirst%3DK.%26atitle%3DDacituzumab%2520govitecan-hziy%2520in%2520refractory%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26spage%3D741%26epage%3D751%26doi%3D10.1056%2Fnejmoa1814213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurutani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denduluri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab deruxtecan in previously treated HER2-positive breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1914510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1056%2FNEJMoa1914510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=31825192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlChur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=610-621&author=S.+Modiauthor=C.+Sauraauthor=T.+Yamashitaauthor=Y.+H.+Parkauthor=S.-B.+Kimauthor=K.+Tamuraauthor=F.+Andreauthor=H.+Iwataauthor=Y.+Itoauthor=J.+Tsurutaniauthor=J.+Sohnauthor=N.+Denduluriauthor=C.+Perrinauthor=K.+Aogiauthor=E.+Tokunagaauthor=S.-A.+Imauthor=K.+S.+Leeauthor=S.+A.+Hurvitzauthor=J.+Cortesauthor=C.+Leeauthor=S.+Chenauthor=L.+Zhangauthor=J.+Shahidiauthor=A.+Yverauthor=I.+Krop&title=Trastuzumab+deruxtecan+in+previously+treated+HER2-positive+breast+cancer&doi=10.1056%2Fnejmoa1914510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab deruxtecan in previously treated HER2-positive breast cancer</span></div><div class="casAuthors">Modi, S.; Saura, C.; Yamashita, T.; Park, Y. H.; Kim, S.-B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; Sohn, J.; Denduluri, N.; Perrin, C.; Aogi, K.; Tokunaga, E.; Im, S.-A.; Lee, K. S.; Hurvitz, S. A.; Cortes, J.; Lee, C.; Chen, S.; Zhang, L.; Shahidi, J.; Yver, A.; Krop, I.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">610-621</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathol. documented HER2-pos. metastatic breast cancer who had received previous treatment with trastuzumab emtansine.  In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose.  Key secondary end points were the disease-control rate, clin.-benefit rate, duration of response and progression-free survival, and safety. results Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kg of body wt.).  During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%).  On independent adjudication, the trial drug was assocd. with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). conclusions Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-pos. metastatic breast cancer.  In addn. to nausea and myelosuppression, interstitial lung disease was obsd. in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Uc2NDB76h7Vg90H21EOLACvtfcHk0liJJzHFfNLqsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlChur8%253D&md5=0b142802a47c4f50f0b2cdc82f22ce87</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1914510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1914510%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DS.%26aulast%3DSaura%26aufirst%3DC.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DKim%26aufirst%3DS.-B.%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DTsurutani%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DJ.%26aulast%3DDenduluri%26aufirst%3DN.%26aulast%3DPerrin%26aufirst%3DC.%26aulast%3DAogi%26aufirst%3DK.%26aulast%3DTokunaga%26aufirst%3DE.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShahidi%26aufirst%3DJ.%26aulast%3DYver%26aufirst%3DA.%26aulast%3DKrop%26aufirst%3DI.%26atitle%3DTrastuzumab%2520deruxtecan%2520in%2520previously%2520treated%2520HER2-positive%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D610%26epage%3D621%26doi%3D10.1056%2Fnejmoa1914510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chowdari, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprakasam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sufi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derwin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passmore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangan, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardarelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangwar, S.</span></span> <span> </span><span class="NLM_article-title">Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">466</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1016%2Fj.bmcl.2018.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=30579797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFygu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=466-470&author=N.+S.+Chowdariauthor=C.+Panauthor=C.+Raoauthor=D.+R.+Langleyauthor=P.+Sivaprakasamauthor=B.+Sufiauthor=D.+Derwinauthor=Y.+Wangauthor=E.+Kwokauthor=D.+Passmoreauthor=V.+S.+Ranganauthor=S.+Deshpandeauthor=P.+Cardarelliauthor=G.+Viteauthor=S.+Gangwar&title=Uncialamycin+as+a+novel+payload+for+antibody+drug+conjugate+%28ADC%29+based+targeted+cancer+therapy&doi=10.1016%2Fj.bmcl.2018.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy</span></div><div class="casAuthors">Chowdari, Naidu S.; Pan, Chin; Rao, Chetana; Langley, David R.; Sivaprakasam, Prasanna; Sufi, Bilal; Derwin, Daniel; Wang, Yichong; Kwok, Eilene; Passmore, David; Rangan, Vangipuram S.; Deshpande, Shrikant; Cardarelli, Pina; Vite, Gregory; Gangwar, Sanjeev</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">466-470</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Uncialamycin analogs were evaluated as potential cytotoxic agents in an antibody-drug conjugate (ADC) approach to treating human cancer.  These analogs were synthesized using Hauser annulations of substituted phthalides as a key step.  A highly potent uncialamycin analog 3c with a valine-citrulline dipeptide linker was conjugated to an anti-mesothelin monoclonal antibody (mAb) through lysines to generate a meso-13 conjugate.  This conjugate demonstrated subnanomolar potency (IC50 = 0.88 nM, H226 cell line) in in vitro cytotoxicity expts. with good immunol. specificity to mesothelin-pos. lung cancer cell lines.  The potency and mechanism of action of this uncialamycin class of enediyne antitumor antibiotics make them attractive payloads in ADC-based cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqBfRZz2Cfk7Vg90H21EOLACvtfcHk0liJJzHFfNLqsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFygu7rJ&md5=371237eb33fc1f2dd6230a8649d75233</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DChowdari%26aufirst%3DN.%2BS.%26aulast%3DPan%26aufirst%3DC.%26aulast%3DRao%26aufirst%3DC.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DSivaprakasam%26aufirst%3DP.%26aulast%3DSufi%26aufirst%3DB.%26aulast%3DDerwin%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKwok%26aufirst%3DE.%26aulast%3DPassmore%26aufirst%3DD.%26aulast%3DRangan%26aufirst%3DV.%2BS.%26aulast%3DDeshpande%26aufirst%3DS.%26aulast%3DCardarelli%26aufirst%3DP.%26aulast%3DVite%26aufirst%3DG.%26aulast%3DGangwar%26aufirst%3DS.%26atitle%3DUncialamycin%2520as%2520a%2520novel%2520payload%2520for%2520antibody%2520drug%2520conjugate%2520%2528ADC%2529%2520based%2520targeted%2520cancer%2520therapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D466%26epage%3D470%26doi%3D10.1016%2Fj.bmcl.2018.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span> <span> </span><span class="NLM_article-title">The development of pyrrolobenzodiazepines as antitumour agents</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">744</span>, <span class="refDoi"> DOI: 10.1517/13543784.2011.573477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1517%2F13543784.2011.573477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=21457108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVSktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=733-744&author=J.+A.+Hartley&title=The+development+of+pyrrolobenzodiazepines+as+antitumour+agents&doi=10.1517%2F13543784.2011.573477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The development of pyrrolobenzodiazepines as antitumour agents</span></div><div class="casAuthors">Hartley, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">733-744</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: DNA interacting agents play a major role in cancer chemotherapy, either as single agents, in combination drug regimens, or as components of novel targeted therapies.  The search for more selective and efficacious drugs that can deliver crit. DNA damage with minimal side effects continues.  Areas covered: The development of the pyrrolobenzodiazepines (PBDs) from their discovery as natural products in the 1960s, through synthetic PBD monomers, PBD hybrids and conjugates, and PBD dimers is described.  The latter mols. are capable of forming sequence selective, non-distorting and potently cytotoxic DNA interstrand cross-links in the minor groove of DNA.  In particular, the development of PBD dimer SJG-136 (SG2000), currently in Phase II clin. trials, is presented.  Potential future cancer therapeutic applications of PBDs, including their use as components of targeting strategies, are also discussed.  Expert opinion: The culmination of over four decades of study on structure--activity relationships of PBDs has led to a detailed understanding of how to introduce structural modification to enhance biol. activity and potency.  The challenge for the next phase in the development of the PBDs is to harness this activity and potency in a new generation of cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi0QG1axF_kLVg90H21EOLACvtfcHk0lgno4CbvsOeqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVSktbc%253D&md5=bb7cf4096261862fe33b22f49c16c137</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.573477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.573477%26sid%3Dliteratum%253Aachs%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520development%2520of%2520pyrrolobenzodiazepines%2520as%2520antitumour%2520agents%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26spage%3D733%26epage%3D744%26doi%3D10.1517%2F13543784.2011.573477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mantaj, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span> <span> </span><span class="NLM_article-title">From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs)</span>. <i>Angew. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1002/anie.201510610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1002%2Fanie.201510610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVGitrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=462-488&author=J.+Mantajauthor=P.+J.+M.+Jacksonauthor=K.+M.+Rahmanauthor=D.+E.+Thurston&title=From+anthramycin+to+pyrrolobenzodiazepine+%28PBD%29-containing+antibody-drug+conjugates+%28ADCs%29&doi=10.1002%2Fanie.201510610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)</span></div><div class="casAuthors">Mantaj, Julia; Jackson, Paul J. M.; Rahman, Khondaker M.; Thurston, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">462-488</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a family of sequence-selective DNA minor-groove binding agents that form a covalent aminal bond between their C11-position and the C2-NH2 groups of guanine bases.  The first example of a PBD monomer, the natural product anthramycin, was discovered in the 1960s, and the best known PBD dimer, SJG-136 (also known as SG2000, NSC 694501 or BN2629), was synthesized in the 1990s and has recently completed Phase II clin. trials in patients with leukemia and ovarian cancer.  More recently, PBD dimer analogs are being attached to tumor-targeting antibodies to create antibody-drug conjugates (ADCs), a no. of which are now in clin. trials, with many others in pre-clin. development.  This Review maps the development from anthramycin to the first PBD dimers, and then to PBD-contg. ADCs, and explores both structure-activity relationships (SARs) and the biol. of PBDs, and the strategies for their use as payloads for ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9tjTimo4Cv7Vg90H21EOLACvtfcHk0lgno4CbvsOeqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVGitrnO&md5=8a87ad3c033b2a20798c861accba46a6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fanie.201510610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201510610%26sid%3Dliteratum%253Aachs%26aulast%3DMantaj%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DP.%2BJ.%2BM.%26aulast%3DRahman%26aufirst%3DK.%2BM.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DFrom%2520anthramycin%2520to%2520pyrrolobenzodiazepine%2520%2528PBD%2529-containing%2520antibody-drug%2520conjugates%2520%2528ADCs%2529%26jtitle%3DAngew.%2520Chem.%26date%3D2017%26volume%3D56%26spage%3D462%26epage%3D488%26doi%3D10.1002%2Fanie.201510610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiske, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholas, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okeley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1256</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1021/bc400217g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc400217g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFKjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=1256-1263&author=S.+C.+Jeffreyauthor=P.+J.+Burkeauthor=R.+P.+Lyonauthor=D.+W.+Meyerauthor=D.+Sussmanauthor=M.+Andersonauthor=J.+H.+Hunterauthor=C.+I.+Leiskeauthor=J.+B.+Miyamotoauthor=N.+D.+Nicholasauthor=N.+M.+Okeleyauthor=R.+J.+Sandersonauthor=I.+J.+Stoneauthor=W.+Zengauthor=S.+J.+Gregsonauthor=L.+Mastersonauthor=A.+C.+Tiberghienauthor=P.+W.+Howardauthor=D.+E.+Thurstonauthor=C.-L.+Lawauthor=P.+D.+Senter&title=A+potent+anti-CD70+antibody-drug+conjugate+combining+a+dimeric+pyrrolobenzodiazepine+drug+with+site-specific+conjugation+technology&doi=10.1021%2Fbc400217g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology</span></div><div class="casAuthors">Jeffrey, Scott C.; Burke, Patrick J.; Lyon, Robert P.; Meyer, David W.; Sussman, Django; Anderson, Martha; Hunter, Joshua H.; Leiske, Chris I.; Miyamoto, Jamie B.; Nicholas, Nicole D.; Okeley, Nicole M.; Sanderson, Russell J.; Stone, Ivan J.; Zeng, Weiping; Gregson, Stephen J.; Masterson, Luke; Tiberghien, Arnaud C.; Howard, Philip W.; Thurston, David E.; Law, Che-Leung; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1256-1263</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A highly cytotoxic DNA crosslinking pyrrolobenzodiazepine (PBD) dimer with a valine-alanine dipeptide linker was conjugated to the anti-CD70 h1F6 mAb either through endogenous interchain cysteines or, site-specifically, through engineered cysteines at position 239 of the heavy chains.  The h1F6239C-PBD conjugation strategy proved to be superior to interchain cysteine conjugation, affording an antibody-drug conjugate (ADC) with high uniformity in drug-loading and low levels of aggregation.  In vitro cytotoxicity expts. demonstrated that the h1F6239C-PBD was potent and immunol. specific on CD70-pos. renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL) cell lines.  The conjugate was resistant to drug loss in plasma and in circulation, and had a pharmacokinetic profile closely matching that of the parental h1F6239C antibody capped with N-ethylmaleimide (NEM).  Evaluation in CD70-pos. RCC and NHL mouse xenograft models showed pronounced antitumor activities at single or weekly doses as low as 0.1 mg/kg of ADC.  The ADC was tolerated at 2.5 mg/kg.  These results demonstrate that PBDs can be effectively used for antibody-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVruNGtWHpsbVg90H21EOLACvtfcHk0lgno4CbvsOeqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFKjs7c%253D&md5=31841b0267e41ae861eaf05240c97b15</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fbc400217g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc400217g%26sid%3Dliteratum%253Aachs%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DMeyer%26aufirst%3DD.%2BW.%26aulast%3DSussman%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DJ.%2BH.%26aulast%3DLeiske%26aufirst%3DC.%2BI.%26aulast%3DMiyamoto%26aufirst%3DJ.%2BB.%26aulast%3DNicholas%26aufirst%3DN.%2BD.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DStone%26aufirst%3DI.%2BJ.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26aulast%3DLaw%26aufirst%3DC.-L.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DA%2520potent%2520anti-CD70%2520antibody-drug%2520conjugate%2520combining%2520a%2520dimeric%2520pyrrolobenzodiazepine%2520drug%2520with%2520site-specific%2520conjugation%2520technology%26jtitle%3DBioconjugate%2520Chem.%26date%3D2013%26volume%3D24%26spage%3D1256%26epage%3D1263%26doi%3D10.1021%2Fbc400217g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankovich, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aujay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bheddah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escarpe, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laysang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Molina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pysz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slingerland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torgov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foord, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jassem, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badzio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czapiewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harpole, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowlati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massion, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travis, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietanza, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stull, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dylla, S. J.</span></span> <span> </span><span class="NLM_article-title">A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">302ra136</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aac9459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1126%2Fscitranslmed.aac9459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=26311731" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=302ra136&author=L.+R.+Saundersauthor=A.+J.+Bankovichauthor=W.+C.+Andersonauthor=M.+A.+Aujayauthor=S.+Bheddahauthor=K.+Blackauthor=R.+Desaiauthor=P.+A.+Escarpeauthor=J.+Hamplauthor=A.+Laysangauthor=D.+Liuauthor=J.+Lopez-Molinaauthor=M.+Miltonauthor=A.+Parkauthor=M.+A.+Pyszauthor=H.+Shaoauthor=B.+Slingerlandauthor=M.+Torgovauthor=S.+A.+Williamsauthor=O.+Foordauthor=P.+Howardauthor=J.+Jassemauthor=A.+Badzioauthor=P.+Czapiewskiauthor=D.+H.+Harpoleauthor=A.+Dowlatiauthor=P.+P.+Massionauthor=W.+D.+Travisauthor=M.+C.+Pietanzaauthor=J.+T.+Poirierauthor=C.+M.+Rudinauthor=R.+A.+Stullauthor=S.+J.+Dylla&title=A+DLL3-targeted+antibody-drug+conjugate+eradicates+high-grade+pulmonary+neuroendocrine+tumor-initiating+cells+in+vivo&doi=10.1126%2Fscitranslmed.aac9459"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aac9459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aac9459%26sid%3Dliteratum%253Aachs%26aulast%3DSaunders%26aufirst%3DL.%2BR.%26aulast%3DBankovich%26aufirst%3DA.%2BJ.%26aulast%3DAnderson%26aufirst%3DW.%2BC.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBheddah%26aufirst%3DS.%26aulast%3DBlack%26aufirst%3DK.%26aulast%3DDesai%26aufirst%3DR.%26aulast%3DEscarpe%26aufirst%3DP.%2BA.%26aulast%3DHampl%26aufirst%3DJ.%26aulast%3DLaysang%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DLopez-Molina%26aufirst%3DJ.%26aulast%3DMilton%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DA.%26aulast%3DPysz%26aufirst%3DM.%2BA.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DSlingerland%26aufirst%3DB.%26aulast%3DTorgov%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%2BA.%26aulast%3DFoord%26aufirst%3DO.%26aulast%3DHoward%26aufirst%3DP.%26aulast%3DJassem%26aufirst%3DJ.%26aulast%3DBadzio%26aufirst%3DA.%26aulast%3DCzapiewski%26aufirst%3DP.%26aulast%3DHarpole%26aufirst%3DD.%2BH.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DMassion%26aufirst%3DP.%2BP.%26aulast%3DTravis%26aufirst%3DW.%2BD.%26aulast%3DPietanza%26aufirst%3DM.%2BC.%26aulast%3DPoirier%26aufirst%3DJ.%2BT.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DStull%26aufirst%3DR.%2BA.%26aulast%3DDylla%26aufirst%3DS.%2BJ.%26atitle%3DA%2520DLL3-targeted%2520antibody-drug%2520conjugate%2520eradicates%2520high-grade%2520pulmonary%2520neuroendocrine%2520tumor-initiating%2520cells%2520in%2520vivo%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26spage%3D302ra136%26doi%3D10.1126%2Fscitranslmed.aac9459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishkin, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteman, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovtun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audette, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modafferi, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinkas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldmacher, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span> <span> </span><span class="NLM_article-title">A new class of antibody–drug conjugates with potent DNA alkylating activity</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1870</span>– <span class="NLM_lpage">1878</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-16-0184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1158%2F1535-7163.MCT-16-0184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=27216304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oks77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=1870-1878&author=M.+L.+Millerauthor=N.+E.+Fishkinauthor=W.+Liauthor=K.+R.+Whitemanauthor=Y.+Kovtunauthor=E.+E.+Reidauthor=K.+E.+Archerauthor=E.+K.+Maloneyauthor=C.+A.+Audetteauthor=M.+F.+Mayoauthor=A.+Wilhelmauthor=H.+A.+Modafferiauthor=R.+Singhauthor=J.+Pinkasauthor=V.+Goldmacherauthor=J.+M.+Lambertauthor=R.+V.+J.+Chari&title=A+new+class+of+antibody%E2%80%93drug+conjugates+with+potent+DNA+alkylating+activity&doi=10.1158%2F1535-7163.mct-16-0184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity</span></div><div class="casAuthors">Miller, Michael L.; Fishkin, Nathan E.; Li, Wei; Whiteman, Kathleen R.; Kovtun, Yelena; Reid, Emily E.; Archer, Katie E.; Maloney, Erin K.; Audette, Charlene A.; Mayo, Michele F.; Wilhelm, Alan; Modafferi, Holly A.; Singh, Rajeeva; Pinkas, Jan; Goldmacher, Victor; Lambert, John M.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1870-1878</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The promise of tumor-selective delivery of cytotoxic agents in the form of antibody-drug conjugates (ADC) has now been realized, evidenced by the approval of two ADCs, both of which incorporate highly cytotoxic tubulin-interacting agents, for cancer therapy.  An ongoing challenge remains in identifying potent agents with alternative mechanisms of cell killing that can provide ADCs with high therapeutic indexes and favorable tolerability.  Here, we describe the development of a new class of potent DNA alkylating agents that meets these objectives.  Through chem. design, we changed the mechanism of action of our novel DNA crosslinking agent to a monofunctional DNA alkylator.  This modification, coupled with linker optimization, generated ADCs that were well tolerated in mice and demonstrated robust antitumor activity in multiple tumor models at doses 1.5% to 3.5% of maximally tolerated levels.  These properties underscore the considerable potential of these purpose-created, unique DNA-interacting conjugates for broadening the clin. application of ADC technol.  Mol Cancer Ther; 15(8); 1870-8. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt5MUcMyl9MbVg90H21EOLACvtfcHk0lilrtoobDTlOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oks77F&md5=39217fa47540ea33e2c7c25d57daa19c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0184%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DFishkin%26aufirst%3DN.%2BE.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DReid%26aufirst%3DE.%2BE.%26aulast%3DArcher%26aufirst%3DK.%2BE.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DMayo%26aufirst%3DM.%2BF.%26aulast%3DWilhelm%26aufirst%3DA.%26aulast%3DModafferi%26aufirst%3DH.%2BA.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DPinkas%26aufirst%3DJ.%26aulast%3DGoldmacher%26aufirst%3DV.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26atitle%3DA%2520new%2520class%2520of%2520antibody%25E2%2580%2593drug%2520conjugates%2520with%2520potent%2520DNA%2520alkylating%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D1870%26epage%3D1878%26doi%3D10.1158%2F1535-7163.mct-16-0184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">McDonald, I. M.</span>; <span class="NLM_string-name">Chowdari, N. S.</span>; <span class="NLM_string-name">Tram, H.</span>; <span class="NLM_string-name">Borzilleri, R. M.</span>; <span class="NLM_string-name">Gangwar, S.</span></span> <span> </span><span class="NLM_article-title">Benzodiazepine Dimers, Conjugates Thereof, and Methods of Making and Using</span>. U.S. Patent <span class="NLM_patent">9,527,871 B2</span>, Dec 27, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Zhang&author=I.+M.+McDonald&author=N.+S.+Chowdari&author=H.+Tram&author=R.+M.+Borzilleri&author=S.+Gangwar&title=Benzodiazepine+Dimers%2C+Conjugates+Thereof%2C+and+Methods+of+Making+and+Using"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DBenzodiazepine%2520Dimers%252C%2520Conjugates%2520Thereof%252C%2520and%2520Methods%2520of%2520Making%2520and%2520Using%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I. M.</span>; <span class="NLM_string-name">Chowdari, N. S.</span>; <span class="NLM_string-name">Johnson, W. J.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Borzilleri, R. M.</span>; <span class="NLM_string-name">Gangwar, S.</span></span> <span> </span><span class="NLM_article-title">Heteroarylene-bridged Benzodiazepine Dimers, Conjugates Thereof, and Methods of Making and Using</span>. U.S. Patent <span class="NLM_patent">9,526,801 B2</span>, Dec 27, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=I.+M.+McDonald&author=N.+S.+Chowdari&author=W.+J.+Johnson&author=Y.+Zhang&author=R.+M.+Borzilleri&author=S.+Gangwar&title=Heteroarylene-bridged+Benzodiazepine+Dimers%2C+Conjugates+Thereof%2C+and+Methods+of+Making+and+Using"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonald%26aufirst%3DI.%2BM.%26atitle%3DHeteroarylene-bridged%2520Benzodiazepine%2520Dimers%252C%2520Conjugates%2520Thereof%252C%2520and%2520Methods%2520of%2520Making%2520and%2520Using%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jammalamadaka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borkin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrado, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of isoquinolidinobenzodiazepine dimers, a novel class of antibody–drug conjugate payload</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00436</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00436" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaqsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=56-60&author=S.+W.+Smithauthor=V.+Jammalamadakaauthor=D.+Borkinauthor=J.+Zhuauthor=S.+J.+Degradoauthor=J.+Luauthor=J.+Huangauthor=Y.-P.+Jiangauthor=N.+Jainauthor=J.+R.+Junutula&title=Design+and+synthesis+of+isoquinolidinobenzodiazepine+dimers%2C+a+novel+class+of+antibody%E2%80%93drug+conjugate+payload&doi=10.1021%2Facsmedchemlett.7b00436"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Isoquinolidinobenzodiazepine Dimers, a Novel Class of Antibody-Drug Conjugate Payload</span></div><div class="casAuthors">Smith, Sean W.; Jammalamadaka, Vasu; Borkin, Dmitry; Zhu, Jianyu; Degrado, Sylvia J.; Lu, Jennifer; Huang, Jianqing; Jiang, Ying-Ping; Jain, Nareshkumar; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-60</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) represent an important class of emerging cancer therapeutics.  Recent ADC development efforts highlighted the use of pyrrolobenzodiazepine (PBD) dimer payload for the treatment of several cancers.  The authors identified the isoquinolidinobenzodiazepine (IQB) payload (D211), a new class of PBD dimer family of DNA damaging payloads.  The authors have successfully synthesized all three IQB stereoisomers, exptl. showed that the purified (S,S)-D211 isomer is functionally more active than (R,R)-D221 and (S,R)-D231 isomers by >50,000-fold and ∼200-fold, resp.  The authors also synthesized a linker-payload (D212) that uses (S,S)-D211 payload with a cathepsin cleavable linker, a hydrophilic PEG8 spacer, and a thiol reactive maleimide.  Homogeneous ADCs generated using D212 linker-payload exhibited ideal physicochem. properties, and anti-CD33 ADC displayed a robust target-specific potency on AML cell lines.  D212 linker-payload described here can be used for developing novel ADC therapeutics for targeted cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbr6bg3ED4NLVg90H21EOLACvtfcHk0lgDOsD2N_80hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaqsL%252FP&md5=50142e330f23c1c2fc8e51abb4bb4d41</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00436%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DS.%2BW.%26aulast%3DJammalamadaka%26aufirst%3DV.%26aulast%3DBorkin%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DDegrado%26aufirst%3DS.%2BJ.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.-P.%26aulast%3DJain%26aufirst%3DN.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520isoquinolidinobenzodiazepine%2520dimers%252C%2520a%2520novel%2520class%2520of%2520antibody%25E2%2580%2593drug%2520conjugate%2520payload%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D56%26epage%3D60%26doi%3D10.1021%2Facsmedchemlett.7b00436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kothakonda, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bose, D. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a novel tetrahydroisoquinolino[2,1-c][1,4]benzodiazepine ring system with DNA recognition potential</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4371</span>– <span class="NLM_lpage">4373</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1016%2Fj.bmcl.2004.07.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=4371-4373&author=K.+K.+Kothakondaauthor=D.+S.+Bose&title=Synthesis+of+a+novel+tetrahydroisoquinolino%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepine+ring+system+with+DNA+recognition+potential&doi=10.1016%2Fj.bmcl.2004.07.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DKothakonda%26aufirst%3DK.%2BK.%26aulast%3DBose%26aufirst%3DD.%2BS.%26atitle%3DSynthesis%2520of%2520a%2520novel%2520tetrahydroisoquinolino%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepine%2520ring%2520system%2520with%2520DNA%2520recognition%2520potential%26jtitle%3DTetrahedron%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D4371%26epage%3D4373%26doi%3D10.1016%2Fj.bmcl.2004.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, C. R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laughton, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shnyder, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loadman, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5442</span>– <span class="NLM_lpage">5461</span>, <span class="refDoi"> DOI: 10.1021/jm051199z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051199z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvVaksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5442-5461&author=G.+Wellsauthor=C.+R.+H.+Martinauthor=P.+W.+Howardauthor=Z.+A.+Sandsauthor=C.+A.+Laughtonauthor=A.+Tiberghienauthor=C.+K.+Wooauthor=L.+A.+Mastersonauthor=M.+J.+Stephensonauthor=J.+A.+Hartleyauthor=T.+C.+Jenkinsauthor=S.+D.+Shnyderauthor=P.+M.+Loadmanauthor=M.+J.+Waringauthor=D.+E.+Thurston&title=Design%2C+synthesis%2C+and+biophysical+and+biological+evaluation+of+a+series+of+pyrrolobenzodiazepine-poly%28N-methylpyrrole%29+conjugates&doi=10.1021%2Fjm051199z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biophysical and Biological Evaluation of a Series of Pyrrolobenzodiazepine-Poly(N-methylpyrrole) Conjugates</span></div><div class="casAuthors">Wells, Geoff; Martin, Christopher R. H.; Howard, Philip W.; Sands, Zara A.; Laughton, Charles A.; Tiberghien, Arnaud; Woo, Chi Kit; Masterson, Luke A.; Stephenson, Marissa J.; Hartley, John A.; Jenkins, Terence C.; Shnyder, Steven D.; Loadman, Paul M.; Waring, Michael J.; Thurston, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5442-5461</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of six Me ester-terminated C8-linked pyrrolobenzodiazepine (PBD)-poly(N-methylpyrrole) conjugates has been synthesized and their DNA interaction evaluated by thermal denaturation, DNA footprinting, and in vitro transcription stop assays.  The synergistic effect of attaching a PBD unit to a polypyrrole fragment is illustrated by the large increase in DNA binding affinity (up to 50-fold) compared to the individual PBD and pyrrole components.  The conjugates were found to bind mainly to identical DNA sequences but with apparent binding site widths increasing with mol. length and the majority of sites conforming to the consensus motif 5'-XGXWz (z = 3±1; W = A or T; X = any base but preferably a purine).  They also provided robust sequence-selective blockade of transcription at sites corresponding approx. to their DNA footprints.  The conjugates were shown to have good cellular/nuclear penetration properties, and a degree of correlation between cytotoxicity and DNA-binding affinity was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0EDeZEws47rVg90H21EOLACvtfcHk0lgDOsD2N_80hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvVaksrk%253D&md5=ba74219df193a55a984edd07635e731a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm051199z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051199z%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DC.%2BR.%2BH.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DSands%26aufirst%3DZ.%2BA.%26aulast%3DLaughton%26aufirst%3DC.%2BA.%26aulast%3DTiberghien%26aufirst%3DA.%26aulast%3DWoo%26aufirst%3DC.%2BK.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DStephenson%26aufirst%3DM.%2BJ.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DJenkins%26aufirst%3DT.%2BC.%26aulast%3DShnyder%26aufirst%3DS.%2BD.%26aulast%3DLoadman%26aufirst%3DP.%2BM.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biophysical%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520pyrrolobenzodiazepine-poly%2528N-methylpyrrole%2529%2520conjugates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5442%26epage%3D5461%26doi%3D10.1021%2Fjm051199z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guille, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span> <span> </span><span class="NLM_article-title">Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8′ ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Dimers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1161</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1021/jm030897l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030897l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFWhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1161-1174&author=S.+J.+Gregsonauthor=P.+W.+Howardauthor=D.+R.+Gullickauthor=A.+Hamaguchiauthor=K.+E.+Corcoranauthor=N.+A.+Brooksauthor=J.+A.+Hartleyauthor=T.+C.+Jenkinsauthor=S.+Patelauthor=M.+J.+Guilleauthor=D.+E.+Thurston&title=Linker+length+modulates+DNA+cross-linking+reactivity+and+cytotoxic+potency+of+C8%2FC8%E2%80%B2+ether-linked+C2-exo-unsaturated+pyrrolo%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepine+%28PBD%29+Dimers&doi=10.1021%2Fjm030897l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Linker Length Modulates DNA Cross-Linking Reactivity and Cytotoxic Potency of C8/C8' Ether-Linked C2-exo-Unsaturated Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Dimers</span></div><div class="casAuthors">Gregson, Stephen J.; Howard, Philip W.; Gullick, Darren R.; Hamaguchi, Anzu; Corcoran, Kathryn E.; Brooks, Natalie A.; Hartley, John A.; Jenkins, Terence C.; Patel, Sejal; Guille, Matthew J.; Thurston, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1161-1174</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A C2/C2'-exo-unsatd. pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimer (DRG-16) with a C8-O(CH2)nO-C8' diether linkage (n = 5) has been synthesized that shows markedly superior in vitro cytotoxic potency (e.g., >3400-fold in IGROV1 ovarian cells) and interstrand DNA crosslinking reactivity (>10-fold) compared to the shorter homolog (SJG-136; n = 3).  In contrast, for the C-ring unsubstituted series, the corresponding n = 5 dimer is generally less cytotoxic and has a lower interstrand crosslinking reactivity compared to its shorter n = 3 homolog.  Dimer DRG-16 cross-links DNA with >10-fold efficiency compared to 4a, and also inhibits the activity of the restriction endonuclease BamH1 more efficiently.  The C2-exo-unsatd. PBD dimers 4a,b are not only more effective than their C-ring satd. counterparts in terms of induced ΔTm shift, but they also exert this effect more rapidly.  Mol. modeling shows a rank order of DRG-16 (n = 5) > SJG-136 (n = 3) in terms of binding energy toward duplexes contg. embedded target 5'-GAT1-2C cross-link sequences, reflecting the superior fit of the C2-exo-unsatd. rather than satd. C-rings of the PBD dimers.  A novel synthesis of core synthetic building blocks for PBD dimers via stepwise Mitsunobu reaction and nitration with Cu(NO3)2 is also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv_FYScSSSFLVg90H21EOLACvtfcHk0lhpsYfyZ4tTsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFWhsQ%253D%253D&md5=ed9b4a4a43930d3316188bbd9e50401b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm030897l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030897l%26sid%3Dliteratum%253Aachs%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DGullick%26aufirst%3DD.%2BR.%26aulast%3DHamaguchi%26aufirst%3DA.%26aulast%3DCorcoran%26aufirst%3DK.%2BE.%26aulast%3DBrooks%26aufirst%3DN.%2BA.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DJenkins%26aufirst%3DT.%2BC.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DGuille%26aufirst%3DM.%2BJ.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DLinker%2520length%2520modulates%2520DNA%2520cross-linking%2520reactivity%2520and%2520cytotoxic%2520potency%2520of%2520C8%252FC8%25E2%2580%25B2%2520ether-linked%2520C2-exo-unsaturated%2520pyrrolo%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepine%2520%2528PBD%2529%2520Dimers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1161%26epage%3D1174%26doi%3D10.1021%2Fjm030897l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terret, J. A.</span>; <span class="NLM_string-name">Pogue, S. L.</span>; <span class="NLM_string-name">Toy, K.</span>; <span class="NLM_string-name">Yang, L.</span>; <span class="NLM_string-name">Rao, C. R.</span>; <span class="NLM_string-name">Chen, B.</span></span> <span> </span><span class="NLM_article-title">Human Antibodies That Bind Mesothelin, and Uses Thereof</span>. U.S. Patent <span class="NLM_patent">8,425,904 B2</span>, Apr 23, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+A.+Terret&author=S.+L.+Pogue&author=K.+Toy&author=L.+Yang&author=C.+R.+Rao&author=B.+Chen&title=Human+Antibodies+That+Bind+Mesothelin%2C+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTerret%26aufirst%3DJ.%2BA.%26atitle%3DHuman%2520Antibodies%2520That%2520Bind%2520Mesothelin%252C%2520and%2520Uses%2520Thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, K.</span></span> <span> </span><span class="NLM_article-title">Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>211</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/s0378-5173(00)00590-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1016%2FS0378-5173%2800%2900590-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=11137340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BD3MXosl2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=2000&pages=67-78&author=C.+Weberauthor=S.+Reissauthor=K.+Langer&title=Preparation+of+surface+modified+protein+nanoparticles+by+introduction+of+sulfhydryl+groups&doi=10.1016%2Fs0378-5173%2800%2900590-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups</span></div><div class="casAuthors">Weber, C.; Reiss, S.; Langer, K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">67-78</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The objective of the present study was to establish several methods for the introduction of thiol groups onto the surface of human serum albumin (HSA) nanoparticles.  Besides the ε-amino groups of lysine, the carboxyl groups of aspartic and glutaminic acid, and the carbonyl groups of the crosslinker glutaraldehyde, sulfhydryl groups are possible targets for the covalent linkage of drugs to particle surfaces.  In principle, the thiol groups were introduced by the reaction with dithiothreitol (DDT) or 2-iminothiolane, by quenching reactive aldehyde residues with cystaminium dichloride or by coupling L-cysteine and cystaminium dichloride by the aq. carbodiimide reaction.  The resulting nanoparticulate systems were characterized concerning the no. of available sulfhydryl groups, particle size and particle d.  It was shown, that by variation of the reaction conditions, e.g., the concn. of the coupling reagent or the sulfhydryl contg. component as well as the reaction time, the proposed methods enabled the prepn. of HSA nanoparticles with a well defined surface characteristic.  Stability studies showed that the introduced thiol groups were relatively stable and lost their reactivity with a half-life of 28.2 days independently of the method used for the sulfhydryl group introduction.  Besides the quantification of free sulfhydryl groups the covalent attachment of cystaminium dichloride by the carbodiimide reaction was used to calc. the amt. of free carboxyl groups on the surface of the nanoparticles.  The toxicity of the modified nanoparticles was evaluated in cell culture expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcGF665AynEbVg90H21EOLACvtfcHk0lhpsYfyZ4tTsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXosl2htQ%253D%253D&md5=dd3551dce604511d54d6c9cc661da6aa</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0378-5173%2800%2900590-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5173%252800%252900590-1%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DC.%26aulast%3DReiss%26aufirst%3DS.%26aulast%3DLanger%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520surface%2520modified%2520protein%2520nanoparticles%2520by%2520introduction%2520of%2520sulfhydryl%2520groups%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2000%26volume%3D211%26spage%3D67%26epage%3D78%26doi%3D10.1016%2Fs0378-5173%2800%2900590-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strop, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaria, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foletti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasa-Moreno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorywalska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farias, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pios, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dushin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navaratnam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajpal, A.</span></span> <span> </span><span class="NLM_article-title">Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">694</span>– <span class="NLM_lpage">696</span>, <span class="refDoi"> DOI: 10.1038/nbt.3274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1038%2Fnbt.3274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=26154005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ensLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=694-696&author=P.+Stropauthor=K.+Delariaauthor=D.+Folettiauthor=J.+M.+Wittauthor=A.+Hasa-Morenoauthor=K.+Poulsenauthor=M.+G.+Casasauthor=M.+Dorywalskaauthor=S.+Fariasauthor=A.+Piosauthor=V.+Luiauthor=R.+Dushinauthor=D.+Zhouauthor=T.+Navaratnamauthor=T.-T.+Tranauthor=J.+Suttonauthor=K.+C.+Lindquistauthor=B.+Hanauthor=S.-H.+Liuauthor=D.+L.+Sheltonauthor=J.+Ponsauthor=A.+Rajpal&title=Site-specific+conjugation+improves+therapeutic+index+of+antibody+drug+conjugates+with+high+drug+loading&doi=10.1038%2Fnbt.3274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading</span></div><div class="casAuthors">Strop, Pavel; Delaria, Kathy; Foletti, Davide; Witt, Jody Melton; Hasa-Moreno, Adela; Poulsen, Kris; Casas, Meritxell Galindo; Dorywalska, Magdalena; Farias, Santiago; Pios, Ariel; Lui, Victor; Dushin, Russell; Zhou, Dahui; Navaratnam, Thayalan; Tran, Thomas-Toan; Sutton, Janette; Lindquist, Kevin C.; Han, Bora; Liu, Shu-Hui; Shelton, David L.; Pons, Jaume; Rajpal, Arvind</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">694-696</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt9y4CtErWAbVg90H21EOLACvtfcHk0lhpsYfyZ4tTsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ensLbK&md5=43b6c9f702e02a91887c3f27a5ab7353</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnbt.3274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.3274%26sid%3Dliteratum%253Aachs%26aulast%3DStrop%26aufirst%3DP.%26aulast%3DDelaria%26aufirst%3DK.%26aulast%3DFoletti%26aufirst%3DD.%26aulast%3DWitt%26aufirst%3DJ.%2BM.%26aulast%3DHasa-Moreno%26aufirst%3DA.%26aulast%3DPoulsen%26aufirst%3DK.%26aulast%3DCasas%26aufirst%3DM.%2BG.%26aulast%3DDorywalska%26aufirst%3DM.%26aulast%3DFarias%26aufirst%3DS.%26aulast%3DPios%26aufirst%3DA.%26aulast%3DLui%26aufirst%3DV.%26aulast%3DDushin%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DNavaratnam%26aufirst%3DT.%26aulast%3DTran%26aufirst%3DT.-T.%26aulast%3DSutton%26aufirst%3DJ.%26aulast%3DLindquist%26aufirst%3DK.%2BC.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DS.-H.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DPons%26aufirst%3DJ.%26aulast%3DRajpal%26aufirst%3DA.%26atitle%3DSite-specific%2520conjugation%2520improves%2520therapeutic%2520index%2520of%2520antibody%2520drug%2520conjugates%2520with%2520high%2520drug%2520loading%26jtitle%3DNat.%2520Biotechnol.%26date%3D2015%26volume%3D33%26spage%3D694%26epage%3D696%26doi%3D10.1038%2Fnbt.3274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strop, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorywalska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaria, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dushin, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farias, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdiche, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekaran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krimm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dilley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaparro-Riggers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filzen, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajpal, A.</span></span> <span> </span><span class="NLM_article-title">Location matters: Site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1016%2Fj.chembiol.2013.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=23438745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=161-167&author=P.+Stropauthor=S.-H.+Liuauthor=M.+Dorywalskaauthor=K.+Delariaauthor=R.+G.+Dushinauthor=T.-T.+Tranauthor=W.-H.+Hoauthor=S.+Fariasauthor=M.+G.+Casasauthor=Y.+Abdicheauthor=D.+Zhouauthor=R.+Chandrasekaranauthor=C.+Samainauthor=C.+Looauthor=A.+Rossiauthor=M.+Rickertauthor=S.+Krimmauthor=T.+Wongauthor=S.+M.+Chinauthor=J.+Yuauthor=J.+Dilleyauthor=J.+Chaparro-Riggersauthor=G.+F.+Filzenauthor=C.+J.+O%E2%80%99Donnellauthor=F.+Wangauthor=J.+S.+Myersauthor=J.+Ponsauthor=D.+L.+Sheltonauthor=A.+Rajpal&title=Location+matters%3A+Site+of+conjugation+modulates+stability+and+pharmacokinetics+of+antibody+drug+conjugates&doi=10.1016%2Fj.chembiol.2013.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates</span></div><div class="casAuthors">Strop, Pavel; Liu, Shu-Hui; Dorywalska, Magdalena; Delaria, Kathy; Dushin, Russell G.; Tran, Thomas-Toan; Ho, Wei-Hsien; Farias, Santiago; Casas, Meritxell Galindo; Abdiche, Yasmina; Zhou, Dahui; Chandrasekaran, Ramalakshmi; Samain, Caroline; Loo, Carole; Rossi, Andrea; Rickert, Mathias; Krimm, Stellanie; Wong, Teresa; Chin, Sherman Michael; Yu, Jessica; Dilley, Jeanette; Chaparro-Riggers, Javier; Filzen, Gary F.; O'Donnell, Christopher J.; Wang, Fang; Myers, Jeremy S.; Pons, Jaume; Shelton, David L.; Rajpal, Arvind</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-167</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Antibody drug conjugates (ADCs) are a therapeutic class offering promise for cancer therapy.  The attachment of cytotoxic drugs to antibodies can result in an effective therapy with better safety potential than nontargeted cytotoxics.  To understand the role of conjugation site, we developed an enzymic method for site-specific antibody drug conjugation using microbial transglutaminase.  This allowed us to attach diverse compds. at multiple positions and investigate how the site influences stability, toxicity, and efficacy.  We show that the conjugation site has significant impact on ADC stability and pharmacokinetics in a species-dependent manner.  These differences can be directly attributed to the position of the linkage rather than the chem. instability, as was obsd. with a maleimide linkage.  With this method, it is possible to produce homogeneous ADCs and tune their properties to maximize the therapeutic window.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIo4ZEVMFX2LVg90H21EOLACvtfcHk0lgyYIbD1KA65g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWht74%253D&md5=0b419848b5fd4dfa4863a29de0555cf4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DStrop%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DS.-H.%26aulast%3DDorywalska%26aufirst%3DM.%26aulast%3DDelaria%26aufirst%3DK.%26aulast%3DDushin%26aufirst%3DR.%2BG.%26aulast%3DTran%26aufirst%3DT.-T.%26aulast%3DHo%26aufirst%3DW.-H.%26aulast%3DFarias%26aufirst%3DS.%26aulast%3DCasas%26aufirst%3DM.%2BG.%26aulast%3DAbdiche%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DChandrasekaran%26aufirst%3DR.%26aulast%3DSamain%26aufirst%3DC.%26aulast%3DLoo%26aufirst%3DC.%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DRickert%26aufirst%3DM.%26aulast%3DKrimm%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DChin%26aufirst%3DS.%2BM.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DDilley%26aufirst%3DJ.%26aulast%3DChaparro-Riggers%26aufirst%3DJ.%26aulast%3DFilzen%26aufirst%3DG.%2BF.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMyers%26aufirst%3DJ.%2BS.%26aulast%3DPons%26aufirst%3DJ.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DRajpal%26aufirst%3DA.%26atitle%3DLocation%2520matters%253A%2520Site%2520of%2520conjugation%2520modulates%2520stability%2520and%2520pharmacokinetics%2520of%2520antibody%2520drug%2520conjugates%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D161%26epage%3D167%26doi%3D10.1016%2Fj.chembiol.2013.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, I. S.</span></span> <span> </span><span class="NLM_article-title">CD70 as a therapeutic target in human malignancies</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1517/14728222.12.3.341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1517%2F14728222.12.3.341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=18269343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslKqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=341-351&author=I.+S.+Grewal&title=CD70+as+a+therapeutic+target+in+human+malignancies&doi=10.1517%2F14728222.12.3.341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">CD70 as a therapeutic target in human malignancies</span></div><div class="casAuthors">Grewal, Iqbal S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-351</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Expression of CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T and B lymphocytes and mature dendritic cells.  CD70 has also been detected on hematol. tumors and on carcinomas.  The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics.  Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clin. candidates.  Anti-CD70 antibodies for therapeutic use have been developed and used to validate CD70 as a target for cancers.  Antibodies are also used as a vehicle to deliver potent cytotoxic drugs to target CD70+malignant cells.  Both unconjugated antibodies and antibody-drug conjugates targeting CD70 have been tested in animal models of human cancers.  To describe the expression of CD70 in cancer cells and the development of antibody-based therapies against CD70.  A review of the available literature.  Humanized anti-CD70 antibodies have shown significant antitumor activity in preclin. xenograft models of cancer.  Addnl., anti-CD70 antibody-drug conjugates exhibit potent antitumor activity in solid tumor xenograft models, confirming increased therapeutic efficacy through cytotoxic drug delivery.  Thus, preclin. animal models have provided strong evidence that targeting CD70 either with unconjugated antibodies or with antibody-drug conjugates represents a promising approach to treat human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAVG1bz-F3nrVg90H21EOLACvtfcHk0lgyYIbD1KA65g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslKqu7g%253D&md5=576c0320d4f2683e0be9956a158a802e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1517%2F14728222.12.3.341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.12.3.341%26sid%3Dliteratum%253Aachs%26aulast%3DGrewal%26aufirst%3DI.%2BS.%26atitle%3DCD70%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520malignancies%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2008%26volume%3D12%26spage%3D341%26epage%3D351%26doi%3D10.1517%2F14728222.12.3.341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ponath, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyasu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strachan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBlanc, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangan, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristea, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardarelli, P. M.</span></span> <span> </span><span class="NLM_article-title">A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5178</span>– <span class="NLM_lpage">5189</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-18-0018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1158%2F1078-0432.CCR-18-0018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=30021910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsl2gsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=5178-5189&author=P.+Ponathauthor=D.+Menezesauthor=C.+Panauthor=B.+Chenauthor=M.+Oyasuauthor=D.+Strachanauthor=H.+LeBlancauthor=H.+Sunauthor=X.-T.+Wangauthor=V.+S.+Ranganauthor=S.+Deshpandeauthor=S.+Cristeaauthor=K.-S.+Parkauthor=J.+Sageauthor=P.+M.+Cardarelli&title=A+novel%2C+fully+human+anti-fucosyl-GM1+antibody+demonstrates+potent+in+vitro+and+in+vivo+antitumor+activity+in+preclinical+models+of+small+cell+lung+cancer&doi=10.1158%2F1078-0432.ccr-18-0018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer</span></div><div class="casAuthors">Ponath, Paul; Menezes, Daniel; Pan, Chin; Chen, Bing; Oyasu, Miho; Strachan, Debbie; LeBlanc, Heidi; Sun, Huadong; Wang, Xi-Tao; Rangan, Vangipuram S.; Deshpande, Shrikant; Cristea, Sandra; Park, Kwon-Sik; Sage, Julien; Cardarelli, Pina M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5178-5189</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The ganglioside fucosyl-GM1 (FucGM1) is a tumor-assocd. antigen expressed in a large percentage of human small cell lung cancer (SCLC) tumors, but absent in most normal adult tissues, making it a promising target in immuno-oncol.  This study was undertaken to evaluate the preclin. efficacy of BMS-986012, a novel, nonfucosylated, fully human IgG1 antibody that binds specifically to FucGM1.  Exptl. Design: The antitumor activity of BMS-986012 was evaluated in in vitro assays using SCLC cells and in mouse xenograft and syngeneic tumor models, with and without chemotherapeutic agents and checkpoint inhibitors.  Results: BMS-986012 showed a high binding affinity for FcγRIIIa (CD16), which resulted in enhanced antibody-dependent cellular cytotoxicity (ADCC) against FucGM1-expressing tumor cell lines.  BMS-986012-mediated tumor cell killing was also obsd. in complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP) assays.  In several mouse SCLC models, BMS-986012 demonstrated efficacy and was well tolerated.  In the DMS79 xenograft model, tumor regression was achieved with BMS-986012 doses of 0.3 mg/kg and greater; antitumor activity was enhanced when BMS-986012 was combined with std.-of-care cisplatin or etoposide.  In a syngeneic model, tumors derived from a genetically engineered model of SCLC were treated with BMS-986012 or anti-FucGM1 with a mouse IgG2a Fc and their responses evaluated; when BMS-986012 was combined with anti-PD-1 or anti-CD137 antibody, therapeutic responses significantly improved.  Conclusions: Single-agent BMS-986012 demonstrated robust antitumor activity, with the addn. of chemotherapeutic or immunomodulatory agents further inhibiting SCLC growth in the same models.  These preclin. data supported evaluation of BMS-986012 in a phase I clin. trial of patients with relapsed, refractory SCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2I3l3szsPmrVg90H21EOLACvtfcHk0lgj60CuciqovA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsl2gsr4%253D&md5=3f60f55d89c41e28135b612619038520</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-0018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-0018%26sid%3Dliteratum%253Aachs%26aulast%3DPonath%26aufirst%3DP.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DOyasu%26aufirst%3DM.%26aulast%3DStrachan%26aufirst%3DD.%26aulast%3DLeBlanc%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.-T.%26aulast%3DRangan%26aufirst%3DV.%2BS.%26aulast%3DDeshpande%26aufirst%3DS.%26aulast%3DCristea%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DK.-S.%26aulast%3DSage%26aufirst%3DJ.%26aulast%3DCardarelli%26aufirst%3DP.%2BM.%26atitle%3DA%2520novel%252C%2520fully%2520human%2520anti-fucosyl-GM1%2520antibody%2520demonstrates%2520potent%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activity%2520in%2520preclinical%2520models%2520of%2520small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D5178%26epage%3D5189%26doi%3D10.1158%2F1078-0432.ccr-18-0018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastalerz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton King, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstead, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasch, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P. A.</span></span> <span> </span><span class="NLM_article-title">Doxorubicin immunoconjugates containing bivalent, lysosomal cleavable linkages</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1529</span>– <span class="NLM_lpage">1532</span>, <span class="refDoi"> DOI: 10.1016/s0960-894x(02)00194-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1016%2FS0960-894X%2802%2900194-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=12031335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjsl2ltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=1529-1532&author=G.+M.+Dubowchikauthor=S.+Radiaauthor=H.+Mastalerzauthor=M.+A.+Walkerauthor=R.+A.+Firestoneauthor=H.+Dalton+Kingauthor=S.+J.+Hofsteadauthor=D.+Willnerauthor=S.+J.+Laschauthor=P.+A.+Trail&title=Doxorubicin+immunoconjugates+containing+bivalent%2C+lysosomal+cleavable+linkages&doi=10.1016%2Fs0960-894x%2802%2900194-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages</span></div><div class="casAuthors">Dubowchik, Gene M.; Radia, Shilpa; Mastalerz, Harold; Walker, Michael A.; Firestone, Raymond A.; King, H. Dalton; Hofstead, Sandra J.; Willner, David; Lasch, Shirley J.; Trail, Pamela A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1529-1532</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Bivalent doxorubicin (DOX)-dipeptides were prepd. and conjugated to the monoclonal antibody BR96.  The dipeptides are cleaved by lysosomal proteases following internalization of the resulting immunoconjugates.  Conjugate I (R = BR96) demonstrated antigen-specific in vitro tumor cell killing activity (IC50=0.2 μM) that was equipotent to DOX with a near doubling of drug mols./MAb.  Size exclusion chromatog. showed I to be a noncovalent dimer that was formed immediately upon conjugation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriP8-FshjnXLVg90H21EOLACvtfcHk0lgj60CuciqovA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjsl2ltr8%253D&md5=6a7dc51aa0d83a17ab9dc97e4705d886</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900194-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900194-4%26sid%3Dliteratum%253Aachs%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DRadia%26aufirst%3DS.%26aulast%3DMastalerz%26aufirst%3DH.%26aulast%3DWalker%26aufirst%3DM.%2BA.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26aulast%3DDalton%2BKing%26aufirst%3DH.%26aulast%3DHofstead%26aufirst%3DS.%2BJ.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DLasch%26aufirst%3DS.%2BJ.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DDoxorubicin%2520immunoconjugates%2520containing%2520bivalent%252C%2520lysosomal%2520cleavable%2520linkages%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D1529%26epage%3D1532%26doi%3D10.1016%2Fs0960-894x%2802%2900194-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donnel, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangwar, S.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic pyrrolobenzodiazepine dimers as antibody-drug conjugate payloads</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">5267</span>– <span class="NLM_lpage">5271</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1016%2Fj.bmcl.2017.10.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=29102228" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=5267-5271&author=A.+F.+Donnelauthor=Y.+Zhangauthor=D.+D.+Weiauthor=A.+J.+Tebbenauthor=H.+L.+Perezauthor=G.+M.+Schroederauthor=C.+Panauthor=C.+Raoauthor=R.+M.+Borzilleriauthor=G.+D.+Viteauthor=S.+Gangwar&title=Macrocyclic+pyrrolobenzodiazepine+dimers+as+antibody-drug+conjugate+payloads&doi=10.1016%2Fj.bmcl.2017.10.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DDonnel%26aufirst%3DA.%2BF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DD.%2BD.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DPerez%26aufirst%3DH.%2BL.%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DPan%26aufirst%3DC.%26aulast%3DRao%26aufirst%3DC.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DGangwar%26aufirst%3DS.%26atitle%3DMacrocyclic%2520pyrrolobenzodiazepine%2520dimers%2520as%2520antibody-drug%2520conjugate%2520payloads%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D5267%26epage%3D5271%26doi%3D10.1016%2Fj.bmcl.2017.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiberghien, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, J.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of Tesirine, a clinical antibody–drug conjugate pyrrolobenzodiazepine dimer payload</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00062</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00062" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFSgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=983-987&author=A.+C.+Tiberghienauthor=J.-N.+Levyauthor=L.+A.+Mastersonauthor=N.+V.+Patelauthor=L.+R.+Adamsauthor=S.+Corbettauthor=D.+G.+Williamsauthor=J.+A.+Hartleyauthor=P.+W.+Howard&title=Design+and+synthesis+of+Tesirine%2C+a+clinical+antibody%E2%80%93drug+conjugate+pyrrolobenzodiazepine+dimer+payload&doi=10.1021%2Facsmedchemlett.6b00062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload</span></div><div class="casAuthors">Tiberghien, Arnaud C.; Levy, Jean-Noel; Masterson, Luke A.; Patel, Neki V.; Adams, Lauren R.; Corbett, Simon; Williams, David G.; Hartley, John A.; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">983-987</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyrrolobenzodiazepine dimers are an emerging class of warhead in the field of antibody-drug conjugates (ADCs).  Tesirine (SG3249) was designed to combine potent antitumor activity with desirable physicochem. properties such as favorable hydrophobicity and improved conjugation characteristics.  One of the reactive imines was capped with a cathepsin B-cleavable valine-alanine linker.  A robust synthetic route was developed to allow the prodn. of tesirine on clin. scale, employing a flexible, convergent strategy.  Tesirine was evaluated in vitro both in stochastic and engineered ADC constructs and was confirmed as a potent and versatile payload.  The conjugation of tesirine to anti-DLL3 rovalpituzumab has resulted in rovalpituzumab-tesirine (Rova-T), currently under evaluation for the treatment of small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYid7RNts7s7Vg90H21EOLACvtfcHk0ljwmcbRSEFznA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFSgu70%253D&md5=7e4bbdd55b944ff712f01d31d58c0d13</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00062%26sid%3Dliteratum%253Aachs%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DLevy%26aufirst%3DJ.-N.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DPatel%26aufirst%3DN.%2BV.%26aulast%3DAdams%26aufirst%3DL.%2BR.%26aulast%3DCorbett%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DD.%2BG.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520Tesirine%252C%2520a%2520clinical%2520antibody%25E2%2580%2593drug%2520conjugate%2520pyrrolobenzodiazepine%2520dimer%2520payload%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D983%26epage%3D987%26doi%3D10.1021%2Facsmedchemlett.6b00062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neelarapu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzle, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velaparthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunsteiner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blond, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petukhov, P. A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4350</span>– <span class="NLM_lpage">4364</span>, <span class="refDoi"> DOI: 10.1021/jm2001025</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2001025" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntVemsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4350-4364&author=R.+Neelarapuauthor=D.+L.+Holzleauthor=S.+Velaparthiauthor=H.+Baiauthor=M.+Brunsteinerauthor=S.+Y.+Blondauthor=P.+A.+Petukhov&title=Design%2C+synthesis%2C+docking%2C+and+biological+evaluation+of+novel+diazide-containing+isoxazole-+and+pyrazole-based+histone+deacetylase+probes&doi=10.1021%2Fjm2001025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Docking, and Biological Evaluation of Novel Diazide-Containing Isoxazole- and Pyrazole-Based Histone Deacetylase Probes</span></div><div class="casAuthors">Neelarapu, Raghupathi; Holzle, Denise L.; Velaparthi, Subash; Bai, He; Brunsteiner, Michael; Blond, Sylvie Y.; Petukhov, Pavel A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4350-4364</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, docking, and biol. evaluation of novel potent HDAC3 and HDAC8 isoxazole- and pyrazole-based diazide probes suitable for binding ensemble profiling with photoaffinity labeling (BEProFL) expts. in cells is described.  Both the isoxazole- and pyrazole-based probes exhibit low nanomolar inhibitory activity against HDAC3 and HDAC8, resp.  The pyrazole-based probe I appears to be one of the most active HDAC8 inhibitors reported in the literature with an IC50 of 17 nM.  Our docking studies suggest that unlike the isoxazole-based ligands the pyrazole-based ligands are flexible enough to occupy the second binding site of HDAC8.  Probes/inhibitors II, III (R = H, N3) and I exerted the antiproliferative and neuroprotective activities at micromolar concns. through inhibition of nuclear HDACs, indicating that they are cell permeable and the presence of an azide or a diazide group does not interfere with the neuroprotection properties, or enhance cellular cytotoxicity, or affect cell permeability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhXV9jmEswzLVg90H21EOLACvtfcHk0ljwmcbRSEFznA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntVemsbw%253D&md5=274a01467ab7108b87dd6634562f4635</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm2001025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2001025%26sid%3Dliteratum%253Aachs%26aulast%3DNeelarapu%26aufirst%3DR.%26aulast%3DHolzle%26aufirst%3DD.%2BL.%26aulast%3DVelaparthi%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DH.%26aulast%3DBrunsteiner%26aufirst%3DM.%26aulast%3DBlond%26aufirst%3DS.%2BY.%26aulast%3DPetukhov%26aufirst%3DP.%2BA.%26atitle%3DDesign%252C%2520synthesis%252C%2520docking%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520diazide-containing%2520isoxazole-%2520and%2520pyrazole-based%2520histone%2520deacetylase%2520probes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4350%26epage%3D4364%26doi%3D10.1021%2Fjm2001025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, J. G. H.</span>; <span class="NLM_string-name">Wentzel, M.</span>; <span class="NLM_string-name">Knoetze, S.</span></span> <span> </span><span class="NLM_article-title">Aromatic Compounds and Metal Complexes Thereof</span>. <span class="NLM_patent">WO 2012153253 A2</span>, Nov 15, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+G.+H.+Perez&author=M.+Wentzel&author=S.+Knoetze&title=Aromatic+Compounds+and+Metal+Complexes+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DJ.%2BG.%2BH.%26atitle%3DAromatic%2520Compounds%2520and%2520Metal%2520Complexes%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howáth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köntös, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerencsér, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszthy, P.</span></span> <span> </span><span class="NLM_article-title">A new efficient method for the preparation of 2,6-pyridinedimethylditosylates from dimethyl 2,6-pyridinedicarboxylates</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3719</span>– <span class="NLM_lpage">3731</span>, <span class="refDoi"> DOI: 10.1080/00397919908086011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;key=10.1080%2F00397919908086011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1999&pages=3719-3731&author=G.+How%C3%A1thauthor=C.+Rusaauthor=Z.+K%C3%B6nt%C3%B6sauthor=J.+Gerencs%C3%A9rauthor=P.+Huszthy&title=A+new+efficient+method+for+the+preparation+of+2%2C6-pyridinedimethylditosylates+from+dimethyl+2%2C6-pyridinedicarboxylates&doi=10.1080%2F00397919908086011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1080%2F00397919908086011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397919908086011%26sid%3Dliteratum%253Aachs%26aulast%3DHow%25C3%25A1th%26aufirst%3DG.%26aulast%3DRusa%26aufirst%3DC.%26aulast%3DK%25C3%25B6nt%25C3%25B6s%26aufirst%3DZ.%26aulast%3DGerencs%25C3%25A9r%26aufirst%3DJ.%26aulast%3DHuszthy%26aufirst%3DP.%26atitle%3DA%2520new%2520efficient%2520method%2520for%2520the%2520preparation%2520of%25202%252C6-pyridinedimethylditosylates%2520from%2520dimethyl%25202%252C6-pyridinedicarboxylates%26jtitle%3DSynth.%2520Commun.%26date%3D1999%26volume%3D29%26spage%3D3719%26epage%3D3731%26doi%3D10.1080%2F00397919908086011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i142"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01385">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_22178"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01385?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01385</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">LC traces of compounds <b>17</b>, <b>45</b>, and <b>46</b> and LCMS analysis of DNA cross-linking adduct with compound <b>27</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01385/suppl_file/jm0c01385_si_001.pdf">PDF</a>)</p></li><li><p class="inline">PDB file for the molecular model displayed in <a id="rightTab-" class=" internalNav" href="#fig2">Figure <a id="rightTab-" class=" internalNav" href="#fig2">2</a></a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01385/suppl_file/jm0c01385_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings of new compounds in <a class="ref showTableEvent internalNav" href="#tbl1">Tables <a class="ref showTableEvent internalNav" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" href="#tbl4">4</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01385/suppl_file/jm0c01385_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01385/suppl_file/jm0c01385_si_001.pdf">jm0c01385_si_001.pdf (305.18 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01385/suppl_file/jm0c01385_si_002.pdb">jm0c01385_si_002.pdb (63.09 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01385/suppl_file/jm0c01385_si_003.csv">jm0c01385_si_003.csv (7.12 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01385&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01385%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-22" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01385" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679940a5d98b21d6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
